

TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS**CROSS-REFERENCE**

[0001] This application claims the benefit of U.S. Provisional Application No. 63/211,379, filed June 16, 2021, which application is incorporated herein by reference in its entirety.

BACKGROUND

[0002] Neurological disorders are a common problem, particularly in the older population. Improved therapeutics are needed for treating these disorders.

SUMMARY

[0003] Described herein are compositions comprising an oligonucleotide that targets MTRES1. Described herein are compositions comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount reduces a MTRES1 mRNA or protein level. Described herein are compositions comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases central nervous system (CNS) MTRES1. In some embodiments, the CNS MTRES1 decreased by about 10% or more, as compared to prior to administration. Disclosed herein, in some embodiments, are compositions comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount increases cognitive function or slows cognitive decline. In some embodiments, the cognitive function is increased by about 10% or more, as compared to prior to administration. In some embodiments, the cognitive decline is slowed by about 10% or more, as compared to prior to administration. Disclosed herein, in some embodiments, are compositions comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases a marker of neurodegeneration. In some embodiments, the marker of neurodegeneration comprises a central nervous system (CNS) or cerebrospinal fluid (CSF) marker of neurodegeneration. In some embodiments, the marker of neurodegeneration comprises a measurement of central nervous system (CNS) amyloid plaques, CNS tau accumulation, cerebrospinal fluid (CSF) beta-amyloid 42, CSF tau, CSF phospho-tau, CSF or plasma neurofilament light chain (NFL), Lewy bodies, or CSF alpha-synuclein. In some embodiments, the marker of neurodegeneration is decreased by about 10% or more, as compared to prior to administration. Disclosed herein, in some embodiments, are compositions comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount increases cognitive function. In some embodiments, the cognitive function is increased by about 10% or more, as compared to prior to administration. Disclosed herein, in some embodiments, are compositions comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases central nervous system (CNS) amyloid plaques, CNS tau accumulation, cerebrospinal fluid (CSF) beta-amyloid 42, CSF tau, CSF phospho-tau, Lewy bodies, or CSF alpha-synuclein. In some embodiments, the CNS amyloid plaques, CNS tau accumulation, CSF beta-amyloid 42, CSF tau, CSF phospho-tau, Lewy bodies, or CSF alpha-synuclein, is decreased by about 10% or more, as compared to prior to administration. In some embodiments, the oligonucleotide comprises a modified internucleoside linkage. In some embodiments, the modified internucleoside linkage comprises alkylphosphonate,

phosphorothioate, methylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester, or a combination thereof. In some embodiments, the modified internucleoside linkage comprises one or more phosphorothioate linkages. In some embodiments, the oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 modified internucleoside linkages. In some embodiments, the oligonucleotide comprises a modified nucleoside. In some embodiments, the modified nucleoside comprises a locked nucleic acid (LNA), hexitol nucleic acid (HLA), cyclohexene nucleic acid (CeNA), 2'-methoxyethyl, 2'-O-alkyl, 2'-O-allyl, 2'-O-allyl, 2'-fluoro, or 2'-deoxy, or a combination thereof. In some embodiments, the modified nucleoside comprises a LNA. In some embodiments, the modified nucleoside comprises a 2',4' constrained ethyl nucleic acid. In some embodiments, the modified nucleoside comprises a 2'-O-methyl nucleoside, 2'-deoxyfluoro nucleoside, 2'-O-N-methylacetamido (2'-O-NMA) nucleoside, a 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE) nucleoside, 2'-O-aminopropyl (2'-O-AP) nucleoside, or 2'-ara-F, or a combination thereof. In some embodiments, the modified nucleoside comprises one or more 2' fluoro modified nucleosides. In some embodiments, the modified nucleoside comprises a 2' O-alkyl modified nucleoside. In some embodiments, the oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 modified nucleosides. In some embodiments, the oligonucleotide comprises a lipophilic moiety attached at a 3' or 5' terminus of the oligonucleotide. In some embodiments, the lipophilic moiety comprises cholesterol, retinoic acid, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, ibuprofen, naproxen, dimethoxytrityl, or phenoxazine. In some embodiments, the lipophilic moiety comprises a C4-C30 hydrocarbon chain. In some embodiments, the lipophilic moiety comprises a lipid. In some embodiments, the lipid comprises myristoyl, palmitoyl, stearoyl, lithocholoyl, docosanoyl, docosahexaenoyl, myristyl, palmityl stearyl, or α -tocopherol, or a combination thereof. In some embodiments, the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand. In some embodiments, the sense strand is 12-30 nucleosides in length. In some embodiments, the antisense strand is 12-30 nucleosides in length. Disclosed herein, in some embodiments, are compositions comprising an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, each strand is independently about 12-30 nucleosides in length, and at least one of the sense strand and the antisense strand comprises a nucleoside sequence comprising about 12-30 contiguous nucleosides of SEQ ID NO: 2443. In some embodiments, any one of the following is true with regard to the sense strand: all purines comprise 2' fluoro modified purines, and all pyrimidines comprise a mixture of 2' fluoro and 2' methyl modified pyrimidines; all purines comprise 2' methyl modified purines, and all pyrimidines comprise a mixture of 2' fluoro and 2' methyl modified pyrimidines; all purines comprise 2' fluoro modified purines, and all pyrimidines comprise 2' methyl modified pyrimidines; all pyrimidines comprise 2' fluoro modified pyrimidines, and all purines comprise a mixture of 2' fluoro and 2' methyl modified purines; all pyrimidines comprise 2' methyl modified

pyrimidines, and all purines comprise a mixture of 2' fluoro and 2' methyl modified purines; or all pyrimidines comprise 2' fluoro modified pyrimidines, and all purines comprise 2' methyl modified purines. In some embodiments, the sense strand comprises any one of modification patterns 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S. In some embodiments, any one of the following is true with regard to the antisense strand: all purines comprise 2' fluoro modified purines, and all pyrimidines comprise a mixture of 2' fluoro and 2' methyl modified pyrimidines; all purines comprise 2' methyl modified purines, and all pyrimidines comprise a mixture of 2' fluoro and 2' methyl modified pyrimidines; all purines comprise 2' methyl modified purines, and all pyrimidines comprise 2' fluoro modified pyrimidines; all pyrimidines comprise 2' fluoro modified pyrimidines, and all purines comprise a mixture of 2' fluoro and 2' methyl modified purines; all pyrimidines comprise 2' methyl modified pyrimidines, and all purines comprise a mixture of 2' fluoro and 2' methyl modified purines; or all pyrimidines comprise 2' methyl modified pyrimidines, and all purines comprise 2' fluoro modified purines. In some embodiments, the antisense strand comprises any one of modification patterns 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the oligonucleotide comprises a phosphate at the 5' end of the antisense strand. In some embodiments, the oligonucleotide comprises a phosphate mimic at the 5' end of the antisense strand. In some embodiments, the phosphate mimic comprises a 5'-vinyl phosphonate (VP). In some embodiments, the sense strand comprises the nucleic acid sequence of any one of SEQ ID NOs: 1-1140, and the antisense strand comprises the nucleic acid sequence of any one of SEQ ID NOs: 1141-2280. In some embodiments, the oligonucleotide comprises an antisense oligonucleotide (ASO). In some embodiments, the ASO is 12-30 nucleosides in length. Disclosed herein, in some embodiments, are compositions comprising an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an ASO about 12-30 nucleosides in length and a nucleoside sequence complementary to about 12-30 contiguous nucleosides of SEQ ID NO: 2443. Some embodiments include a pharmaceutically acceptable carrier. Disclosed herein, in some embodiments, are methods of treating a subject having a neurological disorder, comprising administering an effective amount of the composition to the subject. In some embodiments, the neurological disorder comprises dementia, Alzheimer's disease, delirium, cognitive decline, vascular dementia, or Parkinson's disease.

BRIEF DESCRIPTION OF THE DRAWINGS

[0004] FIG. 1 is an image of a western blot of MTRES1 protein.

[0005] FIG. 2 is a plot quantifying MTRES1 western blot data.

[0006] FIG. 3 is a plot of *MTRES1* mRNA blot data.

DETAILED DESCRIPTION

[0007] Large-scale human genetic data can improve the success rate of pharmaceutical discovery and development. A Genome Wide Association Study (GWAS) may detect associations between genetic variants and traits in a population sample. A GWAS may enable better understanding of the biology of disease, and provide applicable treatments. A GWAS can utilize genotyping and/or sequencing data, and

often involves an evaluation of millions of genetic variants that are relatively evenly distributed across the genome. The most common GWAS design is the case-control study, which involves comparing variant frequencies in cases versus controls. If a variant has a significantly different frequency in cases versus controls, that variant is said to be associated with disease. Association statistics that may be used in a GWAS are p-values, as a measure of statistical significance; odds ratios (OR), as a measure of effect size; or beta coefficients (beta), as a measure of effect size. Researchers often assume an additive genetic model and calculate an allelic odds ratio, which is the increased (or decreased) risk of disease conferred by each additional copy of an allele (compared to carrying no copies of that allele). An additional concept in design and interpretation of GWAS is that of linkage disequilibrium, which is the non-random association of alleles. The presence of linkage disequilibrium can obfuscate which variant is “causal.”

[0008] Functional annotation of variants and/or wet lab experimentation can identify the causal genetic variant identified via GWAS, and in many cases may lead to the identification of disease-causing genes. In particular, understanding the functional effect of a causal genetic variant (for example, loss of protein function, gain of protein function, increase in gene expression, or decrease in gene expression) may allow that variant to be used as a proxy for therapeutic modulation of the target gene, or to gain insight into potential therapeutic efficacy and safety of a therapeutic that modulates that target.

[0009] Identification of such gene-disease associations has provided insights into disease biology and may be used to identify novel therapeutic targets for the pharmaceutical industry. In order to translate the therapeutic insights derived from human genetics, disease biology in patients may be exogenously ‘programmed’ into replicating the observation from human genetics. There are several potential options for therapeutic modalities that may be brought to bear in translating therapeutic targets identified via human genetics into novel medicines. These may include well established therapeutic modalities such as small molecules and monoclonal antibodies, maturing modalities such as oligonucleotides, and emerging modalities such as gene therapy and gene editing. The choice of therapeutic modality can depend on several factors including the location of a target (for example, intracellular, extracellular, or secreted), a relevant tissue (for example, brain) and a relevant indication.

[0010] The *MTRES1* gene is located on chromosome 6, and encodes mitochondrial transcription rescue factor 1 (MTRES1), also known as chromosome 6 open reading frame 203 (C6orf203). The *MTRES1* gene may also be referred to as the *C6orf203* gene. MTRES1 may include 240 amino acids and have a mass of about 28 kDa. MTRES1 may be expressed in neural cells. MTRES1 may be cytoplasmic or intracellular. MTRES1 may be localized in mitochondria within the cell. MTRES1 may be involved in mitochondrial transcription regulation. An example of a MTRES1 amino acid sequence, and further description of MTRES1 is included at uniprot.org under accession no. Q9P0P8 (last modified October 1, 2000).

[0011] Here it is shown that loss of function *MTRES1* variants may protect against neurological diseases. For example, a loss of function *MTRES1* variant was associated with protective associations against Alzheimer’s disease, family history of Alzheimer’s disease, dementia, vascular dementia, anticholinesterase medication use, and delirium. Therefore, inhibition of MTRES1 may serve as a

therapeutic for treatment of a neurological disorder such as dementia, Alzheimer's disease, delirium, cognitive decline, vascular dementia, or Parkinson's disease.

[0012] Disclosed herein are compositions comprising an oligonucleotide that targets MTRES1. Where inhibition or targeting of MTRES1 is disclosed, it is contemplated that some embodiments may include inhibiting or targeting a MTRES1 protein or MTRES1 RNA. For example, by inhibiting or targeting an RNA (e.g. mRNA) encoded by the *MTRES1* gene using an oligonucleotide described herein, the MTRES1 protein may be inhibited or targeted as a result of there being less production of the MTRES1 protein by translation of the MTRES1 RNA; or a MTRES1 protein may be targeted or inhibited by an oligonucleotide that binds or interacts with a MTRES1 RNA and reduces production of the MTRES1 protein from the MTRES1 RNA. Thus, targeting MTRES1 may refer to binding a MTRES1 RNA and reducing MTRES1 RNA or protein levels. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a neurological disorder by providing an oligonucleotide that targets MTRES1 to a subject in need thereof.

I. COMPOSITIONS

[0013] Disclosed herein, in some embodiments, are compositions comprising an oligonucleotide. In some embodiments, the composition comprises an oligonucleotide that targets MTRES1. In some embodiments, the composition consists of an oligonucleotide that targets MTRES1. In some embodiments, the oligonucleotide reduces MTRES1 mRNA expression in the subject. In some embodiments, the oligonucleotide reduces MTRES1 protein expression in the subject. The oligonucleotide may include a small interfering RNA (siRNA) described herein. The oligonucleotide may include an antisense oligonucleotide (ASO) described herein. In some embodiments, a composition described herein is used in a method of treating a disorder in a subject in need thereof. Some embodiments relate to a composition comprising an oligonucleotide for use in a method of treating a disorder as described herein. Some embodiments relate to use of a composition comprising an oligonucleotide, in a method of treating a disorder as described herein.

[0014] Some embodiments include a composition comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases MTRES1 mRNA or protein levels in a cell, fluid or tissue. In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases MTRES1 mRNA levels in a cell or tissue. In some embodiments, the cell is a neural cell such as a central nervous system (CNS) cell. Some examples of CNS cells include neurons, glia, microglia, astrocytes, or oligodendrocytes. In some embodiments, the tissue is CNS or brain tissue. In some embodiments, the MTRES1 mRNA levels are decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the MTRES1 mRNA levels are decreased by about 10% or more, as compared to prior to administration. In some embodiments, the MTRES1 mRNA levels are decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the MTRES1 mRNA levels are decreased by no more than about

2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the MTRES1 mRNA levels are decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the MTRES1 mRNA levels are decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the MTRES1 mRNA levels are decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0015] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases MTRES1 protein levels in a cell, fluid or tissue. In some embodiments, the cell is a neural cell such as a central nervous system (CNS) cell. Some examples of CNS cells include neurons, glia, microglia, astrocytes, or oligodendrocytes. In some embodiments, the tissue is CNS or brain tissue. In some embodiments, the MTRES1 protein levels are decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the MTRES1 protein levels are decreased by about 10% or more, as compared to prior to administration. In some embodiments, the MTRES1 protein levels are decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the MTRES1 protein levels are decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the MTRES1 protein levels are decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the MTRES1 protein levels are decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the MTRES1 protein levels are decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0016] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount diminishes a neurological disorder phenotype. The neurological disorder disease may include dementia, Alzheimer's disease, delirium, cognitive decline, vascular dementia, or Parkinson's disease. In some embodiments, the neurological disorder phenotype is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the neurological disorder phenotype is decreased by about 10% or more, as compared to prior to administration. In some embodiments, the neurological disorder phenotype is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the neurological disorder phenotype is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to

administration. In some embodiments, the neurological disorder phenotype is decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the neurological disorder phenotype is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the neurological disorder phenotype is decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0017] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount enhances a protective phenotype against a neurological disorder in the subject. The neurological disorder may include dementia, Alzheimer's disease, delirium, cognitive decline, vascular dementia, or Parkinson's disease. In some embodiments, the protective phenotype is increased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the protective phenotype is increased by about 10% or more, as compared to prior to administration. In some embodiments, the protective phenotype is increased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100% or more, as compared to prior to administration. In some embodiments, the protective phenotype is increased by about 200% or more, about 300% or more, about 400% or more, about 500% or more, about 600% or more, about 700% or more, about 800% or more, about 900% or more, or about 1000% or more, as compared to prior to administration. In some embodiments, the protective phenotype is increased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the protective phenotype is increased by no more than about 10%, as compared to prior to administration. In some embodiments, the protective phenotype is increased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100%, as compared to prior to administration. In some embodiments, the protective phenotype is increased by no more than about 200%, no more than about 300%, no more than about 400%, no more than about 500%, no more than about 600%, no more than about 700%, no more than about 800%, no more than about 900%, or no more than about 1000%, as compared to prior to administration. In some embodiments, the protective phenotype is increased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 250%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000%, or by a range defined by any of the two aforementioned percentages.

[0018] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases a marker of neurodegeneration in the subject. Some example markers of neurodegeneration may include central nervous system (CNS) amyloid plaques, CNS tau accumulation, cerebrospinal fluid (CSF) beta-amyloid 42, CSF tau, CSF phospho-tau,

CSF or plasma neurofilament light chain (NFL), Lewy bodies, or CSF alpha-synuclein. In some embodiments, the marker of neurodegeneration is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the marker of neurodegeneration is decreased by about 10% or more, as compared to prior to administration. In some embodiments, the marker of neurodegeneration is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the marker of neurodegeneration is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the marker of neurodegeneration is decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the marker of neurodegeneration is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the marker of neurodegeneration is decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0019] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases central nervous system (CNS) amyloid plaques in the subject. In some embodiments, the CNS amyloid plaques are decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the CNS amyloid plaques are decreased by about 10% or more, as compared to prior to administration. In some embodiments, the CNS amyloid plaques are decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the CNS amyloid plaques are decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the CNS amyloid plaques are decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the CNS amyloid plaques are decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the CNS amyloid plaques are decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0020] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases central nervous system (CNS) tau accumulation in the subject. In some embodiments, the CNS tau accumulation is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the CNS tau accumulation is decreased by about 10% or more, as compared to prior to

administration. In some embodiments, the CNS tau accumulation is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the CNS tau accumulation is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the CNS tau accumulation is decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the CNS tau accumulation is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the CNS tau accumulation is decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0021] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases cerebrospinal fluid (CSF) beta-amyloid 42 in the subject. In some embodiments, the CSF beta-amyloid 42 is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the CSF beta-amyloid 42 is decreased by about 10% or more, as compared to prior to administration. In some embodiments, the CSF beta-amyloid 42 is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the CSF beta-amyloid 42 is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the CSF beta-amyloid 42 is decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the CSF beta-amyloid 42 is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the CSF beta-amyloid 42 is decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0022] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases cerebrospinal fluid (CSF) tau in the subject. In some embodiments, the CSF tau is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the CSF tau is decreased by about 10% or more, as compared to prior to administration. In some embodiments, the CSF tau is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the CSF tau is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration.

In some embodiments, the CSF tau is decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the CSF tau is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the CSF tau is decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0023] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases cerebrospinal fluid (CSF) tau in the subject. In some embodiments, the CSF phospho-tau is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the CSF phospho-tau is decreased by about 10% or more, as compared to prior to administration. In some embodiments, the CSF phospho-tau is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the CSF phospho-tau is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the CSF phospho-tau is decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the CSF phospho-tau is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the CSF phospho-tau is decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0024] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases cerebrospinal fluid (CSF) alpha-synuclein in the subject. In some embodiments, the CSF alpha-synuclein is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the CSF alpha-synuclein is decreased by about 10% or more, as compared to prior to administration. In some embodiments, the CSF alpha-synuclein is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the CSF alpha-synuclein is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the CSF alpha-synuclein is decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the CSF alpha-synuclein is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In

some embodiments, the CSF alpha-synuclein is decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0025] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases Lewy bodies in the subject. In some embodiments, the Lewy bodies are decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the Lewy bodies are decreased by about 10% or more, as compared to prior to administration. In some embodiments, the Lewy bodies are decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, as compared to prior to administration. In some embodiments, the Lewy bodies are decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the Lewy bodies are decreased by no more than about 10%, as compared to prior to administration. In some embodiments, the Lewy bodies are decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, or no more than about 90%, as compared to prior to administration. In some embodiments, the Lewy bodies are decreased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, or by a range defined by any of the two aforementioned percentages.

[0026] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount increases cognitive function. In some embodiments, the cognitive function is increased by about 2.5% or more, about 5% or more, or about 7.5% or more, as compared to prior to administration. In some embodiments, the cognitive function is increased by about 10% or more, as compared to prior to administration. In some embodiments, the cognitive function is increased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100% or more, as compared to prior to administration. In some embodiments, the cognitive function is increased by about 200% or more, about 300% or more, about 400% or more, about 500% or more, about 600% or more, about 700% or more, about 800% or more, about 900% or more, or about 1000% or more, as compared to prior to administration. In some embodiments, the cognitive function is increased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, as compared to prior to administration. In some embodiments, the cognitive function is increased by no more than about 10%, as compared to prior to administration. In some embodiments, the cognitive function is increased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100%, as compared to prior to administration. In some embodiments, the cognitive function is increased by no more than about 200%, no more than about 300%, no more than about 400%, no more than about 500%, no more than about 600%, no more than about 700%, no more than about 800%, no more than about 900%,

or no more than about 1000%, as compared to prior to administration. In some embodiments, the cognitive function is increased by 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 250%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000%, or by a range defined by any of the two aforementioned percentages.

A. siRNAs

[0027] In some embodiments, the composition comprises an oligonucleotide that targets MTRES1, wherein the oligonucleotide comprises a small interfering RNA (siRNA). In some embodiments, the composition comprises an oligonucleotide that targets MTRES1, wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand.

[0028] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the sense strand is 12-30 nucleosides in length. In some embodiments, the composition comprises a sense strand that is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleosides in length, or a range defined by any of the two aforementioned numbers. The sense strand may be 14-30 nucleosides in length. In some embodiments, the composition comprises an antisense strand is 12-30 nucleosides in length. In some embodiments, the composition comprises an antisense strand that is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleosides in length, or a range defined by any of the two aforementioned numbers. The antisense strand may be 14-30 nucleosides in length.

[0029] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, each strand is independently about 12-30 nucleosides in length, and at least one of the sense strand and the antisense strand comprises a nucleoside sequence comprising about 12-30 contiguous nucleosides of a full-length human MTRES1 mRNA sequence such as SEQ ID NO: 2443. In some embodiments, at least one of the sense strand and the antisense strand comprise a nucleoside sequence comprising at least about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more contiguous nucleosides of one of SEQ ID NO: 2443.

[0030] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, each strand is independently about 12-30 nucleosides in length, and at least one of the sense strand and the antisense strand comprises a nucleoside sequence comprising about 12-30 contiguous nucleosides of a full-length human MTRES1 mRNA sequence such as SEQ ID NO: 2462. In some embodiments, at least one of the sense strand and the antisense strand comprise a nucleoside sequence comprising at least about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more contiguous nucleosides of one of SEQ ID NO: 2462.

[0031] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense

strand, wherein the sense strand and the antisense strand form a double-stranded RNA duplex. In some embodiments, the first base pair of the double-stranded RNA duplex is an AU base pair.

[0032] In some embodiments, the sense strand further comprises a 3' overhang. In some embodiments, the 3' overhang comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosides, or a range of nucleotides defined by any two of the aforementioned numbers. In some embodiments, the 3' overhang comprises 1, 2, or more nucleosides. In some embodiments, the 3' overhang comprises 2 nucleosides. In some embodiments, the sense strand further comprises a 5' overhang. In some embodiments, the 5' overhang comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosides, or a range of nucleotides defined by any two of the aforementioned numbers. In some embodiments, the 5' overhang comprises 1, 2, or more nucleosides. In some embodiments, the 5' overhang comprises 2 nucleosides.

[0033] In some embodiments, the antisense strand further comprises a 3' overhang. In some embodiments, the 3' overhang comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosides, or a range of nucleotides defined by any two of the aforementioned numbers. In some embodiments, the 3' overhang comprises 1, 2, or more nucleosides. In some embodiments, the 3' overhang comprises 2 nucleosides. In some embodiments, the antisense strand further comprises a 5' overhang. In some embodiments, the 5' overhang comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosides, or a range of nucleotides defined by any two of the aforementioned numbers. In some embodiments, the 5' overhang comprises 1, 2, or more nucleosides. In some embodiments, the 5' overhang comprises 2 nucleosides.

[0034] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the siRNA binds with a 19mer in a human MTRES1 mRNA. In some embodiments, the siRNA binds with a 12mer, a 13mer, a 14mer, a 15mer, a 16mer, a 17mer, a 18mer, a 19mer, a 20mer, a 21mer, a 22mer, a 23mer, a 24mer, or a 25mer in a human MTRES1 mRNA.

[0035] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the siRNA binds with a 17mer in a non-human primate MTRES1 mRNA. In some embodiments, the siRNA binds with a 12mer, a 13mer, a 14mer, a 15mer, a 16mer, a 17mer, a 18mer, a 19mer, a 20mer, a 21mer, a 22mer, a 23mer, a 24mer, or a 25mer in a non-human primate MTRES1 mRNA.

[0036] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the siRNA binds with a human MTRES1 mRNA and less than or equal to 20 human off-targets, with no more than 2 mismatches in the antisense strand. In some embodiments, the siRNA binds with a human MTRES1 mRNA and less than or equal to 10 human off-targets, with no more than 2 mismatches in the antisense strand. In some embodiments, the siRNA binds with a human MTRES1 mRNA and less than or equal to 30 human off-targets, with no more than 2 mismatches in the antisense strand. In some embodiments, the siRNA binds with a human MTRES1 mRNA and less than or equal to 40 human off-targets, with no more than 2 mismatches in the antisense strand. In some embodiments, the

siRNA binds with a human MTRES1 mRNA and less than or equal to 50 human off-targets, with no more than 2 mismatches in the antisense strand. In some embodiments, the siRNA binds with a human MTRES1 mRNA and less than or equal to 10 human off-targets, with no more than 3 mismatches in the antisense strand. In some embodiments, the siRNA binds with a human MTRES1 mRNA and less than or equal to 20 human off-targets, with no more than 3 mismatches in the antisense strand. In some embodiments, the siRNA binds with a human MTRES1 mRNA and less than or equal to 30 human off-targets, with no more than 3 mismatches in the antisense strand. In some embodiments, the siRNA binds with a human MTRES1 mRNA and less than or equal to 40 human off-targets, with no more than 3 mismatches in the antisense strand. In some embodiments, the siRNA binds with a human MTRES1 mRNA and less than or equal to 50 human off-targets, with no more than 3 mismatches in the antisense strand.

[0037] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, siRNA binds with a human MTRES1 mRNA target site that does not harbor an SNP, with a minor allele frequency (MAF) greater or equal to 1% (pos. 2-18). In some embodiments, the MAF is greater or equal to about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, or about 20%.

[0038] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the sense strand comprises a nucleoside sequence comprising or consisting of the sequence of any one of SEQ ID NOs: 1-1140, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand comprises a nucleoside sequence comprising or consisting of the sequence of any one of SEQ ID NOs: 1-1140, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand further comprises a 3' overhang. In some embodiments, the 3' overhang comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosides, or a range of nucleotides defined by any two of the aforementioned numbers. In some embodiments, the 3' overhang comprises 1, 2, or more nucleosides. In some embodiments, the 3' overhang comprises 2 nucleosides. In some embodiments, the sense strand further comprises a 5' overhang. In some embodiments, the 5' overhang comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosides, or a range of nucleotides defined by any two of the aforementioned numbers. In some embodiments, the 5' overhang comprises 1, 2, or more nucleosides. In some embodiments, the 5' overhang comprises 2 nucleosides. In some embodiments, the sense strand comprises a nucleoside sequence comprising or consisting of the sequence of any one of SEQ ID NOs: 1-1140, or a nucleic acid sequence thereof having 1 or 2 nucleoside additions at the 3' end. In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the sense strand

comprises a nucleoside sequence comprising or consisting of the sequence of any one of SEQ ID NOs: 1-1140.

[0039] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the antisense strand comprises a nucleoside sequence comprising or consisting of the sequence of any one of SEQ ID NOs: 1141-2280, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises a nucleoside sequence comprising or consisting of the sequence of any one of SEQ ID NOs: 1141-2280, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand further comprises a 3' overhang. In some embodiments, the 3' overhang comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosides, or a range of nucleotides defined by any two of the aforementioned numbers. In some embodiments, the 3' overhang comprises 1, 2, or more nucleosides. In some embodiments, the 3' overhang comprises 2 nucleosides. In some embodiments, the antisense strand further comprises a 5' overhang. In some embodiments, the 5' overhang comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleosides, or a range of nucleotides defined by any two of the aforementioned numbers. In some embodiments, the 5' overhang comprises 1, 2, or more nucleosides. In some embodiments, the 5' overhang comprises 2 nucleosides. In some embodiments, the antisense strand comprises a nucleoside sequence comprising or consisting of the sequence of any one of SEQ ID NOs: 1141-2280, or a nucleic acid sequence thereof having 1 or 2 nucleoside additions at the 3' end. In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the antisense strand comprises a nucleoside sequence comprising or consisting of the sequence of any one of SEQ ID NOs: 1141-2280.

[0040] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in any one of **Tables 2-7**, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in any one of **Tables 2-7**, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in any one of **Tables 2-7**. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more internucleoside linkages and/or one or more nucleoside modifications.

[0041] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 11B**, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 11B**, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 11B**. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more

internucleoside linkages and/or one or more nucleoside modifications. The siRNA may include a moiety such as a lipid moiety or a GalNAc moiety.

[0042] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 13B**, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 13B**, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 13B**. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more internucleoside linkages and/or one or more nucleoside modifications. The siRNA may include a moiety such as a lipid moiety or a GalNAc moiety.

[0043] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 15B**, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 15B**, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 15B**. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more internucleoside linkages and/or one or more nucleoside modifications. The siRNA may include a moiety such as a lipid moiety or a GalNAc moiety.

[0044] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset A, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset A, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset A. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more internucleoside linkages and/or one or more nucleoside modifications.

[0045] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset B, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset B, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset B. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more internucleoside linkages and/or one or more nucleoside modifications.

[0046] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset C, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions,

additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset C, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset C. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more internucleoside linkages and/or one or more nucleoside modifications.

[0047] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset D, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset D, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset D. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more internucleoside linkages and/or one or more nucleoside modifications.

[0048] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset E, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset E, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset E. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more internucleoside linkages and/or one or more nucleoside modifications.

[0049] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset F, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset F, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA of subset F. In some embodiments, the siRNA is cross-reactive with a non-human primate (NHP) MTRES1 mRNA. The siRNA may include one or more internucleoside linkages and/or one or more nucleoside modifications.

[0050] In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2576. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2576, at least 80% identical to SEQ ID NO: 2576, at least 85% identical to SEQ ID NO: 2576, at least 90% identical to SEQ ID NO: 2576, or at least 95% identical to SEQ ID NO: 2576. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO 2576, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2576, or a sense strand sequence thereof having 1 or 2 nucleoside

substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2576. The sense strand may comprise any modifications or modification pattern described herein. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2638. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2638, at least 80% identical to SEQ ID NO: 2638, at least 85% identical to SEQ ID NO: 2638, at least 90% identical to SEQ ID NO: 2638, or at least 95% identical to SEQ ID NO: 2638. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO 2638, or an antisense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO: 2638, or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2638. The antisense strand may comprise any modifications or modification pattern described herein. The antisense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety.

[0051] In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2582. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2582, at least 80% identical to SEQ ID NO: 2582, at least 85% identical to SEQ ID NO: 2582, at least 90% identical to SEQ ID NO: 2582, or at least 95% identical to SEQ ID NO: 2582. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO 2582, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2582, or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2582. The sense strand may comprise any modifications or modification pattern described herein. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2644. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2644, at least 80% identical to SEQ ID NO: 2644, at least 85% identical to SEQ ID NO: 2644, at least 90% identical to SEQ ID NO: 2644, or at least 95% identical to SEQ ID NO: 2644. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO 2644, or an antisense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO: 2644, or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2644. The antisense strand may comprise any modifications or modification pattern described herein. The antisense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety.

[0052] In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2583. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2583, at least 80% identical to SEQ ID NO: 2583, at least 85% identical to SEQ ID NO: 2583, at least 90% identical to SEQ ID NO: 2583, or at least 95% identical to SEQ ID NO: 2583. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO 2583, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2583, or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2583. The sense strand may comprise any modifications or modification pattern described herein. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2645. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2645, at least 80% identical to SEQ ID NO: 2645, at least 85% identical to SEQ ID NO: 2645, at least 90% identical to SEQ ID NO: 2645, or at least 95% identical to SEQ ID NO: 2645. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO 2645, or an antisense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO: 2645, or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2645. The antisense strand may comprise any modifications or modification pattern described herein. The antisense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety.

[0053] In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2584. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2584, at least 80% identical to SEQ ID NO: 2584, at least 85% identical to SEQ ID NO: 2584, at least 90% identical to SEQ ID NO: 2584, or at least 95% identical to SEQ ID NO: 2584. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO 2584, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2584, or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2584. The sense strand may comprise any modifications or modification pattern described herein. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2646. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2646, at least 80% identical to SEQ ID NO: 2646, at least 85% identical to SEQ ID NO: 2646, at least 90% identical to SEQ ID NO:

2646, or at least 95% identical to SEQ ID NO: 2646. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO 2646, or an antisense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO: 2646, or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2646. The antisense strand may comprise any modifications or modification pattern described herein. The antisense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety.

[0054] In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2604. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2604, at least 80% identical to SEQ ID NO: 2604, at least 85% identical to SEQ ID NO: 2604, at least 90% identical to SEQ ID NO: 2604, or at least 95% identical to SEQ ID NO: 2604. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO 2604, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2604, or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2604. The sense strand may comprise any modifications or modification pattern described herein. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2666. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2666, at least 80% identical to SEQ ID NO: 2666, at least 85% identical to SEQ ID NO: 2666, at least 90% identical to SEQ ID NO: 2666, or at least 95% identical to SEQ ID NO: 2666. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO 2666, or an antisense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO: 2666, or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2666. The antisense strand may comprise any modifications or modification pattern described herein. The antisense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety.

B. ASOs

[0055] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an antisense oligonucleotide (ASO). In some embodiments, the ASO is 12-30 nucleosides in length. In some embodiments, the ASO is 14-30 nucleosides in length. In some embodiments, the ASO is at least about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleosides in length, or a range defined by any of the

two aforementioned numbers. In some embodiments, the ASO is 15-25 nucleosides in length. In some embodiments, the ASO is 20 nucleosides in length.

[0056] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an ASO about 12-30 nucleosides in length and comprising a nucleoside sequence complementary to about 12-30 contiguous nucleosides of a full-length human MTRES1 mRNA sequence such as SEQ ID NO: 2443; wherein (i) the oligonucleotide comprises a modification comprising a modified nucleoside and/or a modified internucleoside linkage, and/or (ii) the composition comprises a pharmaceutically acceptable carrier. In some embodiments, the ASO comprise a nucleoside sequence complementary to at least about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more contiguous nucleosides of one of SEQ ID NO: 2443.

[0057] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an ASO about 12-30 nucleosides in length and comprising a nucleoside sequence complementary to about 12-30 contiguous nucleosides of a full-length human MTRES1 mRNA sequence such as SEQ ID NO: 2462; wherein (i) the oligonucleotide comprises a modification comprising a modified nucleoside and/or a modified internucleoside linkage, and/or (ii) the composition comprises a pharmaceutically acceptable carrier. In some embodiments, the ASO comprise a nucleoside sequence complementary to at least about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more contiguous nucleosides of one of SEQ ID NO: 2462.

C. Modification patterns

[0058] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a modification comprising a modified nucleoside and/or a modified internucleoside linkage, and/or (ii) the composition comprises a pharmaceutically acceptable carrier. In some embodiments, the oligonucleotide comprises a modification comprising a modified nucleoside and/or a modified internucleoside linkage. In some embodiments, the oligonucleotide comprises a modified internucleoside linkage. In some embodiments, the modified internucleoside linkage comprises alkylphosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester, or a combination thereof. In some embodiments, the modified internucleoside linkage comprises one or more phosphorothioate linkages. A phosphorothioate may include a nonbridging oxygen atom in a phosphate backbone of the oligonucleotide that is replaced by sulfur. Modified internucleoside linkages may be included in siRNAs or ASOs. Benefits of the modified internucleoside linkage may include decreased toxicity or improved pharmacokinetics.

[0059] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a modified internucleoside linkage, wherein the oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 modified internucleoside linkages, or a range of modified internucleoside linkages defined by any two of the aforementioned numbers. In some embodiments, the oligonucleotide comprises no more than 18 modified internucleoside linkages. In some embodiments, the oligonucleotide comprises no more than 20 modified

internucleoside linkages. In some embodiments, the oligonucleotide comprises 2 or more modified internucleoside linkages, 3 or more modified internucleoside linkages, 4 or more modified internucleoside linkages, 5 or more modified internucleoside linkages, 6 or more modified internucleoside linkages, 7 or more modified internucleoside linkages, 8 or more modified internucleoside linkages, 9 or more modified internucleoside linkages, 10 or more modified internucleoside linkages, 11 or more modified internucleoside linkages, 12 or more modified internucleoside linkages, 13 or more modified internucleoside linkages, 14 or more modified internucleoside linkages, 15 or more modified internucleoside linkages, 16 or more modified internucleoside linkages, 17 or more modified internucleoside linkages, 18 or more modified internucleoside linkages, 19 or more modified internucleoside linkages, or 20 or more modified internucleoside linkages.

[0060] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises the modified nucleoside. In some embodiments, the modified nucleoside comprises a locked nucleic acid (LNA), hexitol nucleic acid (HLA), cyclohexene nucleic acid (CeNA), 2'-methoxyethyl, 2'-O-alkyl, 2'-O-allyl, 2'-fluoro, or 2'-deoxy, or a combination thereof. In some embodiments, the modified nucleoside comprises a LNA. In some embodiments, the modified nucleoside comprises a 2',4' constrained ethyl nucleic acid. In some embodiments, the modified nucleoside comprises HLA. In some embodiments, the modified nucleoside comprises CeNA. In some embodiments, the modified nucleoside comprises a 2'-methoxyethyl group. In some embodiments, the modified nucleoside comprises a 2'-O-alkyl group. In some embodiments, the modified nucleoside comprises a 2'-O-allyl group. In some embodiments, the modified nucleoside comprises a 2'-fluoro group. In some embodiments, the modified nucleoside comprises a 2'-deoxy group. In some embodiments, the modified nucleoside comprises a 2'-O-methyl nucleoside, 2'-deoxyfluoro nucleoside, 2'-O-N-methylacetamido (2'-O-NMA) nucleoside, a 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE) nucleoside, 2'-O-aminopropyl (2'-O-AP) nucleoside, or 2'-ara-F, or a combination thereof. In some embodiments, the modified nucleoside comprises a 2'-O-methyl nucleoside. In some embodiments, the modified nucleoside comprises a 2'-deoxyfluoro nucleoside. In some embodiments, the modified nucleoside comprises a 2'-O-NMA nucleoside. In some embodiments, the modified nucleoside comprises a 2'-O-DMAEOE nucleoside. In some embodiments, the modified nucleoside comprises a 2'-O-aminopropyl (2'-O-AP) nucleoside. In some embodiments, the modified nucleoside comprises 2'-ara-F. In some embodiments, the modified nucleoside comprises one or more 2' fluoro modified nucleosides. In some embodiments, the modified nucleoside comprises a 2' O-alkyl modified nucleoside. Benefits of the modified nucleoside may include decreased toxicity or improved pharmacokinetics.

[0061] In some embodiments, the oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 modified nucleosides, or a range of nucleosides defined by any two of the aforementioned numbers. In some embodiments, the oligonucleotide comprises no more than 19 modified nucleosides. In some embodiments, the oligonucleotide comprises no more than 21 modified nucleosides. In some embodiments, the oligonucleotide comprises 2 or more modified nucleosides, 3 or more modified nucleosides, 4 or more modified nucleosides, 5 or more modified nucleosides, 6 or more modified

nucleosides, 7 or more modified nucleosides, 8 or more modified nucleosides, 9 or more modified nucleosides, 10 or more modified nucleosides, 11 or more modified nucleosides, 12 or more modified nucleosides, 13 or more modified nucleosides, 14 or more modified nucleosides, 15 or more modified nucleosides, 16 or more modified nucleosides, 17 or more modified nucleosides, 18 or more modified nucleosides, 19 or more modified nucleosides, 20 or more modified nucleosides, or 21 or more modified nucleosides.

[0062] Some embodiments include an oligonucleotide comprising: a sense strand having a 5' end, a 3' end and a region of complementarity with an antisense strand; an antisense strand having a 5' end, a 3' end and a region of complementarity with the sense strand and a region of complementarity to an mRNA target; an overhang region at the 3' end of the sense strand having at least 3 contiguous phosphorothioated nucleotides; and an overhang region at the 3' end of the antisense strand having at least 3 contiguous phosphorothioated nucleotides.

[0063] Some embodiments include an oligonucleotide comprising: a sense strand having a 5' end, a 3' end and a region of complementarity with an antisense strand; an antisense strand having a 5' end, a 3' end and a region of complementarity with the sense strand and a region of complementarity to an mRNA target; and an overhang region at the 3' end of the sense strand having at least 3 contiguous phosphorothioated nucleotides.

[0064] In some embodiments, the oligonucleotide includes two to eight oligonucleotides attached through a linker. The linker may be hydrophobic. In some embodiments, the oligonucleotides independently have substantial chemical stabilization (e.g., at least 40% of the constituent bases are chemically-modified). In some embodiments, the oligonucleotides have full chemical stabilization (i.e., all of the constituent bases are chemically-modified). In some embodiments, the oligonucleotide includes one or more single-stranded phosphorothioated tails, each independently having two to twenty nucleotides. In some embodiments, each single-stranded tail has eight to ten nucleotides.

[0065] In certain embodiments, a compound (e.g. moiety attached to the oligonucleotide) includes three properties: (1) a branched structure, (2) full metabolic stabilization, and (3) the presence of a single-stranded tail comprising phosphorothioate linkers. In a particular embodiment, a compound has 2 or 3 branches. The increased overall size of the branched structures promote increased uptake. Also, without being bound by a particular theory of activity, multiple adjacent branches (e.g., 2 or 3) allow each branch to act cooperatively and thus dramatically enhance rates of internalization, trafficking and release. The compound may include an oligonucleotide described herein, as part of the compound.

[0066] In certain embodiments, a compound includes the following properties: (1) two or more branched oligonucleotides linked via a non-natural linker (2) substantially chemically stabilized, e.g., wherein more than 40%, optimally 100%, of oligonucleotides are chemically modified (e.g., no RNA and optionally no DNA); and (3) phosphorothioated single oligonucleotides containing at least 3, optimally 5-20 phosphorothioated bonds.

[0067] In some embodiments, the oligonucleotide comprises a phosphate at a 5' end. In some embodiments, the oligonucleotide comprises a phosphate at a 3' end. In some embodiments, the

oligonucleotide comprises a phosphate mimic at a 5' end. In some embodiments, the oligonucleotide comprises a phosphate mimic at a 3' end.

[0068] The oligonucleotide may include purines. Examples of purines include adenine (A) or guanine (G), or modified versions thereof. The oligonucleotide may include pyrimidines. Examples of pyrimidines include cytosine (C), thymine (T), or uracil (U), or modified versions thereof.

[0069] In some embodiments, purines of the oligonucleotide comprise 2' fluoro modified purines. In some embodiments, purines of the oligonucleotide comprise 2'-O-methyl modified purines. In some embodiments, purines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some embodiments, all purines of the oligonucleotide comprise 2' fluoro modified purines. In some embodiments, all purines of the oligonucleotide comprise 2'-O-methyl modified purines. In some embodiments, all purines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. 2'-O-methyl may include 2' O-methyl. Where 2'-O-methyl modifications are described, it is contemplated that a 2'-methyl modification may be included, and vice versa.

[0070] In some embodiments, pyrimidines of the oligonucleotide comprise 2' fluoro modified pyrimidines. In some embodiments, pyrimidines of the oligonucleotide comprise 2'-O-methyl modified pyrimidines. In some embodiments, pyrimidines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, all pyrimidines of the oligonucleotide comprise 2' fluoro modified pyrimidines. In some embodiments, all pyrimidines of the oligonucleotide comprise 2'-O-methyl modified pyrimidines. In some embodiments, all pyrimidines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines.

[0071] In some embodiments, purines of the oligonucleotide comprise 2' fluoro modified purines, and pyrimidines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, purines of the oligonucleotide comprise 2'-O-methyl modified purines, and pyrimidines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, purines of the oligonucleotide comprise 2' fluoro modified purines, and pyrimidines of the oligonucleotide comprise 2'-O-methyl modified pyrimidines. In some embodiments, purines of the oligonucleotide comprise 2'-O-methyl modified purines, and pyrimidines of the oligonucleotide comprise 2' fluoro modified pyrimidines. In some embodiments, pyrimidines of the oligonucleotide comprise 2' fluoro modified pyrimidines, and purines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some embodiments, pyrimidines of the oligonucleotide comprise 2'-O-methyl modified pyrimidines, and purines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some embodiments, pyrimidines of the oligonucleotide comprise 2' fluoro modified pyrimidines, and purines of the oligonucleotide comprise 2'-O-methyl modified purines. In some embodiments, pyrimidines of the oligonucleotide comprise 2'-O-methyl modified pyrimidines, and purines of the oligonucleotide comprise 2' fluoro modified purines.

[0072] In some embodiments, all purines of the oligonucleotide comprise 2' fluoro modified purines, and all pyrimidines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, all purines of the oligonucleotide comprise 2'-O-methyl modified

purines, and all pyrimidines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, all purines of the oligonucleotide comprise 2' fluoro modified purines, and all pyrimidines of the oligonucleotide comprise 2'-O-methyl modified pyrimidines. In some embodiments, all purines of the oligonucleotide comprise 2'-O-methyl modified purines, and all pyrimidines of the oligonucleotide comprise 2' fluoro modified pyrimidines. In some embodiments, all pyrimidines of the oligonucleotide comprise 2' fluoro modified pyrimidines, and all purines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some embodiments, all pyrimidines of the oligonucleotide comprise 2'-O-methyl modified pyrimidines, and all purines of the oligonucleotide comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some embodiments, all pyrimidines of the oligonucleotide comprise 2' fluoro modified pyrimidines, and all purines of the oligonucleotide comprise 2'-O-methyl modified purines. In some embodiments, all pyrimidines of the oligonucleotide comprise 2'-O-methyl modified pyrimidines, and all purines of the oligonucleotide comprise 2' fluoro modified purines.

[0073] In some cases, the oligonucleotide comprises a particular modification pattern. In some embodiments, position 9 counting from the 5' end of the of a strand of the oligonucleotide may have a 2'F modification. In some embodiments, when position 9 of a strand of the oligonucleotide is a pyrimidine, then all purines in a strand of the oligonucleotide have a 2'OMe modification. In some embodiments, when position 9 is the only pyrimidine between positions 5 and 11 of the sense stand, then position 9 is the only position with a 2'F modification in a strand of the oligonucleotide. In some embodiments, when position 9 and only one other base between positions 5 and 11 of a strand of the oligonucleotide are pyrimidines, then both of these pyrimidines are the only two positions with a 2'F modification in a strand of the oligonucleotide. In some embodiments, when position 9 and only two other bases between positions 5 and 11 of a strand of the oligonucleotide are pyrimidines, and those two other pyrimidines are in adjacent positions so that there would be not three 2'F modifications in a row, then any combination of 2'F modifications can be made that give three 2'F modifications in total. In some embodiments, when there are more than 2 pyrimidines between positions 5 and 11 of a strand of the oligonucleotide, then all combinations of pyrimidines having the 2'F modification are allowed that have three to five 2'F modifications in total, provided that a strand of the oligonucleotide does not have three 2'F modifications in a row. In some cases, a strand of the oligonucleotide of any of the siRNAs comprises a modification pattern which conforms to any or all of these a strand of the oligonucleotide rules.

[0074] In some embodiments, when position 9 of a strand of the oligonucleotide is a purine, then all purines in a strand of the oligonucleotide have a 2'OMe modification. In some embodiments, when position 9 is the only purine between positions 5 and 11 of the sense stand, then position 9 is the only position with a 2'F modification in a strand of the oligonucleotide. In some embodiments, when position 9 and only one other base between positions 5 and 11 of a strand of the oligonucleotide are purines, then both of these purines are the only two positions with a 2'F modification in a strand of the oligonucleotide. In some embodiments, when position 9 and only two other bases between positions 5 and 11 of a strand of the oligonucleotide are purines, and those two other purines are in adjacent positions so that there would

be not three 2' F modifications in a row, then any combination of 2' F modifications can be made that give three 2' F modifications in total. In some embodiments, when there are more than 2 purines between positions 5 and 11 of a strand of the oligonucleotide, then all combinations of purines having the 2' F modification are allowed that have three to five 2' F modifications in total, provided that a strand of the oligonucleotide does not have three 2' F modifications in a row. In some cases, a strand of the oligonucleotide of any of the siRNAs comprises a modification pattern which conforms to any or all of these a strand of the oligonucleotide rules.

[0075] In some cases, position 9 of a strand of the oligonucleotide can be a 2' deoxy. In these cases, 2' F and 2' OMe modifications may occur at the other positions of a strand of the oligonucleotide. In some cases, a strand of the oligonucleotide of any of the siRNAs comprises a modification pattern which conforms to these a strand of the oligonucleotide rules.

[0076] In some embodiments, position nine of the sense strand comprises a 2' fluoro-modified pyrimidine. In some embodiments, all purines of the sense strand comprise 2' -O-methyl modified purines. In some embodiments, 1, 2, 3, 4, or 5 pyrimidines between positions 5 and 11 comprise a 2' fluoro-modified pyrimidine, provided there are not three 2' fluoro-modified pyrimidines in a row. In some embodiments, the odd-numbered positions of the antisense strand comprise 2' -O-methyl modified nucleotides. In some embodiments, the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides and unmodified deoxyribonucleotide. In some embodiments, the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides, 2' -O-methyl modified nucleotides and unmodified deoxyribonucleotide. In some embodiments, position nine of the sense strand comprises a 2' fluoro-modified pyrimidine; all purines of the sense strand comprises 2' -O-methyl modified purines; 1, 2, 3, 4, or 5 pyrimidines between positions 5 and 11 comprise a 2' fluoro-modified pyrimidine, provided there are not three 2' fluoro-modified pyrimidines in a row; the odd-numbered positions of the antisense strand comprise 2' -O-methyl modified nucleotides; and the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides and unmodified deoxyribonucleotides.

[0077] In some embodiments, position nine of the sense strand comprises a 2' fluoro-modified purine. In some embodiments, all pyrimidines of the sense strand comprise 2' -O-methyl modified purines. In some embodiments, 1, 2, 3, 4, or 5 purines between positions 5 and 11 comprise a 2' fluoro-modified purine, provided there are not three 2' fluoro-modified purine in a row. In some embodiments, the odd-numbered positions of the antisense strand comprise 2' -O-methyl modified nucleotides. In some embodiments, the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides and unmodified deoxyribonucleotide. In some embodiments, the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides, 2' -O-methyl modified nucleotides and unmodified deoxyribonucleotide. In some embodiments, position nine of the sense strand comprises a 2' fluoro-modified purine; all pyrimidine of the sense strand comprises 2' -O-methyl modified pyrimidines; 1, 2, 3, 4, or 5 purines between positions 5 and 11 comprise a 2' fluoro-modified purines, provided there are not three 2' fluoro-modified purines in a row; the odd-numbered positions of the antisense strand comprise 2' -

O-methyl modified nucleotides; and the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides and unmodified deoxyribonucleotides. In some embodiments, there are not three 2' fluoro-modified purines in a row. In some embodiments, there are not three 2' fluoro-modified pyrimidines in a row.

[0078] In some embodiments, position nine of the sense strand comprises an unmodified deoxyribonucleotide. In some embodiments, positions 5, 7, and 8 of the sense strand comprise 2' fluoro-modified nucleotides. In some embodiments, all pyrimidines in positions 10 to 21 of the sense strand comprise 2'-O-methyl modified pyrimidines and all purines in positions 10 to 21 of the comprise 2'-O-methyl modified purines or 2' fluoro-modified purines. In some embodiments, the odd-numbered positions of the antisense strand comprise 2'-O-methyl modified nucleotides. In some embodiments, the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides and unmodified deoxyribonucleotides. In some embodiments, the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides, 2'-O-methyl modified nucleotides and unmodified deoxyribonucleotides. In some embodiments, position nine of the sense strand comprises an unmodified deoxyribonucleotide; positions 5, 7, and 8 of the sense strand comprise 2' fluoro-modified nucleotides; all pyrimidines in positions 10 to 21 of the sense strand comprise 2'-O-methyl modified pyrimidines and all purines in positions 10 to 21 of the comprise 2'-O-methyl modified purines or 2' fluoro-modified purines; the odd-numbered positions of the antisense strand comprise 2'-O-methyl modified nucleotides; and the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides and unmodified deoxyribonucleotides.


[0079] In some embodiments, position nine of the sense strand comprises an unmodified deoxyribonucleotide. In some embodiments, positions 5, 7, and 8 of the sense strand comprise 2' fluoro-modified nucleotides. In some embodiments, all purines in positions 10 to 21 of the sense strand comprise 2'-O-methyl modified purines and all pyrimidines in positions 10 to 21 of the comprise 2'-O-methyl modified pyrimidines or 2' fluoro-modified pyrimidines. In some embodiments, the odd-numbered positions of the antisense strand comprise 2'-O-methyl modified nucleotides. In some embodiments, the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides and unmodified deoxyribonucleotides. In some embodiments, the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides, 2'-O-methyl modified nucleotides and unmodified deoxyribonucleotides. In some embodiments, position nine of the sense strand comprises an unmodified deoxyribonucleotide; positions 5, 7, and 8 of the sense strand comprise 2' fluoro-modified nucleotides; all purines in positions 10 to 21 of the sense strand comprise 2'-O-methyl modified purines and all pyrimidines in positions 10 to 21 of the comprise 2'-O-methyl modified pyrimidines or 2' fluoro-modified pyrimidines; the odd-numbered positions of the antisense strand comprise 2'-O-methyl modified nucleotides; and the even-numbered positions of the antisense strand comprise 2' fluoro-modified nucleotides and unmodified deoxyribonucleotide.

[0080] In some embodiments, the moiety includes a negatively charged group attached at a 5' end of the oligonucleotide. This may be referred to as a 5'-end group. In some embodiments, the negatively charged

group is attached at a 5' end of an antisense strand of an siRNA disclosed herein. The 5'-end group may be or include a 5'-end phosphorothioate, 5'-end phosphorodithioate, 5'-end vinylphosphonate (5'-VP), 5'-end methylphosphonate, 5'-end cyclopropyl phosphonate, or a 5'-deoxy-5'-C-malonyl. The 5'-end group may comprise 5'-VP. In some embodiments, the 5'-VP comprises a trans-vinylphosphate or cis-vinylphosphate. The 5'-end group may include an extra 5' phosphate. A combination of 5'-end groups may be used.

[0081] In some embodiments, the oligonucleotide includes a negatively charged group. The negatively charged group may aid in cell or tissue penetration. The negatively charged group may be attached at a 5' or 3' end (e.g. a 5' end) of the oligonucleotide. This may be referred to as an end group. The end group may be or include a phosphorothioate, phosphorodithioate, vinylphosphonate, methylphosphonate, cyclopropyl phosphonate, or a deoxy-C-malonyl. The end group may include an extra 5' phosphate such as an extra 5' phosphate. A combination of end groups may be used.

[0082] In some embodiments, the oligonucleotide includes a phosphate mimic. In some embodiments, the phosphate mimic comprises vinyl phosphonate. In some embodiments, the vinyl phosphonate comprises a trans-vinylphosphate. In some embodiments, the vinyl phosphonate comprises a cis-vinylphosphate. An example of a nucleotide that includes a vinyl phosphonate is shown below.



5' vinylphosphonate 2' O Methyl Uridine

[0083] In some embodiments, the vinyl phosphonate increases the stability of the oligonucleotide. In some embodiments, the vinyl phosphonate increases the accumulation of the oligonucleotide in tissues. In some embodiments, the vinyl phosphonate protects the oligonucleotide from an exonuclease or a phosphatase. In some embodiments, the vinyl phosphonate improves the binding affinity of the oligonucleotide with the siRNA processing machinery.

[0084] In some embodiments, the oligonucleotide includes 1 vinyl phosphonate. In some embodiments, the oligonucleotide includes 2 vinyl phosphonates. In some embodiments, the oligonucleotide includes 3 vinyl phosphonates. In some embodiments, the oligonucleotide includes 4 vinyl phosphonates. In some embodiments, the antisense strand of the oligonucleotide comprises a vinyl phosphonate at the 5' end. In some embodiments, the antisense strand of the oligonucleotide comprises a vinyl phosphonate at the 3' end. In some embodiments, the sense strand of the oligonucleotide comprises a vinyl phosphonate at the 5' end. In some embodiments, the sense strand of the oligonucleotide comprises a vinyl phosphonate at the 3' end.

1. *Hydrophobic moieties*

[0085] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a moiety attached at a 3' or 5' terminus of the oligonucleotide. Examples of moieties include a hydrophobic moiety or a sugar moiety, or a combination thereof. In some embodiments, the oligonucleotide is an siRNA having a sense strand, and the moiety is attached to a 5' end of the sense strand. In some embodiments, the oligonucleotide is an siRNA having a sense strand, and the moiety is attached to a 3' end of the sense strand. In some embodiments, the oligonucleotide is an siRNA having an antisense strand, and the moiety is attached to a 5' end of the antisense strand. In some embodiments, the oligonucleotide is an siRNA having an antisense strand, and the moiety is attached to a 3' end of the antisense strand. In some embodiments, the oligonucleotide is an ASO, and the moiety is attached to a 5' end of the ASO. In some embodiments, the oligonucleotide is an ASO, and the moiety is attached to a 3' end of the ASO.

[0086] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a hydrophobic moiety. The hydrophobic moiety may be attached at a 3' or 5' terminus of the oligonucleotide. The hydrophobic moiety may include a lipid such as a fatty acid. The hydrophobic moiety may include a hydrocarbon. The hydrocarbon may be linear. The hydrocarbon may be non-linear. The hydrophobic moiety may include a lipid moiety or a cholesterol moiety, or a combination thereof.

[0087] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a lipid attached at a 3' or 5' terminus of the oligonucleotide. In some embodiments, the lipid comprises cholesterol, myristoyl, palmitoyl, stearoyl, lithocholoyl, docosanoyl, docosahexaenoyl, myristyl, palmityl stearyl, or α -tocopherol, or a combination thereof.

[0088] In some embodiments, the oligonucleotide comprises a lipophilic moiety attached at a 3' or 5' terminus of the oligonucleotide. In some embodiments, the lipophilic moiety comprises cholesterol, retinoic acid, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, a heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholonic acid, ibuprofen, naproxen, dimethoxytrityl, or phenoxazine, or a combination thereof. The lipophilic moiety may include a steroid such as cholesterol. The lipophilic moiety may include retinoic acid. The lipophilic moiety may include cholic acid. The lipophilic moiety may include adamantane acetic acid. The lipophilic moiety may include 1-pyrene butyric acid. The lipophilic moiety may include dihydrotestosterone. The lipophilic moiety may include 1,3-bis-O(hexadecyl)glycerol. The lipophilic moiety may include geranyloxyhexanol. The lipophilic moiety may include hexadecylglycerol. The lipophilic moiety may include borneol. The lipophilic moiety may include menthol. The lipophilic moiety may include 1,3-propanediol. The lipophilic moiety may include a heptadecyl group. The lipophilic moiety may include palmitic acid. The lipophilic moiety may include myristic acid. The lipophilic moiety may include O3-(oleoyl)lithocholic acid. The lipophilic moiety may include O3-(oleoyl)cholonic acid. The lipophilic

moiety may include ibuprofen. The lipophilic moiety may include naproxen. The lipophilic moiety may include dimethoxytrityl. The lipophilic moiety may include phenoxazine.

[0089] In some embodiments, the lipophilic moiety comprises a hydrocarbon chain. The hydrocarbon chain may comprise or consist of a C4-C30 hydrocarbon chain. In some embodiments, the lipophilic moiety comprises a lipid.

[0090] In some embodiments, the oligonucleotide includes one or more lipophilic monomers, containing one or more lipophilic moieties, conjugated to one or more positions on at least one strand of the oligonucleotide, optionally via a linker or carrier. For instance, some embodiments provide an oligonucleotide comprising: an antisense strand which is complementary to a target gene; a sense strand which is complementary to said antisense strand; and one or more lipophilic monomers, containing one or more lipophilic moieties, conjugated to one or more positions on at least one strand, optionally via a linker or carrier. In some embodiments, the lipophilicity of the lipophilic moiety, measured by octanol-water partition coefficient, logP, exceeds 0.

[0091] In some embodiments, the lipophilic moiety is an aliphatic, cyclic such as alicyclic, or polycyclic such as polyalicyclic compound, such as a steroid (e.g., steroid), a linear or branched aliphatic hydrocarbon, or an aromatic. Exemplary lipophilic moieties may include lipid, cholesterol, retinoic acid, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3- (oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, ibuprofen, naproxen, dimethoxytrityl, or phenoxazine. Suitable lipophilic moieties may also include those containing a saturated or unsaturated C4-C30 hydrocarbon chain (e.g., C4-C30 alkyl or alkenyl), and an optional functional group selected from the group consisting of hydroxyl, amine, carboxylic acid, sulfonate, phosphate, thiol, azide, and alkyne. The functional group may be useful to attach the lipophilic moiety to the oligonucleotide. In some embodiments, the lipophilic moiety contains a saturated or unsaturated C6-C18 hydrocarbon chain (e.g., a linear C6-C18 alkyl or alkenyl). In some embodiments, the lipophilic moiety contains a saturated or unsaturated C16 hydrocarbon chain (e.g., a linear C16 alkyl or alkenyl). In some embodiments, the lipophilic moiety contains two or more carbon-carbon double bonds.

[0092] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a hydrophobic moiety. The hydrophobic moiety may be attached at a 3' or 5' terminus of the oligonucleotide. The hydrophobic moiety may include a lipid such as a fatty acid. The hydrophobic moiety may include a hydrocarbon. The hydrocarbon may be linear. The hydrocarbon may be non-linear. The hydrophobic moiety may include a lipid moiety or a cholesterol moiety, or a combination thereof.


[0093] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a lipid attached at a 3' or 5' terminus of the oligonucleotide. In some embodiments, the lipid comprises cholesterol, myristoyl, palmitoyl, stearyl, lithocholoyl, docosanoyl, docosahexaenoyl, myristyl, palmityl, stearyl, or α -tocopherol, or a combination thereof.

[0094] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a hydrophobic ligand or moiety. In some embodiments, the hydrophobic ligand or moiety comprises cholesterol. In some embodiments, the hydrophobic ligand or moiety comprises a cholesterol derivative. In some embodiments, the hydrophobic ligand or moiety is attached at a 3' terminus of the oligonucleotide. In some embodiments, the hydrophobic ligand or moiety is attached at a 5' terminus of the oligonucleotide. In some embodiments, the composition comprises a sense strand, and the hydrophobic ligand or moiety is attached to the sense strand (e.g. attached to a 5' end of the sense strand, or attached to a 3' end of the sense strand). In some embodiments, the composition comprises an antisense strand, and the hydrophobic ligand or moiety is attached to the antisense strand (e.g. attached to a 5' end of the antisense strand, or attached to a 3' end of the antisense strand). In some embodiments, the composition comprises a hydrophobic ligand or moiety attached at a 3' or 5' terminus of the oligonucleotide.


[0095] In some embodiments, a hydrophobic moiety is attached to the oligonucleotide (e.g. a sense strand and/or an antisense strand of a siRNA). In some embodiments, a hydrophobic moiety is attached at a 3' terminus of the oligonucleotide. In some embodiments, a hydrophobic moiety is attached at a 5' terminus of the oligonucleotide. In some embodiments, the hydrophobic moiety comprises cholesterol. In some embodiments, the hydrophobic moiety includes a cyclohexanyl.

[0096] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a lipid attached at a 3' or 5' terminus of the oligonucleotide. In some embodiments, a lipid is attached at a 3' terminus of the oligonucleotide. In some embodiments, a lipid is attached at a 5' terminus of the oligonucleotide. In some embodiments, the lipid comprises cholesterol, myristoyl, palmitoyl, stearoyl, lithocholoyl, docosanoyl, docosahexaenoyl, myristyl, palmityl, stearyl, or α -tocopherol, or a combination thereof. In some embodiments, the lipid comprises stearyl, lithocholoyl, docosanyl, docosahexaenyl, or myristyl. In some embodiments, the lipid comprises cholesterol. In some embodiments, the lipid includes a sterol such as cholesterol. In some embodiments, the lipid comprises stearyl, t-butylphenol, n-butylphenol, octylphenol, dodecylphenol, phenyl n-dodecyl, octadecylbenzamide, hexadecylbenzamide, or octadecylcyclohexyl. In some embodiments, the lipid comprises phenyl para C12.

[0097] In some embodiments, the oligonucleotide comprises any aspect of the following structure:




. In some embodiments, the oligonucleotide comprises any



aspect of the following structure:

. In some

embodiments, the oligonucleotide comprises any aspect of the following structure:












. In some embodiments, the

oligonucleotide comprises any aspect of the following structure: The aspect included in the oligonucleotide may include the entire structure, or may include the lipid moiety, of any of the structures shown. In some embodiments, n is 1-3. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, R is an alkyl group. In some embodiments, the alkyl group contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbons. In some embodiments, the alkyl group contains 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 carbons, or a range defined by any two of the aforementioned numbers of carbons. In some embodiments, the alkyl group contains 4-18 carbons. In some embodiments, the lipid moiety comprises an alcohol or ether.

[0098] In some embodiments, the lipid includes a fatty acid. In some embodiments, the lipid comprises a lipid depicted in **Table 1**. The example lipid moieties in **Table 1** are shown attached at a 5' end of an oligonucleotide, in which the 5' terminal phosphate of the oligonucleotide is shown with the lipid moiety. In some embodiments, a lipid moiety in **Table 1** may be attached at a different point of attachment than shown. For example, the point of attachment of any of the lipid moieties in the table may be at a 3' oligonucleotide end. In some embodiments, the lipid is used for targeting the oligonucleotide to a non-hepatic cell or tissue.


Table 1: Hydrophobic moiety examples

Hydrophobic Moiety Description	Hydrophobic Moiety Name	Example Conjugation
stearyl	ETL3	
t-butylphenyl	ETL7	
n-butylphenyl	ETL8	
octylphenyl	ETL9	
dodecylphenyl	ETL10	
phenyl n-dodecyl	ETL12	

octadecylbenzamide	ETL13	
hexadecylbenzamide	ETL15	
octadecylcyclohexyl	ETL16	


[0099] In some embodiments, the lipid or lipid moiety includes 16 to 18 carbons. In some embodiments, the lipid includes 16 carbons. In some embodiments, the lipid includes 17 carbons. In some embodiments, the lipid includes 18 carbons. In some embodiments, the lipid moiety includes 16 carbons. In some embodiments, the lipid moiety includes 17 carbons. In some embodiments, the lipid moiety includes 18 carbons.

[00100] The hydrophobic moiety may include a linker that comprises a carbocycle. The carbocycle may be six-membered. Some examples of a carbocycle include phenyl or cyclohexyl. The linker may include a phenyl. The linker may include a cyclohexyl. The lipid may be attached to the carbocycle, which may in turn be attached at a phosphate (e.g. 5' or 3' phosphate) of the oligonucleotide. In some embodiments, the lipid or hydrocarbon, and the end of the sense are connected to the phenyl or cyclohexyl linker in the 1,4; 1,3; or 1,2 substitution pattern (e.g. the para, meta, or ortho phenyl configuration). In some embodiments, the lipid or hydrocarbon, and the end of the sense are connected to the phenyl or cyclohexyl linker in the 1,4 substitution pattern (e.g. the para phenyl configuration). The lipid may be attached to the carbocycle in the 1,4 substitution pattern relative to the oligonucleotide. The lipid may be attached to the carbocycle in the 1,3 substitution pattern relative to the oligonucleotide. The lipid may be attached to the carbocycle in the 1,2 substitution pattern relative to the oligonucleotide. The lipid may be attached to the carbocycle in the ortho orientation relative to the oligonucleotide. The lipid may be attached to the carbocycle in the para orientation relative to the oligonucleotide. The lipid may be attached to the carbocycle in the meta orientation relative to the oligonucleotide.




[00101] The lipid moiety may comprise or consist of the following structure:

In some embodiments, the lipid moiety comprises or consists of the following structure:




. In some embodiments, the lipid moiety comprises the



following structure:

. In some embodiments, the lipid



moiety comprises or consist of the following structure:

. In some


embodiments, the dotted line indicates a covalent connection. The covalent connection may be to an end of the sense or antisense strand. For example, the connection may be to the 5' end of the sense strand. In some embodiments, n is 0-3. In some embodiments, n is 1-3. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, R is an alkyl group. In some embodiments, the alkyl group contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbons. In some embodiments, the alkyl group contains 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 carbons, or a range defined by any two of the aforementioned numbers of carbons. In some embodiments, R comprises or consists of an alkyl group containing 4-18 carbons.

[00102] The lipid moiety may be attached at a 5' end of the oligonucleotide. The 5' end may have one phosphate linking the lipid moiety to a 5' carbon of a sugar of the oligonucleotide. The 5' end may have two phosphates linking the lipid moiety to a 5' carbon of a sugar of the oligonucleotide. The 5' end may have three phosphates linking the lipid moiety to a 5' carbon of a sugar of the oligonucleotide. The 5' end may have one phosphate connected to the 5' carbon of a sugar of the oligonucleotide, where the one phosphate is connected to the lipid moiety. The 5' end may have two phosphates connected to the 5' carbon of a sugar of the oligonucleotide, where the one of the two phosphates is connected to the lipid moiety. The 5' end may have three phosphates connected to the 5' carbon of a sugar of the oligonucleotide, where the one of the three phosphates is connected to the lipid moiety. The sugar may



include a ribose. The sugar may include a deoxyribose. The sugar may be modified such as a 2' modified sugar (e.g. a 2' O-methyl or 2' fluoro ribose). A phosphate of the 5' end may include a modification such as a sulfur in place of an oxygen. Two phosphates of the 5' end may include a modification such as a sulfur in place of an oxygen. Three phosphates of the 5' end may include a modification such as a sulfur in place of an oxygen.

[00103] In some embodiments, the oligonucleotide includes 1 lipid moiety. In some embodiments, the oligonucleotide includes 2 lipid moieties. In some embodiments, the oligonucleotide includes 3 lipid moieties. In some embodiments, the oligonucleotide includes 4 lipid moieties.

[00104] Some embodiments relate to a method of making an oligonucleotide comprising a hydrophobic conjugate. A strategy for making hydrophobic conjugates may include use of a phosphoramidite reagent based upon a 6-membered ring alcohol such as a phenol or cyclohexanol. The phosphoramidite may be reacted to a nucleotide to connect the nucleotide to the hydrophobic moiety, and thereby produce the hydrophobic conjugate. Some examples of phosphoramidite reagents that may be used to produce a



hydrophobic conjugate are provided as follows:



. In some embodiments, n is 1-3. In

some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, R is an alkyl group. In some embodiments, the alkyl group contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbons. In some embodiments, the alkyl group contains 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 carbons, or a range defined by any two of the aforementioned numbers of carbons. In some embodiments, R comprises or consists of an alkyl group

containing 4-18 carbons. Any one of the phosphoramidite reagents may be reacted to a 5' end of an oligonucleotide to produce an oligonucleotide comprising a hydrophobic moiety. In some embodiments, the phosphoramidite reagents is reacted to a 5' end of a sense strand of an siRNA. The sense strand may then be hybridized to an antisense strand to form a duplex. The hybridization may be performed by incubating the sense and antisense strands in solution at a given temperature. The temperature may be gradually reduced. The temperature may comprise or include a temperature comprising an annealing temperature for the sense and antisense strands. The temperature may be below or include a temperature below the annealing temperature for the sense and antisense strands. The temperature may be below a melting temperature of the sense and antisense strands.

[00105] The lipid may be attached to the oligonucleotide by a linker. The linker may include a polyethyleneglycol (e.g. tetraethyleneglycol).

[00106] The modifications described herein may be useful for delivery to a cell or tissue, for example, extrahepatic delivery or targeting of an oligonucleotide composition. The modifications described herein may be useful for targeting an oligonucleotide composition to a cell or tissue.

2. *Sugar moieties*


[00107] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a sugar moiety. The sugar moiety may include an N-acetyl galactose moiety (e.g. an N-acetylgalactosamine (GalNAc) moiety), an N-acetyl glucose moiety (e.g. an N-acetylglucosamine (GlcNAc) moiety), a fucose moiety, or a mannose moiety. The sugar moiety may include 1, 2, 3, or more sugar molecules. The sugar moiety may be attached at a 3' or 5' terminus of the oligonucleotide. The sugar moiety may include an N-acetyl galactose moiety. The sugar moiety may include an N-acetylgalactosamine (GalNAc) moiety. The sugar moiety may include an N-acetyl glucose moiety. The sugar moiety may include N-acetylglucosamine (GlcNAc) moiety. The sugar moiety may include a fucose moiety. The sugar moiety may include a mannose moiety. N-acetyl glucose, GlcNAc, fucose, or mannose may be useful for targeting macrophages when they target or bind a mannose receptor such as CD206. The sugar moiety may be useful for binding or targeting an asialoglycoprotein receptor such as an asialoglycoprotein receptor of a hepatocyte. The GalNAc moiety may bind to an asialoglycoprotein receptor. The GalNAc moiety may target a hepatocyte.

[00108] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an N-acetylgalactosamine (GalNAc) moiety. GalNAc may be useful for hepatocyte targeting. The GalNAc moiety may include a bivalent or trivalent branched linker. The oligo may be attached to 1, 2 or 3 GalNAcs through a bivalent or trivalent branched linker. The GalNAc moiety may include 1, 2, 3, or more GalNAc molecules. The GalNAc moiety may be attached at a 3' or 5' terminus of the oligonucleotide.

[00109] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an N-acetylgalactosamine (GalNAc) ligand for hepatocyte targeting. In some embodiments, the composition comprises GalNAc. In some embodiments, the composition comprises a GalNAc derivative. In some embodiments, the GalNAc ligand is attached at

a 3' terminus of the oligonucleotide. In some embodiments, the GalNAc ligand is attached at a 5' terminus of the oligonucleotide. In some embodiments, the composition comprises a sense strand, and the GalNAc ligand is attached to the sense strand (e.g. attached to a 5' end of the sense strand, or attached to a 3' end of the sense strand). In some embodiments, the composition comprises an antisense strand, and the GalNAc ligand is attached to the antisense strand (e.g. attached to a 5' end of the antisense strand, or attached to a 3' end of the antisense strand). In some embodiments, the composition comprises a GalNAc ligand attached at a 3' or 5' terminus of the oligonucleotide.

[00110] Disclosed herein, in some embodiments, are compositions comprising an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises a GalNAc moiety. The GalNAc moiety may be included in any formula, structure, or GalNAc moiety shown below. In some embodiments, described herein is a compound (e.g. oligonucleotide) represented by Formula (I) or (II):



or a salt thereof, wherein

J is an oligonucleotide;

each w is independently selected from any value from 1 to 20;

each v is independently selected from any value from 1 to 20;

n is selected from any value from 1 to 20;

m is selected from any value from 1 to 20;

z is selected from any value from 1 to 3, wherein

if z is 3, Y is C

if z is 2, Y is CR⁶, or

if z is 1, Y is C(R⁶)₂;

Q is selected from:

C₃₋₁₀ carbocycle optionally substituted with one or more substituents independently selected from halogen, -CN, -NO₂, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -C(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)N(R⁷)₂, -OC(O)N(R⁷)₂, -N(R⁷)C(O)OR⁷, -C(O)OR⁷, -OC(O)R⁷, -S(O)R⁷, and C₁₋₆ alkyl, wherein the C₁₋₆ alkyl, is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, -SH, -NO₂, and -NH₂;

R¹ is a linker selected from:

-O-, -S-, -N(R⁷)-, -C(O)-, -C(O)N(R⁷)-, -N(R⁷)C(O)-, -N(R⁷)C(O)N(R⁷)-, -OC(O)N(R⁷)-, -N(R⁷)C(O)O-, -C(O)O-, -OC(O)-, -S(O)-, -S(O)₂-, -OS(O)₂-, -OP(O)(OR⁷)O-, -SP(O)(OR⁷)O-, -

OP(S)(OR⁷)O-, -OP(O)(SR⁷)O-, -OP(O)(OR⁷)S-, -OP(O)(O⁻)O-, -SP(O)(O⁻)O-, -OP(S)(O⁻)O-, -
 OP(O)(S⁻)O-, -OP(O)(O⁻)S-, -OP(O)(OR⁷)NR⁷-, -OP(O)(N(R⁷)₂)NR⁷-, -OP(OR⁷)O-, -
 OP(N(R⁷)₂)O-, -OP(OR⁷)N(R⁷)-, and -OPN(R⁷)₂NR⁷-;

each R² is independently selected from:

C₁₋₆ alkyl optionally substituted with one or more substituents independently selected from halogen, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -C(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)N(R⁷)₂, -OC(O)N(R⁷)₂, -N(R⁷)C(O)OR⁷, -C(O)OR⁷, -OC(O)R⁷, and -S(O)R⁷;

R³ and R⁴ are each independently selected from:

-OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -C(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)N(R⁷)₂, -OC(O)N(R⁷)₂, -N(R⁷)C(O)OR⁷, -C(O)OR⁷, -OC(O)R⁷, and -S(O)R⁷;

each R⁵ is independently selected from:

-OC(O)R⁷, -OC(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)N(R⁷)₂, -N(R⁷)C(O)OR⁷, -C(O)R⁷, -C(O)OR⁷, and -C(O)N(R⁷)₂;

each R⁶ is independently selected from:

hydrogen;
 halogen, -CN, -NO₂, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -C(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)N(R⁷)₂, -OC(O)N(R⁷)₂, -N(R⁷)C(O)OR⁷, -C(O)OR⁷, -OC(O)R⁷, and -S(O)R⁷; and
 C₁₋₆ alkyl optionally substituted with one or more substituents independently selected from halogen, -CN, -NO₂, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -C(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)N(R⁷)₂, -OC(O)N(R⁷)₂, -N(R⁷)C(O)OR⁷, -C(O)OR⁷, -OC(O)R⁷, and -S(O)R⁷;

each R⁷ is independently selected from:

hydrogen;
 C₁₋₆ alkyl, C₂₋₆ alkenyl, and C₂₋₆ alkynyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, -SH, -NO₂, -NH₂, =O, =S, -O-C₁₋₆ alkyl, -S-C₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, -NH(C₁₋₆ alkyl), C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle; and
 C₃₋₁₀ carbocycle, and 3- to 10-membered heterocycle, each of which is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, -SH, -NO₂, -NH₂, =O, =S, -O-C₁₋₆ alkyl, -S-C₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, -NH(C₁₋₆ alkyl), C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ carbocycle, 3- to 10-membered heterocycle, and C₁₋₆ haloalkyl.


In some embodiments, each w is independently selected from any value from 1 to 10. In some embodiments, each w is independently selected from any value from 1 to 5. In some embodiments, each w is 1. In some embodiments, each v is independently selected from any value from 1 to 10. In some embodiments, each v is independently selected from any value from 1 to 5. In some embodiments, each v is 1. In some embodiments, n is selected from any value from 1 to 10. In some embodiments, n is selected from any value from 1 to 5. In some embodiments, n is 2. In some embodiments, m is selected from any value from 1 to 10. In some embodiments, m is selected from any value from 1 to 5. In some embodiments, m is selected from 1 and 2. In some embodiments, z is 3 and Y is C. In some embodiments,


Q is selected from C₅₋₆ carbocycle optionally substituted with one or more substituents independently selected from halogen, -CN, -NO₂, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -C(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)N(R⁷)₂, -OC(O)N(R⁷)₂, -N(R⁷)C(O)OR⁷, -C(O)OR⁷, -OC(O)R⁷, and -S(O)R⁷. In some embodiments, Q is selected from C₅₋₆ carbocycle optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, -SH, -NO₂, and -NH₂. In some embodiments, Q is selected from phenyl and cyclohexyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, -SH, -NO₂, and -NH₂. In some embodiments, Q is selected from phenyl. In some embodiments, Q is selected from cyclohexyl. In some embodiments, R¹ is selected from -OP(O)(OR⁷)O-, -SP(O)(OR⁷)O-, -OP(S)(OR⁷)O-, -OP(O)(SR⁷)O-, -OP(O)(OR⁷)S-, -OP(O)(O-)O-, -SP(O)(O-)O-, -OP(S)(O-)O-, -OP(O)(S-)O-, -OP(O)(O-)S-, -OP(O)(OR⁷)NR⁷-, -OP(O)(N(R⁷)₂)NR⁷-, -OP(OR⁷)O-, -OP(N(R⁷)₂)O-, -OP(OR⁷)N(R⁷)-, and -OPN(R⁷)₂NR⁷. In some embodiments, R¹ is selected from -OP(O)(OR⁷)O-, -SP(O)(OR⁷)O-, -OP(S)(OR⁷)O-, -OP(O)(SR⁷)O-, -OP(O)(OR⁷)S-, -OP(O)(O-)O-, -SP(O)(O-)O-, -OP(S)(O-)O-, -OP(O)(S-)O-, -OP(O)(O-)S-, and -OP(OR⁷)O-. In some embodiments, R¹ is selected from -OP(O)(OR⁷)O-, -OP(S)(OR⁷)O-, -OP(O)(O-)O-, -OP(S)(O-)O-, -OP(O)(S-)O-, and -OP(OR⁷)O-. In some embodiments, R¹ is selected from -OP(O)(OR⁷)O- and -OP(OR⁷)O-. In some embodiments, R² is selected from C₁₋₃ alkyl substituted with one or more substituents independently selected from halogen, -OR⁷, -OC(O)R⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, and -S(O)R⁷. In some embodiments, R² is selected from C₁₋₃ alkyl substituted with one or more substituents independently selected from -OR⁷, -OC(O)R⁷, -SR⁷, and -N(R⁷)₂. In some embodiments, R² is selected from C₁₋₃ alkyl substituted with one or more substituents independently selected from -OR⁷ and -OC(O)R⁷. In some embodiments, R³ is selected from halogen, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -OC(O)R⁷, and -S(O)R⁷. In some embodiments, R³ is selected from -OR⁷, -SR⁷, -OC(O)R⁷, and -N(R⁷)₂. In some embodiments, R³ is selected from -OR⁷ and -OC(O)R⁷. In some embodiments, R⁴ is selected from halogen, -OR⁷, -SR⁷, -N(R⁷)₂, -C(O)R⁷, -OC(O)R⁷, and -S(O)R⁷. In some embodiments, R⁴ is selected from -OR⁷, -SR⁷, -OC(O)R⁷, and -N(R⁷)₂. In some embodiments, R⁴ is selected from -OR⁷ and -OC(O)R⁷. In some embodiments, R⁵ is selected from -OC(O)R⁷, -OC(O)N(R⁷)₂, -N(R⁷)C(O)R⁷, -N(R⁷)C(O)N(R⁷)₂, and -N(R⁷)C(O)OR⁷. In some embodiments, R⁵ is selected from -OC(O)R⁷ and -N(R⁷)C(O)R⁷. In some embodiments, each R⁷ is independently selected from: hydrogen; and C₁₋₆ alkyl optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, -SH, -NO₂, -NH₂, =O, =S, -O-C₁₋₆ alkyl, -S-C₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, -NH(C₁₋₆ alkyl), C₃₋₁₀ carbocycle, or 3- to 10-membered heterocycle. In some embodiments, each R⁷ is independently selected from C₁₋₆ alkyl optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, -SH, -NO₂, -NH₂, =O, =S, -O-C₁₋₆ alkyl, -S-C₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, and -NH(C₁₋₆ alkyl). In some embodiments, each R⁷ is independently selected from C₁₋₆ alkyl optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, and -SH. In some embodiments, w is 1; v is 1; n is 2; m is 1 or 2; z is 3 and Y is C; Q is phenyl or cyclohexyl, each of which is optionally substituted with one or more substituents independently selected from halogen, -CN, -OH, -SH, -NO₂, -NH₂, and C₁₋₃ alkyl; R¹ is


selected from $-\text{OP}(\text{O})(\text{OR}^7)\text{O}-$, $-\text{OP}(\text{S})(\text{OR}^7)\text{O}-$, $-\text{OP}(\text{O})(\text{O})\text{O}-$, $-\text{OP}(\text{S})(\text{O})\text{O}-$, $-\text{OP}(\text{O})(\text{S})\text{O}-$, and $-\text{OP}(\text{OR}^7)\text{O}-$; R^2 is C_1 alkyl substituted with $-\text{OH}$ or $-\text{OC}(\text{O})\text{CH}_3$;


R^3 is $-\text{OH}$ or $-\text{OC}(\text{O})\text{CH}_3$; R^4 is $-\text{OH}$ or $-\text{OC}(\text{O})\text{CH}_3$; and R^5 is $-\text{NH}(\text{O})\text{CH}_3$. In some embodiments, the

compound comprises:















In some embodiments, the oligonucleotide (J) is attached at a 5' end or a 3' end of the oligonucleotide. In some embodiments, the oligonucleotide comprises DNA. In some embodiments, the oligonucleotide comprises RNA. In some embodiments, the oligonucleotide comprises one or more modified internucleoside linkages. In some embodiments, the one or more modified internucleoside linkages comprise alkylphosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester, or a combination thereof. In some embodiments, the oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 modified internucleoside linkages. In some embodiments, the compound binds to an asialoglycoprotein receptor. In some embodiments, the compound targets a hepatocyte.

[00111] Some embodiments include the following, where J is the oligonucleotide:




J may

include one or more additional phosphates, or one or more phosphorothioates linking to the


oligonucleotide. J may include one or more additional phosphates linking to the oligonucleotide. J may include one or more phosphorothioates linking to the oligonucleotide.

[00112] Some embodiments include the following, where J is the oligonucleotide:



may include one or more additional phosphates, or one or more phosphorothioates linking to the oligonucleotide. J may include one or more additional phosphates linking to the oligonucleotide. J may include one or more phosphorothioates linking to the oligonucleotide.


[00113] Some embodiments include the following, where J is the oligonucleotide:



include one or more phosphates or phosphorothioates linking to the oligonucleotide. J may include one or


more phosphates linking to the oligonucleotide. J may include a phosphate linking to the oligonucleotide. J may include one or more phosphorothioates linking to the oligonucleotide. J may include a phosphorothioate linking to the oligonucleotide.

[00114] Some embodiments include the following, where J is the oligonucleotide:




. The structure in this compound attached to the oligonucleotide (J) may be referred to as “ETL17,” and is an example of a GalNAc moiety. J may include one or more phosphates or phosphorothioates linking to the oligonucleotide. J may include one or more phosphates linking to the oligonucleotide. J may include a phosphate linking to the oligonucleotide. J may include one or more phosphorothioates linking to the oligonucleotide. J may include a phosphorothioate linking to the oligonucleotide.


[00115] Some embodiments include the following, where the phosphate or “5'” indicates a connection to the oligonucleotide:



[00116] Some embodiments include the following, where the phosphate or “5” indicates a connection to the oligonucleotide:




[00117] Some embodiments include the following, where J is the oligonucleotide:



include one or more phosphates or phosphorothioates linking to the oligonucleotide. J may include one or more phosphates linking to the oligonucleotide. J may include a phosphate linking to the oligonucleotide. J may include one or more phosphorothioates linking to the oligonucleotide. J may include a phosphorothioate linking to the oligonucleotide.

[00118] Some embodiments include the following, where J is the oligonucleotide:



The structure in this compound attached to the oligonucleotide (J) may be referred to as “ETL1,” and is an example of a GalNAc moiety. J may include one or more phosphates or phosphorothioates linking to the oligonucleotide. J may include one or more phosphates linking to the oligonucleotide. J may include a

phosphate linking to the oligonucleotide. J may include one or more phosphorothioates linking to the oligonucleotide. J may include a phosphorothioate linking to the oligonucleotide.

3. *siRNA modification patterns*

[00119] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the sense strand comprises modification pattern 1S:

5'-NfsnsNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2444), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 2S:

5'-nsnsnnNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2445), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 3S:

5'-nsnsnnNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2446), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 4S:

5'-NfsnsNfnNfnNfnNfnNfnNfnNfnNfsnsN-moiety-3' (SEQ ID NO: 2447), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, "s" is a phosphorothioate linkage, and N comprises one or more nucleosides. In some embodiments, the sense strand comprises modification pattern 5S:

5'-nsnsnnNfnNfnNfnNfnNfnNfnNfnNfsnsN-moiety-3' (SEQ ID NO: 2448), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, "s" is a phosphorothioate linkage, and N comprises one or more nucleosides. In some embodiments, the moiety in modification pattern 4S or 5S is a lipophilic moiety. In some embodiments, the moiety in modification pattern 4S or 5S is a lipid moiety. In some embodiments, the sense strand comprises modification pattern 6S:

5'-NfsnsNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2449), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 7S:

5'-nsnsnnNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2450), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 8S:

5'-nsnsnnnnNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2451), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 9S:

5'-nsnsnnnnNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2452), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 10S:

5'-NfsnsnnNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2525), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 11S:

5'-nsnsNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2526), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In

some embodiments, the sense strand comprises modification pattern 12S:

5'-NfsnsNfnNfnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2527), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 13S:

5'-nsnsnnnnNfnNfnNfnNfnNfnNfsnsn-3' (SEQ ID NO: 2528), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 14S:

5'-snnnnnnNfNfNfNfnnnnnnnnnsnsn-3' (SEQ ID NO: 2529), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 15S:

5'-snnnnNfNfNfNfnnnnnnnnnsnsn-3' (SEQ ID NO: 2530), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 16S:

5'-snnnnNfnNfnNfdNnnnnnnnnnsnsn-3' (SEQ ID NO: 2531), wherein "Nf" is a 2' fluoro-modified nucleoside, "dN" is a 2' deoxy-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 17S:

5'-snnnnNfNfnNfnnnnnnnnnnsnsn-3' (SEQ ID NO: 2532), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 18S: 5'-snnnnnnNfnNfnNfnnnnnnnnnnsnsn-3' (SEQ ID NO: 2533), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 19S: 5'-snnnnNfnNfnNfnNfnnnnnnnnsnsn-3' (SEQ ID NO: 2534), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 20S:

5'-snnnnNfnNfnNfnnnnnnnnnnsnsn-3' (SEQ ID NO: 2535), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 21S: 5'-snnnnNfnNfnNfnNfnnnnnnnnnnsnsn-3' (SEQ ID NO: 2536), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 22S: 5'-snnnnNfnNfnNfnNfnnnnnnnnsnsn-3' (SEQ ID NO: 2537), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 23S:

5'-snnnnNfnNfnNfnnnnnnnnnnsnsn-3' (SEQ ID NO: 2538), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 24S: 5'-snnnnnnNfNfNfNfnnnnnnnnsnsn-3' (SEQ ID NO: 2539), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 25S: 5'-snnnnNfNfNfNfNfnnnnnnnnsnsn-3' (SEQ ID NO: 2540), wherein "Nf" is

a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 26S:

5'-snnnnnNfNfNfNfnnnnnnnnsnsn-3' (SEQ ID NO: 2541), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 27S: 5'-snnnnnnnNfNfNfNfnnnnnnnnsnsn-3' (SEQ ID NO: 2542), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 28S: 5'-snnnnNfNfNfNfNfnnnnnnnnsnsn-3' (SEQ ID NO: 2543), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 29S:

5'-snnnnnnnNfNfNfnnnnnnnnsnsn-3' (SEQ ID NO: 2544), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 30S: 5'-snnnnNfNfnNfNfnnnnnnnnsnsn-3' (SEQ ID NO: 2545), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 31S: 5'-snnnnNfNfNfNfNfnnnnnnnnsnsn-3' (SEQ ID NO: 2546), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the sense strand comprises modification pattern 32S:

5'-snnnnnNfNfdNNfnnnnnnnnsnsn-3' (SEQ ID NO: 2547), wherein "Nf" is a 2' fluoro-modified nucleoside, "dN" is a 2' deoxy-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage.

[00120] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the antisense strand comprises modification pattern 1AS:

5'-nsNfsnNfNfNfNfNfnnnNfNfNfnnsnsn-3' (SEQ ID NO: 2453), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the antisense strand comprises modification pattern 2AS:

5'-nsNfsnnnNfNfNfNfnnnNfNfnnsnsn-3' (SEQ ID NO: 2454), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the antisense strand comprises modification pattern 3AS:

5'-nsNfsnnnNfnnnnnnnNfNfnnsnsn-3' (SEQ ID NO: 2455), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the antisense strand comprises modification pattern 4AS:

5'-nsNfsnNfNfNfnnnnnnnNfNfnnsnsn-3' (SEQ ID NO: 2456), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the antisense strand comprises modification pattern 5AS:

5'-nsNfsnnnnnnnnnnNfNfnnsnsn-3' (SEQ ID NO: 2457), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some

embodiments, the antisense strand comprises modification pattern 6AS:

5'-nsNfsnnnNfnNfnnnnNfnNfnnsnsn-3' (SEQ ID NO: 2458), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the antisense strand comprises modification pattern 7AS:

5'-nsNfsnNfnNfnNfnNfnNfnNfnNfnnsn-3' (SEQ ID NO: 2459), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the antisense strand comprises modification pattern 8AS:

5'-nsNfsnnnnnnnnnnNfnnnnsnsn-3' (SEQ ID NO: 2460), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the antisense strand comprises modification pattern 9AS:

5'-nsNfsnnnNfnNfnnnnnNfnNfnnsnsn-3' (SEQ ID NO: 2548), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage. In some embodiments, the antisense strand comprises modification pattern 10AS:

5'-nsNfsnNfsnNfnNfnNfnNfnNfnNfnnsn-3' (SEQ ID NO: 2549), wherein "Nf" is a 2' fluoro-modified nucleoside, "n" is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage.

[00121] In some embodiments, the composition comprises an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, wherein the sense strand comprises pattern 1S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 2S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 3S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 4S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 5S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 6S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 7S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 8S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 9S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 10S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 11S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 12S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the sense strand comprises pattern 13S and the antisense strand comprises pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the

[00122] In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S and the antisense strand comprises pattern 1AS. In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S and the antisense strand comprises pattern 2AS. In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S,

30S, 31S, or 32S and the antisense strand comprises pattern 3AS. In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S and the antisense strand comprises pattern 4AS. In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S and the antisense strand comprises pattern 5AS. In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S and the antisense strand comprises pattern 6AS. In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S and the antisense strand comprises pattern 7AS. In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S and the antisense strand comprises pattern 8AS. In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S and the antisense strand comprises pattern 9AS. In some embodiments, the sense strand comprises pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S and the antisense strand comprises pattern 10AS.

[00123] In some embodiments, the sense strand comprises any one of modification patterns 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, or 9S. In some embodiments, the sense strand comprises any one of modification patterns 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S. In some embodiments, the sense strand comprises modification pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, or 8AS. In some embodiments, the antisense strand comprises modification pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, 8AS, 9AS or 10AS. In some embodiments, the antisense strand comprises modification pattern 1AS, 2AS, 3AS, 4AS, 5AS, 6AS, 7AS, or 8AS. In some embodiments, the antisense strand comprises modification pattern 1S, 2S, 3S, 4S, 5S, 6S, 7S, 8S, 9S, 10S, 11S, 12S, 13S, 14S, 15S, 16S, 17S, 18S, 19S, 20S, 21S, 22S, 23S, 24S, 25S, 26S, 27S, 28S, 29S, 30S, 31S, or 32S. In some embodiments, the sense strand or the antisense strand comprises modification pattern ASO1.

[00124] In some embodiments, purines of the sense strand comprise 2' fluoro modified purines. In some embodiments, purines of the sense strand comprise 2'-O-methyl modified purines. In some embodiments, purines of the sense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some embodiments, all purines of the sense strand comprise 2' fluoro modified purines. In some embodiments, all purines of the sense strand comprise 2'-O-methyl modified purines. In some embodiments, all purines of the sense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified purines.

[00125] In some embodiments, pyrimidines of the sense strand comprise 2' fluoro modified pyrimidines. In some embodiments, pyrimidines of the sense strand comprise 2'-O-methyl modified pyrimidines. In

[00126] In some embodiments, purines of the sense strand comprise 2' fluoro modified purines, and pyrimidines of the sense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, purines of the sense strand comprise 2'-O-methyl modified purines, and pyrimidines of the sense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, purines of the sense strand comprise 2' fluoro modified purines, and pyrimidines of the sense strand comprise 2'-O-methyl modified pyrimidines. In some embodiments, purines of the sense strand comprise 2'-O-methyl modified purines, and pyrimidines of the sense strand comprise 2' fluoro modified pyrimidines. In some embodiments, pyrimidines of the sense strand comprise 2' fluoro modified pyrimidines, and purines of the sense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some embodiments, pyrimidines of the sense strand comprise 2'-O-methyl modified pyrimidines, and purines of the sense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some embodiments, pyrimidines of the sense strand comprise 2' fluoro modified pyrimidines, and purines of the sense strand comprise 2'-O-methyl modified purines. In some embodiments, pyrimidines of the sense strand comprise 2'-O-methyl modified pyrimidines, and purines of the sense strand comprise 2' fluoro modified purines.

[00128] In some embodiments, purines of the antisense strand comprise 2' fluoro modified purines. In some embodiments, purines of the antisense strand comprise 2' -O-methyl modified purines. In some embodiments, purines of the antisense strand comprise a mixture of 2' fluoro and 2' -O-methyl modified

[00129] In some embodiments, pyrimidines of the antisense strand comprise 2' fluoro modified pyrimidines. In some embodiments, pyrimidines of the antisense strand comprise 2'-O-methyl modified pyrimidines. In some embodiments, pyrimidines of the antisense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, all pyrimidines of the antisense strand comprise 2' fluoro modified pyrimidines. In some embodiments, all pyrimidines of the antisense strand comprise 2'-O-methyl modified pyrimidines. In some embodiments, all pyrimidines of the antisense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines.

[00131] In some embodiments, all purines of the antisense strand comprise 2' fluoro modified purines, and all pyrimidines of the antisense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, all purines of the antisense strand comprise 2'-O-methyl modified purines, and all pyrimidines of the antisense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified pyrimidines. In some embodiments, all purines of the antisense strand comprise 2' fluoro modified purines, and all pyrimidines of the antisense strand comprise 2'-O-methyl modified pyrimidines. In some embodiments, all purines of the antisense strand comprise 2'-O-methyl modified purines, and all pyrimidines of the antisense strand comprise 2' fluoro modified pyrimidines. In some embodiments, all pyrimidines of the antisense strand comprise 2' fluoro modified pyrimidines, and all purines of the antisense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some embodiments, all pyrimidines of the antisense strand comprise 2'-O-methyl modified pyrimidines, and all purines of the antisense strand comprise a mixture of 2' fluoro and 2'-O-methyl modified purines. In some

embodiments, all pyrimidines of the antisense strand comprise 2' fluoro modified pyrimidines, and all purines of the antisense strand comprise 2'-O-methyl modified purines. In some embodiments, all pyrimidines of the antisense strand comprise 2'-O-methyl modified pyrimidines, and all purines of the antisense strand comprise 2' fluoro modified purines.

[00132] Disclosed herein, in some embodiments, are modified oligonucleotides. The modified oligonucleotide may be an siRNA that includes modifications to the ribose rings, and phosphate linkages. The modifications may be in particular patterns that maximize cell delivery, stability, and efficiency. The siRNA may also include a vinyl phosphonate and a hydrophobic group. These modifications may aid in delivery to a cell or tissue within a subject. The modified oligonucleotide may be used in a method such as a treatment method or a method of reducing gene expression.

[00133] In some embodiments, the oligonucleotide comprises a duplex consisting of 21 nucleotide single strands with base pairing between 19 of the base pairs. In some embodiments, the duplex comprises single-stranded 2 nucleotide overhangs at the 3' ends of each strand. One strand (antisense strand) is complementary to a MTRES1 mRNA. Each end of the antisense strand has one to two phosphorothioate bonds. The 5' end has an optional phosphate mimic such as a vinyl phosphonate. In some embodiments, the oligonucleotide is used to knock down a MTRES1 mRNA or a target protein. In some embodiments, the sense strand has the same sequence as the MTRES1 mRNA. In some embodiments, there are 1-2 phosphorothioates at the 3' end. In some embodiments, there are 1 or no phosphorothioates at the 5' end. In some embodiments, there is a hydrophobic conjugate of 12 to 25 carbons attached at the 5' end via a phosphodiester bond.

[00134] In some cases, the sense strand of any of the siRNAs comprises siRNA with a particular modification pattern. In some embodiments of the modification pattern, position 9 counting from the 5' end of the sense strand may have a 2'F modification. In some embodiments, when position 9 of the sense strand is a pyrimidine, then all purines in the sense strand have a 2'OMe modification. In some embodiments, when position 9 is the only pyrimidine between positions 5 and 11 of the sense strand, then position 9 is the only position with a 2'F modification in the sense strand. In some embodiments, when position 9 and only one other base between positions 5 and 11 of the sense strand are pyrimidines, then both of these pyrimidines are the only two positions with a 2'F modification in the sense strand. In some embodiments, when position 9 and only two other bases between positions 5 and 11 of the sense strand are pyrimidines, and those two other pyrimidines are in adjacent positions so that there would be not three 2'F modifications in a row, then any combination of 2'F modifications can be made that give three 2'F modifications in total. In some embodiments, when there are more than 2 pyrimidines between positions 5 and 11 of the sense strand, then all combinations of pyrimidines having the 2'F modification are allowed that have three to five 2'F modifications in total, provided that the sense strand does not have three 2'F modifications in a row. In some cases, the sense strand of any of the siRNAs comprises a modification pattern which conforms to any or all of these sense strand rules.

[00135] In some embodiments, when position 9 of the sense strand is a purine, then all purines in the sense strand have a 2'OMe modification. In some embodiments, when position 9 is the only purine between

positions 5 and 11 of the sense strand, then position 9 is the only position with a 2'F modification in the sense strand. In some embodiments, when position 9 and only one other base between positions 5 and 11 of the sense strand are purines, then both of these purines are the only two positions with a 2'F modification in the sense strand. In some embodiments, when position 9 and only two other bases between positions 5 and 11 of the sense strand are purines, and those two other purines are in adjacent positions so that there would be not three 2'F modifications in a row, then any combination of 2'F modifications can be made that give three 2'F modifications in total. In some embodiments, when there are more than 2 purines between positions 5 and 11 of the sense strand, then all combinations of purines having the 2'F modification are allowed that have three to five 2'F modifications in total, provided that the sense strand does not have three 2'F modifications in a row. In some cases, the sense strand of any of the siRNAs comprises a modification pattern which conforms to any or all of these sense strand rules.

[00136] In some cases, position 9 of the sense strand can be a 2'deoxy. In these cases, 2'F and 2'OMe modifications may occur at the other positions of the sense strand. In some cases, the sense strand of any of the siRNAs comprises a modification pattern which conforms to these sense strand rules.

[00137] In some cases, the sense strand of any of the siRNAs comprises a modification pattern which conforms to these sense strand rules.

[00138] Terminal modifications useful for modulating activity include modification of the 5' end of the antisense strand with phosphate or phosphate analogs. In certain embodiments, the 5' end of the antisense strand is phosphorylated or includes a phosphoryl analog. Exemplary 5'-phosphate modifications include those which are compatible with RNA-induced silencing complex (RISC) mediated gene silencing. In some embodiments, the 3' end of the antisense strand is phosphorylated or includes a phosphoryl analog. In some embodiments, the 5' end of the sense strand is phosphorylated or includes a phosphoryl analog. In some embodiments, the 3' end of the sense strand is phosphorylated or includes a phosphoryl analog.

[00139] In some embodiments, the oligonucleotide comprises a phosphate or phosphate mimic at the 5' end of the antisense strand. In some embodiment, the phosphate mimic includes a 5'-vinyl phosphonate (VP). In some embodiment, the phosphate mimic is a 5'-VP. In some embodiments, the oligonucleotide comprises a phosphate or phosphate mimic at the 3' end of the antisense strand. In some embodiments, the oligonucleotide comprises a phosphate or phosphate mimic at the 5' end of the sense strand. In some embodiments, the oligonucleotide comprises a phosphate or phosphate mimic at the 3' end of the sense strand.

[00140] Disclosed herein, in some embodiments are compositions comprising an oligonucleotide that targets MTRES1 and when administered to a cell decreases expression of MTRES1, wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand, wherein the sense strand comprises a sense strand sequence described herein in which at least one internucleoside linkage is modified and at least one nucleoside is modified, or an sense strand sequence comprising 1 or 2 nucleoside substitutions, additions, or deletions of the oligonucleotide sequence in which at least one internucleoside linkage is modified and at least one nucleoside is modified, and wherein the antisense strand comprises an antisense strand sequence described herein in which at least one

internucleoside linkage is modified and at least one nucleoside is modified, or an oligonucleotide sequence comprising 1 or 2 nucleoside substitutions, additions, or deletions of the antisense strand sequence in which at least one internucleoside linkage is modified and at least one nucleoside is modified. Some embodiments relate to methods that include administering the composition to a subject.

[00141]In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 8**, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 8**, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 8**. The siRNA may include the same internucleoside linkage modifications or nucleoside modifications as those in **Table 8**. The siRNA may include any different internucleoside linkage modifications or nucleoside modifications different from those in **Table 8**. The siRNA may include some unmodified internucleoside linkages or nucleosides.

[00142]In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 9**, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 9**, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 9**. The siRNA may include the same internucleoside linkage modifications or nucleoside modifications as those in **Table 9**. The siRNA may include any different internucleoside linkage modifications or nucleoside modifications different from those in **Table 9**. The siRNA may include some unmodified internucleoside linkages or nucleosides.

[00143]In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 11A**, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 11A**, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 11A**. The siRNA may include the same internucleoside linkage modifications or nucleoside modifications as those in **Table 11A**. The siRNA may include any different internucleoside linkage modifications or nucleoside modifications different from those in **Table 11A**. The siRNA may include some unmodified internucleoside linkages or nucleosides.

[00144]In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 13A**, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 13A**, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 13A**. The siRNA may include the same internucleoside linkage modifications or nucleoside modifications as those in **Table 13A**. The siRNA may

include any different internucleoside linkage modifications or nucleoside modifications different from those in **Table 13A**. The siRNA may include some unmodified internucleoside linkages or nucleosides.

[00145] In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 15A**, or a nucleic acid sequence thereof having 3 or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 15A**, or a nucleic acid sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the siRNA comprises the sense strand and/or the antisense strand sequence of an siRNA in **Table 15A**. The siRNA may include the same internucleoside linkage modifications or nucleoside modifications as those in **Table 15A**. The siRNA may include any different internucleoside linkage modifications or nucleoside modifications different from those in **Table 15A**. The siRNA may include some unmodified internucleoside linkages or nucleosides.

[00146] In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2472. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2472, at least 80% identical to SEQ ID NO: 2472, at least 85% identical to SEQ ID NO: 2472, at least 90% identical to SEQ ID NO: 2472, or at least 95% identical to SEQ ID NO: 2472. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO 2472, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2472, or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2472. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2489. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2489, at least 80% identical to SEQ ID NO: 2489, at least 85% identical to SEQ ID NO: 2489, at least 90% identical to SEQ ID NO: 2489, or at least 95% identical to SEQ ID NO: 2489. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO 2489, or an antisense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO: 2489, or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2489. The antisense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety.

[00147] In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2478. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2478, at least 80% identical to SEQ ID NO: 2478, at least 85% identical to SEQ ID NO: 2478, at least 90% identical to SEQ ID NO: 2478, or at least 95% identical to SEQ ID NO: 2478. In some embodiments, the sense strand sequence comprises or consists of the

sequence of SEQ ID NO 2478, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2478, or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2478. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2495. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2495, at least 80% identical to SEQ ID NO: 2495, at least 85% identical to SEQ ID NO: 2495, at least 90% identical to SEQ ID NO: 2495, or at least 95% identical to SEQ ID NO: 2495. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO 2495, or an antisense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO: 2495, or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2495. The antisense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety.

[00148] In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2479. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2479, at least 80% identical to SEQ ID NO: 2479, at least 85% identical to SEQ ID NO: 2479, at least 90% identical to SEQ ID NO: 2479, or at least 95% identical to SEQ ID NO: 2479. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO 2479, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2479, or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2479. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2496. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2496, at least 80% identical to SEQ ID NO: 2496, at least 85% identical to SEQ ID NO: 2496, at least 90% identical to SEQ ID NO: 2496, or at least 95% identical to SEQ ID NO: 2496. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO 2496, or an antisense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO: 2496, or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of a sequence 100% identical to

SEQ ID NO: 2496. The antisense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety.

[00149]In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2480. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2480, at least 80% identical to SEQ ID NO: 2480, at least 85% identical to SEQ ID NO: 2480, at least 90% identical to SEQ ID NO: 2480, or at least 95% identical to SEQ ID NO: 2480. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO 2480, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2480, or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2480. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2497. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2497, at least 80% identical to SEQ ID NO: 2497, at least 85% identical to SEQ ID NO: 2497, at least 90% identical to SEQ ID NO: 2497, or at least 95% identical to SEQ ID NO: 2497. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO 2497, or an antisense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of the sequence of SEQ ID NO: 2497, or an antisense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the antisense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2497. The antisense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety.

[00150]In some embodiments, the siRNA comprises a sense strand having a sequence in accordance with SEQ ID NO: 2507. In some embodiments, the sense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2507, at least 80% identical to SEQ ID NO: 2507, at least 85% identical to SEQ ID NO: 2507, at least 90% identical to SEQ ID NO: 2507, or at least 95% identical to SEQ ID NO: 2507. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO 2507, or a sense strand sequence thereof having 1, 2, 3, or 4 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of the sequence of SEQ ID NO: 2507, or a sense strand sequence thereof having 1 or 2 nucleoside substitutions, additions, or deletions. In some embodiments, the sense strand sequence comprises or consists of a sequence 100% identical to SEQ ID NO: 2507. The sense strand may comprise a moiety such as a GalNAc moiety or a lipid moiety. In some embodiments, the siRNA comprises an antisense strand having a sequence in accordance with SEQ ID NO: 2517. In some embodiments, the antisense strand sequence comprises or consists of sequence at least 75% identical to SEQ ID NO: 2517, at least 80% identical to SEQ ID NO: 2517, at least 85% identical to SEQ ID NO: 2517, at least 90% identical to

4. ASO modification patterns

D. Formulations

[00154] In some embodiments, the composition is formulated to cross the blood brain barrier. In some embodiments, the composition is formulated for central nervous system (CNS) delivery. In some embodiments, the composition includes a lipophilic compound. The lipophilic compound may be useful for crossing the blood brain barrier or for CNS delivery.

[00155] Disclosed herein, in some embodiments, are methods of administering a composition described herein to a subject. Some embodiments relate to use a composition described herein, such as administering the composition to a subject.

[00156] Some embodiments relate to a method of treating a disorder in a subject in need thereof. Some embodiments relate to use of a composition described herein in the method of treatment. Some embodiments include administering a composition described herein to a subject with the disorder. In some embodiments, the administration treats the disorder in the subject. In some embodiments, the composition treats the disorder in the subject.

[00157] In some embodiments, the treatment comprises prevention, inhibition, or reversion of the disorder in the subject. Some embodiments relate to use of a composition described herein in the method of preventing, inhibiting, or reversing the disorder. Some embodiments relate to a method of preventing, inhibiting, or reversing a disorder a disorder in a subject in need thereof. Some embodiments include administering a composition described herein to a subject with the disorder. In some embodiments, the administration prevents, inhibits, or reverses the disorder in the subject. In some embodiments, the composition prevents, inhibits, or reverses the disorder in the subject.

[00158] Some embodiments relate to a method of preventing a disorder a disorder in a subject in need thereof. Some embodiments relate to use of a composition described herein in the method of preventing the disorder. Some embodiments include administering a composition described herein to a subject with the disorder. In some embodiments, the administration prevents the disorder in the subject. In some embodiments, the composition prevents the disorder in the subject.

[00159] Some embodiments relate to a method of inhibiting a disorder a disorder in a subject in need thereof. Some embodiments relate to use of a composition described herein in the method of inhibiting the disorder. Some embodiments include administering a composition described herein to a subject with the disorder. In some embodiments, the administration inhibits the disorder in the subject. In some embodiments, the composition inhibits the disorder in the subject.

[00160] Some embodiments relate to a method of reversing a disorder a disorder in a subject in need thereof. Some embodiments relate to use of a composition described herein in the method of reversing the disorder. Some embodiments include administering a composition described herein to a subject with the disorder. In some embodiments, the administration reverses the disorder in the subject. In some embodiments, the composition reverses the disorder in the subject.

[00161] In some embodiments, the administration is systemic. In some embodiments, the administration is intravenous. In some embodiments, the administration is by injection.

A. Disorders

[00162] Some embodiments of the methods described herein include treating a disorder in a subject in need thereof. In some embodiments, the disorder is a neurological disorder. Non-limiting examples of neurological disorders include dementia, Alzheimer's disease, delirium, cognitive decline, vascular dementia, or Parkinson's disease. In some embodiments, the neurological disorder includes cognitive decline. In some embodiments, the neurological disorder includes delirium. In some embodiments, the neurological disorder includes dementia. In some embodiments, the neurological disorder includes vascular dementia. In some embodiments, the neurological disorder includes Alzheimer's disease. In some embodiments, the neurological disorder includes Parkinson's disease. The neurological disorder

may include a neurodegenerative disease. The neurological disorder may be characterized by protein aggregation.

B. Subjects

[00163] Some embodiments of the methods described herein include treatment of a subject. Non-limiting examples of subjects include vertebrates, animals, mammals, dogs, cats, cattle, rodents, mice, rats, primates, monkeys, and humans. In some embodiments, the subject is a vertebrate. In some embodiments, the subject is an animal. In some embodiments, the subject is a mammal. In some embodiments, the subject is a dog. In some embodiments, the subject is a cat. In some embodiments, the subject is a cattle. In some embodiments, the subject is a mouse. In some embodiments, the subject is a rat. In some embodiments, the subject is a primate. In some embodiments, the subject is a monkey. In some embodiments, the subject is an animal, a mammal, a dog, a cat, cattle, a rodent, a mouse, a rat, a primate, or a monkey. In some embodiments, the subject is a human.

[00164] In some embodiments, the subject is male. In some embodiments, the subject is female.

[00165] In some embodiments, the subject is an adult (e.g. at least 18 years old). In some embodiments, the subject is ≥ 90 years of age. In some embodiments, the subject is ≥ 85 years of age. In some embodiments, the subject is ≥ 80 years of age. In some embodiments, the subject is ≥ 70 years of age. In some embodiments, the subject is ≥ 60 years of age. In some embodiments, the subject is ≥ 50 years of age. In some embodiments, the subject is ≥ 40 years of age. In some embodiments, the subject is ≥ 30 years of age. In some embodiments, the subject is ≥ 20 years of age. In some embodiments, the subject is ≥ 10 years of age. In some embodiments, the subject is ≥ 1 years of age. In some embodiments, the subject is ≥ 0 years of age.

[00166] In some embodiments, the subject is ≤ 100 years of age. In some embodiments, the subject is ≤ 90 years of age. In some embodiments, the subject is ≤ 85 years of age. In some embodiments, the subject is ≤ 80 years of age. In some embodiments, the subject is ≤ 70 years of age. In some embodiments, the subject is ≤ 60 years of age. In some embodiments, the subject is ≤ 50 years of age. In some embodiments, the subject is ≤ 40 years of age. In some embodiments, the subject is ≤ 30 years of age. In some embodiments, the subject is ≤ 20 years of age. In some embodiments, the subject is ≤ 10 years of age. In some embodiments, the subject is ≤ 1 years of age.

[00167] In some embodiments, the subject is between 0 and 100 years of age. In some embodiments, the subject is between 20 and 90 years of age. In some embodiments, the subject is between 30 and 80 years of age. In some embodiments, the subject is between 40 and 75 years of age. In some embodiments, the subject is between 50 and 70 years of age. In some embodiments, the subject is between 40 and 85 years of age.

C. Baseline measurements

[00168] Some embodiments of the methods described herein include obtaining a baseline measurement from a subject. For example, in some embodiments, a baseline measurement is obtained from the subject prior to treating the subject. Non-limiting examples of baseline measurements include a baseline cognitive function measurement, a baseline central nervous system (CNS) amyloid plaque measurement, a baseline

CNS tau accumulation measurement, a baseline cerebrospinal fluid (CSF) beta-amyloid 42 measurement, a baseline CSF tau measurement, a baseline CSF phospho-tau measurement, a baseline neurofilament light (NfL) measurement, a baseline CSF alpha-synuclein measurement, a baseline Lewy body measurement, a baseline MTRES1 protein measurement, or a baseline *MTRES1* mRNA measurement.

[00169] In some embodiments, the baseline measurement is obtained directly from the subject. In some embodiments, the baseline measurement is obtained by observation, for example by observation of the subject or of the subject's tissue. In some embodiments, the baseline measurement is obtained noninvasively using an imaging device.

[00170] In some embodiments, the baseline measurement is obtained in a sample from the subject. In some embodiments, the baseline measurement is obtained in one or more histological tissue sections. In some embodiments, the baseline measurement is obtained by performing an assay such as an immunoassay, a colorimetric assay, or a fluorescence assay, on the sample obtained from the subject. In some embodiments, the baseline measurement is obtained by an immunoassay, a colorimetric assay, a fluorescence assay, or a chromatography (e.g. HPLC) assay. In some embodiments, the baseline measurement is obtained by PCR.

[00171] In some embodiments, the baseline measurement is a baseline cognitive function measurement. The baseline cognitive function measurement may be obtained directly from the subject. For example, the subject may be administered a test. The test may include a cognitive test such as the Montreal Cognitive Assessment (MoCA), Mini-Mental State Exam (MMSE), or Mini-Cog. The test may include assessment of basic cognitive functions such as memory, language, executive frontal lobe function, apraxia, visuospatial ability, behavior, mood, orientation, or attention. The baseline cognitive function measurement may include a score. The baseline cognitive function measurement may be indicative of mild cognitive impairment, or of severe cognitive impairment. The baseline cognitive function measurement may be indicative of a neurological disorder.

[00172] The baseline measurement may include a baseline In some embodiments, the marker of neurodegeneration measurement. Examples of marker of neurodegeneration may include central nervous system (CNS) amyloid plaques, CNS tau accumulation, cerebrospinal fluid (CSF) beta-amyloid 42, CSF tau, CSF phospho-tau, CSF or plasma neurofilament light chain (NfL), Lewy bodies, or CSF alpha-synuclein. Any of these measurements may be reduced in relation to the baseline measurement. Some examples of ways to measure these may include an assay such as an immunoassay, colorimetric assay, or microscopy.

[00173] In some embodiments, the baseline measurement is a baseline amyloid plaque measurement. The baseline amyloid plaque measurement may include a central nervous system (CNS) amyloid plaque measurement. In some embodiments, the baseline amyloid plaque measurement includes a baseline concentration or amount. The baseline amyloid plaque measurement may be performed using an imaging device. The imaging device may include a positron emission tomography (PET) device. The baseline amyloid plaque measurement may be performed on a biopsy. The baseline amyloid plaque measurement may be performed using a spinal tap (for example, when the baseline amyloid plaque measurement

includes a baseline cerebrospinal fluid (CSF) amyloid plaque measurement). In some embodiments, the baseline amyloid plaque measurement is obtained by an assay such as an immunoassay. The baseline beta amyloid plaque measurement may be indicative of a neurodegenerative disease such as Alzheimer's disease.

[00174] In some embodiments, the baseline measurement is a baseline beta-amyloid 42 measurement. The baseline beta-amyloid 42 measurement may include a cerebrospinal fluid (CSF) beta-amyloid 42 measurement. In some embodiments, the baseline beta-amyloid 42 measurement includes a baseline concentration or amount. The baseline beta-amyloid 42 measurement may be performed on a biopsy. The baseline beta-amyloid 42 measurement may be performed using a spinal tap (for example, when the baseline beta-amyloid 42 measurement includes a baseline CSF beta-amyloid 42 measurement). In some embodiments, the baseline beta-amyloid 42 measurement is obtained by an assay such as an immunoassay. The baseline beta-amyloid 42 measurement may be indicative of a neurodegenerative disease such as Alzheimer's disease.

[00175] In some embodiments, the baseline measurement is a baseline tau measurement. In some embodiments, the baseline tau measurement includes a baseline concentration or amount. The baseline tau measurement may be performed on a biopsy. In some embodiments, the baseline tau measurement is obtained by an assay such as an immunoassay. The baseline tau measurement may be indicative of a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00176] In some embodiments, the baseline tau measurement is a baseline central nervous system (CNS) tau measurement. The baseline tau measurement may include a baseline total tau measurement. The baseline tau measurement may include a baseline unphosphorylated tau measurement. The baseline tau measurement may include a baseline phosphorylated tau (phospho-tau) measurement. In some embodiments, the baseline tau measurement is a baseline tau accumulation measurement. In some embodiments, the baseline tau measurement is a baseline CNS tau accumulation measurement. The baseline CNS tau accumulation measurement may be indicative of a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00177] The baseline tau measurement may include a cerebrospinal fluid (CSF) tau measurement. The baseline CSF tau measurement may be performed after use of a spinal tap. The baseline CSF tau measurement may be indicative of a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00178] The baseline CSF tau measurement may include a baseline CSF phospho-tau measurement. The baseline CSF phospho-tau measurement may include an amount of phospho-tau in relation to total tau or unphosphorylated tau. For example, the baseline CSF phospho-tau measurement may include a phospho-tau/tau ratio. The baseline CSF phospho-tau measurement may be indicative of a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00179] In some embodiments, the baseline neurofilament light chain (NfL) measurement includes a baseline CSF or plasma NfL measurement. The baseline NfL measurement may be a baseline CSF NfL measurement. The baseline NfL measurement may be a baseline plasma NfL measurement. The NfL

measurement may include a concentration or an amount. The baseline NfL measurement may be indicative of a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00180] In some embodiments, the baseline measurement is a baseline alpha-synuclein measurement. The baseline alpha-synuclein measurement may include a cerebrospinal fluid (CSF) alpha-synuclein measurement. In some embodiments, the baseline alpha-synuclein measurement includes a baseline concentration or amount. The baseline alpha-synuclein measurement may be performed on a biopsy. The baseline alpha-synuclein measurement may be performed using a spinal tap (for example, when the baseline alpha-synuclein measurement includes a baseline CSF alpha-synuclein measurement). In some embodiments, the baseline alpha-synuclein measurement is obtained by an assay such as an immunoassay. The baseline alpha-synuclein measurement may be indicative of a neurodegenerative disease such as Parkinson's disease. The baseline alpha-synuclein measurement may be indicative of dementia.

[00181] In some embodiments, the baseline measurement is a baseline Lewy body measurement. The baseline Lewy body measurement may include a central nervous system (CNS) Lewy body measurement. In some embodiments, the baseline Lewy body measurement includes a baseline concentration or amount. The baseline Lewy body measurement may be performed using an imaging device. The imaging device may include a positron emission tomography (PET) device. The baseline beta Lewy body measurement may be indicative of dementia.

[00182] In some embodiments, the baseline measurement is a baseline MTRES1 protein measurement. In some embodiments, the baseline MTRES1 protein measurement comprises a baseline MTRES1 protein level. In some embodiments, the baseline MTRES1 protein level is indicated as a mass or percentage of MTRES1 protein per sample weight. In some embodiments, the baseline MTRES1 protein level is indicated as a mass or percentage of MTRES1 protein per sample volume. In some embodiments, the baseline MTRES1 protein level is indicated as a mass or percentage of MTRES1 protein per total protein within the sample. In some embodiments, the baseline MTRES1 protein measurement is a baseline CNS or CSF MTRES1 protein measurement. In some embodiments, the baseline MTRES1 protein measurement is obtained by an assay such as an immunoassay, a colorimetric assay, or a fluorescence assay.

[00183] In some embodiments, the baseline measurement is a baseline MTRES1 mRNA measurement. In some embodiments, the baseline MTRES1 mRNA measurement comprises a baseline MTRES1 mRNA level. In some embodiments, the baseline MTRES1 mRNA level is indicated as an amount or percentage of MTRES1 mRNA per sample weight. In some embodiments, the baseline MTRES1 mRNA level is indicated as an amount or percentage of MTRES1 mRNA per sample volume. In some embodiments, the baseline MTRES1 mRNA level is indicated as an amount or percentage of MTRES1 mRNA per total mRNA within the sample. In some embodiments, the baseline MTRES1 mRNA level is indicated as an amount or percentage of MTRES1 mRNA per total nucleic acids within the sample. In some embodiments, the baseline MTRES1 mRNA level is indicated relative to another mRNA level, such as an mRNA level of a housekeeping gene, within the sample. In some embodiments, the baseline MTRES1 mRNA measurement is a baseline CNS or CSF MTRES1 mRNA measurement. In some embodiments,

the baseline MTRES1 mRNA measurement is obtained by an assay such as a polymerase chain reaction (PCR) assay. In some embodiments, the PCR comprises quantitative PCR (qPCR). In some embodiments, the PCR comprises reverse transcription of the MTRES1 mRNA.

[00184] Some embodiments of the methods described herein include obtaining a sample from a subject. In some embodiments, the baseline measurement is obtained in a sample obtained from the subject. In some embodiments, the sample is obtained from the subject prior to administration or treatment of the subject with a composition described herein. In some embodiments, a baseline measurement is obtained in a sample obtained from the subject prior to administering the composition to the subject.

[00185] In some embodiments, the sample comprises a fluid. In some embodiments, the sample is a fluid sample. In some embodiments, the fluid sample is a CSF sample. In some embodiments, the fluid sample includes a central nervous system (CNS) fluid sample. The CNS fluid may include cerebrospinal fluid (CSF). In some embodiments, the fluid sample includes a CSF sample. In some embodiments, the sample is a blood, plasma, or serum sample. In some embodiments, the sample comprises blood. In some embodiments, the sample is a blood sample. In some embodiments, the sample is a whole-blood sample. In some embodiments, the blood is fractionated or centrifuged. In some embodiments, the sample comprises plasma. In some embodiments, the sample is a plasma sample. A blood sample may be a plasma sample. In some embodiments, the sample comprises serum. In some embodiments, the sample is a serum sample. A blood sample may be a serum sample.

[00186] In some embodiments, the sample comprises a tissue. In some embodiments, the sample is a tissue sample. In some embodiments, the tissue comprises central nervous system (CNS) tissue. For example, the baseline *MTRES1* mRNA measurement, or the baseline MTRES1 protein measurement, may be obtained in a CNS tissue sample obtained from the patient. The CNS tissue may include brain tissue. The CNS tissue may include nerve tissue. The CNS tissue may include neurons, glia, microglia, astrocytes, or oligodendrocytes, or a combination thereof. The CNS tissue may include neurons. The CNS tissue may include glia. The CNS tissue may include microglia. The CNS tissue may include astrocytes. The CNS tissue may include oligodendrocytes.

[00187] In some embodiments, the sample includes cells. In some embodiments, the sample comprises a cell. In some embodiments, the cell comprises a CNS cell. The CNS cell may include a brain cell. The CNS cell may include a nerve cell. The CNS cell may be a neuron, glial cell, microglial cell, astrocyte, or oligodendrocyte. The CNS cell may be a neuron. The CNS cell may be a glial cell. The CNS cell may be a microglial cell. The CNS cell may be an astrocyte. The CNS cell may be an oligodendrocyte.

D. Effects

[00188] In some embodiments, the composition or administration of the composition affects a measurement such as a cognitive function measurement, a central nervous system (CNS) amyloid plaque measurement, a CNS tau accumulation measurement, a cerebrospinal fluid (CSF) beta-amyloid 42 measurement, a CSF tau measurement, a CSF phospho-tau measurement, a NfL measurement, a CSF alpha-synuclein measurement, a Lewy body measurement, a MTRES1 protein measurement, or a *MTRES1* mRNA measurement, relative to the baseline measurement.

[00189] Some embodiments of the methods described herein include obtaining the measurement from a subject. For example, the measurement may be obtained from the subject after treating the subject. In some embodiments, the measurement is obtained in a second sample (such as a fluid or tissue sample described herein) obtained from the subject after the composition is administered to the subject. In some embodiments, the measurement is an indication that the disorder has been treated.

[00190] In some embodiments, the measurement is obtained directly from the subject. In some embodiments, the measurement is obtained noninvasively using an imaging device. In some embodiments, the measurement is obtained in a second sample from the subject. In some embodiments, the measurement is obtained in one or more histological tissue sections. In some embodiments, the measurement is obtained by performing an assay on the second sample obtained from the subject. In some embodiments, the measurement is obtained by an assay, such as an assay described herein. In some embodiments, the assay is an immunoassay, a colorimetric assay, a fluorescence assay, a chromatography (e.g. HPLC) assay, or a PCR assay. In some embodiments, the measurement is obtained by an assay such as an immunoassay, a colorimetric assay, a fluorescence assay, or a chromatography (e.g. HPLC) assay. In some embodiments, the measurement is obtained by PCR. In some embodiments, the measurement is obtained by histology. In some embodiments, the measurement is obtained by observation. In some embodiments, additional measurements are made, such as in a 3rd sample, a 4th sample, or a fifth sample.

[00191] In some embodiments, the measurement is obtained within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 12 hours, within 18 hours, or within 24 hours after the administration of the composition. In some embodiments, the measurement is obtained within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, or within 7 days after the administration of the composition. In some embodiments, the measurement is obtained within 1 week, within 2 weeks, within 3 weeks, within 1 month, within 2 months, within 3 months, within 6 months, within 1 year, within 2 years, within 3 years, within 4 years, or within 5 years after the administration of the composition. In some embodiments, the measurement is obtained after 1 hour, after 2 hours, after 3 hours, after 4 hours, after 5 hours, after 6 hours, after 12 hours, after 18 hours, or after 24 hours after the administration of the composition. In some embodiments, the measurement is obtained after 1 day, after 2 days, after 3 days, after 4 days, after 5 days, after 6 days, or after 7 days after the administration of the composition. In some embodiments, the measurement is obtained after 1 week, after 2 weeks, after 3 weeks, after 1 month, after 2 months, after 3 months, after 6 months, after 1 year, after 2 years, after 3 years, after 4 years, or after 5 years, following the administration of the composition.

[00192] In some embodiments, the composition reduces the measurement relative to the baseline measurement. For example, an adverse phenotype of a neurological disorder may be reduced upon administration of the composition. The neurological disorder may include dementia, Alzheimer's disease, delirium, cognitive decline, vascular dementia, or Parkinson's disease. In some embodiments, the reduction is measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the reduction is measured directly in the subject after administering the composition to the subject. In some embodiments, the measurement is decreased by about 2.5% or more,

about 5% or more, or about 7.5% or more, relative to the baseline measurement. In some embodiments, the measurement is decreased by about 10% or more, relative to the baseline measurement. In some embodiments, the measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline measurement. In some embodiments, the measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline measurement. In some embodiments, the measurement is decreased by no more than about 10%, relative to the baseline measurement. In some embodiments, the measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline measurement. In some embodiments, the measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00193] In some embodiments, the composition increases the measurement relative to the baseline measurement. For example, a protective phenotype of a neurological disorder may be increased upon administration of the composition. The neurological disorder may include dementia, Alzheimer's disease, delirium, cognitive decline, vascular dementia, or Parkinson's disease. In some embodiments, the increase is measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the increase is measured directly in the subject after administering the composition to the subject. In some embodiments, the measurement is increased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline measurement. In some embodiments, the measurement is increased by about 10% or more, relative to the baseline measurement. In some embodiments, the measurement is increased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline measurement. In some embodiments, the measurement is increased by about 100% or more, increased by about 250% or more, increased by about 500% or more, increased by about 750% or more, or increased by about 1000% or more, relative to the baseline measurement. In some embodiments, the measurement is increased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline measurement. In some embodiments, the measurement is increased by no more than about 10%, relative to the baseline measurement. In some embodiments, the measurement is increased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline measurement. In some embodiments, the measurement is increased by no more than about 100%, increased by no more than about 250%, increased by no more than about 500%, increased by no more than about 750%, or increased by no more than about 1000%, relative to the baseline measurement. In some embodiments, the measurement is increased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 250%, 500%, 750%, or 1000%, or by a range defined by any of the two aforementioned percentages.

[00194]In some embodiments, the measurement is a cognitive function measurement. The cognitive function measurement may be obtained directly from the subject. For example, the subject may be administered a test. The test may include a cognitive test such as the Montreal Cognitive Assessment (MoCA), Mini-Mental State Exam (MMSE), or Mini-Cog. The test may include assessment of basic cognitive functions such as memory, language, executive frontal lobe function, apraxia, visuospatial ability, behavior, mood, orientation, or attention. The cognitive function measurement may include a score. The cognitive function measurement may be indicative of a lack of cognitive impairment. In some embodiments, the cognitive function measurement is indicative of mild cognitive impairment, and the baseline cognitive function measurement is indicative of severe cognitive impairment. The cognitive function measurement may be indicative of a neurological disorder.

[00195]In some embodiments, the composition increases the cognitive function measurement relative to the baseline cognitive function measurement. In some embodiments, the increase is measured directly in the subject after administering the composition to the subject. In some embodiments, the cognitive function measurement is increased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline cognitive function measurement. In some embodiments, the cognitive function measurement is increased by about 10% or more, relative to the baseline cognitive function measurement. In some embodiments, the cognitive function measurement is increased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline cognitive function measurement. In some embodiments, the cognitive function measurement is increased by about 100% or more, increased by about 250% or more, increased by about 500% or more, increased by about 750% or more, or increased by about 1000% or more, relative to the baseline cognitive function measurement. In some embodiments, the cognitive function measurement is increased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline cognitive function measurement. In some embodiments, the cognitive function measurement is increased by no more than about 10%, relative to the baseline cognitive function measurement. In some embodiments, the cognitive function measurement is increased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline cognitive function measurement. In some embodiments, the cognitive function measurement is increased by no more than about 100%, increased by no more than about 250%, increased by no more than about 500%, increased by no more than about 750%, or increased by no more than about 1000%, relative to the baseline cognitive function measurement. In some embodiments, the cognitive function measurement is increased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 250%, 500%, 750%, or 1000%, or by a range defined by any of the two aforementioned percentages.

[00196]In some embodiments, the measurement is an amyloid plaque measurement. The amyloid plaque measurement may include a central nervous system (CNS) amyloid plaque measurement. In some embodiments, the amyloid plaque measurement includes a concentration or amount. The amyloid plaque

measurement may be performed using an imaging device. The imaging device may include a positron emission tomography (PET) device. The amyloid plaque measurement may be performed on a biopsy. The amyloid plaque measurement may be performed using a spinal tap (for example, when the amyloid plaque measurement includes a cerebrospinal fluid (CSF) amyloid plaque measurement). In some embodiments, the amyloid plaque measurement is obtained by an assay such as an immunoassay. The beta amyloid plaque measurement may be indicative of a treatment effect of the oligonucleotide on a neurodegenerative disease such as Alzheimer's disease.

[00197] In some embodiments, the composition reduces the amyloid plaque measurement relative to the baseline amyloid plaque measurement. In some embodiments, the reduction is measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the reduction is measured directly in the subject after administering the composition to the subject. In some embodiments, the amyloid plaque measurement is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline amyloid plaque measurement. In some embodiments, the amyloid plaque measurement is decreased by about 10% or more, relative to the baseline amyloid plaque measurement. In some embodiments, the amyloid plaque measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline amyloid plaque measurement. In some embodiments, the amyloid plaque measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline amyloid plaque measurement. In some embodiments, the amyloid plaque measurement is decreased by no more than about 10%, relative to the baseline amyloid plaque measurement. In some embodiments, the amyloid plaque measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline amyloid plaque measurement. In some embodiments, the amyloid plaque measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00198] In some embodiments, the measurement is a beta-amyloid 42 measurement. The beta-amyloid 42 measurement may include a cerebrospinal fluid (CSF) beta-amyloid 42 measurement. In some embodiments, the beta-amyloid 42 measurement includes a concentration or amount. The beta-amyloid 42 measurement may be performed on a biopsy. The beta-amyloid 42 measurement may be performed using a spinal tap (for example, when the beta-amyloid 42 measurement includes a CSF beta-amyloid 42 measurement). In some embodiments, the beta-amyloid 42 measurement is obtained by an assay such as an immunoassay. The beta-amyloid 42 measurement may be indicative of a treatment effect of the oligonucleotide on a neurodegenerative disease such as Alzheimer's disease.

[00199] In some embodiments, the composition reduces the CSF beta-amyloid 42 measurement relative to the baseline beta-amyloid 42 measurement. In some embodiments, the reduction is measured in a second sample (for example, a CSF sample) obtained from the subject after administering the composition to the

subject. In some embodiments, the CSF beta-amyloid 42 measurement is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline CSF beta-amyloid 42 measurement. In some embodiments, the CSF beta-amyloid 42 measurement is decreased by about 10% or more, relative to the baseline CSF beta-amyloid 42 measurement. In some embodiments, the CSF beta-amyloid 42 measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline CSF beta-amyloid 42 measurement. In some embodiments, the CSF beta-amyloid 42 measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline CSF beta-amyloid 42 measurement. In some embodiments, the CSF beta-amyloid 42 measurement is decreased by no more than about 10%, relative to the baseline CSF beta-amyloid 42 measurement. In some embodiments, the CSF beta-amyloid 42 measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline CSF beta-amyloid 42 measurement. In some embodiments, the CSF beta-amyloid 42 measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00200] In some embodiments, the measurement is a tau measurement. In some embodiments, the tau measurement includes a concentration or amount. The tau measurement may be performed on a biopsy. In some embodiments, the tau measurement is obtained by an assay such as an immunoassay. The beta tau measurement may be indicative of a treatment effect of the oligonucleotide on a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00201] In some embodiments, the tau measurement is a central nervous system (CNS) tau measurement. The tau measurement may include a total tau measurement. The tau measurement may include a unphosphorylated tau measurement. The tau measurement may include a phosphorylated tau (phospho-tau) measurement. In some embodiments, the tau measurement is a tau accumulation measurement. In some embodiments, the tau measurement is a CNS tau accumulation measurement. The CNS tau accumulation measurement may be indicative of a treatment effect of the oligonucleotide on a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00202] In some embodiments, the composition reduces the CNS tau accumulation measurement relative to the baseline CNS tau accumulation measurement. In some embodiments, the reduction is measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the CNS tau accumulation measurement is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline CNS tau accumulation measurement. In some embodiments, the CNS tau accumulation measurement is decreased by about 10% or more, relative to the baseline CNS tau accumulation measurement. In some embodiments, the CNS tau accumulation measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline CNS tau accumulation measurement. In some embodiments, the CNS tau accumulation

measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline CNS tau accumulation measurement. In some embodiments, the CNS tau accumulation measurement is decreased by no more than about 10%, relative to the baseline CNS tau accumulation measurement. In some embodiments, the CNS tau accumulation measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline CNS tau accumulation measurement. In some embodiments, the CNS tau accumulation measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00203] The tau measurement may include a cerebrospinal fluid (CSF) tau measurement. The CSF tau measurement may be performed after use of a spinal tap. The CSF tau measurement may be indicative of a treatment effect of the oligonucleotide on a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00204] In some embodiments, the composition reduces the CSF tau measurement relative to the baseline CSF tau measurement. In some embodiments, the reduction is measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the reduction is measured in a second CSF sample obtained from the subject after administering the composition to the subject. In some embodiments, the CSF tau measurement is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline CSF tau measurement. In some embodiments, the CSF tau measurement is decreased by about 10% or more, relative to the baseline CSF tau measurement. In some embodiments, the CSF tau measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline CSF tau measurement. In some embodiments, the CSF tau measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline CSF tau measurement. In some embodiments, the CSF tau measurement is decreased by no more than about 10%, relative to the baseline CSF tau measurement. In some embodiments, the CSF tau measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline CSF tau measurement. In some embodiments, the CSF tau measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00205] The CSF tau measurement may include a CSF phospho-tau measurement. The CSF phospho-tau measurement may include an amount of phospho-tau in relation to total tau or unphosphorylated tau. For example, the CSF phospho-tau measurement may include a phospho-tau/tau ratio. The CSF phospho-tau measurement may be indicative of a treatment effect of the oligonucleotide on a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00206] In some embodiments, the composition reduces the CSF phospho-tau measurement relative to the baseline CSF phospho-tau measurement. In some embodiments, the reduction is measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the reduction is measured in a second CSF sample obtained from the subject after administering the composition to the subject. In some embodiments, the CSF phospho-tau measurement is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline CSF phospho-tau measurement. In some embodiments, the CSF phospho-tau measurement is decreased by about 10% or more, relative to the baseline CSF phospho-tau measurement. In some embodiments, the CSF phospho-tau measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline CSF phospho-tau measurement. In some embodiments, the CSF phospho-tau measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline CSF phospho-tau measurement. In some embodiments, the CSF phospho-tau measurement is decreased by no more than about 10%, relative to the baseline CSF phospho-tau measurement. In some embodiments, the CSF phospho-tau measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline CSF phospho-tau measurement. In some embodiments, the CSF phospho-tau measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00207] In some embodiments, the neurofilament light chain (NfL) measurement includes a CSF or plasma NfL measurement. The NfL measurement may be a CSF NfL measurement. The NfL measurement may be a plasma NfL measurement. The NfL measurement may include a concentration or an amount. The NfL measurement may be indicative of a neurodegenerative disease such as Alzheimer's disease or Parkinson's disease.

[00208] In some embodiments, the composition reduces the NfL measurement relative to the baseline NfL measurement. In some embodiments, the reduction is measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the NfL measurement is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline NfL measurement. In some embodiments, the NfL measurement is decreased by about 10% or more, relative to the baseline NfL measurement. In some embodiments, the NfL measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline NfL measurement. In some embodiments, the NfL measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline NfL measurement. In some embodiments, the NfL measurement is decreased by no more than about 10%, relative to the baseline NfL measurement. In some embodiments, the NfL measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no

more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline NfL measurement. In some embodiments, the NfL measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00209] In some embodiments, the measurement is an alpha-synuclein measurement. The alpha-synuclein measurement may include a cerebrospinal fluid (CSF) alpha-synuclein measurement. In some embodiments, the alpha-synuclein measurement includes a concentration or amount. The alpha-synuclein measurement may be performed on a biopsy. The alpha-synuclein measurement may be performed using a spinal tap (for example, when the alpha-synuclein measurement includes a CSF alpha-synuclein measurement). In some embodiments, the alpha-synuclein measurement is obtained by an assay such as an immunoassay. The alpha-synuclein measurement may be indicative of a treatment effect of the oligonucleotide on a neurodegenerative disease such as Parkinson's disease. The alpha-synuclein measurement may be indicative of a treatment effect of the oligonucleotide on dementia.

[00210] In some embodiments, the composition reduces the alpha-synuclein measurement relative to the baseline alpha-synuclein measurement. In some embodiments, the reduction is measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the alpha-synuclein measurement is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline alpha-synuclein measurement. In some embodiments, the alpha-synuclein measurement is decreased by about 10% or more, relative to the baseline alpha-synuclein measurement. In some embodiments, the alpha-synuclein measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline alpha-synuclein measurement. In some embodiments, the alpha-synuclein measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline alpha-synuclein measurement. In some embodiments, the alpha-synuclein measurement is decreased by no more than about 10%, relative to the baseline alpha-synuclein measurement. In some embodiments, the alpha-synuclein measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline alpha-synuclein measurement. In some embodiments, the alpha-synuclein measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00211] In some embodiments, the measurement is a Lewy body measurement. The Lewy body measurement may include a central nervous system (CNS) Lewy body measurement. In some embodiments, the Lewy body measurement includes a concentration or amount. The Lewy body measurement may be performed using an imaging device. The imaging device may include a positron emission tomography (PET) device. The beta Lewy body measurement may be indicative of a treatment effect of the oligonucleotide on dementia.

[00212] In some embodiments, the composition reduces the Lewy body measurement relative to the baseline Lewy body measurement. In some embodiments, the reduction is measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the reduction is measured directly in the subject after administering the composition to the subject. In some embodiments, the Lewy body measurement is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline Lewy body measurement. In some embodiments, the Lewy body measurement is decreased by about 10% or more, relative to the baseline Lewy body measurement. In some embodiments, the Lewy body measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, relative to the baseline Lewy body measurement. In some embodiments, the Lewy body measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline Lewy body measurement. In some embodiments, the Lewy body measurement is decreased by no more than about 10%, relative to the baseline Lewy body measurement. In some embodiments, the Lewy body measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline Lewy body measurement. In some embodiments, the Lewy body measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00213] In some embodiments, the measurement is an MTRES1 protein measurement. In some embodiments, the MTRES1 protein measurement comprises an MTRES1 protein level. In some embodiments, the MTRES1 protein level is indicated as a mass or percentage of MTRES1 protein per sample weight. In some embodiments, the MTRES1 protein level is indicated as a mass or percentage of MTRES1 protein per sample volume. In some embodiments, the MTRES1 protein level is indicated as a mass or percentage of MTRES1 protein per total protein within the sample. In some embodiments, the MTRES1 protein measurement is a CNS tissue or fluid MTRES1 protein measurement. In some embodiments, the MTRES1 protein measurement is obtained by an assay such as an immunoassay, a colorimetric assay, or a fluorescence assay.

[00214] In some embodiments, the composition reduces the MTRES1 protein measurement relative to the baseline MTRES1 protein measurement. In some embodiments, the composition reduces CNS tissue or fluid MTRES1 protein levels relative to the baseline MTRES1 protein measurement. In some embodiments, the reduced MTRES1 protein levels are measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the MTRES1 protein measurement is decreased by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline MTRES1 protein measurement. In some embodiments, the MTRES1 protein measurement is decreased by about 10% or more, relative to the baseline MTRES1 protein measurement. In some embodiments, the MTRES1 protein measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more,

about 90% or more, or about 100%, relative to the baseline MTRES1 protein measurement. In some embodiments, the MTRES1 protein measurement is decreased by no more than about 2.5%, no more than about 5%, or no more than about 7.5%, relative to the baseline MTRES1 protein measurement. In some embodiments, the MTRES1 protein measurement is decreased by no more than about 10%, relative to the baseline MTRES1 protein measurement. In some embodiments, the MTRES1 protein measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100% relative to the baseline MTRES1 protein measurement. In some embodiments, the MTRES1 protein measurement is decreased by 2.5%, 5%, 7.5%, 19%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or by a range defined by any of the two aforementioned percentages.

[00215] In some embodiments, the measurement is an MTRES1 mRNA measurement. In some embodiments, the MTRES1 mRNA measurement comprises an MTRES1 mRNA level. In some embodiments, the MTRES1 mRNA level is indicated as an amount or percentage of MTRES1 mRNA per sample weight. In some embodiments, the MTRES1 mRNA level is indicated as an amount or percentage of MTRES1 mRNA per sample volume. In some embodiments, the MTRES1 mRNA level is indicated as an amount or percentage of MTRES1 mRNA per total mRNA within the sample. In some embodiments, the MTRES1 mRNA level is indicated as an amount or percentage of MTRES1 mRNA per total nucleic acids within the sample. In some embodiments, the MTRES1 mRNA level is indicated relative to another mRNA level, such as an mRNA level of a housekeeping gene, within the sample. In some embodiments, the MTRES1 mRNA measurement is a CNS tissue or fluid MTRES1 mRNA measurement. In some embodiments, the MTRES1 mRNA measurement is obtained by an assay such as a PCR assay. In some embodiments, the PCR comprises qPCR. In some embodiments, the PCR comprises reverse transcription of the MTRES1 mRNA.

[00216] In some embodiments, the composition reduces the MTRES1 mRNA measurement relative to the baseline MTRES1 mRNA measurement. In some embodiments, the MTRES1 mRNA measurement is obtained in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the composition reduces MTRES1 mRNA levels relative to the baseline MTRES1 mRNA levels. In some embodiments, the reduced MTRES1 mRNA levels are measured in a second sample obtained from the subject after administering the composition to the subject. In some embodiments, the second sample is a CNS sample. In some embodiments, the MTRES1 mRNA measurement is reduced by about 2.5% or more, about 5% or more, or about 7.5% or more, relative to the baseline MTRES1 mRNA measurement. In some embodiments, the MTRES1 mRNA measurement is decreased by about 10% or more, relative to the baseline MTRES1 mRNA measurement. In some embodiments, the MTRES1 mRNA measurement is decreased by about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%, relative to the baseline MTRES1 mRNA measurement. In some embodiments, the MTRES1 mRNA measurement is decreased by no more than about 2.5%, no more than

about 5%, or no more than about 7.5%, relative to the baseline MTRES1 mRNA measurement. In some embodiments, the MTRES1 mRNA measurement is decreased by no more than about 10%, relative to the baseline MTRES1 mRNA measurement. In some embodiments, the MTRES1 mRNA measurement is decreased by no more than about 20%, no more than about 30%, no more than about 40%, no more than about 50%, no more than about 60%, no more than about 70%, no more than about 80%, no more than about 90%, or no more than about 100%, relative to the baseline MTRES1 mRNA measurement. In some embodiments, the MTRES1 mRNA measurement is decreased by 2.5%, 5%, 7.5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% or by a range defined by any of the two aforementioned percentages.

III. DEFINITIONS

[00217] Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and/or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.

[00218] Throughout this application, various embodiments may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[00219] As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a sample” includes a plurality of samples, including mixtures thereof.

[00220] The terms “determining,” “measuring,” “evaluating,” “assessing,” “assaying,” and “analyzing” are often used interchangeably herein to refer to forms of measurement. The terms include determining if an element is present or not (for example, detection). These terms can include quantitative, qualitative or quantitative and qualitative determinations. Assessing can be relative or absolute. “Detecting the presence of” can include determining the amount of something present in addition to determining whether it is present or absent depending on the context.

[00221] The terms “subject,” and “patient” may be used interchangeably herein. A “subject” can be a biological entity containing expressed genetic materials. The biological entity can be a plant, animal, or microorganism, including, for example, bacteria, viruses, fungi, and protozoa. The subject can be a mammal. The mammal can be a human. The subject may be diagnosed or suspected of being at high risk

for a disease. In some cases, the subject is not necessarily diagnosed or suspected of being at high risk for the disease.

[00222] As used herein, the term “about” a number refers to that number plus or minus 10% of that number. The term “about” a range refers to that range minus 10% of its lowest value and plus 10% of its greatest value.

[00223] As used herein, the terms “treatment” or “treating” are used in reference to a pharmaceutical or other intervention regimen for obtaining beneficial or desired results in the recipient. Beneficial or desired results include but are not limited to a therapeutic benefit and/or a prophylactic benefit. A therapeutic benefit may refer to eradication or amelioration of symptoms or of an underlying disorder being treated. Also, a therapeutic benefit can be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder. A prophylactic effect includes delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. For prophylactic benefit, a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease may undergo treatment, even though a diagnosis of this disease may not have been made.

[00224] The term “Cx-y” or “Cx-Cy” when used in conjunction with a chemical moiety, such as alkyl, alkenyl, or alkynyl is meant to include groups that contain from x to y carbons in the chain. For example, the term “C1-6alkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from 1 to 6 carbons.

[00225] The terms “Cx-yalkenyl” and “Cx-yalkynyl” refer to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.

[00226] The term “carbocycle” as used herein refers to a saturated, unsaturated or aromatic ring in which each atom of the ring is carbon. Carbocycle includes 3- to 10-membered monocyclic rings, 5- to 12-membered bicyclic rings, 5- to 12-membered spiro bicycles, and 5- to 12-membered bridged rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated, and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. A bicyclic carbocycle includes any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits. A bicyclic carbocycle further includes spiro bicyclic rings such as spiro pentane. A bicyclic carbocycle includes any combination of ring sizes such as 3-3 spiro ring systems, 4-4 spiro ring systems, 4-5 fused ring systems, 5-5 fused ring systems, 5-6 fused ring systems, 6-6 fused ring systems, 5-7 fused ring systems, 6-7 fused ring systems, 5-8 fused ring systems, and 6-8 fused ring systems. Exemplary carbocycles include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, indanyl, naphthyl, and bicyclo[1.1.1]pentanyl.

[00227] The term “aryl” refers to an aromatic monocyclic or aromatic multicyclic hydrocarbon ring system. The aromatic monocyclic or aromatic multicyclic hydrocarbon ring system contains only hydrogen and carbon and from five to eighteen carbon atoms, where at least one of the rings in the ring system is aromatic, i.e., it contains a cyclic, delocalized $(4n+2)$ π -electron system in accordance with the Hückel theory. The ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene.

[00228] The term “cycloalkyl” refers to a saturated ring in which each atom of the ring is carbon. Cycloalkyl may include monocyclic and polycyclic rings such as 3- to 10-membered monocyclic rings, 5- to 12-membered bicyclic rings, 5- to 12-membered spiro bicycles, and 5- to 12-membered bridged rings. In certain embodiments, a cycloalkyl comprises three to ten carbon atoms. In other embodiments, a cycloalkyl comprises five to seven carbon atoms. The cycloalkyl may be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, spiropentane, norbornyl (i.e., bicyclo[2.2.1]heptanyl), decalinyl, 7,7 dimethyl bicyclo[2.2.1]heptanyl, bicyclo[1.1.1]pentanyl, and the like.

[00229] The term “cycloalkenyl” refers to a saturated ring in which each atom of the ring is carbon and there is at least one double bond between two ring carbons. Cycloalkenyl may include monocyclic and polycyclic rings such as 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, and 5- to 12-membered bridged rings. In other embodiments, a cycloalkenyl comprises five to seven carbon atoms. The cycloalkenyl may be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.

[00230] The term “halo” or, alternatively, “halogen” or “halide,” means fluoro, chloro, bromo or iodo. In some embodiments, halo is fluoro, chloro, or bromo.

[00231] The term “haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, for example, trifluoromethyl, dichloromethyl, bromomethyl, 2,2,2 trifluoroethyl, 1 chloromethyl 2 fluoroethyl, and the like. In some embodiments, the alkyl part of the haloalkyl radical is optionally further substituted as described herein.

[00232] The term “heterocycle” as used herein refers to a saturated, unsaturated or aromatic ring comprising one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. Heterocycles include 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, 5- to 12-membered spiro bicycles, and 5- to 12-membered bridged rings. A bicyclic heterocycle includes any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits. In an exemplary embodiment, an aromatic ring, e.g., pyridyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, morpholine, piperidine or cyclohexene. A bicyclic heterocycle includes any combination of ring sizes such as 4-5 fused ring systems, 5-5 fused ring systems, 5-6 fused ring systems, 6-6 fused ring systems, 5-7 fused ring systems, 6-7 fused ring systems, 5-8 fused ring systems, and 6-8 fused ring systems. A bicyclic heterocycle further includes spiro bicyclic rings, e.g., 5 to 12-membered spiro bicycles, such as 2-oxa-6-azaspiro[3.3]heptane.

[00233] The term "heteroaryl" refers to a radical derived from a 5 to 18 membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. As used herein, the heteroaryl radical is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is aromatic, i.e., it contains a cyclic, delocalized $(4n+2)$ π -electron system in accordance with the Hückel theory. Heteroaryl includes fused or bridged ring systems. The heteroatom(s) in the heteroaryl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl is attached to the rest of the molecule through any atom of the ring(s). Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3 benzodioxolyl, benzofuranyl, benzoxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4 benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothieryl (benzothiophenyl), benzothieno[3,2 d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2 a]pyridinyl, carbazolyl, cinnolyl, cyclopenta[d]pyrimidinyl, 6,7 dihydro 5H cyclopenta[4,5]thieno[2,3 d]pyrimidinyl, 5,6 dihydrobenzo[h]quinazolinyl, 5,6 dihydrobenzo[h]cinnolyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furo[3,2 c]pyridinyl, 5,6,7,8,9,10 hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10 hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10 hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolyl, isoindolyl, isoquinolyl, indolizyl, isoxazolyl, 5,8 methano 5,6,7,8 tetrahydroquinazolinyl, naphthyridinyl, 1,6 naphthyridinonyl, oxadiazolyl, 2 oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a octahydrobenzo[h]quinazolinyl, 1 phenyl 1H pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4 d]pyrimidinyl, pyridinyl, pyrido[3,2 d]pyrimidinyl, pyrido[3,4 d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolyl, isoquinolyl, tetrahydroquinolyl, 5,6,7,8 tetrahydroquinazolinyl, 5,6,7,8 tetrahydrobenzo[4,5]thieno[2,3 d]pyrimidinyl, 6,7,8,9 tetrahydro 5H cyclohepta[4,5]thieno[2,3 d]pyrimidinyl, 5,6,7,8 tetrahydropyrido[4,5 c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3 d]pyrimidinyl, thieno[3,2 d]pyrimidinyl, thieno[2,3 c]pyridinyl, and thiophenyl (i.e. thienyl).

[00234] The term "heterocycloalkyl" refers to a saturated ring with carbon atoms and at least one heteroatom. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. Heterocycloalkyl may include monocyclic and polycyclic rings such as 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, 5- to 12-membered spiro bicycles, and 5- to 12-membered bridged rings. The heteroatoms in the heterocycloalkyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocycloalkyl is attached to the rest of the molecule through any atom of the heterocycloalkyl, valence permitting, such as any carbon or nitrogen atoms of the heterocycloalkyl. Examples of heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2 oxopiperazinyl, 2 oxopiperidinyl, 2 oxopyrrolidinyl,

oxazolidinyl, piperidinyl, piperazinyl, 4 piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1 oxo thiomorpholinyl, 2-oxa-6-azaspiro[3.3]heptane, and 1,1 dioxo thiomorpholinyl.

[00235] The term "heterocycloalkenyl" refers to an unsaturated ring with carbon atoms and at least one heteroatom and there is at least one double bond between two ring carbons. Heterocycloalkenyl does not include heteroaryl rings. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. Heterocycloalkenyl may include monocyclic and polycyclic rings such as 3- to 10-membered monocyclic rings, 6- to 12-membered bicyclic rings, and 5- to 12-membered bridged rings. In other embodiments, a heterocycloalkenyl comprises five to seven ring atoms. The heterocycloalkenyl may be attached to the rest of the molecule by a single bond. Examples of monocyclic cycloalkenyls include, e.g., pyrroline (dihydropyrrole), pyrazoline (dihydropyrazole), imidazoline (dihydroimidazole), triazoline (dihydrotriazole), dihydrofuran, dihydrothiophene, oxazoline (dihydrooxazole), isoxazoline (dihydroisoxazole), thiazoline (dihydrothiazole), isothiazoline (dihydroisothiazole), oxadiazoline (dihydrooxadiazole), thiadiazoline (dihydrothiadiazole), dihydropyridine, tetrahydropyridine, dihydropyridazine, tetrahydropyridazine, dihydropyrimidine, tetrahydropyrimidine, dihydropyrazine, tetrahydropyrazine, pyran, dihydropyran, thiopyran, dihydrothiopyran, dioxine, dihydrodioxine, oxazine, dihydrooxazine, thiazine, and dihydrothiazine.

[00236] The term "substituted" refers to moieties having substituents replacing a hydrogen on one or more carbons or substitutable heteroatoms, e.g., an NH or NH₂ of a compound. It will be understood that "substitution" or "substituted with" includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, i.e., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. In certain embodiments, substituted refers to moieties having substituents replacing two hydrogen atoms on the same carbon atom, such as substituting the two hydrogen atoms on a single carbon with an oxo, imino or thioxo group. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds.

[00237] In some embodiments, substituents may include any substituents described herein, for example: halogen, hydroxy, oxo (=O), thioxo (=S), cyano (-CN), nitro (-NO₂), imino (=N-H), oximo (=N-OH), hydrazino (=N-NH₂), -Rb ORa, -Rb OC(O) Ra, -Rb OC(O) ORa, -Rb OC(O) N(Ra)₂, -Rb N(Ra)₂, -Rb C(O)Ra, -Rb C(O)ORa, -Rb C(O)N(Ra)₂, -Rb O Rc C(O)N(Ra)₂, -Rb N(Ra)C(O)ORa, -Rb N(Ra)C(O)Ra, -Rb N(Ra)S(O)tRa (where t is 1 or 2), -Rb S(O)tRa (where t is 1 or 2), -Rb S(O)tORa (where t is 1 or 2), and -Rb S(O)tN(Ra)₂ (where t is 1 or 2); and alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, aralkynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, and heteroarylalkyl, any of which may be optionally substituted by alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thioxo (=S), cyano (-CN), nitro (-NO₂), imino (=N-H), oximo (=N-

OH), hydrazine (=N-NH₂), -Rb ORa, -Rb OC(O) Ra, -Rb OC(O) ORa, -Rb OC(O) N(Ra)₂, -Rb N(Ra)₂, -Rb C(O)Ra, -Rb C(O)ORa, -Rb C(O)N(Ra)₂, -Rb O Rc C(O)N(Ra)₂, -Rb N(Ra)C(O)ORa, -Rb N(Ra)C(O)Ra, -Rb N(Ra)S(O)tRa (where t is 1 or 2), -Rb S(O)tRa (where t is 1 or 2), -Rb S(O)tORa (where t is 1 or 2) and -Rb S(O)tN(Ra)₂ (where t is 1 or 2); wherein each Ra is independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl, wherein each Ra, valence permitting, may be optionally substituted with alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO₂), imino (=N-H), oximo (=N-OH), hydrazine (=N-NH₂), -Rb ORa, -Rb OC(O) Ra, -Rb OC(O) ORa, -Rb OC(O) N(Ra)₂, -Rb N(Ra)₂, -Rb C(O)Ra, -Rb C(O)ORa, -Rb C(O)N(Ra)₂, -Rb O Rc C(O)N(Ra)₂, -Rb N(Ra)C(O)ORa, -Rb N(Ra)C(O)Ra, -Rb N(Ra)S(O)tRa (where t is 1 or 2), -Rb S(O)tRa (where t is 1 or 2), -Rb S(O)tORa (where t is 1 or 2) and -Rb S(O)tN(Ra)₂ (where t is 1 or 2); and wherein each Rb is independently selected from a direct bond or a straight or branched alkylene, alkenylene, or alkynylene chain, and each Rc is a straight or branched alkylene, alkenylene or alkynylene chain.

[00238] Double bonds to oxygen atoms, such as oxo groups, are represented herein as both “=O” and “(O)”. Double bonds to nitrogen atoms are represented as both “=NR” and “(NR)”. Double bonds to sulfur atoms are represented as both “=S” and “(S)”.

[00239] In some embodiments, a "derivative" polypeptide or peptide is one that is modified, for example, by glycosylation, pegylation, phosphorylation, sulfation, reduction/alkylation, acylation, chemical coupling, or mild formalin treatment. A derivative may also be modified to contain a detectable label, either directly or indirectly, including, but not limited to, a radioisotope, fluorescent, and enzyme label.

[00240] Some embodiments refer to nucleic acid sequence information. It is contemplated that in some embodiments, thymine (T) may be interchanged with uracil (U), or vice versa. For example, some sequences in the sequence listing may recite Ts, but these may be replaced with Us in some embodiments. In some oligonucleotides with nucleic acid sequences that include uracil, the uracil may be replaced with thymine. Similarly, in some oligonucleotides with nucleic acid sequences that include thymine, the thymine may be replaced with uracil. In some embodiments, an oligonucleotide such as an siRNA comprises or consists of RNA. In some embodiments, the oligonucleotide may comprise or consist of DNA. For example, an ASO may include DNA.

[00241] Some aspects include sequences with nucleotide modifications or modified internucleoside linkages. Generally, and unless otherwise specified, Nf (e.g. Af, Cf, Gf, Tf, or Uf) refers to a 2' fluoro-modified nucleoside, dN (e.g. dA, dC, dG, dT, or dU) refers to a 2' deoxy nucleoside, n (e.g. a, c, g, t, or u) refers to a 2' O-methyl modified nucleoside, and “s” refers to a phosphorothioate linkage.

[00242] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

VI. EXAMPLES

Example 1: A Loss of Function Variant in *MTRES1* Demonstrates Protective Associations for Dementia and Alzheimer's Disease Related Traits

[00243] Variants in *MTRES1* were evaluated for associations with dementia, Alzheimer's disease and related traits in approximately 452,000 individuals with genotype data from the UK Biobank cohort. rs117058816 is a rare (AAF=0.006) splice donor variant (c.3+1G>A) in *MTRES1*. This variant is considered to be a loss of function variant that results in a decrease in the abundance or activity of the *MTRES1* gene product.

[00244] The analyses resulted in identification of dementia and Alzheimer's disease-related associations for the *MTRES1* loss of function variant. For example, rs117058816 was associated with decreased risk of Alzheimer's disease, dementia, delirium, and vascular dementia. rs117058816 was also associated with decreased risk of family history of Alzheimer's disease and decreased risk of dementia medication use (Table 1A and 1B).

Table 1A. *MTRES1* Dementia, Alzheimer's and related trait associations

Variant	Gene	Function	AAF	Alzheimer's Disease (n=2,864)		Family History of Alzheimer's Disease (n=53,344)	
				P value	OR	P value	OR
rs117058816	MTRES1	Splice donor; c.3+1G>A	0.006	2.58E-04	↓0.459	9.54E-03	↓0.893

Table 1B. *MTRES1* Dementia, Alzheimer's and related trait associations

Variant	Dementia (n=4,009)		Anticholinesterase Medication (n=813)		Delirium (n=3,901)		Vascular Dementia (n=807)	
	P value	OR	P value	OR	P value	OR	P value	OR
rs117058816	7.92E-07	↓0.489	8.04E-03	↓0.613	7.75E-03	↓0.667	7.44E-04	↓0.208

[00245] These results indicate that loss of function of *MTRES1* results in protection from dementia and Alzheimer's disease and related diseases. These results further indicate that therapeutic inhibition of *MTRES1* may result in similar disease-protective effects.

Protective variants in MTRES1 result in a reduction of MTRES1 mRNA and MTRES1 protein

[00246] Minigene expression constructs encoding for wild type and rs117058816 (c.3+1G>A) *MTRES1* proteins were generated. Minigene constructs (<10kb) are easier to synthesize and have greater transfection efficiency in downstream experiments than constructs that exceed 10kb in length. The minigene constructs have a portion of internal, intronic sequence removed, but retain all exons and UTRs. Therefore, the pre-mRNA of the exons, reduced introns, and 5' and 3' UTRs of the protein coding transcript (ENST00000625458) of *MTRES1* was cloned into a pcDNA3.1(+) vector driven by a CMV promoter. Empty vector was used as control. For rs117058816 expression constructs, the A allele replaced the G allele at DNA sequence position chr6:107030108 (human genome build 38). This leads to the loss of a splice donor site (c.3+1G>A).

[00247] Transfections of HEK-293 cells were optimized. HEK-293 cells were plated in a 6-well plate in complete growth media and grown for 48 hours followed by a media change. Cells were then transfected with 2 µg of plasmid DNA and 7 µl of TransIT-2020. Cells were incubated for 48 hours, and then harvested.

[00248] Cell lysates from transfected cells were assayed to evaluate intracellular MTRES1 protein by western blot (FIG. 1). In empty vector transfected HEK-293 cells, a faint band representing endogenous MTRES1 expression was detected by western blot as a band at 24 kDa. In cells transfected with the wild type construct, significant expression of MTRES1 was detected by western blot as a band 24 kDa. In cells transfected with the rs117058816 construct, reduced MTRES1 protein compared with wild type was detected by western blot as a band between 24 kDa. When normalizing to total protein, cells transfected with the rs117058816 construct express approximately 75% less MTRES1 protein compared with cells transfected with the wild type construct (FIG. 2).

[00249] Cell lysates from transfected cells were also assayed to evaluate *MTRES1* mRNA by qPCR. Cells transfected with the rs117058816 construct express approximately 60% less *MTRES1* mRNA compared with cells transfected with the wild type construct (FIG. 3).

[00250] These data provide experimental verification that *MTRES1* gene variants associated with protection from dementia and Alzheimer's disease result in loss of MTRES1 protein and *MTRES1* mRNA abundance or function. Accordingly, in some cases therapeutic inhibition or modulation of MTRES1 may be an effective genetically-informed method of treatment for these diseases.

Example 2: Bioinformatic selection of sequences in order to identify therapeutic siRNAs to downmodulate expression of the MTRES1 mRNA

[00251] Screening sets were defined based on bioinformatic analysis. Therapeutic siRNAs were designed to target human MTRES1, and the MTRES1 sequence of at least one toxicology-relevant species, in this case, the non-human primates (NHP) rhesus and cynomolgus monkeys. Drivers for the design of the screening set were predicted specificity of the siRNAs against the transcriptome of the relevant species as well as cross-reactivity between species. Predicted specificity in human, rhesus monkey, cynomolgus monkey, mouse and rat was determined for sense (S) and antisense (AS) strands. These were assigned a "specificity score" which considers the likelihood of unintended downregulation of any other transcript by full or partial complementarity of an siRNA strand (up to 4 mismatches within positions 2-18) as well as the number and positions of mismatches. Thus, off-target(s) for antisense and sense strands of each siRNA were identified. In addition, the number of potential off-targets was used as an additional specificity factor in the specificity score. As identified, siRNAs with high specificity and a low number of predicted off-targets provide a benefit of increased targeting specificity.

[00252] In addition to selecting siRNA sequences with high sequence specificity to MTRES1 mRNA, siRNA sequences within the seed region were analyzed for similarity to seed regions of known miRNAs. siRNAs can function in a miRNA like manner via base-pairing with complementary sequences within the 3'-UTR of mRNA molecules. The complementarity typically encompasses the 5'-bases at positions 2-7 of the miRNA (seed region). To circumvent siRNAs to act via functional miRNA binding sites, siRNA

strands containing natural miRNA seed regions were avoided. Seed regions identified in miRNAs from human, mouse, rat, rhesus monkey, dog, rabbit and pig are referred to as “conserved”. Combining the “specificity score” with miRNA seed analysis yielded a “specificity category”. This is divided into categories 1-4, with 1 having the highest specificity and 4 having the lowest specificity. Each strand of the siRNA is assigned to a specificity category.

[00253] Specificity and species cross-reactivity was assessed for human, cynomolgus monkey, rhesus monkey, mouse and rat MTRES1. The analysis was based on a canonical siRNA design using 19 bases and 17 bases (without considering positions 1 and 19) for cross-reactivity. Full match as well as single mismatch analyses were included.

[00254] Analysis of the human Single Nucleotide Polymorphism (SNP) database (NCBI-DB-SNP) to identify siRNAs targeting regions with known SNPs was also carried out to identify siRNAs that may be non-functional in individuals containing the SNP. Information regarding the positions of SNPs within the target sequence as well as minor allele frequency (MAF) in case data was obtained in this analysis.

[00255] Initial analysis of the relevant MTRES1 mRNA sequence revealed few sequences that fulfil the specificity parameters and at the same time target MTRES1 mRNA in all of the analyzed relevant species. Therefore, it was decided to design independent screening subsets for the therapeutic siRNAs.

[00256] The siRNAs in these subsets recognize the human, cynomolgus monkey, rhesus monkey MTRES1 sequences. Therefore, the siRNAs in these subsets can be used to target human MTRES1 in a therapeutic setting.

[00257] The number of siRNA sequences that can be derived from human MTRES1 mRNA (ENST00000311381.8, SEQ ID NO: 2443) without consideration of specificity or species cross-reactivity was 1140 (sense and antisense strand sequences included in SEQ ID NOS: 1-2280).

[00258] Prioritizing sequences for target specificity, species cross-reactivity, miRNA seed region sequences and SNPs as described above yields subset A. Subset A contains 82 siRNAs whose base sequences are shown in **Table 2**.

Table 2. Sequences in siRNA subset A

siRNA Name	SEQ ID NO:	sense strand sequence (5'-3')	SEQ ID NO:	antisense strand sequence (5'-3')
siRNA 78	78	UAAGCGCCAUGGCUAUGGC	1218	GCCAUAGCCAUGGCGCUUA
siRNA 81	81	GCGCCAUGGCUAUGGCUAG	1221	CUAGCCAUGCCAUGGCGC
siRNA 87	87	UGGCUAUGGCUAGUGUAA	1227	UUAACACUAGCCAUGCCA
siRNA 154	154	GGGUGUUCUCGAGGGACA	1294	UGUCCUCGAGAACACCC
siRNA 156	156	GUGUUCUCGAGGGACACC	1296	GGUGUCCUCGAGAACAC
siRNA 158	158	GUUCUCGAGGGACACCUU	1298	AAGGUGUCCUCGAGAAC
siRNA 178	178	AUCAUACAAACUCUGUACU	1318	AGUACAGAUUUGAU GAU
siRNA 182	182	UACAAACUCUGUACUCCU	1322	AGGAAGUACAGAUUUGUA
siRNA 190	190	CUGUACUCCUGGAAUCGA	1330	UCGAUCCAGGAAGUACAG
siRNA 191	191	UGUACUCCUGGAAUCGAU	1331	AUCGAUCCAGGAAGUACA
siRNA 192	192	GUACUCCUGGAAUCGAUA	1332	UAUCGAUCCAGGAAGUAC
siRNA 193	193	UACUCCUGGAAUCGAUAC	1333	GUUACGAUCCAGGAAGUA
siRNA 194	194	ACUCCUGGAAUCGAUACU	1334	AGUACGAUCCAGGAAGU
siRNA 195	195	CUUCUGGAAUCGAUACUU	1335	AAGUACGAUCCAGGAAG
siRNA 197	197	UCCUGGAAUCGAUACUUGU	1337	ACAA GAU CGAUUCCAGGA
siRNA 198	198	CCUGGAAUCGAUACUUGUA	1338	UACAAGUACGAUCCAGG
siRNA 199	199	CUGGAAUCGAUACUUGUAA	1339	AUACAAGUACGAUCCAG

WO 2022/266045

PCT/US2022/033356

siRNA 202	202	GAAUCGAUACUUGUAUUUU	1342	AAAAUACAAGUAUCGAUUC
siRNA 220	220	UUCUAGUACCAAGUUACGU	1360	ACGUAA CUUGGUACUAGAA
siRNA 222	222	CUAGUACCAAGUUACGUGC	1362	GCACGUAA CUUGGUACUAG
siRNA 223	223	UAGUACCAAGUUACGUGCA	1363	UGCACGUAA CUUGGUACUAA
siRNA 224	224	AGUACCAAGUUACGUGCAC	1364	GUGCACGUAA CUUGGUACU
siRNA 225	225	GUACCAAGUUACGUGCACC	1365	GGUGCACGUAA CUUGGUAC
siRNA 226	226	UACCAAGUUACGUGCACCA	1366	UGGUGCACGUAA CUUGGUA
siRNA 227	227	ACCAAGUUACGUGCACCAA	1367	UUGGUGCACGUAA CUUGGU
siRNA 228	228	CCAAGUUACGUGCACCAAA	1368	UUUGGUGCACGUAA CUUGG
siRNA 229	229	CAAGUUACGUGCACCAAAU	1369	AUUUGGUGCACGUAA CUUG
siRNA 230	230	AAGUUACGUGCACCAAAUU	1370	AAUUUGGUGCACGUAA CUU
siRNA 231	231	AGUUACGUGCACCAAAUUA	1371	UAAUUUGGUGCACGUAA CU
siRNA 232	232	GUUACGUGCACCAAAUUAU	1372	AUAAUUUGGUGCACGUAA C
siRNA 233	233	UUACGUGCACCAAAUUUAU	1373	UAUAUUUUUGGUGCACGUAA
siRNA 235	235	ACGUGCACCAAAUUUAUAAA	1375	UUUAUAUUUUUGGUGCACGU
siRNA 331	331	AAGACUCAAAGUAAUUAUA	1471	UAUAUUACUUUUAGUCUUU
siRNA 358	358	AAAAUCUACUAAAAGUCU	1498	AGACUUUUUAGUAGAUUUU
siRNA 360	360	AAUCUACUAAAAGUCUCU	1500	AGAGACUUUUUAGUAGAUU
siRNA 361	361	AUCUACUAAAAGUCUCUG	1501	CAGAGACUUUUUAGUAGAU
siRNA 362	362	UCUACUAAAAGUCUCUGC	1502	GCAGAGACUUUUUAGUAGA
siRNA 528	528	UGAAGACGGGCUAGAUAU	1668	AUAUCUAGCCCCGUUUCA
siRNA 534	534	CGGGGCUAGAUAUUGGGAG	1674	CUCCCAAUAUCUAGCCCCG
siRNA 539	539	CUAGAUAUUGGGAGAAACA	1679	UGUUUCUCCCAAUAUCUAG
siRNA 619	619	AAGCAGAACGGUGAAAGUG	1759	CACUUUCACCGUUCUGCUU
siRNA 620	620	AGCAGAACGGUGAAAGUGG	1760	CCACUUUCACCGUUCUGCU
siRNA 621	621	GCAGAACGGUGAAAGUGGG	1761	CCCACUUUCACCGUUCUGC
siRNA 632	632	AAAGUGGGAGAUACAUUGG	1772	CCAAUGUAUCUCCACUUU
siRNA 633	633	AAGUGGGAGAUACAUUGGA	1773	UCCAAUGUAUCUCCACUU
siRNA 634	634	AGUGGGAGAUACAUUGGAU	1774	AUCCAAUGUAUCUCCACU
siRNA 636	636	UGGGAGAUACAUUGGAUCU	1776	AGAUCCAAUGUAUCUCCCA
siRNA 642	642	AUACAUUGGAUCUUCUCAU	1782	AUGAGAAGAUCCAAUGUAU
siRNA 645	645	CAUUGGAUCUUCUCAUUGG	1785	CCAAUGAGAA GAUCCAAUG
siRNA 646	646	AUUGGAUCUUCUCAUUGGA	1786	UCCAAUGAGAA GAUCCAAU
siRNA 647	647	UUGGAUCUUCUCAUUGGAG	1787	CUCCAAUGAGAA GAUCCAA
siRNA 648	648	UGGAUCUUCUCAUUGGAGA	1788	UCUCCAAUGAGAA GAUCCA
siRNA 650	650	GAUCUUCUCAUUGGAGAGG	1790	CCUCUCCAAUGAGAA GAUC
siRNA 654	654	UUCUCAUUGGAGAGGAUAA	1794	UUAUCCUCUCCAAUGAGAA
siRNA 656	656	CUCAUUGGAGAGGAUAAAG	1796	CUUUAUCCUCUCCAAUGAG
siRNA 687	687	AGACAGUU AUGCGGAUUCU	1827	AGAAUCCGCAUACUGUCU
siRNA 688	688	GACAGUU AUGCGGAUUCUC	1828	GAGAAUCCGCAUACUGUC
siRNA 690	690	CAGUUAUGCGGAUUCUCU	1830	AAGAGAAUCCGCAUACUG
siRNA 693	693	UUAUGCGGAUUCUCUUGAA	1833	UUCAAGAGAAUCCGCAUAA
siRNA 694	694	UAUGCGGAUUCUCUUGAAA	1834	UUUCAAGAGAAUCCGCAUA
siRNA 695	695	AUGCGGAUUCUCUUGAAAA	1835	UUUUCAAGAGAAUCCGCAU
siRNA 745	745	AUACAGAGUGGUGUACGG	1885	CCGUAACACACUCUGUAU
siRNA 746	746	UACAGAGUGGUGUACGGC	1886	GCCGUAACACACUCUGUA
siRNA 748	748	CAGAGUGGUGUACGGCGG	1888	CCGCCGUAACACACUCUG
siRNA 749	749	AGAGUGGUGUACGGCGGU	1889	ACCGCCGUAACACACUCU
siRNA 751	751	AGUGGUGUACGGCGGUGG	1891	CCACCGCCGUAACACACU
siRNA 752	752	GUGGUGUACGGCGGUGGA	1892	UCCACCGCCGUAACACAC
siRNA 753	753	UGGUGUACGGCGGUGGAA	1893	UUCCACCGCCGUAACACCA
siRNA 754	754	GGUGUACGGCGGUGGAAA	1894	UUUCCACCGCCGUAACACC
siRNA 755	755	GUGUACGGCGGUGGAAAA	1895	UUUUCCACCGCCGUAACAC
siRNA 756	756	UGUACGGCGGUGGAAAAG	1896	CUUUUCCACCGCCGUAACA
siRNA 757	757	GUUACGGCGGUGGAAAAGU	1897	ACUUUUCCACCGCCGUAAC
siRNA 758	758	UUACGGCGGUGGAAAAGUU	1898	AACUUUUCCACCGCCGUA
siRNA 759	759	UACGGCGGUGGAAAAGUUU	1899	AAACUUUUCCACCGCCGUA
siRNA 761	761	CGGCGGUGGAAAAGUUUA	1901	UUAAACUUUUCCACCGCCG
siRNA 773	773	AGUUUAAAAGUUGCCUAAGA	1913	UCUUAGGCAACUUUAAACU
siRNA 775	775	UUUAAAAGUUGCCUAAGAAG	1915	CUUCUUAGGCAACUUUAAA
siRNA 808	808	AAUGGAUUGCUUUUAGCA	1948	UGCUAAAAGCAUCCAAU

siRNA 810	810	UGGAUUGC UUUUAGCAAU	1950	AUUGC UAAAAAGCAAUCCA
siRNA 852	852	GAAGGGGU CACCUGAAAAA	1992	UUUUUCAGGUGACCCCUUC
siRNA 853	853	AAGGGGUC ACCUGAAAAAU	1993	AUUUUUCAGGUGACCCCUU
siRNA 887	887	AAAUAAAGUUCUUAAGCG	2027	CGCUAAGAGAACUUUAUUU

[00259] The siRNAs in subset A have the following characteristics:

- Cross-reactivity: With 19mer in human MTRES1 mRNA, with 17mer/19mer in NHP MTRES1
- Specificity category: For human and NHP: AS2 or better, SS3 or better
- miRNA seeds: AS+SS strand: seed region not conserved in human, mouse, and rat and not present in >4 species
- Off-target frequency: ≤20 human off-targets matched with 2 mismatches in antisense strand
- SNPs: siRNA target sites do not harbor SNPs with a MAF ≥ 1% (pos. 2-18)

[00260] The siRNA sequences in subset A were selected for more stringent specificity to yield subset B.

Subset B includes 73 siRNAs whose base sequences are shown in **Table 3**.

Table 3. Sequences in siRNA subset B

SEQ ID NO:	sense strand sequence (5'-3')	SEQ ID NO:	antisense strand sequence (5'-3')
78	UAAGCGCCAUGGCUAUGGC	1218	GCCAUAGCCAUGGCGCUUA
81	GCGCCAUGGCUAUGGCUAG	1221	CUAGCCAUAGCCAUGGCGC
87	UGGCUAUGGCUAGUGUUA	1227	UUAACACUAGCCAUAGCCA
154	GGGUGUUCUCGAGGGACA	1294	UGUCCUCGAGAACACCC
156	GUGUUCUCGAGGGACACC	1296	GGUGUCCUCGAGAACAC
158	GUUCUCGAGGGACACCUU	1298	AAGGUGUCCUCGAGAAC
178	AUCAUACAAACUCUGUACU	1318	AGUACAGAUUUGUAGAU
182	UACAAACUCUGUACUCCU	1322	AGGAAGUACAGAUUUGUA
190	CUGUACUUCUGGAAUCGA	1330	UCGAUCCAGGAAGUACAG
191	UGUACUUCUGGAAUCGAU	1331	AUCGAUCCAGGAAGUACA
192	GUACUUCUGGAAUCGAUA	1332	UAUCGAUUCAGGAAGUAC
193	UACUUCUGGAAUCGAUAC	1333	GUUACGAUUCAGGAAGUA
195	CUUCUGGAAUCGAUACU	1335	AAGUACGAUUCAGGAAG
197	UCCUGGAAUCGAUACUUGU	1337	ACAAGUACGAUUCAGGA
198	CCUGGAAUCGAUACUUGUA	1338	UACAAGUACGAUUCAGG
199	CUGGAAUCGAUACUUGUAU	1339	AUACAAGUACGAUUCAG
202	GAUACGAUACUUGAUUUU	1342	AAAAUACAAGUACGAUUC
220	UUCUAGUACCAAGUACGU	1360	ACGUAAUUGGUACUAGAA
222	CUAGUACCAAGUACGUGC	1362	GCACGUAAUUGGUACUAG
223	UAGUACCAAGUACGUGCA	1363	UGCACGUAAUUGGUACUA
224	AGUACCAAGUACGUGCAC	1364	GUGCACGUAAUUGGUACU
225	GUACCAAGUACGUGCACC	1365	GGUGCACGUAAUUGGUAC
226	UACCAAGUACGUGCACCA	1366	UGGUGCACGUAAUUGGU
227	ACCAAGUACGUGCACCAA	1367	UUGGUGCACGUAAUUGGU
228	CCAAGUACGUGCACCAAA	1368	UUUGGUGCACGUAAUUGG
229	CAAGUACGUGCACCAAAU	1369	AUUUGGUGCACGUAAUUG
230	AAGUACGUGCACCAAAUU	1370	AAUUUGGUGCACGUAAUU
231	AGUACGUGCACCAAAUUA	1371	UAAUUUGGUGCACGUAAU
232	GUUACGUGCACCAAAUUAU	1372	AUAAUUUGGUGCACGUAA
233	UUACGUGCACCAAAUUAUA	1373	UAUAAUUUGGUGCACGUAA
235	ACGUGCACCAAAUUAUAAA	1375	UUUAUAAUUUGGUGCACGU
358	AAAAUCUACUAAAAAGUCU	1498	AGACUUUUUAGUAGAUUU
360	AAUCUACUAAAAAGUCUCU	1500	AGAGACUUUUUAGUAGAUU
362	UCUACUAAAAAGUCUCUGC	1502	GCAGAGACUUUUUAGUAGA
528	UGAAGACGGGGCUAGAUUAU	1668	AUAUCUAGCCCCGUUUAU
534	CGGGGCUAGAUUAUUGGGAG	1674	CUCCCAAUAUCUAGCCCCG
539	CUAGAUUAUUGGAGAAACA	1679	UGUUUCUCCCAAUAUCUAG

619	AAGCAGAACGGUGAAAGUG	1759	CACUUUCACCGUUCUGCUU
620	AGCAGAACGGUGAAAGUGG	1760	CCACUUUCACCGUUCUGCU
621	GCAGAACGGUGAAAGUGGG	1761	CCCACUUUCACCGUUCUGC
632	AAAGUGGGAGAUACAUGG	1772	CCAAUGUAUCUCCACUUU
633	AAGUGGGAGAUACAUGGA	1773	UCCAAUGUAUCUCCACUU
636	UGGGAGAUACAUGGAUCU	1776	AGAUCCAAUGUAUCUCCCA
642	AUACAUGGAUCUUCUCAU	1782	AUGAGAAGAUCCAAUGUAU
645	CAUUGGAUCUUCUCAUUGG	1785	CCAAUGAGAAGAUCCAAUG
647	UUGGAUCUUCUCAUUGGAG	1787	CUCCAAUGAGAAGAUCCAA
648	UGGAUCUUCUCAUUGGAGA	1788	UCUCCAAUGAGAAGAUCCA
654	UUCUCAUUGGAGAGGAUAA	1794	UUAUCCUCUCCAAUGAGAA
656	CUCAUUGGAGAGGAUAAAG	1796	CUUUAUCCUCUCCAAUGAG
687	AGAGGUAUUGCGGAUUCU	1827	AGAAUCCGCAUAACUGUCU
688	GACAGUUAUGCGGAUUCUC	1828	GAGAAUCCGCAUAACUGUC
690	CAGUUAUGCGGAUUCUCU	1830	AAGAGAAUCCGCAUAACUG
693	UUAUGCGGAUUCUCUUGAA	1833	UUCAAGAGAAUCCGCAUAA
694	UAUGCGGAUUCUCUUGAAA	1834	UUUCAAGAGAAUCCGCAUA
695	AUGCGGAUUCUCUUGAAAA	1835	UUUUCAAGAGAAUCCGCAU
745	AUACAGAGUGGUUACCGG	1885	CCGUAAACACACUCUGUAU
746	UACAGAGUGGUUACCGGC	1886	GCCGUAAACACACUCUGUA
748	CAGAGUGGUUACCGCGG	1888	CCGCGUAAACACACUCUG
749	AGAGUGGUUACCGCGGU	1889	ACCGCGUAAACACACUCU
751	AGUGGUUACCGCGGUGG	1891	CCACCGCGUAAACACACU
752	GUGGUUACCGCGGUGGA	1892	UCCACCGCGUAAACACAC
753	UGGUUACCGCGGUGGAA	1893	UUCCACCGCGUAAACACCA
754	GGUGUACCGCGGUGGAAA	1894	UUUCCACCGCGUAAACACC
755	GUGUACCGCGGUGGAAAA	1895	UUUUCCACCGCGUAAACAC
756	UGUUACCGCGGUGGAAAAG	1896	CUUUUCCACCGCGUAAACA
757	GUUACCGCGGUGGAAAAGU	1897	ACUUUUCCACCGCGUAAAC
758	UUACCGCGGUGGAAAAGUU	1898	AAUUUUUCCACCGCGUAA
759	UACCGCGGUGGAAAAGUUU	1899	AAACUUUUUCCACCGCGUA
761	CGGCGGUGGAAAAGUUUA	1901	UUAAACUUUUUCCACCGCG
773	AGUUUAAAAGUUGCUAAGA	1913	UCUUAGGCAACUUUAAACU
808	AAUGGAUUGCUUUUAGCA	1948	UGCUA AAAAGCAAUCCA AU
852	GAAGGGGUCACCUGAAAAA	1992	UUUUUCAGGUGACCCCUUC
853	AAGGGGUCACCUGAAAAAU	1993	AUUUUUCAGGUGACCCCUU

[00261] The siRNAs in subset B have the following characteristics:

- Cross-reactivity: With 19mer in human MTRES1 mRNA, with 17mer/19mer in NHP MTRES1
- Specificity category: For human and NHP: AS2 or better, SS3 or better
- miRNA seeds: AS+SS strand: seed region not conserved in human, mouse, and rat and not present in >4 species
- Off-target frequency: ≤15 human off-targets matched with 2 mismatches in antisense strand
- SNPs: siRNA target sites do not harbor SNPs with a MAF ≥ 1% (pos. 2-18)

[00262] The siRNA sequences in subset B were further selected for absence of seed regions in the AS strand that are identical to a seed region of known human miRNA to yield subset C. Subset C includes 54 siRNAs whose base sequences are shown in **Table 4**.

Table 4. Sequences in siRNA subset C

SEQ ID NO:	sense strand sequence (5'-3')	SEQ ID NO:	antisense strand sequence (5'-3')
78	UAAGCGCAUGGCUAUGGC	1218	GCCAUGGCAUGGCGCUUA
87	UGGCUAUGGCUAGUUA	1227	UUAAACUAGCCAUGCCA
154	GGGUGUUCUGGAGGACA	1294	UGUCCUCGGAGAACCCC
158	GUUCUCCGAGGACACCU	1298	AAGGUGUCCUCGGAGAAC

178	AUCAUACAAACUCUGUACU	1318	AGUACAGAGUUUGUAUGAU
182	UACAAACUCUGUACUCCU	1322	AGGAAGUACAGAUUUGUA
190	CUGUACUCCUGGAAUCGA	1330	UCCAUUCCAGGAAGUACAG
191	UGUACUCCUGGAAUCGAU	1331	AUCGAUCCAGGAAGUACA
192	GUACUCCUGGAAUCGAUA	1332	UAUCGAUCCAGGAAGUAC
193	UACUCCUGGAAUCGAUAC	1333	GUACGAUCCAGGAAGUA
195	CUUCCUGGAAUCGAUACU	1335	AAGUAUCGAUCCAGGAAG
199	CUGGAAUCGAUACUUGUAU	1339	AUACAAGUAUCGAUCCAG
202	GAAUCGAUACUUGUAUUU	1342	AAAAUACAAGUAUCGAUUC
220	UUCUAGUACCAAGUACGU	1360	ACGUAAAUUGGUACUAGAA
222	CUAGUACCAAGUACGUGC	1362	GCACGUAAAUUGGUACUAG
223	UAGUACCAAGUACGUGCA	1363	UGCAGUAACUUGGUACUA
224	AGUACCAAGUACGUGCAC	1364	GUGCACGUAAAUUGGUACU
225	GUACCAAGUACGUGCACC	1365	GGUGCACGUAAAUUGGUAC
226	UACCAAGUACGUGCACCA	1366	UGGUGCACGUAAAUUGGUA
227	ACCAAGUACGUGCACCAA	1367	UUUGUGCACGUAAAUUGGU
228	CCAAGUACGUGCACCAAA	1368	UUUGGUACGUAACUUGG
229	CAAGUACGUGCACCAAAU	1369	AUUUGGUGCACGUAAAUUG
231	AGUUAACGUGCACCAAUUA	1371	UAAUUUGGUGCACGUAAAU
233	UUACGUGCACCAAUUAUA	1373	UAUAUUUGGUGCACGUAA
235	ACGUGCACCAAUUAUAAA	1375	UUUAUAUUUGGUGCACGU
358	AAAAUCUACUAAAAAGUCU	1498	AGACUUUUUAGUAGAUUUU
528	UGAAGACGGGCUAGAUUAU	1668	AUAUCUAGCCCGUCUUA
534	CGGGGCUAGAUUUUGGAG	1674	CUCCCAAUAUCUAGCCCCG
539	CUAGAUUUUGGAGAAACA	1679	UGUUUCUCCCAAUAUCUAG
619	AAGCAGAACGGUGAAAGUG	1759	CACUUUCACCGUUCUGCUU
620	AGCAGAACGGUGAAAGUGG	1760	CCACUUUCACCGUUCUGCU
621	GCAGAACGGUGAAAGUGGG	1761	CCACUUUCACCGUUCUGC
632	AAAGUGGGAGAUACAUUGG	1772	CCAAUGUAUCUCCACUUU
633	AAGUGGGAGAUACAUUGGA	1773	UCCAAUGUAUCUCCACUU
636	UGGGAGAUACAUUGGAUCU	1776	AGAUCCAAUGUAUCUCCCA
645	CAUUGGAUCUUCUCAUUGG	1785	CCAAUGAGAAUGUCCAAUG
647	UUGGAUCUUCUCAUUGGAG	1787	CUCCAAUGAGAAUGUCCAA
656	CUCAUUGGAGAGGAUAAAG	1796	CUUUUACCUUCUCCAAUGAG
687	AGCAGUUUAGCGGAUUCU	1827	AGAAUCCGCAUAACUGUCU
688	GACAGUUUAGCGGAUUCUC	1828	GAGAAUCCGCAUAACUGUC
745	AUACAGAGUGGUUUAACGG	1885	CCGUAAACACACUCUGUAU
746	UACAGAGUGGUUUAACGGC	1886	GCCGUAAACACACUCUGUA
748	CAGAGUGGUUUAACGGCGG	1888	CCGCCGUAAACACACUCUG
749	AGAGUGGUUUAACGGCGGU	1889	ACCGCCGUAAACACACUCU
751	AGUGGUUUAACGGCGGUGG	1891	CCACCGCCGUAAACACACU
752	GUGGUUUAACGGCGGUGGA	1892	UCCACCGCCGUAAACACAC
753	UGGUUUAACGGCGGUGGAA	1893	UUCCACCGCCGUAAACACCA
755	GUGUUAACGGCGGUGGAAA	1895	UUUUCCACCGCCGUAAACAC
756	UGUUAACGGCGGUGGAAAAG	1896	CUUUUCCACCGCCGUAAACA
759	UACGGCGGUGGAAAAGUUU	1899	AAACUUUUCCACCGCCGUA
761	CGGCGGUGGAAAAGUUUAA	1901	UUAAACUUUUCCACCGCCG
773	AGUUUAAAGUUGCCUAAGA	1913	UCUUAGGCAACUUUAAACU
808	AAUGGAUUGCUUUUAGCA	1948	UGCUGAAAAGCAAUCCAUC
853	AAGGGGUCACCGAAAAAU	1993	AUUUUUUCAGGUGACCCCUU

[00263] The siRNAs in subset C have the following characteristics:

- Cross-reactivity: With 19mer in human MTRES1 mRNA, with 17mer/19mer in NHP MTRES1
- Specificity category: For human and NHP: AS2 or better, SS3 or better
- miRNA seeds: AS+SS strand: seed region not conserved in human, mouse, and rat and not present in >4 species. AS strand: seed region not identical to seed region of known human miRNA
- Off-target frequency: ≤15 human off-targets matched with 2 mismatches by antisense strand

- SNPs: siRNA target sites do not harbor SNPs with a MAF $\geq 1\%$ (pos. 2-18)

[00264] The siRNA sequences in subset C were also selected for absence of seed regions in the AS or S strands that are identical to a seed region of known human miRNA to yield subset D. Subset D includes 35 siRNAs whose base sequences are shown in Table 5.

Table 5. Sequences in siRNA subset D

SEQ ID NO:	sense strand sequence (5'-3')	SEQ ID NO:	antisense strand sequence (5'-3')
87	UGGCUAUGGCUAGUGUAA	1227	UUAACACUAGCCAAGCCA
182	UACAAACUCUGUACUCCU	1322	AGGAAGUACAGAGUUUGUA
190	CUGUACUCCUGGAAUCGA	1330	UCGAUUCAGGAAGUACAG
191	UGUACUCCUGGAAUCGAU	1331	AUCGAUUCAGGAAGUACA
193	UACUCCUGGAAUCGAUAC	1333	GUUACGAUUCAGGAAGUA
194	ACUUCUGGAAUCGAUACU	1334	AGUACGAUUCAGGAAGU
202	GAAUCGAUACUUGAUUUU	1342	AAAAUACAAGUACGAUUC
220	UUCUAGUACCAAGUACGU	1360	ACGUAAUUGGUACUAGAA
222	CUAGUACCAAGUACGUGC	1362	GCACGUAAUUGGUACUAG
224	AGUACCAAGUACGUGCAC	1364	GUGCACGUAAUUGGUACU
225	GUACCAAGUACGUGCACC	1365	GGUGCACGUAAUUGGUAC
226	UACCAAGUACGUGCACCA	1366	UGGUGCACGUAAUUGGU
228	CCAAGUACGUGCACCAAA	1368	UUUGGUGCACGUAAUUGG
229	CAAGUACGUGCACCAAAU	1369	AUUUGGUGCACGUAAUUG
231	AGUACGUGCACCAAAUUA	1371	UAAUUUGGUGCACGUAAU
233	UUACGUGCACCAAAUUAUA	1373	UAUAAUUUGGUGCACGUAA
358	AAAAUCUACUAAAAAGUCU	1498	AGACUUUUUAGUAGAUUUU
361	AUCUACUAAAAAGUCUCUG	1501	CAGAGACUUUUUAGUAGAU
528	UGAAGACGGGGCUAGAUUA	1668	AUAUCUAGCCCGUCUUCA
539	CUAGAUUUGGGAGAAACA	1679	UGUUUCUCCAAUUAUCUAG
619	AAGCAGAACGGUGAAGUG	1759	CACUUUCACCGUUCUGCUU
645	CAUUGGAUCUUCUCAUUGG	1785	CCAAUGAGAAUAUCCAAUG
647	UUGGAUCUUCUCAUUGGAG	1787	CUCCAAUGAGAAUAUCCAA
688	GACAGUUAUGCGGAUUCUC	1828	GAGAAUCCGCAUAAUCUGC
745	AUACAGAGUGGUGUACGG	1885	CCGUAAACACACUCUGUAU
751	AGUGGUGUACGGCGGUGG	1891	CCACCGCCGUAAACACACU
752	GUGGUGUACGGCGGUGGA	1892	UCCACCGCCGUAAACACAC
755	GUGUACGGCGGUGGAAAA	1895	UUUUCCACCGCCGUAAACAC
756	UGUACGGCGGUGGAAAAG	1896	CUUUUCACCGCCGUAAACA
759	UACGGCGGUGGAAAAGUUU	1899	AAACUUUUCCACCGCCGUA
761	CGGCGGUGGAAAAGUUUAA	1901	UUAAACUUUUCCACCGCCG
773	AGUUUAAAGUUGCCUAAGA	1913	UCUUAGGCAACUUUAAACU
775	UUUAAAGUUGCCUAAGAAG	1915	CUUCUUAGGCAACUUUAAA
810	UGGAUUGCUUUUAGCAAU	1950	AUUGCUAAAAAGCAAUCCA
887	AAAUAAAGUUCUUAAGCG	2027	CGCUAAGAGAACUUUUAUUU

[00265] The siRNAs in subset D have the following characteristics:

- Cross-reactivity: With 19mer in human MTRES1 mRNA, with 17mer/19mer in NHP MTRES1
- Specificity category: For human and NHP: AS2 or better, SS3 or better
- miRNA seeds: AS+SS strand: seed region not conserved in human, mouse, and rat and not present in >4 species. AS+SS strand: seed region not identical to seed region of known human miRNA
- Off-target frequency: ≤ 20 human off-targets matched with 2 mismatches by antisense strand
- SNPs: siRNA target sites do not harbor SNPs with a MAF $\geq 1\%$ (pos. 2-18)

[00266] The siRNA sequences in subset D were further selected for more stringent specificity to yield subset E. Subset E includes 30 siRNAs whose base sequences are shown in **Table 6**.

Table 6. Sequences in siRNA subset E

SEQ ID NO:	sense strand sequence (5'-3')	SEQ ID NO:	antisense strand sequence (5'-3')
87	UGGCUAUGGCUAGUUA	1227	UUAACACUAGCCAAGCCA
182	UACAAACUCUGACUCCU	1322	AGGAAGUACAGAUUUGUA
190	CUGUACUCCUGGAAUCGA	1330	UCGAUCCAGGAAGUACAG
191	UGUACUCCUGGAAUCGAU	1331	AUCGAUCCAGGAAGUACA
193	UACUCCUGGAAUCGAUAC	1333	GUUACGAUCCAGGAAGUA
202	GAAUCGAUACUUGAUUUU	1342	AAAAUACAAGUACGAUUC
220	UUCUAGUACCAAGUACGU	1360	ACGUACUUGGUACUAGAA
222	CUAGUACCAAGUACGUGC	1362	GCACGUACUUGGUACUAG
224	AGUACCAAGUACGUGCAC	1364	GUGCACGUACUUGGUACU
225	GUACCAAGUACGUGCACC	1365	GGUGCACGUACUUGGUAC
226	UACCAAGUACGUGCACCA	1366	UGGUGCACGUACUUGGUAC
228	CCAAGUACGUGCACCAAA	1368	UUUGGUGCACGUACUUGG
229	CAAGUACGUGCACCAAAU	1369	AUUUGGUGCACGUACUUG
231	AGUACGUGCACCAAAUUA	1371	UAAUUUGGUGCACGUACU
233	UUACGUGCACCAAAUUAU	1373	UAUAAUUUGGUGCACGUAA
358	AAAAUCUACUAAAAGUCU	1498	AGACUUUUUAGUAGAUUUU
528	UGAAGACGGGCUAGAUAU	1668	AUAUCUAGCCCGUCUUA
539	CUAGAUAUUGGAGAAACA	1679	UGUUUCUCCAAUAUCUAG
619	AAGCAGAACGGUGAAAAGUG	1759	CACUUUACCCGUGUCUUC
645	CAUUGGAUCUUCUUAUUGG	1785	CCAAUGAGAAGAUCCAAUG
647	UUGGAUCUUCUUAUUGGAG	1787	CUCCAAUGAGAAGAUCCAA
688	GACAGUUAUGCGAUUCUC	1828	GAGAAUCCGCAUACUGUC
745	AUACAGAGUGGUUUAACGG	1885	CCGUAAACACACUCUGUAU
751	AGUGGUUUAACGGCGGUGG	1891	CCACCGCCGUAAACACCACU
752	GUGGUUUAACGGCGGUGGA	1892	UCCACCGCCGUAAACACCAC
755	GUGUUAACGGCGGUGGAAA	1895	UUUUCCACCGCGUAAACAC
756	UGUUAACGGCGGUGGAAAG	1896	CUUUUCACCGCGUAAACA
759	UACGGCGGUGGAAAGUUU	1899	AAACUUUUCCACCGCGGUA
761	CGGCGGUGGAAAGUUUAA	1901	UUAAACUUUUCCACCGCGG
773	AGUUUAAAGUUGCCUAGA	1913	UCUUAGGCAACUUUAAACU

[00267] The siRNAs in subset E have the following characteristics:

- Cross-reactivity: With 19mer in human MTRES1 mRNA, with 17mer/19mer in NHP MTRES1
- Specificity category: For human and NHP: AS2 or better, SS3 or better
- miRNA seeds: AS+SS strand: seed region not conserved in human, mouse, and rat and not present in >4 species. AS+SS strand: seed region not identical to seed region of known human miRNA
- Off-target frequency: ≤ 15 human off-targets matched with 2 mismatches by antisense strand
- SNPs: siRNA target sites do not harbor SNPs with a MAF $\geq 1\%$ (pos. 2-18)

[00268] Subset F includes 54 siRNAs. The siRNAs in subset F include siRNAs from subset A, and are included in **Table 7**. In some cases, the sense strand of any of the siRNAs of subset F comprises modification pattern 6S (**Table 8**). In some cases, the antisense strand of any of the siRNAs of subset F comprises modification pattern 7AS (**Table 8**, “subset G”). In some cases, the sense strand of any of the siRNAs of subset F contains an alternative modification pattern (**Table 9**, “subset H”). In some cases, the antisense strand of any of the siRNAs of subset F comprises modification pattern 7AS (**Table 9**). The

siRNAs in subset F may comprise any other modification pattern(s). In **Table 8** and **Table 9**, Nf (e.g. Af, Cf, Gf, Tf, or Uf) is a 2' fluoro-modified nucleoside, n (e.g. a, c, g, t, or u) is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage.

Table 7. Sequences in siRNA subset F

SEQ ID NO:	sense strand sequence (5'-3')	SEQ ID NO:	antisense strand sequence (5'-3')
87	UGGCUAUGGCUAGUGUUA	1227	UUAACACUAGCCAUGCCA
178	AUCAUACAAACUCUGUACU	1318	AGUACAGAGUUUGUAUGAU
190	CUGUACUCCUGGAAUCGA	1330	UCGAUUCAGGAAGUACAG
191	UGUACUCCUGGAAUCGAU	1331	AUCGAUUCAGGAAGUACA
192	GUACUCCUGGAAUCGAUA	1332	UAUCGAUUCAGGAAGUAC
193	UACUCCUGGAAUCGAUAC	1333	GUUACGAUUCAGGAAGUA
195	CUUCCUGGAAUCGAUCUU	1335	AAGUAUCGAUUCAGGAAG
199	CUGGAAUCGAUACUUGUAU	1339	AUACAAUAUCGAUUCAG
202	GAAUCGAUACUUGUAUUUU	1342	AAAAUACAAGUAUCGAUUC
222	CUAGUACCAAGUACGUGC	1362	GCACGUAACUUGGUACUAG
223	UAGUACCAAGUACGUGCA	1363	UGCACGUAACUUGGUACUA
224	AGUACCAAGUACGUGCAC	1364	GUGCACGUAACUUGGUACU
225	GUACCAAGUACGUGCACC	1365	GGUGCACGUAACUUGGUAC
226	UACCAAGUACGUGCACC	1366	UGGUGCACGUAACUUGGUA
228	CCAAGUACGUGCACCAAA	1368	UUUGGUGCACGUAACUUGG
229	CAAGUACGUGCACCAAAU	1369	AUUUGGUGCACGUAACUUG
230	AAGUACGUGCACCAAAUU	1370	AAUUUGGUGCACGUAACUU
232	GUUACGUGCACCAAAUAU	1372	AUAAUUUGGUGCACGUAAC
233	UUACGUGCACCAAAUAUA	1373	UAUAUUUGGUGCACGUAA
331	AAGACUCAAAGUAUAUA	1471	UAUAUUACUUUGAGUCUU
358	AAAACUACUAAAAGUCU	1498	AGACUUUUUAGUAUUUUU
362	UCUACUAAAAGUCUCUGC	1502	GCAGAGACUUUUUAGUAGA
528	UGAAGACGGGGCUAGAUUA	1668	AUAUCUAGCCCGUCUUA
539	CUAGAUUAUGGGAGAAACA	1679	UGUUUCUCCCAAUAUCUAG
620	AGCAGAACGGUGAAAGUGG	1760	CCACUUUCACCGUUCUGCU
632	AAAGUGGGAGAUACAUGG	1772	CCAAUGUAUCUCCACUUU
633	AAGUGGGAGAUACAUGGA	1773	UCCAAUGUAUCUCCACUU
634	AGUGGGAGAUACAUGGAU	1774	AUCCAAUGUAUCUCCACU
636	UGGGAGAUACAUGGAUCU	1776	AGAUCCAAUGUAUCUCCCA
642	AUACAUGGAUCUUCUUAU	1782	AUGAGAAGAUCCAAUGUAU
645	CAUUGGAUCUUCUUAUGG	1785	CCAAUGAGAAGAUCCAAUG
646	AUUGGAUCUUCUUAUGGA	1786	UCCAAUGAGAAGAUCCAAU
647	UUGGAUCUUCUUAUGGAG	1787	CUCCAAUGAGAAGAUCCAA
648	UGGAUCUUCUUAUGGAGA	1788	UCUCCAAUGAGAAGAUCCA
650	GAUCUUCUUAUGGAGAGG	1790	CCUCUCCAAUGAGAAGAU
654	UUCUCAUUGGAGAGGAUA	1794	UUUCCUCUCUUAUGAGAA
656	CUCAUUGGAGAGGAUAAAG	1796	CUUUUCCUCUCCAAUGAG
687	AGACAGUUAUGCGGAUUCU	1827	AGAAUCCGCAUAACUGUCU
688	GACAGUUAUGCGGAUUCUC	1828	GAGAAUCCGCAUAACUGUC
693	UUAUGCGGAUUCUCUUGAA	1833	UUCAAGAGAAUCCGCAUAA
694	UAUGCGGAUUCUUGGAAA	1834	UUUCAAGAGAAUCCGCAUA
695	AUGCGGAUUCUCUUGAAAA	1835	UUUUCAAGAGAAUCCGCAU
746	UACAGAGUGGUGUACGGC	1886	GCCGUAACACACUCUGUA
755	GUGUACGGCGGUGGAAAA	1895	UUUUCCACCGCGUAACAC
756	UGUACGGCGGUGGAAAAAG	1896	CUUUUCCACCGCGUAACA
757	GUUACGGCGGUGGAAAAAGU	1897	ACUUUUCCACCGCGUAAC
758	UUACGGCGGUGGAAAAAGUU	1898	AACUUUUCCACCGCGUAAC
759	UACGGCGGUGGAAAAAGUUU	1899	AAACUUUUCCACCGCGUA
761	CGGCGGUGGAAAAAGUUUA	1901	UUAAACUUUUCCACCGCGG
773	AGUUUAAAGUUGCCUAAGA	1913	UCUUAGGCAACUUUAAACU
775	UUUAAAGUUGCCUAAGAAAG	1915	CUUCUUAGGCAACUUUAAAA
810	UGGAUUGCUUUUAGCAAU	1950	AUUGCUAAAAAGCAAUCCA

852	GAAGGGGUCACCUGAAAAA	1992	UUUUUCAGGUGACCCCUUC
887	AAAUAAAGUUCUUAAGCG	2027	CGCUAAGAGAACUUUAUUU

Table 8. Sequences in siRNA subset G

SEQ ID NO:	sense strand sequence (5'-3')	SEQ ID NO:	antisense strand sequence (5'-3')
2281	UfsgsGfcUfaUfgGfcUfaGf uGfuUfaAfsusu	2335	usUfsaAfcAfcUfaGfcCfaUf aGfcCfasusu
2282	AfsusCfaUfaCfaAfaCfuCf uGfuAfcAfsusu	2336	usGfsuAfcAfgAfgUfuUfgUf aUfgAfsusu
2283	CfsusGfuAfcUfuCfcUfgGf aAfuCfGafAfsusu	2337	usCfsgAfuUfcCfaGfgAfaGf uAfcAfgsusu
2284	UfsgsUfaCfuUfcCfuGfgAf aUfcGfaAfsusu	2338	usUfscGfaUfuCfcAfgGfaAf gUfaCfasusu
2285	GfsusAfcUfuCfcUfgGfaAf uCfGafuAfsusu	2339	usAfsuCfGafuUfcCfaGfgAf aGfuAfcusu
2286	UfsasCfuUfcCfuGfgAfaUf cGfaUfaAfsusu	2340	usUfsaUfcGfaUfuCfcAfgGf aAfgUfasusu
2287	CfsusUfcCfuGfgAfaUfcGf aUfaCfuAfsusu	2341	usAfsuUfaUfcGfaUfuCfcAf gGfaAfgsusu
2288	CfsusGfgAfaUfcGfaUfaCf uUfgUfaAfsusu	2342	usUfsaCfaAfgUfaUfcGfaUf uCfcAfgsusu
2289	GfsasAfuCfGafuAfcUfuGf uAfuUfuAfsusu	2343	usAfsaAfuAfcAfaGfuAfuCf gAfuUfcusu
2290	CfsusAfgUfaCfcAfaGfuUf aCfGufGafAfsusu	2344	usCfsaCfGufAfaCfuGfgUf aCfuAfgsusu
2291	UfsasGfuAfcCfaAfgUfuAf cGfuGfcAfsusu	2345	usGfscAfcGfuAfaCfuUfgGf uAfcUfasusu
2292	AfsgsUfaCfcAfaGfuUfaCf gUfgCfaAfsusu	2346	usUfsgCfaCfGufAfaCfuUfuGf gUfaCfususu
2293	GfsusAfcCfaAfgUfuAfcGf uGfcAfcAfsusu	2347	usGfsuGfcAfcGfuAfaCfuUf gGfuAfcusu
2294	UfsasCfcAfaGfuUfaCfGuf gCfaCfcAfsusu	2348	usGfsgUfgCfaCfGufAfaCfuUf uGfgUfasusu
2295	CfscsAfaGfuUfaCfGufGfCf aCfcAfaAfsusu	2349	usUfsuGfgUfgCfaCfGufAfaCf cUfuGfgsusu
2296	CfsasAfgUfuAfcGfuGfcAf cCfaAfaAfsusu	2350	usUfsuUfgGfuGfcAfcGfuAf aCfuUfgsusu
2297	AfsasGfuUfaCfGufGfCfaCf cAfaAfuAfsusu	2351	usAfsuUfuGfgUfgCfaCfGuf aAfcUfususu
2298	GfsusUfaCfGufGfCfaCfcAf aAfuUfaAfsusu	2352	usUfsaAfuUfuGfgUfgCfaCf gUfaAfcusu
2299	UfsusAfcGfuGfcAfcCfaAf aUfuAfuAfsusu	2353	usAfsuAfaUfuUfgGfuGfcAf cGfuAfasusu
2300	AfsasGfaCfuCfaAfaAfgUf aAfuAfuAfsusu	2354	usAfsuAfuUfaCfuUfuUfgAf gUfcUfususu
2301	AfsasAfaUfcUfaCfuAfaAf aAfgUfcAfsusu	2355	usGfsaCfuUfuUfuAfgUfaGf aUfuUfususu
2302	UfscsUfaCfuAfaAfaAfgUf cUfcUfgAfsusu	2356	usCfsaGfaGfaCfuUfuUfuAf gUfaGfasusu
2303	UfsgsAfaGfaCfGfgGfcUf aGfaUfaAfsusu	2357	usUfsaUfcUfaGfcCfcCfGuf cUfuCfasusu
2304	CfsusAfgAfuAfuUfgGfgAf gAfaAfcAfsusu	2358	usGfsuUfuCfuCfcCfaAfuAf uCfuAfgsusu
2305	AfsgsCfaGfaAfcGfgUfgAf aAfgUfgAfsusu	2359	usCfsaCfuUfuCfaCfcGfuUf cUfgCfususu
2306	AfsasAfgUfgGfgAfgAfuAf cAfuUfgAfsusu	2360	usCfsaAfuGfuAfuCfuCfcCf aCfuUfususu
2307	AfsasGfuGfgGfaGfaUfaCf aUfuGfgAfsusu	2361	usCfscAfaUfgUfaUfcUfcCf cAfcUfususu
2308	AfsgsUfgGfgAfgAfuAfcAf uUfgGfaAfsusu	2362	usUfscCfaAfuGfuAfuCfuCf cCfaCfususu

2309	UfsgsGfgAfgAfuAfcAfuUf gGfaUfcAfsusu	2363	usGfSaUfcCfaAfuGfuAfuCf uCfcCfasusu
2310	AfsusAfcAfuUfgGfaUfcUf uCfuCfaAfsusu	2364	usUfsgAfgAfaGfaUfcCfaAf uGfuAfsusu
2311	CfsasUfuGfgAfuCfuUfcUf cAfuUfgAfsusu	2365	usCfSaAfuGfaGfaAfgAfuCf cAfaUfgsusu
2312	AfsusUfgGfaUfcUfuCfuCf aUfuGfgAfsusu	2366	usCfscAfaUfgAfgAfaGfaUf cCfaAfsusu
2313	UfsusGfgAfuCfuUfcUfcAf uUfgGfaAfsusu	2367	usUfscCfaAfuGfaGfaAfgAf uCfcAfsusu
2314	UfsgsGfaUfcUfuCfuCfaUf uGfgAfgAfsusu	2368	usCfsuCfcAfaUfgAfgAfaGf aUfcCfasusu
2315	GfsasUfcUfuCfuCfaUfuGf gAfgAfgAfsusu	2369	usCfsuCfuCfcAfaUfgAfgAf aGfaUfcsusu
2316	UfsusCfuCfaUfuGfgAfgAf gGfaUfaAfsusu	2370	usUfSaUfcCfuCfuCfcAfaUf gAfgAfsusu
2317	CfsusCfaUfuGfgAfgAfgGf aUfaAfaAfsusu	2371	usUfSuUfaUfcCfuCfuCfcAf aUfgAfgsusu
2318	AfsgsAfcAfgUfuAfuGfcGf gAfuUfcAfsusu	2372	usGfSaAfuCfcGfcAfuAfaCf uGfuCfususu
2319	GfsasCfaGfuUfaUfgCfgGf aUfuCfuAfsusu	2373	usAfgsAfaUfcCfcGfaUfaAf cUfgUfcsusu
2320	UfsusAfuGfcGfgAfuUfcUf cUfuGfaAfsusu	2374	usUfscAfaGfaGfaAfuCfcGf cAfaAfsusu
2321	UfsasUfgCfgGfaUfuCfuCf uUfgAfaAfsusu	2375	usUfSuCfaAfgAfgAfaUfcCf gCfaUfasusu
2322	AfsusGfcGfgAfuUfcUfcUf uGfaAfaAfsusu	2376	usUfSuUfcAfaGfaGfaAfuCf cGfcAfsusu
2323	UfsasCfaGfaGfuGfgUfgUf uAfcGfgAfsusu	2377	usCfscGfuAfaCfaCfcAfcUf cUfgUfasusu
2324	GfsusGfuUfaCfgGfcGfgUf gGfaAfaAfsusu	2378	usUfSuUfcCfaCfcGfcCfgUf aAfcAfcusu
2325	UfsgsUfuAfcGfgCfgGfuGf gAfaAfaAfsusu	2379	usUfSuUfuCfcAfcCfcGfcGf uAfaCfasusu
2326	GfsusUfaCfgGfcGfgUfgGf aAfaAfgAfsusu	2380	usCfsuUfuUfcCfaCfcGfcCf gUfaAfcusu
2327	UfsusAfcGfgCfgGfuGfgAf aAfaGfuAfsusu	2381	usAfcUfuUfuCfcAfcCfcGf cGfuAfasusu
2328	UfsasCfgGfcGfgUfgGfaAf aAfgUfuAfsusu	2382	usAfsaCfuUfuUfcCfaCfcGf cCfgUfasusu
2329	CfsgsGfcGfgUfgGfaAfaAf gUfuUfaAfsusu	2383	usUfSaAfaCfuUfuUfcCfaCf cGfcCfgsusu
2330	AfsgsUfuUfaAfaGfuUfgCf cUfaAfgAfsusu	2384	usCfsuUfaGfgCfaAfcUfuUf aAfaCfususu
2331	UfsusUfaAfaGfuUfgCfcUf aAfgAfaAfsusu	2385	usUfSuCfuUfaGfgCfaAfcUf uUfaAfasusu
2332	UfsgsGfaUfuGfcUfuUfuUf aGfcAfaAfsusu	2386	usUfSuGfcUfaAfaAfaGfcAf aUfcCfasusu
2333	GfsasAfgGfgGfuCfaCfcUf gAfaAfaAfsusu	2387	usUfSuUfuCfaGfgUfgAfcCf cCfuUfcsusu
2334	AfsasAfuAfaAfgUfuCfuCf uUfaGfcAfsusu	2388	usGfscUfaAfgAfgAfaCfuUf uAfuUfususu

Table 9. Sequences in siRNA subset H

siRNA Name	SEQ ID NO:	sense strand sequence (5'-3')	SEQ ID NO:	antisense strand sequence (5'-3')
ETD01220	2389	usgsgcuAfuGfgfcuagu guuaasusu	2335	usUfSaAfcAfcUfaGfcCfaUfa GfcCfasusu
ETD01221	2390	asuscauAfcAfafacucu guacasusu	2336	usGfsuAfcAfgAfgUfuUfgUfa UfgAfsusu
ETD01222	2391	csusguaCfuuCfcfugga aucgasusu	2337	usCfsgAfuUfcCfaGfgAfaGfu AfcAfgsusu

ETD01223	2392	usgsuaCfuuCfCfuggaa ucgaasusu	2338	usUfscGfaUfuCfCfGfaAfg UfaCfasusu
ETD01224	2393	gsusacUfUfccUfggaau cgauasusu	2339	usAfsuCfGfaUfuCfCfGfaAfa GfuAfcusu
ETD01225	2394	usascuuccuGfGfaaucg auaasusu	2340	usUfscUfcGfaUfuCfCfGfaAfg UfaCfasusu
ETD01226	2395	csusuccuGfGfAfAfucg auacuasusu	2341	usAfsGfUfaUfcGfaUfuCfCfGfaAfg GfaAfgusu
ETD01227	2396	csusggAfAfucGfAfuaac uuguaasusu	2342	usUfscCfaAfgUfaUfcGfaUfu CfCfGfasusu
ETD01228	2397	gsasaucGfAfAfucugu auuuaasusu	2343	usAfsaAfuAfcAfaGfuAfuCfG AfuUfcusu
ETD01229	2398	csusaguAfccAfAfguua cgugasusu	2344	usCfscCfGfUfaAfcUfuGfgUfa CfuAfgusu
ETD01230	2399	usasguAfcAfAfGuuaac gugcasusu	2345	usGfscAfcGfuAfaCfuUfgGfu AfcUfasusu
ETD01231	2400	asgsuaccAfaGfuuaacgu gcaasusu	2346	usUfsgCfaCfGfUfaAfcUfuGfg UfaCfasusu
ETD01232	2401	gsusacCfaagUfuUfacgu gcacasusu	2347	usGfscGfCfGfuAfaCfuUfg GfuAfcusu
ETD01233	2402	usascaagUfuUfaCfGug caccasusu	2348	usGfsgUfgCfaCfGfUfaAfcUfu GfgUfasusu
ETD01234	2403	cscsaagUfuUfaCfGfGfc accaaasusu	2349	usUfscGfgUfgCfaCfGfUfaAfc UfuGfgusu
ETD01235	2404	csasaguuAfcGfuGfcac caaaasusu	2350	usUfscUfgGfuGfCfCfGfuAfa CfuUfgusu
ETD01236	2405	asasguUfaCfGfGfGfc caauuasusu	2351	usAfsuUfuGfgUfgCfaCfGfUfa AfcUfususu
ETD01237	2406	gsusuaCfGugCfaCfcaa auuaasusu	2352	usUfscAfuUfuGfgUfgCfaCfGf UfaAfcusu
ETD01238	2407	ususacGfuGfCfCfcaaa uuuaasusu	2353	usAfsuAfaUfuUfgGfuGfCfCf GfuAfasusu
ETD01239	2408	asasgacucAfAfAfAfGu auuaasusu	2354	usAfsuAfuUfaCfuUfuUfgAfg UfcUfususu
ETD01240	2409	asasaaUfCfuaCfUfaaa aagucasusu	2355	usGfscCfuUfuUfuUfgUfaGfa UfuUfususu
ETD01241	2410	uscsuacuAfAfAfAfAfG ucucugasusu	2356	usCfscGfaGfaCfuUfuUfuAfg UfaGfasusu
ETD01242	2411	usgsaaGfCfGfGfGfGfc uagauaasusu	2357	usUfscUfcUfaGfCfCfCfGfUfc UfuCfasusu
ETD01243	2412	csusagaUfaUfUfgggag aaacasusu	2358	usGfscUfuCfuCfCfCfaAfuAfu CfuAfgusu
ETD01244	2413	asgscaGfaacGfGfGfGfa agugasusu	2359	usCfscCfuUfuCfaCfCfGfuUfc UfgCfasusu
ETD01245	2414	asasaguGfgGfGfGfGfa auugasusu	2360	usCfscAfuGfuAfuCfuCfCfCfa CfuUfususu
ETD01246	2415	asasguGfgGfGfGfGfa uuggasusu	2361	usCfscAfaUfgUfaUfcUfcCfCf AfcUfususu
ETD01247	2416	asgsuggGfGfGfGfGfa uggaasusu	2362	usUfscCfaAfuGfuAfuCfuCfCf CfaCfasusu
ETD01248	2417	usgsGGfGfGfGfGfGfa ggauacasusu	2363	usGfscUfcCfaAfuGfuAfuCfu CfCfCfasusu
ETD01249	2418	asusacAfuUfGfGfaucuu cucaasusu	2364	usUfsgAfgAfaGfaUfcCfaAfu GfuAfasusu
ETD01250	2419	csasuuggaUfCfUfUfcu cauugasusu	2365	usCfscAfuGfaGfaAfgAfuCfCf AfaUfgusu
ETD01251	2420	asusuggaUfCfUfUfcu uuggasusu	2366	usCfscAfaUfgAfgAfaGfaUfc CfaAfasusu
ETD01252	2421	ususggauUfCfUfUfcu uuggaasusu	2367	usUfscCfaAfuGfaGfaAfgAfu CfCfAfasusu
ETD01253	2422	usgsGauCfuUfCfUfaau ggagasusu	2368	usCfscCfCfAfaUfgAfgAfaGfa UfcCfasusu

ETD01254	2423	gsasucUfuCfuCfaugg agagasusu	2369	usCfsuCfuCfcAfaUfgAfgAfa GfaUfcsusu
ETD01255	2424	ususcucAfuUgGfagag gauaasusu	2370	usUfsaUfcCfuCfuCfcAfaUfg AfgAfasusu
ETD01256	2425	csuscauuGfGfAfGfAfg gauaaaaasusu	2371	usUfsuUfaUfcCfuCfuCfcAfa UfgAfgsusu
ETD01257	2426	asgsacAfGfuUfUgGfcg gauucasusu	2372	usGfsaAfuCfcGfcAfaAfaCfu GfuCfususu
ETD01258	2427	gsascagUfUfaUfgcgga uucuasusu	2373	usAfsaAfaUfcCfcCfaUfaAfc UfgUfcsusu
ETD01259	2428	ususauGfcGfGfAfuucuc uugaasusu	2374	usUfscAfaGfaGfaAfuCfcGfc AfaAfasusu
ETD01260	2429	usasugCfGgaUfUfcucu ugaaasusu	2375	usUfsuCfaAfgAfgAfaUfcCfc CfaUfasusu
ETD01261	2430	asusgcggaUfUfcUfcuu gaaaasusu	2376	usUfsuUfcAfaGfaGfaAfuCfc GfcAfasusu
ETD01262	2431	usascaGfaGfuGfGfugu uacggasusu	2377	usCfscGfuAfaCfaCfcAfcUfc UfgUfasusu
ETD01263	2432	gsusguuacGfGfcGfGug gaaaasusu	2378	usUfsuUfcCfaCfcGfcCfcGfu AfaAfasusu
ETD01264	2433	usgsuuaCfGgCfGgugga aaaasusu	2379	usUfsuUfuCfcAfcCfcGfcGfu AfaCfasusu
ETD01265	2434	gsusuacGfGfcGfGfugg aaaagasusu	2380	usCfsuUfuUfcCfaCfcGfcCfc UfaAfcusu
ETD01266	2435	ususacGfGfcGfGfGfGf aaaaguasusu	2381	usAfsuUfuUfuCfcAfcCfcGfc GfuAfasusu
ETD01267	2436	usascggCfGgUfggaaaa guuasusu	2382	usAfsaCfuUfuUfcCfaCfcGfc CfcUfasusu
ETD01268	2437	csgsgcGfGfuGfGfaaaa guuuasusu	2383	usUfsaAfaCfuUfuUfcCfaCfc GfcCfcsusu
ETD01269	2438	asgsuuuAfaAfaGfuugc cuaagasusu	2384	usCfsuUfaGfgCfaAfcUfuUfa AfaCfususu
ETD01270	2439	ususuaaagUfUfgCfcua agaaasusu	2385	usUfsuCfuUfaGfgCfaAfcUfu UfaAfasusu
ETD01271	2440	usgsaUfUfgUfuUfu agcaasusu	2386	usUfsuGfcUfaAfaAfaGfcAfa UfcCfasusu
ETD01272	2441	gsasagggUfCfaCfcug aaaaasusu	2387	usUfsuUfuCfaGfgUfgAfcCfc CfuUfcsusu
ETD01273	2334	AfsasAfuAfaAfgUfuCf uCfuUfaGfcAfsusu	2388	usGfscUfaAfgAfgAfaCfuUfu AfuUfususu

[00269] Any siRNA among any of subsets A-H may comprise any modification pattern described herein. If a sequence is a different number of nucleotides in length than a modification pattern, the modification pattern may still be used with the appropriate number of additional nucleotides added 5' or 3' to match the number of nucleotides in the modification pattern. For example, if a sense or antisense strand of the siRNA among any of subsets A-F comprises 19 nucleotides, and a modification pattern comprises 21 nucleotides, UU may be added onto the 5' end of the sense or antisense strand.

Example 3: Screening *MTRES1* siRNAs for activity in human cells in culture

[00270] Chemically modified *MTRES1* siRNAs in **Table 9** were assayed for *MTRES1* mRNA knockdown activity in cells in culture. SK-LMS-1 cells (ATCC® HTB-88) were seeded in 96-well tissue culture plates at a cell density of 7,500 cells per well in EMEM (ATCC Catalog No. 30-2003) supplemented with 10% fetal bovine serum and incubated overnight in a water-jacketed, humidified incubator at 37°C in an atmosphere composed of air plus 5% carbon dioxide. These siRNAs were derived from sequences in siRNA subset F, and were cross reactive for human and non-human primate. The

MTRES1 siRNAs were individually transfected into SK-LMS-1 cells in duplicate wells at 10 nM and 1 nM final concentration using 0.3 μ L Lipofectamine RNAiMax (Fisher) per well. Silencer Select Negative Control #1 (ThermoFisher, Catalog# 4390843) was transfected at 10 nM and 1 nM final concentration as a control. Silencer Select human *MTRES1* (ThermoFisher, Catalog# 4427037, ID: s27762) was transfected at 10 nM and 1 nM final concentration and used as a positive control. After incubation for 48 hours at 37°C, total RNA was harvested from each well and cDNA prepared using TaqMan® Fast Advanced Cells-to-CT™ Kit (ThermoFisher, Catalog# A35374) according to the manufacturer's instructions. The level of *MTRES1* mRNA from each well was measured in triplicate by real-time qPCR on a QuantStudio™ 6 Pro Real-Time PCR System using TaqMan Gene Expression Assay for human *MTRES1* (ThermoFisher, assay# Hs00360684_m1). The level of *PPIA* mRNA was measured using TaqMan Gene Expression Assay (ThermoFisher, assay# Hs99999904_m1) and used to determine relative *MTRES1* mRNA levels in each well using the delta-delta Ct method. All data was normalized to relative *MTRES1* mRNA levels in untreated SK-LMS-1 cells. The results are shown in **Table 10**. The siRNAs ETD01228, ETD01270, ETD01251, ETD01235, ETD01249, ETD01258, ETD01268, ETD01273, ETD01263, ETD01240, ETD01223, ETD01262, ETD01239, ETD01242, ETD01272, ETD01220, ETD01261, ETD01243, ETD01269, ETD01256, ETD01241, ETD01238, ETD01247 and ETD01266 reduced *MTRES1* levels by greater than 50% when transfected at 10 nM.

Table 10. Knockdown Activity of *MTRES1*-Specific siRNAs at 10 nM and 1 nM in Human SK-LMS-1 Cells

siRNA name	Sense Strand SEQ ID NO:	Antisense Strand SEQ ID NO:	Relative <i>MTRES1</i> mRNA Level	
Untreated Cells	-	-	1.00	
			10 nM siRNA	1 nM siRNA
Negative Control siRNA	-	-	0.93	1.34
Positive Control siRNA	-	-	0.39	0.80
ETD01220	2389	2335	0.34	0.87
ETD01221	2390	2336	0.73	1.24
ETD01222	2391	2337	1.03	1.18
ETD01223	2392	2338	0.39	0.57
ETD01224	2393	2339	0.62	0.86
ETD01225	2394	2340	1.13	1.10
ETD01226	2395	2341	0.50	0.69
ETD01227	2396	2342	1.10	1.21
ETD01228	2397	2343	0.50	0.68
ETD01229	2398	2344	0.52	0.96
ETD01230	2399	2345	1.01	1.14
ETD01231	2400	2346	0.52	1.00
ETD01232	2401	2347	0.78	1.01
ETD01233	2402	2348	0.79	1.11
ETD01234	2403	2349	0.81	0.92

WO 2022/266045

PCT/US2022/033356

ETD01235	2404	2350	0.44	0.75
ETD01236	2405	2351	0.87	1.04
ETD01237	2406	2352	0.57	0.83
ETD01238	2407	2353	0.28	0.49
ETD01239	2408	2354	0.38	0.76
ETD01240	2409	2355	0.41	0.81
ETD01241	2410	2356	0.29	0.59
ETD01242	2411	2357	0.37	0.61
ETD01243	2412	2358	0.32	0.83
ETD01244	2413	2359	1.00	1.15
ETD01245	2414	2360	0.98	1.04
ETD01246	2415	2361	0.85	1.05
ETD01247	2416	2362	0.26	0.52
ETD01248	2417	2363	0.92	1.04
ETD01249	2418	2364	0.44	0.78
ETD01250	2419	2365	1.04	1.10
ETD01251	2420	2366	0.47	0.94
ETD01252	2421	2367	0.83	1.17
ETD01253	2422	2368	0.87	1.04
ETD01254	2423	2369	0.92	1.02
ETD01255	2424	2370	0.84	1.03
ETD01256	2425	2371	0.29	0.57
ETD01257	2426	2372	0.75	1.00
ETD01258	2427	2373	0.44	0.93
ETD01259	2428	2374	0.55	1.00
ETD01260	2429	2375	0.66	1.33
ETD01261	2430	2376	0.33	0.53
ETD01262	2431	2377	0.39	0.92
ETD01263	2432	2378	0.42	0.76
ETD01264	2433	2379	1.00	1.28
ETD01265	2434	2380	1.00	0.94
ETD01266	2435	2381	0.24	0.36
ETD01267	2436	2382	0.90	1.14
ETD01268	2437	2383	0.44	1.06
ETD01269	2438	2384	0.32	0.90
ETD01270	2439	2385	0.50	0.91
ETD01271	2440	2386	0.52	1.15
ETD01272	2441	2387	0.35	0.90
ETD01273	2442	2388	0.44	1.24

Example 4: Determining the IC₅₀ of MTRES1 siRNAs

[00271] The IC₅₀ values for knockdown of MTRES1 mRNA by select MTRES1 siRNAs will be determined in SK-LMS-1 (ATCC® HTB-88) cells. The siRNAs will be assayed individually at 30 nM, 10

nM, 3 nM, 1 nM and 0.3 nM, or 3 nM, 1 nM, 0.3 nM, 0.1 nM and 0.03 nM, or 30 nM, 10 nM, 3 nM, 1 nM, 0.3 nM, 0.1 nM and 0.03 nM. The SK-LMS-1 cells will be seeded in 96-well tissue culture plates at a cell density of 7,500 cells per well in EMEM (ATCC Catalog No. 30-2003) supplemented with 10% fetal bovine serum and incubated overnight in a water-jacketed, humidified incubator at 37°C in an atmosphere composed of air plus 5% carbon dioxide. The MTRES1 siRNAs will be individually transfected into SK-LMS-1 cells in triplicate wells using 0.3 µL Lipofectamine RNAiMax (Fisher) per well. After incubation for 48 hours at 37°C, total RNA will be harvested from each well and cDNA prepared using TaqMan® Fast Advanced Cells-to-CT™ Kit (ThermoFisher, Catalog# A35374) according to the manufacturer's instructions. The level of MTRES1 mRNA from each well will be measured in triplicate by real-time qPCR on a QuantStudio™ 6 Pro Real-Time PCR System using TaqMan Gene Expression Assay for human MTRES1 (ThermoFisher, assay# Hs01568158_m1). The level of PPIA mRNA will be measured using TaqMan Gene Expression Assay (ThermoFisher, assay# Hs99999904_m1) and used to determine relative MTRES1 mRNA levels in each well using the delta-delta Ct method. All data will be normalized to relative MTRES1 mRNA levels in untreated SK-LMS-1 cells. Curve fit will be accomplished using the [inhibitor] vs. response (three parameters) function in GraphPad Prism software.

Example 5: siRNA-mediated knockdown of MTRES1 in HCN-2 cells

[00272] siRNAs targeted to MTRES1 mRNA that downregulate levels of MTRES1 mRNA may lead to a decrease in mRNA abundance of mitochondrially expressed NADH-ubiquinone oxidoreductase chain 5 protein (ND5), NADH-ubiquinone oxidoreductase chain 6 protein (ND6), cytochrome b (CYTB), and mitochondrially encoded 12S ribosomal RNA (12S rRNA), when administered to the cultured human neuronal cell line HCN-2 under conditions of ethidium bromide induced mitochondrial stress.

[00273] On Day 0, HCN-2 cells are to be seeded at 150,000 cells/mL into a Falcon 24-well tissue culture plate (ThermoFisher Cat. No. 353047) at 0.5 mL per well.

[00274] On Day 1, cells are treated with ethidium bromide (100ng/ml), a well-established mitochondrial DNA replication/transcription inhibitor and stressor. Also on Day 1, MTRES1 siRNA and negative control siRNA master mixes are prepared. The MTRES1 siRNA master mix contains 350 µL of Opti-MEM (ThermoFisher Cat. No. 4427037 - s1288 Lot No. AS02B02D) and 3.5 µL of a mixture of two MTRES1 siRNAs (10 µM stock). The negative control siRNA master mix contains 350 µL of Opti-MEM and 3.5 µL of negative control siRNA (ThermoFisher Cat. No. 4390843, 10 µM stock). Next, 3 µL of TransIT-X2 (Mirus Cat. No. MIR-6000) is added to each master mix. The mixes are incubated for 15 minutes to allow transfection complexes to form, then 51 µL of the appropriate master mix + TransIT-X2 is added to duplicate wells of HCN-2 cells with a final siRNA concentration of 10 nM.

[00275] On Day 3, 48 hours post transfection, duplicate wells are lysed using the Cells-to-Ct kit according to the manufacturer's protocol (ThermoFisher Cat. No. 4399002) or protein lysis buffer containing protease and phosphatase inhibitors. For the Cells-to-Ct, cells are washed with 50 µL using cold 1X PBS and lysed by adding 49.5 µL of Lysis Solution and 0.5 µL DNase I per well and pipetting up and down 5 times and incubating for 5 minutes at room temperature. Stop Solution (5 µL/well) is added to each well and mixed by pipetting up and down five times and incubating at room temperature for 2 minutes. The

reverse transcriptase reaction is performed using 22.5 μ L of the lysate according to the manufacturer's protocol. Samples are stored at -80 °C until real-time qPCR is performed in triplicate using TaqMan Gene Expression Assays (Applied Biosystems FAM/MTRES1, FAM/ND5, FAM/ND6, FAM/CYTB and FAM/12srRNA and using a BioRad CFX96 Cat. No. 1855195).

[00276] A decrease in MTRES1 mRNA expression in the HCN-2 cells is expected after transfection with the MTRES1 siRNAs compared to MTRES1 mRNA levels in HCN-2 cells transfected with the non-specific control siRNA 48 hours after transfection. There is an expected decrease in abundance of mitochondrial expressed genes ND5, ND6, CYTB and 12s rRNA mRNA. These results will show that the MTRES1 siRNAs elicit knockdown of MTRES1 mRNA in HCN-2 cells, and that the decrease in MTRES1 expression is correlated with a decrease in abundance of mitochondrial expressed genes ND5, ND6, CYTB and 12s rRNA mRNA.

Example 6: ASO-mediated knockdown of MTRES1 in HCN-2 cells

[00277] ASOs targeted to MTRES1 mRNA that downregulate levels of MTRES1 mRNA may lead to a decrease in mRNA abundance of mitochondrial expressed ND5, ND6, CYTB and 12s rRNA, when administered to the cultured human neuronal cell line HCN-2 under conditions of ethidium bromide induced mitochondrial stress.

[00278] On Day 0, HCN-2 cells are to be seeded at 150,000 cells/mL into a Falcon 24-well tissue culture plate (ThermoFisher Cat. No. 353047) at 0.5 mL per well.

[00279] On Day 1, cells are treated with ethidium bromide (100ng/ml), a well-established mitochondrial DNA replication/transcription inhibitor and stressor. Also on Day 1, MTRES1 ASO and negative control ASO master mixes are prepared. The MTRES1 ASO master mix contains 350 μ L of Opti-MEM (ThermoFisher Cat. No. 4427037 - s1288 Lot No. AS02B02D) and 3.5 μ L of a mixture of two MTRES1 ASOs (10 μ M stock). The negative control ASO master mix contains 350 μ L of Opti-MEM and 3.5 μ L of negative control ASO (ThermoFisher Cat. No. 4390843, 10 μ M stock). Next, 3 μ L of TransIT-X2 (Mirus Cat. No. MIR-6000) is added to each master mix. The mixes are incubated for 15 minutes to allow transfection complexes to form, then 51 μ L of the appropriate master mix + TransIT-X2 is added to duplicate wells of HCN-2 cells with a final ASO concentration of 10 nM.

[00280] On Day 3, 48 hours post transfection, duplicate wells are lysed using the Cells-to-Ct kit according to the manufacturer's protocol (ThermoFisher Cat. No. 4399002) or protein lysis buffer containing protease and phosphatase inhibitors. For the Cells-to-Ct, cells are washed with 50 μ L using cold 1X PBS and lysed by adding 49.5 μ L of Lysis Solution and 0.5 μ L DNase I per well and pipetting up and down 5 times and incubating for 5 minutes at room temperature. Stop Solution (5 μ L/well) is added to each well and mixed by pipetting up and down five times and incubating at room temperature for 2 minutes. The reverse transcriptase reaction is performed using 22.5 μ L of the lysate according to the manufacturer's protocol. Samples are stored at -80 °C until real-time qPCR is performed in triplicate using TaqMan Gene Expression Assays (Applied Biosystems FAM/MTRES1, FAM/ND5, FAM/ND6, FAM/CYTB and FAM/12srRNA and using a BioRad CFX96 Cat. No. 1855195).

[00281] A decrease in MTRES1 mRNA expression in the HCN-2 cells is expected after transfection with the MTRES1 ASOs compared to MTRES1 mRNA levels in HCN-2 cells transfected with the non-specific control ASO 48 hours after transfection. There is an expected decrease in abundance of mitochondrial expressed genes ND5, ND6, CYTB and 12s rRNA mRNA. These results will show that the MTRES1 ASOs elicit knockdown of MTRES1 mRNA in HCN-2 cells, and that the decrease in MTRES1 expression is correlated with a decrease in abundance of mitochondrial expressed genes ND5, ND6, CYTB and 12s rRNA mRNA.

Example 7: Inhibition of MTRES1 in a Mouse Model for Alzheimer's Disease Using MTRES1 siRNAs or ASOs

[00282] In this experiment, a mouse model of Alzheimer's Disease (AD) will be used to evaluate effects of siRNA or ASO inhibition of MTRES1. The model includes Tg2576 mice which express human amyloid beta precursor protein (APP) and presenilin-1 (PSEN1) transgenes with five AD-linked mutations. Cognitive function is measured using a forced swimming test (FST).

[00283] Seven-month-old mice are divided into four groups: Group 1 - a group treated with non-targeting control siRNA, Group 2 - a group treated with non-targeting control ASO, Group 3 - a group treated with MTRES1 siRNA1, Group 4 - a group treated with MTRES1 ASO1. Each group contains eight rats (4 males, 4 females), Group 5 - a group treated with vehicle.

[00284] Administration of siRNA, ASO or vehicle is achieved with a 10 μ L intracerebroventricular (ICV) injection of siRNA or ASO resuspended in PBS at concentration of 10 μ M. On Study Day 0, Group 1 mice will be receive non-targeting control siRNA by ICV, Group 2 mice receive non-targeting control ASO by ICV, Group 3 mice will receive siRNA1 targeting mouse MTRES1 by ICV, Group 4 mice will receive ASO1 targeting mouse MTRES1 by ICV, and Group 5 mice will receive vehicle by ICV. Every other week thereafter animals from each group will be dosed for a total of 4 injections. The behavioral tests are performed 24 hrs after the final injection.

[00285] To rule out nonspecific motor effects that could influence the FST results, the potential effect of siRNA or ASO treatment on locomotor activity is assessed. Mice are evaluated using the openfield paradigm (44 $\times$ 44 $\times$ 40 cm) in a sound-attenuated room. The total distance (cm) traveled by each mouse is recorded for 5 min by a video surveillance system (SMART; Panlab SL, Barcelona, Spain) and is used to quantify activity levels. The floor of the open-field apparatus is cleaned with 10% ethanol between tests.

[00286] The FST includes a behavioral test useful for screening potential drugs that influence cognition and assessing other manipulations that are expected to affect cognitive related behaviors. On the first day, mice are placed individually in the water and allowed to swim for 15 min. The next day, mice are placed again in the water to observe the duration of immobility for 6 min using a camera. Following a 1-min session of acclimation to the apparatus, all behaviors are recorded for 5 min by a video surveillance system (SMART 2.5.21; Panlab SL). Immobility is defined as motionless floating in the water, only allowing movements necessary for the animal to keep its head above the water. The total immobility time in the FST is recorded as an index of cognitive ability.

[00287] Twenty four hours after the behavioral assessment, the mice are sacrificed by cervical dislocation following an intraperitoneal injection of 0.3 ml Nembutal (5 mg/ml) (Sigma Cat. No. 1507002). Brain and spinal cord tissues are removed and placed in RNeasy lysis buffer for mRNA isolation.

[00288] mRNA is isolated from tissue placed in RNeasy lysis buffer using the PureLink kit according to the manufacturer's protocol (ThermoFisher Cat. No. 12183020). The reverse transcriptase reaction is performed according to the manufacturer's protocol. Samples are stored at -80 °C until real-time qPCR was performed in triplicate using TaqMan Gene Expression Assays (Applied Biosystems FAM/MTRES1 using a BioRad CFX96 Cat. No. 1855195). A decrease in MTRES1 mRNA expression in the cortical tissue from mice dosed with the MTRES1 siRNA or ASO1 is expected compared to MTRES1 mRNA levels in the cortical tissue from mice dosed with the non-specific controls. There is an expected decrease in the total immobility time in the FST in mice that receive the MTRES1 siRNA or ASO compared to the total immobility time in the FST in mice that receive the non-specific control along with no change between treatment groups in the locomotor activity test. These results will show that the MTRES1 siRNA or ASO elicit knockdown of MTRES1 mRNA in cortical tissue, and that the decrease in MTRES1 expression is correlated with a decrease in total immobility time in the FST along with no change in locomotor activity. These results will indicate that administration of an oligonucleotide targeting MTRES1 to a mammalian subject may be used to treat neurological disorder that includes cognitive decline.

Example 8: Screening siRNAs targeting human and mouse MTRES1 in mice

[00289] Several siRNAs designed to be cross-reactive with human and mouse *MTRES1* mRNA were tested for activity in mice. The siRNAs were attached to the GalNAc ligand ETL1. The siRNA sequences are shown in **Table 11A**, where Nf is a 2' fluoro-modified nucleoside, n is a 2' O-methyl modified nucleoside, and "s" is a phosphorothioate linkage.

[00290] Six to eight week old female mice (strain ICR, n=3) were given a subcutaneous injection on Day 0 of a single 200 ug dose of a GalNAc-conjugated siRNA or PBS as vehicle control.

[00291] Mice were euthanized on Day 14 after injection and a liver sample from each was collected and placed in RNeasy lysis buffer (ThermoFisher Catalog# AM7020) until processing. Total liver RNA was prepared by homogenizing the liver tissue in homogenization buffer (Maxwell RSC simplyRNA Tissue Kit) using a Percellys 24 tissue homogenizer (Bertin Instruments) set at 5000 rpm for two 10 second cycles. Total RNA from the lysate was purified on a Maxwell RSC 48 platform (Promega Corporation) according to the manufacturer's recommendations. Preparation of cDNA was performed using Quanta qScript cDNA SuperMix (VWR, Catalog# 95048-500) according to the manufacturer's instructions. The relative levels of liver *MTRES1* mRNA were assessed by RT-qPCR in triplicate on a QuantStudio™ 6 Pro Real-Time PCR System using TaqMan assays for mouse *MTRES1* (ThermoFisher, assay# Mm01229834_m1) and the mouse housekeeping gene PPIA (ThermoFisher, assay# Mm02342430_g1) and PerfeCTa® qPCR FastMix®, Low ROX™ (VWR, Catalog# 101419-222). Data were normalized to the mean *MTRES1* mRNA level in animals receiving PBS. Results are shown in **Table 12**. Mice injected with ETD01506,

ETD01507, ETD01508, and ETD01509 had substantially lower levels in mean liver *MTRES1* mRNA on Day 14 relative to mice receiving PBS.

Table 11A. Description of Example siRNAs with Sequences

siRNA Name	Sense Strand SEQ ID NO:	Sense Strand Sequence (5'-3') with GalNAc moiety	Antisense Strand SEQ ID NO:	Antisense Strand Sequence (5'-3')
ETD01506	2463	[ETL1]UfscsgaUfaCfuUfgUfaUfuUfuUfcasusu	2467	usGfsaAfaAfaUfaCfaAfgUfaUfcGfa susu
ETD01507	2464	[ETL1]csusAfcAfaAfgGfuGfaAfcucAfgAfsusu	2468	usCfsugaGfuUfcaccuUfuGfuagsusu
ETD01508	2465	[ETL1]AfsusGfgAfaGfaAfaAfgcaGfaAfcAfsusu	2469	usGfsuucUfgCfuuuucUfuCfcaususu
ETD01509	2466	[ETL1]csusuucUfcAfaAfgGfuGfaAfcAfsusu	2470	usGfsuUfcAfcCfuUfuGfuAfgAfaAfgsusu

Table 11B. Example siRNA Base Sequences

siRNA Name	SEQ ID NO:	Sense Strand Base Sequence (5' to 3')	SEQ ID NO:	Antisense Strand Base Sequence (5' to 3')
ETD01506	2550	UCGAUACUUGUAUUUUUCAUU	2612	UGAAAAAUACAAGUAUCGAUU
ETD01507	2551	CUACAAAGGUGAACUCAGAUU	2613	UCUGAGUUCACCUUUGUAGUU
ETD01508	2552	AUGGAAGAAAAGCAGAACAUU	2614	UGUUCUGCUUUUCUCCAUUU
ETD01509	2553	CUUUCUACAAAGGUGAACAUU	2615	UGUUCACCUUUGUAGAAAGUU
siRNA Name	SEQ ID NO:	Sense Strand Base Sequence (5' to 3'), without 3' overhangs	SEQ ID NO:	Antisense Strand Base Sequence (5' to 3'), without 3' overhangs
ETD01506	2554	UCGAUACUUGUAUUUUUCA	2616	UGAAAAAUACAAGUAUCGA
ETD01507	2555	CUACAAAGGUGAACUCAGA	2617	UCUGAGUUCACCUUUGUAG
ETD01508	2556	AUGGAAGAAAAGCAGACA	2618	UGUUCUGCUUUUCUCCAU
ETD01509	2557	CUUUCUACAAAGGUGAACA	2619	UGUUCACCUUUGUAGAAAG

Table 12. Relative *MTRES1* mRNA Levels in Livers of Mice

Group	n	Treatment	Dose (ug)	Mean <i>MTRES1</i> mRNA (Normalized to Group 1, Day 14)
1	3	PBS	0	1.00
2	3	ETD01506	200	0.27
3	3	ETD01507	200	0.00
4	3	ETD01508	200	0.51
5	3	ETD01509	200	0.51

Example 9: Screening of siRNAs targeting human *MTRES1* mRNA in mice transfected with AAV8-TBG-h-MTRES1

[00292] Several siRNAs designed to be cross-reactive with human and cynomolgus monkey *MTRES1* mRNA were tested for activity in mice following transfection with an adeno-associated viral vector. The siRNAs were attached to the GalNAc ligand ETL17. The siRNA sequences are shown in **Table 13A**, where “Nf” is a 2' fluoro-modified nucleoside, “h” is a 2' O-methyl modified nucleoside, “d” is a deoxynucleoside, and “s” is a phosphorothioate linkage.

[00293] Six to eight week old female mice (C57Bl/6) were injected with 10 uL of a recombinant adeno-associated virus 8 (AAV8) vector (8.8 x 10E12 genome copies/mL) by the retroorbital route on Day -13. The recombinant AAV8 contained the open reading frame and the majority of the 3'UTR of the human *MTRES1* sequence (NM_016487.5) under the control of the human thyroxine binding globulin promoter

in an AAV2 backbone packaged in AAV8 capsid (AAV8-TBG-h-MTRES1). On Day 0, infected mice (n=4) were given a subcutaneous injection of a single 100 ug dose of a GalNAc-conjugated siRNA or PBS as vehicle control.

[00294] Mice were euthanized on Day 10 after subcutaneous injection and a liver sample from each was collected and placed in RNAlater (ThermoFisher Catalog# AM7020) until processing. Total liver RNA was prepared by homogenizing the liver tissue in homogenization buffer (Maxwell RSC simplyRNA Tissue Kit) using a Percellys 24 tissue homogenizer (Bertin Instruments) set at 5000 rpm for two 10 second cycles. Total RNA from the lysate was purified on a Maxwell RSC 48 platform (Promega Corporation) according to the manufacturer's recommendations. Preparation of cDNA was performed using Quanta qScript cDNA SuperMix (VWR, Catalog# 95048-500) according to the manufacturer's instructions. The relative levels of liver *MTRES1* mRNA were assessed by RT-qPCR in triplicate on a QuantStudio™ 6 Pro Real-Time PCR System using TaqMan assays for human *MTRES1* (ThermoFisher, assay# Hs01568158_g1) and the mouse housekeeping gene PPIA (ThermoFisher, assay# Mm02342430_g1) and PerfeCTa® qPCR FastMix®, Low ROX™ (VWR, Catalog# 101419-222). Data were normalized to the mean *MTRES1* mRNA level in animals receiving PBS. Results are shown in **Table 14**. Mice injected with ETD01880, 1886, 1887, 1888, 1893 had greatest reductions in mean liver *MTRES1* mRNA on Day 10 relative to mice receiving PBS.

Table 13A. Example siRNA Sequences

siRNA Name	Sense Strand SEQ ID NO:	Sense Strand Sequence (5'-3') with GalNAc moiety	Antisense Strand SEQ ID NO:	Antisense Strand Sequence (5'-3')
ETD01879	2471	[ETL17]suacaaaCfUfCfUfguac uuccasusu	2488	usGfsgAfaGfuAfcAfgAfgUfu UfgUfasusu
ETD01880	2472	[ETL17]suguaCfUfUfCfCfugg a a u c g a a s u s u	2489	usUfscGfaUfuCfcAfgGfaAfg UfaCfasusu
ETD01881	2473	[ETL17]suacuUfcCfUfdGgaau c g a u a s u s u	2490	usUfsaUfcGfaUfuCfcAfgGfa AfgUfasusu
ETD01882	2474	[ETL17]sgaaucGfAfuAfcuugua uuuasusu	2491	usAfsaAfuAfcAfaGfuAfuCfc AfuUfcsusu
ETD01883	2475	[ETL17]suucuaGfUfaCfCfaaguu a c g a s u s u	2492	usCfsgUfaAfcUfuGfgUfaCfu AfgAfasusu
ETD01884	2476	[ETL17]saguuAfcGfuGfcAfcca a a u u a s u s u	2493	usAfsaUfuUfgGfuGfcAfcGfu AfaCfususu
ETD01885	2477	[ETL17]suuacGfuGfcAfccaaau u a u a s u s u	2494	usAfsuAfaUfuUfgGfuGfcAfc GfuAfasusu
ETD01886	2478	[ETL17]saaaaUfCfuaCfUfaaaa a g u c a s u s u	2495	usGfsaCfuUfuUfuAfgUfaGfa UfuUfususu
ETD01887	2479	[ETL17]saucuAfcuAfAfAfAfa g u c u c u a s u s u	2496	usAfsGfGfAfcUfuUfuUfaGfu AfgAfususu
ETD01888	2480	[ETL17]scuagaUfaUfUfgggaga a a c a s u s u	2497	usGfsuUfuCfuCfcCfaAfuAfu CfuAfgsusu
ETD01889	2481	[ETL17]scauuggaUfCfUfUfcuc a u u g a s u s u	2498	usCfsaAfuGfaGfaAfgAfuCfc AfaUfgsusu
ETD01890	2482	[ETL17]suuggaUfCfUfUfcuc a u u g g a s u s u	2499	usUfscCfaAfuGfaGfaAfgAfu CfcAfasusu
ETD01891	2483	[ETL17]sauacAfgAfGfdTggug u u a c g a s u s u	2500	usCfsgUfaAfcAfcCfaCfuCfu GfuAfususu
ETD01892	2484	[ETL17]saguuuAfAfAfGfuugc c u a a g a s u s u	2501	usCfsuUfaGfgCfaAfcUfuUfa AfaCfususu

ETD01893	2485	[ETL17]suuuuaagUfUfgCfcuaa ga a asusu	2502	usUfsuCfuUfaGfgCfaAfcUfu Ufa Afasusu
ETD01894	2486	[ETL17]su ggaUfUfgCfUfuUfu ua gcaaasusu	2503	usUfsUGfcUfaAfaAfaGfcAfa UfcCfasusu
ETD01895	2487	[ETL17]saaauAfaAfGfdTucucu ua gcasusu	2504	usGfscUfaAfgAfgAfaCfuUfu AfuUfususu

Table 13B. Example siRNA Base Sequences

siRNA Name	SEQ ID NO:	Sense Strand Base Sequence (5' to 3')	SEQ ID NO:	Antisense Strand Base Sequence (5' to 3')
ETD01879	2558	UACAAACUCUGUACUCCAUU	2620	UGGAAGUACAGAGUUUGUAUU
ETD01880	2559	UGUACUUCUGGAAUCGAAUU	2621	UUCGAUUCAGGAAGUACAUU
ETD01881	2560	UACUUCUGGAAUCGAUAAUU	2622	UUAUCGAUUCAGGAAGUAUU
ETD01882	2561	GAAUCGAUACUUGUAUUUUUU	2623	UAAAUACAAGUAUCGAUUCUU
ETD01883	2562	UUCUAGUACCAAGUUACGAUU	2624	UCGUAACUUGGUACUAGAAUU
ETD01884	2563	AGUUACGUGCACC AAAUUAUU	2625	UAAUUUGGUGCAGUAACUUU
ETD01885	2564	UUACGUGCACC AAAUUAUUUU	2626	UAUAAUUUGGUGCAGUAUUU
ETD01886	2565	AAAAUCUACUAAAAAGUCAUU	2627	UGACUUUUUAGUAGAUUUUUU
ETD01887	2566	AUCUACUAAAAAGUCUCUAUU	2628	UAGAGACUUUUUAGUAGAUUU
ETD01888	2567	CUAGAUUUUGGAGAAACAUU	2629	UGUUUCUCCCAUAUUCUAGUU
ETD01889	2568	CAUUGGAUCUUCUCAUUGGAUU	2630	UCAAUAGAGAAGAUAUCCAUUU
ETD01890	2569	UUGGAUCUUCUCAUUGGAUU	2631	UUCCAAUGAGAAGAUAUCCAUUU
ETD01891	2570	AUACAGAGTGGUGUUACGAUU	2632	UCGUAACACCACUCUGUAUUU
ETD01892	2571	AGUUUAAAGUUGCCUAAGAUUU	2633	UCUUAGGCAACUUUAAAACUUU
ETD01893	2572	UUUAAAAGUUGCCUAAGAAUUU	2634	UUUCUUAGGCAACUUUAAAACUU
ETD01894	2573	UGGAUUGCUUUUUAGCAAAUU	2635	UUUGC UAAAAAGCAAUCCAUU
ETD01895	2574	AAAUAAAAGTUCUCUUAGCAUU	2636	UGC UAAAGAAACUUUAAUUUUU
siRNA Name	SEQ ID NO:	Sense Strand Base Sequence (5' to 3'), without 3' overhangs	SEQ ID NO:	Antisense Strand Base Sequence (5' to 3'), without 3' overhangs
ETD01879	2575	UACAAACUCUGUACUCCAUU	2637	UGGAAGUACAGAGUUUGUAUU
ETD01880	2576	UGUACUUCUGGAAUCGAAUU	2638	UUCGAUUCAGGAAGUACAUU
ETD01881	2577	UACUUCUGGAAUCGAUAAUU	2639	UUAUCGAUUCAGGAAGUAUU
ETD01882	2578	GAAUCGAUACUUGUAUUUUU	2640	UAAAUACAAGUAUCGAUUCUU
ETD01883	2579	UUCUAGUACCAAGUUACGAUU	2641	UCGUAACUUGGUACUAGAAUU
ETD01884	2580	AGUUACGUGCACC AAAUUAUU	2642	UAAUUUGGUGCAGUAACUUU
ETD01885	2581	UUACGUGCACC AAAUUAUUUU	2643	UAUAAUUUGGUGCAGUAUUU
ETD01886	2582	AAAAUCUACUAAAAAGUCAUU	2644	UGACUUUUUAGUAGAUUUUU
ETD01887	2583	AUCUACUAAAAAGUCUCUAUU	2645	UAGAGACUUUUUAGUAGAUUU
ETD01888	2584	CUAGAUUUUGGAGAAACAUU	2646	UGUUUCUCCCAUAUUCUAGUU
ETD01889	2585	CAUUGGAUCUUCUCAUUGGAUU	2647	UCAAUAGAGAAGAUAUCCAUUU
ETD01890	2586	UUGGAUCUUCUCAUUGGAUUU	2648	UUCCAAUGAGAAGAUAUCCAUUU
ETD01891	2587	AUACAGAGTGGUGUUACGAUU	2649	UCGUAACACCACUCUGUAUUU
ETD01892	2588	AGUUUAAAGUUGCCUAAGAAUU	2650	UCUUAGGCAACUUUAAAACUUU
ETD01893	2589	UUUAAAAGUUGCCUAAGAAUUU	2651	UUUCUUAGGCAACUUUAAAACUU
ETD01894	2590	UGGAUUGCUUUUUAGCAAAUU	2652	UUUGC UAAAAAGCAAUCCAUUU
ETD01895	2591	AAAUAAAAGTUCUCUUAGCAUU	2653	UGC UAAAGAAACUUUAAUUUUU

Table 14. Relative human MTRES1 mRNA Levels in Livers of Mice

Group	n	Treatment	Dose (ug)	Mean MTRES1 mRNA (Normalized to Group 1, Day 10)
1	4	PBS	0	1.00
2	4	ETD01879	100	0.70
3	4	ETD01880	100	0.45
4	4	ETD01881	100	0.78
5	4	ETD01882	100	2.07
6	4	ETD01883	100	1.24
7	4	ETD01884	100	1.12
8	4	ETD01885	100	0.97

9	4	ETD01886	100	0.46
10	4	ETD01887	100	0.18
11	4	ETD01888	100	0.14
12	4	ETD01889	100	0.74
13	4	ETD01890	100	1.73
14	4	ETD01891	100	3.21
15	4	ETD01892	100	2.59
16	4	ETD01893	100	0.55
17	4	ETD01894	100	1.12
18	4	ETD01895	100	0.65

Example 10: Screening siRNAs targeting human and mouse *MTRES1* in mice

[00295] Several siRNAs designed to be cross-reactive with human, mouse and cynomolgus monkey *MTRES1* mRNA were tested for activity in mice. The siRNAs were attached to the GalNAc ligand ETL1 or ETL17. The siRNA sequences are shown in **Table 15A**, where Nf is a 2' fluoro-modified nucleoside, n is a 2' O-methyl modified nucleoside, "d" is a deoxynucleoside, and "s" is a phosphorothioate linkage.

[00296] Six to eight week old female mice (strain ICR, n=3) were given a subcutaneous injection on Day 0 of a single 200 ug dose of a GalNAc-conjugated siRNA or PBS as vehicle control.

[00297] Mice were euthanized on Day 10 after injection and a liver sample from each was collected and placed in RNeasy lysis buffer (Qiagen) until processing. Total liver RNA was prepared by homogenizing the liver tissue in homogenization buffer (Maxwell RSC simplyRNA Tissue Kit) using a Percellys 24 tissue homogenizer (Bertin Instruments) set at 5000 rpm for two 10 second cycles. Total RNA from the lysate was purified on a Maxwell RSC 48 platform (Promega Corporation) according to the manufacturer's recommendations. Preparation of cDNA was performed using Quanta qScript cDNA SuperMix (VWR, Catalog# 95048-500) according to the manufacturer's instructions. The relative levels of liver *MTRES1* mRNA were assessed by RT-qPCR in triplicate on a QuantStudio™ 6 Pro Real-Time PCR System using TaqMan assays for mouse *MTRES1* (ThermoFisher, assay# Mm01229834_m1) and the mouse housekeeping gene PPIA (ThermoFisher, assay# Mm02342430_g1) and PerfeCTa® qPCR FastMix®, Low ROX™ (VWR, Catalog# 101419-222). Data were normalized to the mean *MTRES1* mRNA level in animals receiving PBS. Results are shown in **Table 16**. Mice injected with ETD01597, ETD01955, ETD01958, and had substantially lower levels in mean liver *MTRES1* mRNA on Day 10 relative to mice receiving PBS.

Table 15A. Example siRNA Sequences

siRNA Name	Sense Strand SEQ ID NO:	Sense Strand Sequence (5'-3') with GalNAc moiety	Antisense Strand SEQ ID NO:	Antisense Strand Sequence (5'-3')
ETD01597	2505	[ETL1]sguauccuAfgAfauguu auasusu	2515	usAfsuAfaCfaUfuCfuGfgAfgA fuAfcusu
ETD01954	2506	[ETL17]sacuuccuGfGfAfAfuc ga u a casusu	2516	usGfsuAfsuCfGfAfUfcCfaGfg AfaGfususu
ETD01955	2507	[ETL17]scuuccuGfGfAfAfucg auacuasusu	2517	usAfsuUfaUfcGfaUfuCfcAfgG faAfgusu

ETD01956	2508	[ETL17]scuggAfAfucGfAfuac uu guaaasusu	2518	usUfsaCfaAfgUfaUfcGfaUfuCf cAfgsusu
ETD01957	2509	[ETL17]sggaaUfCfgaUfaCfu gua uuaasusu	2519	usAfsaUfaCfaAfgUfaUfcGfaUf uCfcsusu
ETD01958	2510	[ETL17]sgaugCfUfuUfCfuaca aa gguasusu	2520	usAfsCfuUfuGfuAfgAfaAfgC faUfcsusu
ETD01959	2511	[ETL17]sagaaAfAfgCfGfaac ggugaasusu	2521	usUfscAfcCfGfuUfuCfuGfcUfuU fuCfususu
ETD01960	2512	[ETL17]saagcagAfAfdCGfgu gaa aguasusu	2522	usAfsCfuUfuUfcAfcCfGfuUfuCfuG fcUfususu
ETD01961	2513	[ETL17]sagugGfGfaGfAfuAf cauuggaasusu	2523	usUfscCfaAfuGfuAfuCfuCfcCf aCfususu
ETD01962	2514	[ETL17]sugggAfGfauAfcAfu uggaucasusu	2524	usGfsaUfcCfaAfuGfuAfuCfuC fcCfasusu

Table 15B. Example siRNA Base Sequences

siRNA Name	SEQ ID NO:	Sense Strand Base Sequence (5' to 3')	SEQ ID NO:	Antisense Strand Base Sequence (5' to 3')
ETD01597	2592	GUAUCUCCAGAAUGUUAUAAU	2654	UAUAACAUCUUGGAGAUACUU
ETD01954	2593	ACUUCCUGGAAUCGAUACAUU	2655	UGUAUCGAUCCAGGAAGUUU
ETD01955	2594	CUUCCUGGAAUCGAUACUAAU	2656	UAGUAUCGAUCCAGGAAGUU
ETD01956	2595	CUGGAAUCGAUACUUGUAAUU	2657	UUACAAGUAUCGAUCCAGUU
ETD01957	2596	GGAAUCGAUACUUGUAUUAAU	2658	UAAUACAAGUAUCGAUCCUU
ETD01958	2597	GAUGC UUUCUACAAAGGUAUU	2659	UACCUUUGUAGAAAGCAUCUU
ETD01959	2598	AGAAAAGCAGAACGGUGAAUU	2660	UUCACCGUUCUGCUUUUCUUU
ETD01960	2599	AAGCAGAACGGUGAAAGUAUU	2661	UACUUUCACCGUUCUGCUUUU
ETD01961	2600	AGUGGGAGAUACAUUGGAAUU	2662	UUCCAAUGUAUCUCCACUUU
ETD01962	2601	UGGGAGAUACAUUGGAUCAUU	2663	UGAUCCAAUGUAUCUCCCAUU
siRNA Name	SEQ ID NO:	Sense Strand Base Sequence (5' to 3'), without 3' overhangs	SEQ ID NO:	Antisense Strand Base Sequence (5' to 3'), without 3' overhangs
ETD01597	2602	GUAUCUCCAGAAUGUUAUA	2664	UAUAACAUCUUGGAGAUAC
ETD01954	2603	ACUUCCUGGAAUCGAUACA	2665	UGUAUCGAUCCAGGAAGU
ETD01955	2604	CUUCCUGGAAUCGAUACUA	2666	UAGUAUCGAUCCAGGAAG
ETD01956	2605	CUGGAAUCGAUACUUGUAA	2667	UUACAAGUAUCGAUCCAG
ETD01957	2606	GGAAUCGAUACUUGUAUUA	2668	UAAUACAAGUAUCGAUCC
ETD01958	2607	GAUGC UUUCUACAAAGGUA	2669	UACCUUUGUAGAAAGCAUC
ETD01959	2608	AGAAAAGCAGAACGGUGAA	2670	UUCACCGUUCUGCUUUUCU
ETD01960	2609	AAGCAGAACGGUGAAAGUA	2671	UACUUUCACCGUUCUGCUU
ETD01961	2610	AGUGGGAGAUACAUUGGAA	2672	UUCCAAUGUAUCUCCACU
ETD01962	2611	UGGGAGAUACAUUGGAUCA	2673	UGAUCCAAUGUAUCUCCCA

Table 16. Relative MTRES1 mRNA Levels in Livers of Mice

Group	n	Treatment	Dose (ug)	Mean MTRES1 mRNA (Normalized to Group 1, Day 10)
1	3	PBS		1.00
2	3	ETD01597	200	0.13
3	3	ETD01954	200	1.03
4	3	ETD01955	200	0.16
5	3	ETD01956	200	0.62
6	3	ETD01957	200	0.31
7	3	ETD01958	200	0.18
8	3	ETD01959	200	0.53
9	3	ETD01960	200	0.69
10	3	ETD01961	200	0.33
11	3	ETD01962	200	0.79

Example 11: Oligonucleotide Synthesis

[00298] Oligonucleotides such as siRNAs may be synthesized according to phosphoramidite technology on a solid phase. For example, a K&A oligonucleotide synthesizer may be used. Syntheses may be performed on a solid support made of controlled pore glass (CPG, 500 Å or 600 Å, obtained from AM Chemicals, Oceanside, CA, USA). All 2'-OMe and 2'-F phosphoramidites may be purchased from Hongene Biotech (Union City, CA, USA). All phosphoramidites may be dissolved in anhydrous acetonitrile (100 mM) and molecular sieves (3 Å) may be added. 5-Benzylthio-1H-tetrazole (BTT, 250 mM in acetonitrile) or 5-Ethylthio-1H-tetrazole (ETT, 250 mM in acetonitrile) may be used as activator solution. Coupling times may be 9-18 min (e.g. with a GalNAc such as ETL17), 6 min (e.g. with 2'OMe and 2'F). In order to introduce phosphorothioate linkages, a 100 mM solution of 3-phenyl 1,2,4-dithiazoline-5-one (POS, obtained from PolyOrg, Inc., Leominster, Mass., USA) in anhydrous acetonitrile may be employed.



[00299] After solid phase synthesis, the dried solid support may be treated with a 1:1 volume solution of 40 wt. % methylamine in water and 28% ammonium hydroxide solution (Aldrich) for two hours at 30° C. The solution may be evaporated and the solid residue may be reconstituted in water and purified by anionic exchange HPLC using a TKSgel SuperQ-5PW 13u column. Buffer A may be 20 mM Tris, 5 mM EDTA, pH 9.0 and contained 20% Acetonitrile and buffer B may be the same as buffer A with the addition of 1 M sodium chloride. UV traces at 260 nm may be recorded. Appropriate fractions may be pooled then desalted using Sephadex G-25 medium.



[00300] Equimolar amounts of sense and antisense strand may be combined to prepare a duplex. The duplex solution may be prepared in 0.1×PBS (Phosphate-Buffered Saline, 1×, Gibco). The duplex solution may be annealed at 95° C. for 5 min, and cooled to room temperature slowly. Duplex concentration may be determined by measuring the solution absorbance on a UV-Vis spectrometer at 260 nm in 0.1×PBS. For some experiments, a conversion factor may be calculated from an experimentally determined extinction coefficient.

Example 12: GalNAc ligand for hepatocyte targeting of oligonucleotides

[00301] Without limiting the disclosure to these individual methods, there are at least two general methods for attachment of multivalent N-acetylgalactosamine (GalNAc) ligands to oligonucleotides: solid or solution-phase conjugations. GalNAc ligands may be attached to solid phase resin for 3' conjugation or at the 5' terminus using GalNAc phosphoramidite reagents. GalNAc phosphoramidites may be coupled on solid phase as for other nucleosides in the oligonucleotide sequence at any position in the sequence. Reagents for GalNAc conjugation to oligonucleotides are shown in **Table 17**.

Table 17. GalNAc Conjugation Reagents

Type of conjugation	Structure
<p><u>Solid phase 3' attachment</u></p> <p>where squiggly line is rest of oligonucleotide chain and right-most OH is where attachment to solid phase is.</p>	 <p>This GalNAc ligand may be referred to as “GalNAc23” or “GalNAc#23.”</p>
<p><u>Solid phase 5' attachment</u></p> <p>phosphoramidite</p>	

<p><u>Solid phase 5' attachment</u></p> <p>Phosphoramidite</p>	
<p><u>Solution phase</u></p> <p>Carboxylic acid for amide coupling anywhere on oligonucleotide</p>	 <p>Where Ac is an acetyl group or other hydroxyl protecting group that can be removed under basic, acid or reducing conditions.</p>

[00302] In solution phase conjugation, the oligonucleotide sequence—including a reactive conjugation site—is formed on the resin. The oligonucleotide is then removed from the resin and GalNAc is conjugated to the reactive site.

[00303] The carboxy GalNAc derivatives may be coupled to amino-modified oligonucleotides. The peptide coupling conditions are known to the skilled in the art using a carbodiimide coupling agent like DCC (N,N'-Dicyclohexylcarbodiimide), EDC (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide) or EDC.HCl (N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride) and an additive like HOBt (1-hydroxybenzotriazole), HOSu (N-hydroxysuccinimide), TBTU (N,N,N',N'-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate, HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) or HOAt (1-Hydroxy-7-azabenzotriazole) and common combinations thereof such as TBTU/HOBt or HBTU/HOAt to form activated amine-reactive esters.

[00304] Amine groups may be incorporated into oligonucleotides using a number of known, commercially available reagents at the 5' terminus, 3' terminus or anywhere in between.

[00305] Non-limiting examples of reagents for oligonucleotide synthesis to incorporate an amino group include:

- 5' attachment:
- 6-(4-Monomethoxytritylamino)hexyl-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite CAS Number: 114616-27-2
- 5'-Amino-Modifier TEG CE-Phosphoramidite
- 10-(O-trifluoroacetamido-N-ethyl)-triethyleneglycol-1-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite
- 3' attachment:
- 3'-Amino-Modifier Serinol CPG
- 3-Dimethoxytrityloxy-2-(3-(fluorenylmethoxycarbonylamino)propanamido)propyl-1-O-succinyl-long chain alkylamino-CPG (where CPG stands for controlled-pore glass and is the solid support)
- Amino-Modifier Serinol Phosphoramidite
- 3-Dimethoxytrityloxy-2-(3-(fluorenylmethoxycarbonylamino)propanamido)propyl-1-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite

[00306] Internal (base modified):

- Amino-Modifier C6 dT
- 5'-Dimethoxytrityl-5-[N-(trifluoroacetylaminohexyl)-3-acrylimido]-2'-deoxy Uridine, 3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite. CAS Number: 178925-21-8

[00307] Solution phase conjugations may occur after oligonucleotide synthesis via reactions between non-nucleosidic nucleophilic functional groups that are attached to the oligonucleotide and electrophilic GalNAc reagents. Examples of nucleophilic groups include amines and thiols, and examples of electrophilic reagents include activated esters (e.g. N-hydroxysuccinimide, pentafluorophenyl) and maleimides.


Example 13: GalNAc ligands for hepatocyte targeting of oligonucleotides

[00308] Without limiting the disclosure to these individual methods, there are at least two general methods for attachment of multivalent N-acetylgalactosamine (GalNAc) ligands to oligonucleotides: solid or solution-phase conjugations. GalNAc ligands may be attached to solid phase resin for 3' conjugation or at the 5' terminus using GalNAc phosphoramidite reagents. GalNAc phosphoramidites may be coupled on solid phase as for other nucleosides in the oligonucleotide sequence at any position in the sequence. A


Table 18. GalNAc Conjugation Reagent

[00309] The following includes examples of synthesis reactions used to create a GalNAc moiety:

Scheme for the preparation of NAcegal-Linker-TMSOTf




General procedure for preparation of Compound 2A



[00310] To a solution of Compound 1A (500 g, 4.76 mol, 476 mL) in 2-Methly-THF (2.00 L) is added CbzCl (406 g, 2.38 mol, 338 mL) in 2-Methyl-THF (750 mL) dropwise at 0 °C. The mixture is stirred at 25 °C for 2 hrs under N₂ atmosphere. TLC (DCM: MeOH = 20:1, PMA) may indicate CbzCl is consumed completely and one new spot (R_f = 0.43) formed. The reaction mixture is added HCl/EtOAc (1 N, 180 mL) and stirred for 30 mins, white solid is removed by filtration through celite, the filtrate is concentrated under vacuum to give Compound 2A (540 g, 2.26 mol, 47.5% yield) as a pale yellow oil and used into the next step without further purification. ¹H NMR: δ 7.28 - 7.41 (m, 5 H), 5.55 (br s, 1 H), 5.01 - 5.22 (m, 2 H), 3.63 - 3.80 (m, 2 H), 3.46 - 3.59 (m, 4 H), 3.29 - 3.44 (m, 2 H), 2.83 - 3.02 (m, 1 H).


General procedure for preparation of Compound 4A




[00311] To a solution of Compound 3A (1.00 kg, 4.64 mol, HCl) in pyridine (5.00 L) is added acetyl acetate (4.73 kg, 46.4 mol, 4.34 L) dropwise at 0 °C under N₂ atmosphere. The mixture is stirred at 25 °C

for 16 hrs under N₂ atmosphere. TLC (DCM: MeOH = 20:1, PMA) indicated Compound 3A is consumed completely and two new spots (R_f = 0.35) formed. The reaction mixture is added to cold water (30.0 L) and stirred at 0 °C for 0.5 hr, white solid formed, filtered and dried to give Compound 4A (1.55 kg, 3.98 mol, 85.8% yield) as a white solid and used in the next step without further purification. ¹H NMR: δ 7.90 (d, *J* = 9.29 Hz, 1 H), 5.64 (d, *J* = 8.78 Hz, 1 H), 5.26 (d, *J* = 3.01 Hz, 1 H), 5.06 (dd, *J* = 11.29, 3.26 Hz, 1 H), 4.22 (t, *J* = 6.15 Hz, 1 H), 3.95 - 4.16 (m, 3 H), 2.12 (s, 3 H), 2.03 (s, 3 H), 1.99 (s, 3 H), 1.90 (s, 3 H), 1.78 (s, 3 H).


General procedure for preparation of Compound 5A




[00312] To a solution of Compound 4A (300 g, 771 mmol) in DCE (1.50 L) is added TMSOTf (257 g, 1.16 mol, 209 mL) and stirred for 2 hrs at 60 °C, and then stirred for 1 hr at 25 °C. Compound 2A (203 g, 848 mmol) is dissolved in DCE (1.50 L) and added 4 Å powder molecular sieves (150 g) stirring for 30 mins under N₂ atmosphere. Then the solution of Compound 4A in DCE is added dropwise to the mixture at 0 °C. The mixture is stirred at 25 °C for 16 hrs under N₂ atmosphere. TLC (DCM: MeOH = 25:1, PMA) indicated Compound 4A is consumed completely and new spot (R_f = 0.24) formed. The reaction mixture is filtered and washed with sat. NaHCO₃ (2.00 L), water (2.00 L) and sat. brine (2.00 L). The organic layer is dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue is triturated with 2-Me-THE/heptane (5/3, v/v, 1.80 L) for 2 hrs, filtered and dried to give Compound 5A (225 g, 389 mmol, 50.3% yield, 98.4% purity) as a white solid. ¹H NMR: δ 7.81 (d, *J* = 9.29 Hz, 1 H), 7.20 - 7.42 (m, 6 H), 5.21 (d, *J* = 3.26 Hz, 1 H), 4.92 - 5.05 (m, 3 H), 4.55 (d, *J* = 8.28 Hz, 1 H), 3.98 - 4.07 (m, 3 H), 3.82 - 3.93 (m, 1 H), 3.71 - 3.81 (m, 1 H), 3.55 - 3.62 (m, 1 H), 3.43 - 3.53 (m, 2 H), 3.37 - 3.43 (m, 2 H), 3.14 (q, *J* = 5.77 Hz, 2 H), 2.10 (s, 3 H), 1.99 (s, 3 H), 1.89 (s, 3 H), 1.77 (s, 3 H).


General procedure for preparation of NAcegal-Linker-Tosylate salt

[00313] To a solution of Compound 5A (200 g, 352 mmol) in THF (1.0 L) is added dry Pd/C (15.0 g, 10% purity) and TsOH (60.6 g, 352 mmol) under N₂ atmosphere. The suspension is degassed under vacuum and purged with H₂ several times. The mixture is stirred at 25 °C for 3 hrs under H₂ (45 psi) atmosphere. TLC (DCM: MeOH = 10:1, PMA) indicated Compound 5A is consumed completely and one new spot ($R_f = 0.04$) is formed. The reaction mixture is filtered and concentrated (≤ 40 °C) under reduced pressure to give a residue. Diluted with anhydrous DCM (500 mL, dried overnight with 4 Å molecular sieves (dried at 300 °C for 12 hrs)) and concentrate to give a residue and run Karl Fisher (KF) to check for water content. This is repeated 3 times with anhydrous DCM (500 mL) dilutions and concentration to give NAcegal-Linker-TMSOTf (205 g, 95.8% yield, TsOH salt) as a foamy white solid. ¹H NMR: δ 7.91 (d, $J = 9.03$ Hz, 1 H), 7.53 - 7.86 (m, 2 H), 7.49 (d, $J = 8.03$ Hz, 2 H), 7.13 (d, $J = 8.03$ Hz, 2 H), 5.22 (d, $J = 3.26$ Hz, 1 H), 4.98 (dd, $J = 11.29, 3.26$ Hz, 1 H), 4.57 (d, $J = 8.53$ Hz, 1 H), 3.99 - 4.05 (m, 3 H), 3.87 - 3.94 (m, 1 H), 3.79 - 3.85 (m, 1 H), 3.51 - 3.62 (m, 5 H), 2.96 (br t, $J = 5.14$ Hz, 2 H), 2.29 (s, 3 H), 2.10 (s, 3 H), 2.00 (s, 3 H), 1.89 (s, 3 H), 1.78 (s, 3 H).

Scheme for the preparation of TRIS-PEG2-CBZ




General procedure for preparation of Compound 5B




[00314] To a solution of Compound **4B** (400 g, 1.67 mol, 1.00 eq) and NaOH (10 M, 16.7 mL, 0.10 eq) in THF (2.00 L) is added Compound **4B_2** (1.07 kg, 8.36 mol, 1.20 L, 5.00 eq), the mixture is stirred at 30 °C for 2 hrs. LCMS showed the desired MS is given. Five batches of solution are combined to one batch, then the mixture is diluted with water (6.00 L), extracted with ethyl acetate (3.00 L*3), the combined organic layer is washed with brine (3.00 L), dried over Na₂SO₄, filtered and concentrated under vacuum. The crude is purified by column chromatography (SiO₂, petroleum ether : ethyl acetate=100:1-10:1, R_f=0.5) to give Compound **5B** (2.36 kg, 6.43 mol, 76.9% yield) as light yellow oil. HNMR: δ 7.31-7.36 (m, 5 H), 5.38 (s, 1 H), 5.11-5.16 (m, 2 H), 3.75 (t, J=6.4 Hz), 3.54-3.62 (m, 6 H), 3.39 (d, J=5.2 Hz), 2.61 (t, J=6.0 Hz).

General procedure for preparation of 3-oxo-1-phenyl-2,7,10-trioxa-4-azatridecan-13-oic acid (Compound 2B below)



[00315] To a solution of Compound **5B** (741 g, 2.02 mol, 1.00 eq) in DCM (2.80 L) is added TFA (1.43 kg, 12.5 mol, 928 mL, 6.22 eq), the mixture is stirred at 25 °C for 3 hrs. LCMS showed the desired MS is given. The mixture is diluted with DCM (5.00 L), washed with water (3.00 L*3), brine (2.00 L), the combined organic layer is dried over Na₂SO₄, filtered and concentrated under vacuum to give Compound

General procedure for preparation of Compound 3B







Chemical reaction scheme showing the conversion of compound **3B** to **TRIS-PEG2-CBZ**. The reaction is carried out with HCl/dioxane .

-122-


Na₂SO₄, filtered and concentrated under vacuum to give a residue. Then the residue is diluted with MeCN (5.00 L), concentrated under vacuum, repeat this procedure twice to remove water to give TRIS-PEG2-CBZ (1.25 kg, 1.91 mol, 78.1% yield, 95.8% purity) as light yellow oil. ¹HNMR: 400 MHz, MeOD, δ 7.30-7.35 (5 H), 5.07 (s, 2 H), 3.65-3.70 (m, 16 H), 3.59 (s, 4 H), 3.45 (t, *J*=5.6 Hz), 2.51 (t, *J*=6.0 Hz), 2.43 (t, 6.4 Hz).

Scheme for the preparation of TriNGal-TRIS-Peg2-Phosph 8c






TriGNaI-TRIS-Peg2-Phosph 8c


General procedure for preparation of Compound 3C

[00318] To a solution of Compound 1C (155 g, 245 mmol, 1.00 eq) in ACN (1500 mL) is added TBTU (260 g, 811 mmol, 3.30 eq), DIEA (209 g, 1.62 mol, 282 mL, 6.60 eq) and Compound 2C (492 g, 811 mmol, 3.30 eq, TsOH) at 0 °C, the mixture is stirred at 15 °C for 16 hrs. LCMS showed the desired MS is given. The mixture is concentrated under vacuum to give a residue, then the mixture is diluted with DCM (2000 mL), washed with 1 N HCl aqueous solution (700 mL * 2), then saturated NaHCO₃ aqueous solution (700 mL * 2) and concentrated under vacuum. The crude is purified by column chromatography to give Compound 3C (304 g, 155 mmol, 63.1% yield, 96.0% purity) as a yellow solid.


General procedure for preparation of Compound 4C

[00319] Two batches solution of Compound 3C (55.0 g, 29.2 mmol, 1.00 eq) in MeOH (1600 mL) is added Pd/C (6.60 g, 19.1 mmol, 10.0 % purity) and TFA (3.34 g, 29.2 mmol, 2.17 mL, 1.00 eq), the mixture is degassed under vacuum and purged with H₂. The mixture is stirred under H₂ (15 psi) at 15 °C for 2 hours. LCMS showed the desired MS is given. The mixture is filtered and the filtrate is concentrated under vacuum to give Compound 4C (106 g, 54.8 mmol, 93.7% yield, 96.2% purity, TFA) as a white solid.

General procedure for preparation of compound 5C




[00320] Two batches in parallel. To a solution of EDCI (28.8 g, 150 mmol, 1.00 eq) in DCM (125 mL) is added compound **4a** (25.0 g, 150 mmol, 1.00 eq) dropwise at 0 °C, then the mixture is added to compound **4** (25.0 g, 150 mmol, 1.00 eq) in DCM (125 mL) at 0 °C, then the mixture is stirred at 25 °C for 1 hr. TLC (Petroleum ether : Ethyl acetate = 3 : 1, R_f = 0.45) showed the reactant is consumed and one new spot is formed. The reaction mixture is diluted with DCM (100 mL) then washed with aq. NaHCO_3 (250 mL * 1) and brine (250 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue is purified by column chromatography (SiO_2 , Petroleum ether : Ethyl acetate = 100 : 1 to 3 : 1), TLC (SiO_2 , Petroleum ether : Ethyl acetate = 3 : 1), R_f = 0.45, then concentrated under reduced pressure to give a residue. Compound **5C** (57.0 g, 176 mmol, 58.4% yield, 96.9% purity) is obtained as colorless oil and confirmed $^1\text{H NMR}$: EW33072-2-P1A, 400 MHz, DMSO δ 9.21 (s, 1 H), 7.07-7.09 (m, 2 H), 6.67-6.70 (m, 2 H), 3.02-3.04 (m, 2 H), 2.86-2.90 (m, 2 H)

General procedure for preparation of compound 6

[00321] To a mixture of compound **3** (79.0 g, 41.0 mmol, 96.4% purity, 1.00 eq, TFA) and compound **6C** (14.2 g, 43.8 mmol, 96.9% purity, 1.07 eq) in DCM (800 mL) is added TEA (16.6 g, 164 mmol, 22.8 mL, 4.00 eq) dropwise at 0 °C, the mixture is stirred at 15 °C for 16 hrs. LCMS (EW33072-12-P1B, Rt = 0.844 min) showed the desired mass is detected. The reaction mixture is diluted with DCM (400 mL) and washed with aq. NaHCO₃ (400 mL * 1) and brine (400 mL * 1), then the mixture is diluted with DCM (2.00 L) and washed with 0.7 M Na₂CO₃ (1000 mL * 3) and brine (800 mL * 3), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue is used to next step directly without purification. Compound **6** (80.0 g, crude) is obtained as white solid and confirmed via ¹HNMR: EW33072-12-P1A, 400 MHz, MeOD δ 7.02 - 7.04 (m, 2 H), 6.68 - 6.70 (m, 2 H), 5.34 - 5.35 (s, 3 H), 5.07 - 5.08 (d, *J* = 4.00 Hz, 3 H), 4.62 - 4.64 (d, *J* = 8.00 Hz, 3 H), 3.71 - 4.16 (m, 16 H), 3.31 -

3.70 (m, 44 H), 2.80 - 2.83 (m, 2 H), 2.68 (m, 2 H), 2.46 - 2.47 (m, 10 H), 2.14 (s, 9 H), 2.03 (s, 9 H), 1.94 - 1.95 (d, $J = 4.00$ Hz, 18 H).

General procedure for preparation of TriGNal-TRIS-Peg2-Phosph 8c



[00322] Two batches are synthesized in parallel. To a solution of compound **6c** (40.0 g, 21.1 mmol, 1.00 eq) in DCM (600 mL) is added diisopropylammonium tetrazolide (3.62 g, 21.1 mmol, 1.00 eq) and compound **7c** (6.37 g, 21.1 mmol, 6.71 mL, 1.00 eq) in DCM (8.00 mL) drop-wise, the mixture is stirred at 30 °C for 1 hr, then added compound **7c** (3.18 g, 10.6 mmol, 3.35 mL, 0.50 eq) in DCM (8.00 mL) drop-wise, the mixture is stirred at 30 °C for 30 mins, then added compound **7c** (3.18 g, 10.6 mmol, 3.35 mL, 0.50 eq) in DCM (8.00 mL) drop-wise, the mixture is stirred at 30 °C for 1.5 hrs. LCMS (EW33072-

17-P1C1, Rt = 0.921 min) showed the desired MS+1 is detected. LCMS (EW33072-17-P1C2, Rt = 0.919 min) showed the desired MS+1 is detected. Two batches are combined for work-up. The mixture is diluted with DCM (1.20 L), washed with saturated NaHCO₃ aqueous solution (1.60 L * 2), 3% DMF in H₂O (1.60 L * 2), H₂O (1.60 L * 3), brine (1.60 L), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue is purified by column chromatography (SiO₂, DCM : MeOH : TEA = 100 : 3 : 2) TLC (SiO₂, DCM: MeOH = 10:1, R_f = 0.45), then concentrated under reduced pressure to give a residue. **Compound 8C** (76.0 g, 34.8 mmol, 82.5% yield, 96.0% purity) is obtained as white solid and confirmed via ¹HNMR: EW33072-19-P1C, 400 MHz, MeOD

δ 7.13-7.15 (d, J = 8.50 Hz, 2 H), 6.95-6.97 (dd, J = 8.38, 1.13 Hz, 2 H), 5.34 (d, J = 2.88 Hz, 3 H), .09 (dd, J = 11.26, 3.38 Hz, 3 H), 4.64 (d, J = 8.50 Hz, 3 H), 3.99 - 4.20 (m, 12 H), 3.88 - 3.98 (m, 5 H), 3.66 - 3.83 (m, 20 H), 3.51 - 3.65 (m, 17 H), 3.33 - 3.50 (m, 9 H), 2.87 (t, J = 7.63 Hz, 2 H), 2.76 (t, J = 5.94 Hz, 2 H), 2.42 - 2.50 (m, 10 H), 2.14 (s, 9 H), 2.03 (s, 9 H), 1.94 - 1.95 (d, J = 6.13 Hz, 18 H), 1.24-1.26 (d, J = 6.75 Hz, 6 H), 1.18-1.20 (d, J = 6.75 Hz, 6 H)

Example 14: Modification motif 1

[00323] An example MTRES1 siRNA includes a combination of the following modifications:

- Position 9 (from 5' to 3') of the sense strand is 2' F.
- If position 9 is a pyrimidine then all purines in the Sense Strand are 2' OMe, and 1-5 pyrimidines between positions 5 and 11 are 2' F provided that there are never three 2' F modifications in a row.
- If position 9 is a purine then all pyrimidines in the Sense Strand are 2' OMe, and 1-5 purines between positions 5 and 11 are 2' F provided that there are never three 2' F modifications in a row.
- Antisense strand odd-numbered positions are 2' OMe and even-numbered positions are a mixture of 2' F, 2' OMe and 2' deoxy.

Example 15: Modification motif 2

[00324] An example MTRES1 siRNA includes a combination of the following modifications:

- Position 9 (from 5' to 3') of the sense strand is 2' deoxy.
- Sense strand positions 5, 7 and 8 are 2' F.
- All pyrimidines in positions 10-21 are 2' OMe, and purines are a mixture of 2' OMe and 2' F. Alternatively, all purines in positions 10-21 are 2' OMe and all pyrimidines in positions 10-21 are a mixture of 2' OMe and 2' F.
- Antisense strand odd-numbered positions are 2' OMe and even-numbered positions are a mixture of 2' F, 2' OMe and 2' deoxy.

[00325] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and compositions within the scope of these claims and their equivalents be covered thereby.

IV. SEQUENCE INFORMATION

[00326] Some embodiments include one or more nucleic acid sequences in the following tables:

Table 19. Sequence Information

SEQ ID NO:	Description
1-1140	MTRES1 siRNA sense strand sequences
1141-2280	MTRES1 siRNA antisense strand sequences
2281-2334	Modified MTRES1 siRNA sense strand sequences
2335-2388	Modified MTRES1 siRNA antisense strand sequences
2389-2442	Alternatively modified MTRES1 siRNA sense strand sequences
2443	Full-length human MTRES1 mRNA sequence (Ensembl Acc. ENST00000311381.8) (human RNA)
2444-2452	Modification pattern 1S to 9S
2453-2460	Modification pattern 1AS to 8AS
2461	Modification pattern ASO1
2462	Full-length human MTRES1 mRNA sequence (Ensembl Acc. ENST00000625458.1) (human RNA)
2463-2466	Example modified siRNA sense strand sequences
2467-2470	Example modified siRNA antisense strand sequences
2471-2487	Example modified siRNA sense strand sequences
2488-2504	Example modified siRNA antisense strand sequences
2505-2514	Example modified siRNA sense strand sequences
2515-2524	Example modified siRNA antisense strand sequences
2525-2547	Modification pattern 10S to 32S
2549-2549	Modification pattern 9AS to 10AS
2550-2611	Example siRNA sense strand sequences
2612-2673	Example siRNA antisense strand sequences

Table 20. Sequences

siRNA Name	SEQ ID NO:	sense strand sequence (5'-3')	SEQ ID NO:	antisense strand sequence (5'-3')
siRNA 1	1	GCGCAGAUAGGGGUAGCCU	1141	AGGCUACCCCUAUCUGCGC
siRNA 2	2	CGCAGAUAGGGGUAGCCUG	1142	CAGGCUACCCCUAUCUGCG
siRNA 3	3	GCAGAUAGGGGUAGCCUGG	1143	CCAGGCUACCCCUAUCUGC
siRNA 4	4	CAGAUAGGGGUAGCCUGGA	1144	UCCAGGCUACCCCUAUCUG
siRNA 5	5	AGAUAGGGGUAGCCUGGAG	1145	CUCCAGGCUACCCCUAUCU
siRNA 6	6	GAUAGGGGUAGCCUGGAGG	1146	CCUCCAGGCUACCCCUAUC
siRNA 7	7	AUAGGGGUAGCCUGGAGGC	1147	GCCUCCAGGCUACCCCUAU
siRNA 8	8	UAGGGGUAGCCUGGAGGCC	1148	GGCCUCCAGGCUACCCCUA
siRNA 9	9	AGGGGUAGCCUGGAGGCCU	1149	AGGCCUCCAGGCUACCCCU
siRNA 10	10	GGGGUAGCCUGGAGGCCUG	1150	CAGGCCUCCAGGCUACCCC
siRNA 11	11	GGGUAGCCUGGAGGCCUGC	1151	GCAGGCCUCCAGGCUACCC
siRNA 12	12	GGUAGCCUGGAGGCCUGCA	1152	UGCAGGCCUCCAGGCUACC
siRNA 13	13	GUAGCCUGGAGGCCUGCAG	1153	CUGCAGGCCUCCAGGCUAC
siRNA 14	14	UAGCCUGGAGGCCUGCAGU	1154	ACUGCAGGCCUCCAGGCUA
siRNA 15	15	AGCCUGGAGGCCUGCAGUC	1155	GACUGCAGGCCUCCAGGCU
siRNA 16	16	GCCUGGAGGCCUGCAGUCC	1156	GGACUGCAGGCCUCCAGGC
siRNA 17	17	CCUGGAGGCCUGCAGUCCG	1157	CGGACUGCAGGCCUCCAGG
siRNA 18	18	CUGGAGGCCUGCAGUCCGC	1158	GCGGACUGCAGGCCUCCAG
siRNA 19	19	UGGAGGCCUGCAGUCCGCG	1159	CGCGGACUGCAGGCCUCCA
siRNA 20	20	GGAGGCCUGCAGUCCGCGC	1160	GCGCGGACUGCAGGCCUCC

siRNA 21	21	GAGGCCUGCAGUCCGCGCG	1161	CGCGCGGACUGCAGGCCUC
siRNA 22	22	AGGCCUGCAGUCCGCGCGG	1162	CCGCGCGGACUGCAGGCCU
siRNA 23	23	GGCCUGCAGUCCGCGCGGC	1163	GCCGCGCGGACUGCAGGCC
siRNA 24	24	GCCUGCAGUCCGCGCGGCC	1164	GGCCGCGCGGACUGCAGGC
siRNA 25	25	CCUGCAGUCCGCGCGGCCG	1165	CGGCGCGCGGACUGCAGG
siRNA 26	26	CUGCAGUCCGCGCGGCCGC	1166	GCGGCGCGCGGACUGCAG
siRNA 27	27	UGCAGUCCGCGCGGCCGCG	1167	CGCGCGCGCGGACUGCA
siRNA 28	28	GCAGUCCGCGCGGCCGCGG	1168	CCGCGGCCGCGCGGACUGC
siRNA 29	29	CAGUCCGCGCGGCCGCGGG	1169	CCCGCGGCCGCGCGGACUG
siRNA 30	30	AGUCCGCGCGGCCGCGGGG	1170	CCCCGCGGCCGCGCGGACU
siRNA 31	31	GUCCGCGCGGCCGCGGGGA	1171	UCCCGCGGCCGCGCGGAC
siRNA 32	32	UCCGCGCGGCCGCGGGAG	1172	CUCCCGCGGCCGCGCGGA
siRNA 33	33	CCGCGCGGCCGCGGGAGG	1173	CCUCCCGCGGCCGCGCGG
siRNA 34	34	CGCGCGGCCGCGGGAGGG	1174	CCUCCCGCGGCCGCGCG
siRNA 35	35	GCGCGGCCGCGGGAGGGA	1175	UCCUCCCGCGGCCGCGC
siRNA 36	36	CGCGGCCGCGGGAGGGAC	1176	GUCCUCCCGCGGCCGCG
siRNA 37	37	GCGGCCGCGGGAGGGACG	1177	CGUCCUCCCGCGGCCGC
siRNA 38	38	CGGCCGCGGGAGGGACGA	1178	UCGUCCUCCCGCGGCCG
siRNA 39	39	GGCCGCGGGAGGGACGAG	1179	CUCGUCCUCCCGCGGCC
siRNA 40	40	GCCGCGGGAGGGACGAGA	1180	UCUCGUCCUCCCGCGGC
siRNA 41	41	CCGCGGGAGGGACGAGAG	1181	CUCUGUCCUCCCGCGG
siRNA 42	42	CGCGGGAGGGACGAGAGG	1182	CCUCUGUCCUCCCGCG
siRNA 43	43	GCGGGAGGGACGAGAGGG	1183	CCCUUGUCCUCCCGCG
siRNA 44	44	CGGGGAGGGACGAGAGGGC	1184	GCCCUUGUCCUCCCGG
siRNA 45	45	GGGGAGGGACGAGAGGGCC	1185	GGCCUUGUCCUCCCG
siRNA 46	46	GGGAGGGACGAGAGGGCCU	1186	AGGCCUUGUCCUCCCG
siRNA 47	47	GGAGGGACGAGAGGGCCUG	1187	CAGGCCUUGUCCUCCCG
siRNA 48	48	GAGGGACGAGAGGGCCUGA	1188	UCAGGCCUUGUCCUCC
siRNA 49	49	AGGGACGAGAGGGCCUGAC	1189	GUAGGCCUUGUCCUCC
siRNA 50	50	GGGACGAGAGGGCCUGACG	1190	CGUAGGCCUUGUCCUCC
siRNA 51	51	GGACGAGAGGGCCUGACGU	1191	ACGUAGGCCUUGUCCU
siRNA 52	52	GACGAGAGGGCCUGACGUA	1192	UACGUAGGCCUUGUCC
siRNA 53	53	ACGAGAGGGCCUGACGUAC	1193	GUAGGUAGGCCUUGUCC
siRNA 54	54	CGAGAGGGCCUGACGUACA	1194	UGUAGGUAGGCCUUGUCC
siRNA 55	55	GAGAGGGCCUGACGUACAG	1195	CUGUAGGUAGGCCUUGU
siRNA 56	56	AGAGGGCCUGACGUACAGA	1196	UCUGUAGGUAGGCCUUG
siRNA 57	57	GAGGGCCUGACGUACAGAU	1197	AUCUGUAGGUAGGCCU
siRNA 58	58	AGGGCCUGACGUACAGAUU	1198	AAUCUGUAGGUAGGCCU
siRNA 59	59	GGGCCUGACGUACAGAUUA	1199	UAAUCUGUAGGUAGGCC
siRNA 60	60	GGCCUGACGUACAGAUUAU	1200	AUAAUCUGUAGGUAGGCC
siRNA 61	61	GCCUGACGUACAGAUUAUA	1201	UAUAUCUGUAGGUAGGCC
siRNA 62	62	CCUGACGUACAGAUUAUAA	1202	UUAUAUCUGUAGGUAGG
siRNA 63	63	CUGACGUACAGAUUAUAAG	1203	CUUAUAUCUGUAGGUAG
siRNA 64	64	UGACGUACAGAUUAUAAGC	1204	GCUAUAUAUCUGUAGGUA
siRNA 65	65	GACGUACAGAUUAUAAGCG	1205	CGCUUAUAUAUCUGUAG
siRNA 66	66	ACGUACAGAUUAUAAGCGC	1206	GCGCUUAUAUAUCUGUAG
siRNA 67	67	CGUACAGAUUAUAAGCGCC	1207	GGCGCUUAUAUAUCUGUAG
siRNA 68	68	GUACAGAUUAUAAGCGCCA	1208	UGGCGCUUAUAUAUCUGUAG
siRNA 69	69	UACAGAUUAUAAGCGCCA	1209	AUGGCGCUUAUAUAUCUGUAG
siRNA 70	70	ACAGAUUAUAAGCGCCAUG	1210	CAUGGCGCUUAUAUAUCUGUAG
siRNA 71	71	CAGAUUAUAAGCGCCAUGG	1211	CCAUGGCGCUUAUAUAUCUGUAG
siRNA 72	72	AGAUUAUAAGCGCCAUGGC	1212	GCCAUGGCGCUUAUAUAUCUGUAG

siRNA 73	73	GAUUUAAGCGCCAUGGCU	1213	AGCCAUGGCGCUUAUAAUC
siRNA 74	74	AUUUAAGCGCCAUGGCUA	1214	UAGCCAUGGCGCUUAUAAU
siRNA 75	75	UUUAAGCGCCAUGGCUAU	1215	AUAGCCAUGGCGCUUAUAA
siRNA 76	76	UAUAAGCGCCAUGGCUAUG	1216	CAUAGCCAUGGCGCUUAUA
siRNA 77	77	AUAAGCGCCAUGGCUAUGG	1217	CCAUAGCCAUGGCGCUUAU
siRNA 78	78	UAAGCGCCAUGGCUAUGGC	1218	GCCAUAAGCCAUGGCGCUUA
siRNA 79	79	AAGCGCCAUGGCUAUGGCU	1219	AGCCAUAAGCCAUGGCGCUU
siRNA 80	80	AGCGCCAUGGCUAUGGCUA	1220	UAGCCAUAAGCCAUGGCGCU
siRNA 81	81	GCGCCAUGGCUAUGGCUAG	1221	CUAGCCAUAAGCCAUGGCGC
siRNA 82	82	CGCCAUGGCUAUGGCUAGU	1222	ACUAAGCCAUAAGCCAUGGCG
siRNA 83	83	GCCAUGGCUAUGGCUAGUG	1223	CACUAAGCCAUAAGCCAUGGC
siRNA 84	84	CCAUGGCUAUGGCUAGUGU	1224	ACACUAAGCCAUAAGCCAUGG
siRNA 85	85	CAUGGCUAUGGCUAGUGUU	1225	AACACUAAGCCAUAAGCCAUG
siRNA 86	86	AUGGCUAUGGCUAGUGUUA	1226	UAACACUAAGCCAUAAGCCA
siRNA 87	87	UGGCUAUGGCUAGUGUUA	1227	UUAAACUAAGCCAUAAGCCA
siRNA 88	88	GGCUAUGGCUAGUGUUAAA	1228	UUUAACACUAAGCCAUAAGCC
siRNA 89	89	GCUAUGGCUAGUGUUAAAU	1229	AUUUAACACUAAGCCAUAAGC
siRNA 90	90	CUAUGGCUAGUGUUAAAUU	1230	AAUUUAACACUAAGCCAUAAG
siRNA 91	91	UAUGGCUAGUGUUAAAUUG	1231	CAUUUUAAACUAAGCCAUA
siRNA 92	92	AUGGCUAGUGUUAAAUUGC	1232	GCAAUUUAACACUAAGCCA
siRNA 93	93	UGGCUAGUGUUAAAUUGC	1233	AGCAAUUUAACACUAAGCCA
siRNA 94	94	GGCUAGUGUUAAAUUGC	1234	AAGCAAUUUAACACUAAGCC
siRNA 95	95	GCUAGUGUUAAAUUGC	1235	CAAGCAAUUUAACACUAAGC
siRNA 96	96	CUAGUGUUAAAUUGC	1236	GCAAGCAAUUUAACACUAAG
siRNA 97	97	UAGUGUUAAAUUGC	1237	GGCAAGCAAUUUAACACUA
siRNA 98	98	AGUGUUAAAUUGC	1238	CGGCAAGCAAUUUAACACU
siRNA 99	99	GUGUUAAAUUGC	1239	CCGGCAAGCAAUUUAACAC
siRNA 100	100	UGUUAAAUUGC	1240	ACCGCAAGCAAUUUAACA
siRNA 101	101	GUUAAAUUGC	1241	CACCGCAAGCAAUUUAAC
siRNA 102	102	UUAAAUUGC	1242	ACACCGCAAGCAAUUUA
siRNA 103	103	UAAAUUGC	1243	AACACCGCAAGCAAUUUA
siRNA 104	104	AAAUUGC	1244	AAACACCGCAAGCAAUUU
siRNA 105	105	AAUUGC	1245	AAAACACCGCAAGCAAUU
siRNA 106	106	AUUGC	1246	UAAACACCGCAAGCAAU
siRNA 107	107	UUGC	1247	UUAAACACCGCAAGCAA
siRNA 108	108	UGC	1248	CUUAAACACCGCAAGCA
siRNA 109	109	GCU	1249	UCUUAAACACCGCAAGC
siRNA 110	110	CU	1250	UUCUUAAACACCGCAAG
siRNA 111	111	U	1251	UUUCUUAAACACCGCAA
siRNA 112	112	U	1252	CUUUUUAAACACCGCA
siRNA 113	113	G	1253	GCUUUUUAAACACCGGC
siRNA 114	114	C	1254	GGCUUUUUAAACACCGG
siRNA 115	115	C	1255	UGGCUUUUUAAACACCG
siRNA 116	116	G	1256	CUGGCUUUUUAAACACC
siRNA 117	117	G	1257	UCUGGCUUUUUAAACAC
siRNA 118	118	U	1258	AUCUGGCUUUUUAAACA
siRNA 119	119	G	1259	CAUCUGGCUUUUUAAAC
siRNA 120	120	U	1260	GCAUCUGGCUUUUUAAAA
siRNA 121	121	U	1261	GGCAUCUGGCUUUUUAAA
siRNA 122	122	U	1262	AGGCAUCUGGCUUUUUAA
siRNA 123	123	U	1263	CAGGCAUCUGGCUUUUU
siRNA 124	124	A	1264	CCAGGCAUCUGGCUUUUU

siRNA 125	125	AGAAAGCCAGAUCCUGGA	1265	UCCAGGCAUCUGGCUUUCU
siRNA 126	126	GAAAGCCAGAUCCUGGAU	1266	AUCCAGGCAUCUGGCUUUC
siRNA 127	127	AAAGCCAGAUCCUGGAUU	1267	AAUCCAGGCAUCUGGCUUU
siRNA 128	128	AAGCCAGAUCCUGGAUUG	1268	CAAUCCAGGCAUCUGGCUU
siRNA 129	129	AGCCAGAUCCUGGAUUGG	1269	CCAAUCCAGGCAUCUGGCU
siRNA 130	130	GCCAGAUCCUGGAUUGGA	1270	UCCAAUCCAGGCAUCUGGC
siRNA 131	131	CCAGAUCCUGGAUUGGAC	1271	GUCCAAUCCAGGCAUCUGG
siRNA 132	132	CAGAUCCUGGAUUGGACU	1272	AGUCCAAUCCAGGCAUCUG
siRNA 133	133	AGAUGCCUGGAUUGGACUC	1273	GAGUCCAAUCCAGGCAUCU
siRNA 134	134	GAUGCCUGGAUUGGACUCU	1274	AGAGUCCAAUCCAGGCAUC
siRNA 135	135	AUGCCUGGAUUGGACUCUG	1275	CAGAGUCCAAUCCAGGCAU
siRNA 136	136	UGCCUGGAUUGGACUCUGG	1276	CCAGAGUCCAAUCCAGGCA
siRNA 137	137	GCCUGGAUUGGACUCUGGG	1277	CCCAGAGUCCAAUCCAGGC
siRNA 138	138	CCUGGAUUGGACUCUGGGG	1278	CCCCAGAGUCCAAUCCAGG
siRNA 139	139	CUGGAUUGGACUCUGGGGU	1279	ACCCAGAGUCCAAUCCAG
siRNA 140	140	UGGAUUGGACUCUGGGGUG	1280	CACCCAGAGUCCAAUCCA
siRNA 141	141	GGAUUGGACUCUGGGGUGU	1281	ACACCCAGAGUCCAAUCC
siRNA 142	142	GAUUGGACUCUGGGGUGUU	1282	AACACCCAGAGUCCAAUC
siRNA 143	143	AUUGGACUCUGGGGUGUUC	1283	GAACACCCAGAGUCCAAU
siRNA 144	144	UUGGACUCUGGGGUGUUCU	1284	AGAACACCCAGAGUCCAA
siRNA 145	145	UGGACUCUGGGGUGUUCUC	1285	GAGAACACCCAGAGUCCA
siRNA 146	146	GGACUCUGGGGUGUUCUCC	1286	GGAGAACACCCAGAGUCC
siRNA 147	147	GACUCUGGGGUGUUCUCCG	1287	CGGAGAACACCCAGAGUC
siRNA 148	148	ACUCUGGGGUGUUCUCCGA	1288	UCGGAGAACACCCAGAGU
siRNA 149	149	CUCUGGGGUGUUCUCCGAG	1289	CUCGGAGAACACCCAGAG
siRNA 150	150	UCUGGGGUGUUCUCCGAGG	1290	CCUCGGAGAACACCCAGAG
siRNA 151	151	CUGGGGUGUUCUCCGAGGG	1291	CCUCGGAGAACACCCAG
siRNA 152	152	UGGGGUGUUCUCCGAGGGA	1292	UCCUCGGAGAACACCCCA
siRNA 153	153	GGGGUGUUCUCCGAGGGAC	1293	GUCCUCGGAGAACACCCC
siRNA 154	154	GGGUGUUCUCCGAGGGACA	1294	UGUCCUCGGAGAACACCC
siRNA 155	155	GGUGUUCUCCGAGGGACAC	1295	GUGUCCUCGGAGAACACC
siRNA 156	156	GUGUUCUCCGAGGGACACC	1296	GGUGUCCUCGGAGAACAC
siRNA 157	157	UGUUCUCCGAGGGACACCU	1297	AGGUGUCCUCGGAGAACAC
siRNA 158	158	GUUCUCCGAGGGACACCUU	1298	AAGGUGUCCUCGGAGAAC
siRNA 159	159	UUCUCCGAGGGACACCUUC	1299	GAAGGUGUCCUCGGAGAAC
siRNA 160	160	UCUCCGAGGGACACCUUCA	1300	UGAAGGUGUCCUCGGAGAAC
siRNA 161	161	CUCCGAGGGACACCUUCAU	1301	AUGAAGGUGUCCUCGGAG
siRNA 162	162	UCCGAGGGACACCUUCAUC	1302	GAUGAAGGUGUCCUCGGAG
siRNA 163	163	CCGAGGGACACCUUCAUCA	1303	UGAUGAAGGUGUCCUCGG
siRNA 164	164	CGAGGGACACCUUCAUCAU	1304	AUGAUGAAGGUGUCCUCG
siRNA 165	165	GAGGGACACCUUCAUCAUA	1305	UAUGAUGAAGGUGUCCUC
siRNA 166	166	AGGGACACCUUCAUCAUAC	1306	GUAUGAUGAAGGUGUCCUC
siRNA 167	167	GGGACACCUUCAUCAUACA	1307	UGUAUGAUGAAGGUGUCCC
siRNA 168	168	GGACACCUUCAUCAUACAA	1308	UUGUAUGAUGAAGGUGUCC
siRNA 169	169	GACACCUUCAUCAUACAAA	1309	UUUGUAUGAUGAAGGUGUC
siRNA 170	170	ACACCUUCAUCAUACAAAC	1310	GUUUUAUGAUGAAGGUGU
siRNA 171	171	CACCUUCAUCAUACAAACU	1311	AGUUUGUAUGAUGAAGGUG
siRNA 172	172	ACCUUCAUCAUACAAACUC	1312	GAGUUUGUAUGAUGAAGGU
siRNA 173	173	CCUUCAUCAUACAAACUCU	1313	AGAGUUUGUAUGAUGAAGG
siRNA 174	174	CUUCAUCAUACAAACUCUG	1314	CAGAGUUUGUAUGAUGAAG
siRNA 175	175	UUCAUCAUACAAACUCUGU	1315	ACAGAGUUUGUAUGAUGAA
siRNA 176	176	UCAUCAUACAAACUCUGUA	1316	UACAGAGUUUGUAUGAUGA

siRNA 177	177	CAUCAUACAAACUCUGUAC	1317	GUACAGAGUUUGUAUGAUG
siRNA 178	178	AUCAUACAAACUCUGUACU	1318	AGUACAGAGUUUGUAUGAU
siRNA 179	179	UCAUACAAACUCUGUACUU	1319	AAGUACAGAGUUUGUAUGA
siRNA 180	180	CAUACAAACUCUGUACUUC	1320	GAAGUACAGAGUUUGUAUG
siRNA 181	181	AUACAAACUCUGUACUCC	1321	GGAAAGUACAGAGUUUGUAU
siRNA 182	182	UACAAACUCUGUACUCCU	1322	AGGAAGUACAGAGUUUGUA
siRNA 183	183	ACAAACUCUGUACUCCUG	1323	CAGGAAGUACAGAGUUUGU
siRNA 184	184	CAAACUCUGUACUCCUGG	1324	CCAGGAAGUACAGAGUUUG
siRNA 185	185	AAACUCUGUACUCCUGGA	1325	UCCAGGAAGUACAGAGUUU
siRNA 186	186	AACUCUGUACUCCUGGAA	1326	UUCAGGAAGUACAGAGUU
siRNA 187	187	ACUCUGUACUCCUGGAAU	1327	AUUCAGGAAGUACAGAGU
siRNA 188	188	CUCUGUACUCCUGGAAUC	1328	GAUUCAGGAAGUACAGAG
siRNA 189	189	UCUGUACUCCUGGAAUCG	1329	CGAUUCAGGAAGUACAGA
siRNA 190	190	CUGUACUCCUGGAAUCGA	1330	UCGAUUCAGGAAGUACAG
siRNA 191	191	UGUACUCCUGGAAUCGAU	1331	AUCGAUUCAGGAAGUACA
siRNA 192	192	GUACUCCUGGAAUCGAUA	1332	UAUCGAUUCAGGAAGUAC
siRNA 193	193	UACUCCUGGAAUCGAUAC	1333	GUACGAUUCAGGAAGUA
siRNA 194	194	ACUCCUGGAAUCGAUACU	1334	AGUAUCGAUUCAGGAAGU
siRNA 195	195	CUCCUGGAAUCGAUACUU	1335	AAGUAUCGAUUCAGGAAG
siRNA 196	196	UCCUGGAAUCGAUACUUG	1336	CAAGUAUCGAUUCAGGAA
siRNA 197	197	UCCUGGAAUCGAUACUUGU	1337	ACAAGUAUCGAUUCAGGA
siRNA 198	198	CCUGGAAUCGAUACUUGUA	1338	UACAAGUAUCGAUUCAGG
siRNA 199	199	CUGGAAUCGAUACUUGUUA	1339	AUACAAGUAUCGAUUCAG
siRNA 200	200	UGGAAUCGAUACUUGUAUU	1340	AAUACAAGUAUCGAUUC
siRNA 201	201	GGAAUCGAUACUUGUAUUU	1341	AAAUACAAGUAUCGAUUC
siRNA 202	202	GAAUCGAUACUUGUAUUUU	1342	AAAAUACAAGUAUCGAUUC
siRNA 203	203	AAUCGAUACUUGUAUUUUU	1343	AAAAAUACAAGUAUCGAUU
siRNA 204	204	AUCGAUACUUGUAUUUUUC	1344	GAAAAAUACAAGUAUCGAU
siRNA 205	205	UCGAUACUUGUAUUUUUCU	1345	AGAAAAAUACAAGUAUCGA
siRNA 206	206	CGAUACUUGUAUUUUUCUA	1346	UAGAAAAAUACAAGUAUCG
siRNA 207	207	GAUACUUGUAUUUUUCUAG	1347	CUAGAAAAAUACAAGUAUC
siRNA 208	208	AUACUUGUAUUUUUCUAGU	1348	ACUAGAAAAAUACAAGUAU
siRNA 209	209	UACUUGUAUUUUUCUAGUA	1349	UACUAGAAAAAUACAAGUA
siRNA 210	210	ACUUGUAUUUUUCUAGUAC	1350	GUACUAGAAAAAUACAAGU
siRNA 211	211	CUUGUAUUUUUCUAGUACC	1351	GGUACUAGAAAAAUACAAG
siRNA 212	212	UUGUAUUUUUCUAGUACCA	1352	UGGUACUAGAAAAAUACAA
siRNA 213	213	UGUAUUUUUCUAGUACCAA	1353	UUGGUACUAGAAAAAUACA
siRNA 214	214	GUUUUUUCUAGUACCAAG	1354	CUUGGUACUAGAAAAAUAC
siRNA 215	215	UAUUUUUCUAGUACCAAGU	1355	ACUUGGUACUAGAAAAAU
siRNA 216	216	AUUUUUCUAGUACCAAGUU	1356	AACUUGGUACUAGAAAAAU
siRNA 217	217	UUUUUCUAGUACCAAGUUA	1357	UAACUUGGUACUAGAAAA
siRNA 218	218	UUUUCUAGUACCAAGUUAC	1358	GUACUUGGUACUAGAAAA
siRNA 219	219	UUUCUAGUACCAAGUUACG	1359	CGUACUUGGUACUAGAAA
siRNA 220	220	UUCUAGUACCAAGUUACGU	1360	ACGUACUUGGUACUAGAA
siRNA 221	221	UCUAGUACCAAGUUACGUG	1361	CACGUACUUGGUACUAGA
siRNA 222	222	CUAGUACCAAGUUACGUGC	1362	GCACGUACUUGGUACUAG
siRNA 223	223	UAGUACCAAGUUACGUGCA	1363	UGCACGUACUUGGUACUA
siRNA 224	224	AGUACCAAGUUACGUGCAC	1364	GUGCACGUACUUGGUACU
siRNA 225	225	GUACCAAGUUACGUGCACC	1365	GGUGCACGUACUUGGUAC
siRNA 226	226	UACCAAGUUACGUGCACCA	1366	UGGUGCACGUACUUGGUA
siRNA 227	227	ACCAAGUUACGUGCACCAA	1367	UUGGUGCACGUACUUGGU
siRNA 228	228	CCAAGUUACGUGCACCAAA	1368	UUUGGUGCACGUACUUGG

siRNA 229	229	CAAGUUACGUGCACCAAAU	1369	AUUUGGUGCACGUAACUUG
siRNA 230	230	AAGUUACGUGCACCAAAU	1370	AAUUUGGUGCACGUAACUU
siRNA 231	231	AGUUACGUGCACCAAAUUA	1371	UAAUUUGGUGCACGUAACU
siRNA 232	232	GUUACGUGCACCAAAUUAU	1372	AUAAUUUGGUGCACGUAAC
siRNA 233	233	UUACGUGCACCAAAUUAUA	1373	UAUAAUUUGGUGCACGUAA
siRNA 234	234	UACGUGCACCAAAUUAUAA	1374	UUAAUAAUUUGGUGCACGUA
siRNA 235	235	ACGUGCACCAAAUUAUAAA	1375	UUUAUAAUUUGGUGCACGU
siRNA 236	236	CGUGCACCAAAUUAUAAAA	1376	UUUUUAUAAUUUGGUGCACG
siRNA 237	237	GUGCACCAAAUUAUAAAAC	1377	GUUUUAUAAUUUGGUGCAC
siRNA 238	238	UGCACCAAAUUAUAAAACA	1378	UGUUUAUAAUUUGGUGCA
siRNA 239	239	GCACCAAAUUAUAAAACAC	1379	GUGUUUAUAAUUUGGUGC
siRNA 240	240	CACCAAAUUAUAAAACACU	1380	AGUGUUUAUAAUUUGGUG
siRNA 241	241	ACCAAAUUAUAAAACACUU	1381	AAGUGUUUAUAAUUUGGU
siRNA 242	242	CCAAUUAUAAAACACUUU	1382	AAAGUGUUUAUAAUUUGG
siRNA 243	243	CAAAUUAUAAAACACUUUU	1383	AAAAAGUGUUUAUAAUUUG
siRNA 244	244	AAAUUAUAAAACACUUUUU	1384	AAAAAGUGUUUAUAAUUU
siRNA 245	245	AAUUAUAAAACACUUUUUU	1385	AAAAAGUGUUUAUAAUU
siRNA 246	246	AUUAUAAAACACUUUUUUA	1386	UAAAAAGUGUUUAUAAU
siRNA 247	247	UUAUAAAACACUUUUUUAU	1387	AUAAAAAGUGUUUAUAA
siRNA 248	248	UAUAAAACACUUUUUUAUA	1388	UAUAAAAAGUGUUUAUA
siRNA 249	249	AUAAAACACUUUUUUAUAA	1389	UUUAUAAAAAGUGUUUAU
siRNA 250	250	UAAAACACUUUUUUAUAAU	1390	AUUAUAAAAAGUGUUUA
siRNA 251	251	AAAACACUUUUUUAUAAUA	1391	UAUUAUAAAAAGUGUUU
siRNA 252	252	AAACACUUUUUUAUAAUAU	1392	AUAUUAUAAAAAGUGUU
siRNA 253	253	AACACUUUUUUAUAAUAUU	1393	AAUAUUAUAAAAAGUGUU
siRNA 254	254	ACACUUUUUUAUAAUAUUU	1394	AAAUUAUUAUAAAAAGUGU
siRNA 255	255	CACUUUUUUAUAAUAUUUU	1395	AAAAUUAUUAUAAAAAGUG
siRNA 256	256	ACUUUUUUAUAAUAUUUUC	1396	GAAAAUUAUUAUAAAAAGU
siRNA 257	257	CUUUUUUAUAAUAUUUUCU	1397	AGAAAAUUAUUAUAAAAAG
siRNA 258	258	UUUUUUUAUAAUAUUUUCUC	1398	GAGAAAAUUAUUAUAAAAA
siRNA 259	259	UUUUUAUAAUAUUUUCUCA	1399	UGAGAAAAUUAUUAUAAAA
siRNA 260	260	UUUUAUAAUAUUUUCUCAC	1400	GUGAGAAAAUUAUUAUAAAA
siRNA 261	261	UUUAUAAUAUUUUCUCACU	1401	AGUGAGAAAAUUAUUAUAAA
siRNA 262	262	UUAUAUAAUAUUUUCUCACUG	1402	CAGUGAGAAAAUUAUUAUAA
siRNA 263	263	UAUAUAAUAUUUUCUCACUGA	1403	UCAGUGAGAAAAUUAUUAUA
siRNA 264	264	AUAUAUAAUAUUUUCUCACUGAG	1404	CUCAGUGAGAAAAUUAUUAU
siRNA 265	265	UAAUAUAAUAUUUUCUCACUGAGA	1405	UCUCAGUGAGAAAAUUAUA
siRNA 266	266	AAUAUAAUAUUUUCUCACUGAGAC	1406	GUCUCAGUGAGAAAAUAUU
siRNA 267	267	AUAUUUUCUCACUGAGACU	1407	AGUCUCAGUGAGAAAAUAU
siRNA 268	268	UAUUUUCUCACUGAGACUC	1408	GAGUCUCAGUGAGAAAAUA
siRNA 269	269	AUUUUCUCACUGAGACUCC	1409	GGAGUCUCAGUGAGAAAAU
siRNA 270	270	UUUUCUCACUGAGACUCCC	1410	GGGAGUCUCAGUGAGAAAA
siRNA 271	271	UUUCUCACUGAGACUCCCA	1411	UGGGAGUCUCAGUGAGAAA
siRNA 272	272	UUCUCACUGAGACUCCAG	1412	CUGGGAGUCUCAGUGAGAA
siRNA 273	273	UCUCACUGAGACUCCAGG	1413	CCUGGGAGUCUCAGUGAGA
siRNA 274	274	CUCACUGAGACUCCAGGG	1414	CCUGGGAGUCUCAGUGAG
siRNA 275	275	UCACUGAGACUCCAGGGC	1415	GCCCUGGGAGUCUCAGUGA
siRNA 276	276	CACUGAGACUCCAGGGCU	1416	AGCCUGGGAGUCUCAGUG
siRNA 277	277	ACUGAGACUCCAGGGCUU	1417	AAGCCUGGGAGUCUCAGU
siRNA 278	278	CUGAGACUCCAGGGCUUU	1418	AAAGCCUGGGAGUCUCAG
siRNA 279	279	UGAGACUCCAGGGCUUUU	1419	AAAAGCCUGGGAGUCUCA
siRNA 280	280	GAGACUCCAGGGCUUUUA	1420	UAAAAGCCUGGGAGUCUC

siRNA 281	281	AGACUCCAGGGCUUUUAC	1421	GUAAAAGCCCUGGGAGUCU
siRNA 282	282	GACUCCAGGGCUUUUACU	1422	AGUAAAAGCCCUGGGAGUC
siRNA 283	283	ACUCCAGGGCUUUUACUA	1423	UAGUAAAAGCCCUGGGAGU
siRNA 284	284	CUCCAGGGCUUUUACUAU	1424	AUAGUAAAAGCCCUGGGAG
siRNA 285	285	UCCAGGGCUUUUACUAUC	1425	GAUAGUAAAAGCCCUGGGA
siRNA 286	286	CCCAGGGCUUUUACUAUCU	1426	AGAUAGUAAAAGCCCUGGG
siRNA 287	287	CCAGGGCUUUUACUAUCUC	1427	GAGAUAGUAAAAGCCCUGG
siRNA 288	288	CAGGGCUUUUACUAUCUCC	1428	GGAGAUAGUAAAAGCCCUG
siRNA 289	289	AGGGCUUUUACUAUCUCCA	1429	UGGAGAUAGUAAAAGCCCU
siRNA 290	290	GGGCUUUUACUAUCUCCAG	1430	CUGGAGAUAGUAAAAGCCC
siRNA 291	291	GGCUUUUACUAUCUCCAGA	1431	UCUGGAGAUAGUAAAAGCC
siRNA 292	292	GCUUUUACUAUCUCCAGAA	1432	UUCUGGAGAUAGUAAAAGC
siRNA 293	293	CUUUUACUAUCUCCAGAAU	1433	AUUCUGGAGAUAGUAAAAG
siRNA 294	294	UUUUACUAUCUCCAGAAUG	1434	CAUUCUGGAGAUAGUAAAA
siRNA 295	295	UUUACUAUCUCCAGAAUGU	1435	ACAUUCUGGAGAUAGUAAA
siRNA 296	296	UUACUAUCUCCAGAAUGUA	1436	UACAUUCUGGAGAUAGUAA
siRNA 297	297	UACUAUCUCCAGAAUGUAU	1437	AUACAUUCUGGAGAUAGUA
siRNA 298	298	ACUAUCUCCAGAAUGUAUU	1438	AAUACAUUCUGGAGAUAGU
siRNA 299	299	CUAUCUCCAGAAUGUAUUU	1439	AAAUACAUUCUGGAGAUAG
siRNA 300	300	UAUCUCCAGAAUGUAUUUU	1440	AAAAUACAUUCUGGAGAU
siRNA 301	301	AUCUCCAGAAUGUAUUUUU	1441	AAAAAUACAUUCUGGAGAU
siRNA 302	302	UCUCCAGAAUGUAUUUUUC	1442	GAAAAAUACAUUCUGGAGA
siRNA 303	303	CUCCAGAAUGUAUUUUUCC	1443	GGAAAAAUACAUUCUGGAG
siRNA 304	304	UCCAGAAUGUAUUUUUCCU	1444	AGGAAAAAUACAUUCUGGA
siRNA 305	305	CCAGAAUGUAUUUUUCCUU	1445	AAGGAAAAAUACAUUCUGG
siRNA 306	306	CAGAAUGUAUUUUUCCUUU	1446	AAAGGAAAAAUACAUUCUG
siRNA 307	307	AGAAUGUAUUUUUCCUUUU	1447	AAAAGGAAAAAUACAUUCU
siRNA 308	308	GAAUGUAUUUUUCCUUUUU	1448	AAAAAGGAAAAAUACAUUC
siRNA 309	309	AAUGUAUUUUUCCUUUUUC	1449	GAAAAAGGAAAAAUACAUU
siRNA 310	310	AUGUAUUUUUCCUUUUUCC	1450	GGAAAAAGGAAAAAUACAU
siRNA 311	311	UGUAUUUUUCCUUUUUCCG	1451	CGGAAAAAGGAAAAAUACA
siRNA 312	312	GUUUUUUCCUUUUUCCGU	1452	ACGGAAAAAGGAAAAAUAC
siRNA 313	313	UAUUUUUCCUUUUUCCGUA	1453	UACGGAAAAAGGAAAAAU
siRNA 314	314	AUUUUUCCUUUUUCCGUAA	1454	UUACGGAAAAAGGAAAAAU
siRNA 315	315	UUUUUCCUUUUUCCGUAAAG	1455	CUUACGGAAAAAGGAAAAA
siRNA 316	316	UUUUCCUUUUUCCGUAAAGA	1456	UCUUACGGAAAAAGGAAAA
siRNA 317	317	UUUCCUUUUUCCGUAAAGAC	1457	GUCUUACGGAAAAAGGAAA
siRNA 318	318	UUCCUUUUUCCGUAAAGACU	1458	AGUCUUACGGAAAAAGGAA
siRNA 319	319	UCCUUUUUCCGUAAAGACUC	1459	GAGUCUUACGGAAAAAGGA
siRNA 320	320	CCUUUUUCCGUAAAGACUCA	1460	UGAGUCUUACGGAAAAAGG
siRNA 321	321	CUUUUUUCCGUAAAGACUCAA	1461	UUGAGUCUUACGGAAAAAG
siRNA 322	322	UUUUUCCGUAAAGACUCAA	1462	UUUGAGUCUUACGGAAAAA
siRNA 323	323	UUUUCCGUAAAGACUCAAAA	1463	UUUUAGUCUUACGGAAAAA
siRNA 324	324	UUUCCGUAAAGACUCAAAAAG	1464	CUUUUGAGUCUUACGGAAA
siRNA 325	325	UUCCGUAAAGACUCAAAAAGU	1465	ACUUUUAGUCUUACGGGAA
siRNA 326	326	UCCGUAAAGACUCAAAAAGUA	1466	UACUUUUAGAGUCUUACGGA
siRNA 327	327	CCGUAAAGACUCAAAAAGUAA	1467	UUACUUUUAGUCUUACGG
siRNA 328	328	CGUAAAGACUCAAAAAGUAAU	1468	AUUACUUUUAGAGUCUUACG
siRNA 329	329	GUAAGACUCAAAAAGUAAUA	1469	UAUUACUUUUAGUCUUAC
siRNA 330	330	UAAGACUCAAAAAGUAAUAU	1470	AUAUUACUUUUAGAGUCUUA
siRNA 331	331	AAGACUCAAAAAGUAAUAUA	1471	UAUAUUACUUUUAGAGUCUU
siRNA 332	332	AGACUCAAAAAGUAAUAUAA	1472	UUUAUUACUUUUAGAGUCU

siRNA 333	333	GACUCAAAGUAAUAUAG	1473	CUUAUAUUACUUUGAGUC
siRNA 334	334	ACUCAAAGUAAUAUAGG	1474	CCUUAUAUUACUUUGAGU
siRNA 335	335	CUCAAAGUAAUAUAGGU	1475	ACCUUAUAUUACUUUGAG
siRNA 336	336	UCAAAGUAAUAUAGGUC	1476	GACCUUAUAUUACUUUGA
siRNA 337	337	CAAAAGUAAUAUAGGUCU	1477	AGACCUUAUAUUACUUUG
siRNA 338	338	AAAAGUAAUAUAGGUCUA	1478	UAGACCUUAUAUUACUUUU
siRNA 339	339	AAAGUAAUAUAGGUCUAC	1479	GUAGACCUUAUAUUACUUU
siRNA 340	340	AAGUAAUAUAGGUCUACA	1480	UGUAGACCUUAUAUUACUU
siRNA 341	341	AGUAAUAUAGGUCUACAA	1481	UUUGUAGACCUUAUAUUACU
siRNA 342	342	GUAAUAUAGGUCUACAAA	1482	UUUGUAGACCUUAUAUUAC
siRNA 343	343	UAAUAUAGGUCUACAAA	1483	UUUUUGUAGACCUUAUAUU
siRNA 344	344	AAUAUAGGUCUACAAAUA	1484	AUUUUGUAGACCUUAUAUU
siRNA 345	345	AUAUAAGGUCUACAAAUC	1485	GAUUUUUGUAGACCUUAUAU
siRNA 346	346	UAUAAGGUCUACAAAUCU	1486	AGAUUUUGUAGACCUUAUA
siRNA 347	347	AUAAGGUCUACAAAUCUA	1487	UAGAUUUUGUAGACCUUAU
siRNA 348	348	UAAGGUCUACAAAUCUAC	1488	GUAGAUUUUGUAGACCUUA
siRNA 349	349	AAGGUCUACAAAUCUACU	1489	AGUAGAUUUUGUAGACCUU
siRNA 350	350	AGGUCUACAAAUCUACUA	1490	UAGUAGAUUUUGUAGACCU
siRNA 351	351	GGUCUACAAAUCUACUAA	1491	UUAGUAGAUUUUGUAGACC
siRNA 352	352	GUCUACAAAUCUACUAAA	1492	UUUAGUAGAUUUUGUAGAC
siRNA 353	353	UCUACAAAUCUACUAAAA	1493	UUUUAGUAGAUUUUGUAGA
siRNA 354	354	CUACAAAUCUACUAAAAA	1494	UUUUUAGUAGAUUUUGUAG
siRNA 355	355	UACAAAUCUACUAAAAAG	1495	CUUUUUAGUAGAUUUUGUA
siRNA 356	356	ACAAAUCUACUAAAAAGU	1496	ACUUUUUAGUAGAUUUUGU
siRNA 357	357	CAAAUCUACUAAAAAGUC	1497	GACUUUUUAGUAGAUUUUG
siRNA 358	358	AAAAUCUACUAAAAAGUCU	1498	AGACUUUUUAGUAGAUUUU
siRNA 359	359	AAAUUCUACUAAAAAGUCUC	1499	GAGACUUUUUAGUAGAUUU
siRNA 360	360	AAUCUACUAAAAAGUCUCU	1500	AGAGACUUUUUAGUAGAUU
siRNA 361	361	AUCUACUAAAAAGUCUCUG	1501	CAGAGACUUUUUAGUAGAU
siRNA 362	362	UCUACUAAAAAGUCUCUGC	1502	GCAGAGACUUUUUAGUAGA
siRNA 363	363	CUACUAAAAAGUCUCUGCA	1503	UGCAGAGACUUUUUAGUAG
siRNA 364	364	UACUAAAAAGUCUCUGCAA	1504	UUGCAGAGACUUUUUAGUA
siRNA 365	365	ACUAAAAAGUCUCUGCAAA	1505	UUUGCAGAGACUUUUUAGU
siRNA 366	366	CUAAAAAGUCUCUGCAAAA	1506	UUUUGCAGAGACUUUUUAG
siRNA 367	367	UAAAAAGUCUCUGCAAAAA	1507	UUUUUGCAGAGACUUUUUA
siRNA 368	368	AAAAAGUCUCUGCAAAAAG	1508	CUUUUUGCAGAGACUUUUU
siRNA 369	369	AAAAGUCUCUGCAAAAAGU	1509	ACUUUUUGCAGAGACUUUU
siRNA 370	370	AAAGUCUCUGCAAAAAGUA	1510	UACUUUUUGCAGAGACUUU
siRNA 371	371	AAGUCUCUGCAAAAAGUAG	1511	CUACUUUUUGCAGAGACUU
siRNA 372	372	AGUCUCUGCAAAAAGUAGA	1512	UCUACUUUUUGCAGAGACU
siRNA 373	373	GUCUCUGCAAAAAGUAGAU	1513	AUCUACUUUUUGCAGAGAC
siRNA 374	374	UCUCUGCAAAAAGUAGAUG	1514	CAUCUACUUUUUGCAGAGA
siRNA 375	375	CUCUGCAAAAAGUAGAUGA	1515	UCAUCUACUUUUUGCAGAG
siRNA 376	376	UCUGCAAAAAGUAGAUGAA	1516	UUCAUCUACUUUUUGCAGA
siRNA 377	377	CUGCAAAAAGUAGAUGAAG	1517	CUUCAUCUACUUUUUGCAG
siRNA 378	378	UGCAAAAAGUAGAUGAAGA	1518	UCUUCAUCUACUUUUUGCA
siRNA 379	379	GCAAAAAGUAGAUGAAGAG	1519	CUCUUCUACUACUUUUUGC
siRNA 380	380	CAAAAAGUAGAUGAAGAGG	1520	CCUCUUCUACUACUUUUUG
siRNA 381	381	AAAAAGUAGAUGAAGAGGA	1521	UCCUCUUCUACUACUUUUU
siRNA 382	382	AAAAGUAGAUGAAGAGGAC	1522	GUCCUCUUCUACUACUUUU
siRNA 383	383	AAAGUAGAUGAAGAGGACU	1523	AGUCCUCUUCUACUACUUU
siRNA 384	384	AAGUAGAUGAAGAGGACUC	1524	GAGUCCUCUUCUACUACUU

siRNA 385	385	AGUAGAUGAAGAGGACUCU	1525	AGAGUCCUCUUAUCUACU
siRNA 386	386	GUAGAUGAAGAGGACUCUG	1526	CAGAGUCCUCUUAUCUAC
siRNA 387	387	UAGAUGAAGAGGACUCUGA	1527	UCAGAGUCCUCUUAUCUA
siRNA 388	388	AGAUGAAGAGGACUCUGAU	1528	AUCAGAGUCCUCUUAUCU
siRNA 389	389	GAUGAAGAGGACUCUGAUG	1529	CAUCAGAGUCCUCUUAUC
siRNA 390	390	AUGAAGAGGACUCUGAUGA	1530	UCAUCAGAGUCCUCUUAU
siRNA 391	391	UGAAGAGGACUCUGAUGAA	1531	UUCAUCAGAGUCCUCUUA
siRNA 392	392	GAAGAGGACUCUGAUGAAG	1532	CUUCAUCAGAGUCCUCUUC
siRNA 393	393	AAGAGGACUCUGAUGAAGA	1533	UCUUAUCAGAGUCCUCUU
siRNA 394	394	AGAGGACUCUGAUGAAGAA	1534	UUCUUAUCAGAGUCCUCU
siRNA 395	395	GAGGACUCUGAUGAAGAAA	1535	UUUCUUAUCAGAGUCCUC
siRNA 396	396	AGGACUCUGAUGAAGAAAAG	1536	CUUUCUUAUCAGAGUCCU
siRNA 397	397	GGACUCUGAUGAAGAAAAGC	1537	GCUUUCUUAUCAGAGUCC
siRNA 398	398	GACUCUGAUGAAGAAAAGCC	1538	GGCUUUCUUAUCAGAGUC
siRNA 399	399	ACUCUGAUGAAGAAAAGCCA	1539	UGGCUUUCUUAUCAGAGU
siRNA 400	400	CUCUGAUGAAGAAAAGCCAU	1540	AUGGCUUUCUUAUCAGAG
siRNA 401	401	UCUGAUGAAGAAAAGCCAUC	1541	GAUGGCUUUCUUAUCAGA
siRNA 402	402	CUGAUGAAGAAAAGCCAUCA	1542	UGAUGGCUUUCUUAUCAG
siRNA 403	403	UGAUGAAGAAAAGCCAUCAU	1543	AUGAUGGCUUUCUUAUCA
siRNA 404	404	GAUGAAGAAAAGCCAUCAUG	1544	CAUGAUGGCUUUCUUAUC
siRNA 405	405	AUGAAGAAAAGCCAUCAUGA	1545	UCAUGAUGGCUUUCUUAU
siRNA 406	406	UGAAGAAAAGCCAUCAUGAU	1546	AUCAUGAUGGCUUUCUUA
siRNA 407	407	GAAGAAAAGCCAUCAUGAUG	1547	CAUCAUGAUGGCUUUCUUC
siRNA 408	408	AAGAAAAGCCAUCAUGAUGA	1548	UCAUCAUGAUGGCUUUCU
siRNA 409	409	AGAAAAGCCAUCAUGAUGAG	1549	CUCAUCAUGAUGGCUUUCU
siRNA 410	410	GAAAAGCCAUCAUGAUGAGA	1550	UCUCAUCAUGAUGGCUUUC
siRNA 411	411	AAAGCCAUCAUGAUGAGAU	1551	AUCUCAUCAUGAUGGCUUU
siRNA 412	412	AAGCCAUCAUGAUGAGAU	1552	CAUCUCAUCAUGAUGGCUU
siRNA 413	413	AGCCAUCAUGAUGAGAU	1553	UCAUCUCAUCAUGAUGGCU
siRNA 414	414	GCCAUCAUGAUGAGAU	1554	CUCAUCUCAUCAUGAUGGC
siRNA 415	415	CCAUCAUGAUGAGAU	1555	ACUCAUCUCAUCAUGAUGG
siRNA 416	416	CAUCAUGAUGAGAU	1556	CACUCAUCUCAUCAUGAUG
siRNA 417	417	AUCAUGAUGAGAU	1557	UCACUCAUCUCAUCAUGAU
siRNA 418	418	UCAUGAUGAGAU	1558	CUCACUCAUCUCAUCAUGA
siRNA 419	419	CAUGAUGAGAU	1559	GCUCACUCAUCUCAUGAUG
siRNA 420	420	AUGAUGAGAU	1560	UGCUCACUCAUCUCAUCAU
siRNA 421	421	UGAUGAGAU	1561	CUGCUCACUCAUCUCAUCA
siRNA 422	422	GAUGAGAU	1562	CCUGCUCACUCAUCUCAUC
siRNA 423	423	AUGAGAU	1563	UCCUGCUCACUCAUCUCAU
siRNA 424	424	UGAGAU	1564	UCCUGCUCACUCAUCUCA
siRNA 425	425	GAGAU	1565	CUUCUGCUCACUCAUCUC
siRNA 426	426	AGAU	1566	UCUUCUGCUCACUCAUCU
siRNA 427	427	GAUGAU	1567	CUCUUCUGCUCACUCAUC
siRNA 428	428	AUGAU	1568	CCUCUUCUGCUCACUCAU
siRNA 429	429	UGAU	1569	UCCUCUUCUGCUCACUCA
siRNA 430	430	GAGU	1570	CUCCUCUUCUGCUCACUC
siRNA 431	431	AGU	1571	GCUCUCUUCUGCUCACU
siRNA 432	432	GUGU	1572	AGCUCCUCUUCUGCUCAC
siRNA 433	433	UGU	1573	AAGCUCUCUUCUGCUCUA
siRNA 434	434	GAGU	1574	CAAGCUCUCUUCUGCUC
siRNA 435	435	AGC	1575	UCAAGCUCUCUUCUGCUCU
siRNA 436	436	GCAGU	1576	CUCAAGCUCUCUUCUGCUC

siRNA 437	437	CAGGAAGAGGAGCUUGAGG	1577	CCUCAAGCUCCUUCUCCUG
siRNA 438	438	AGGAAGAGGAGCUUGAGGA	1578	UCCUCAAGCUCCUUCUCCU
siRNA 439	439	GGAAGAGGAGCUUGAGGAU	1579	AUCCUCAAGCUCCUUCUCC
siRNA 440	440	GAAGAGGAGCUUGAGGAUG	1580	CAUCCUCAAGCUCCUUCU
siRNA 441	441	AAGAGGAGCUUGAGGAUGA	1581	UCAUCCUCAAGCUCCUUCU
siRNA 442	442	AGAGGAGCUUGAGGAUGAU	1582	AUCAUCCUCAAGCUCCUUCU
siRNA 443	443	GAGGAGCUUGAGGAUGAUC	1583	GAUCAUCCUCAAGCUCCUC
siRNA 444	444	AGGAGCUUGAGGAUGAUCC	1584	GGAUCAUCCUCAAGCUCCU
siRNA 445	445	GGAGCUUGAGGAUGAUCCU	1585	AGGAUCAUCCUCAAGCUCC
siRNA 446	446	GAGCUUGAGGAUGAUCCUA	1586	UAGGAUCAUCCUCAAGCUC
siRNA 447	447	AGCUUGAGGAUGAUCCUAC	1587	GUAGGAUCAUCCUCAAGCU
siRNA 448	448	GCUUGAGGAUGAUCCUACU	1588	AGUAGGAUCAUCCUCAAGC
siRNA 449	449	CUUGAGGAUGAUCCUACUG	1589	CAGUAGGAUCAUCCUCAAG
siRNA 450	450	UUGAGGAUGAUCCUACUGU	1590	ACAGUAGGAUCAUCCUCAAA
siRNA 451	451	UGAGGAUGAUCCUACUGUA	1591	UACAGUAGGAUCAUCCUCA
siRNA 452	452	GAGGAUGAUCCUACUGUAG	1592	CUACAGUAGGAUCAUCCUC
siRNA 453	453	AGGAUGAUCCUACUGUAGU	1593	ACUACAGUAGGAUCAUCCU
siRNA 454	454	GGAUGAUCCUACUGUAGUC	1594	GACUACAGUAGGAUCAUCC
siRNA 455	455	GAUGAUCCUACUGUAGUCA	1595	UGACUACAGUAGGAUCAUC
siRNA 456	456	AUGAUCCUACUGUAGUCAA	1596	UUGACUACAGUAGGAUCAU
siRNA 457	457	UGAUCCUACUGUAGUCAAAA	1597	UUUGACUACAGUAGGAUCA
siRNA 458	458	GAUCCUACUGUAGUCAAAAA	1598	UUUUUACUACAGUAGGAUC
siRNA 459	459	AUCCUACUGUAGUCAAAAAA	1599	UUUUUAGUACAGUAGGAU
siRNA 460	460	UCCUACUGUAGUCAAAAAAC	1600	GUUUUUUACUACAGUAGGA
siRNA 461	461	CCUACUGUAGUCAAAAAACU	1601	AGUUUUUAGUACAGUAGG
siRNA 462	462	CUACUGUAGUCAAAAAACUA	1602	UAGUUUUUAGUACAGUAG
siRNA 463	463	UACUGUAGUCAAAAAACUAU	1603	AUAGUUUUUAGUACAGUA
siRNA 464	464	ACUGUAGUCAAAAAACUAUA	1604	UAUAGUUUUUAGUACAGU
siRNA 465	465	CUGUAGUCAAAAAACUAUAA	1605	UUUAGUUUUUAGUACAG
siRNA 466	466	UGUAGUCAAAAAACUAUAAA	1606	UUUUAUAGUUUUUAGUACA
siRNA 467	467	GUAGUCAAAAAACUAUAAAG	1607	CUUUUAUAGUUUUUAGUAC
siRNA 468	468	UAGUCAAAAAACUAUAAAGA	1608	UCUUUAUAGUUUUUAGUA
siRNA 469	469	AGUCAAAAAACUAUAAAGAC	1609	GUUUUAUAGUUUUUAGUACU
siRNA 470	470	GUCAAAAAACUAUAAAGACC	1610	GGUUUAUAGUUUUUAGUAC
siRNA 471	471	UCAAAAAACUAUAAAGACCU	1611	AGGUUUUAUAGUUUUUAGA
siRNA 472	472	CAAAAAACUAUAAAGACCUG	1612	CAGGUUUUAUAGUUUUUG
siRNA 473	473	AAAAACUAUAAAGACCUGG	1613	CCAGGUUUUAUAGUUUUU
siRNA 474	474	AAAACUAUAAAGACCUGGA	1614	UCCAGGUUUUAUAGUUUU
siRNA 475	475	AAACUAUAAAGACCUGGAA	1615	UUCAGGUUUUAUAGUUU
siRNA 476	476	AACUAUAAAGACCUGGAAA	1616	UUUCAGGUUUUAUAGUU
siRNA 477	477	ACUAUAAAGACCUGGAAAA	1617	UUUUCCAGGUUUUAUAGU
siRNA 478	478	CUAUAAAGACCUGGAAAAA	1618	UUUUUCCAGGUUUUAUAG
siRNA 479	479	UAUAAAGACCUGGAAAAAG	1619	CUUUUUCCAGGUUUUAUA
siRNA 480	480	AUAAAGACCUGGAAAAAGC	1620	GCUUUUUCCAGGUUUUAU
siRNA 481	481	UAAAGACCUGGAAAAAGCA	1621	UGCUUUUUCCAGGUUUUA
siRNA 482	482	AAAGACCUGGAAAAAGCAG	1622	CUGCUUUUUCCAGGUUUU
siRNA 483	483	AAGACCUGGAAAAAGCAGU	1623	ACUGCUUUUUCCAGGUUU
siRNA 484	484	AGACCUGGAAAAAGCAGUU	1624	AACUGCUUUUUCCAGGUUU
siRNA 485	485	GACCUGGAAAAAGCAGUUC	1625	GAACUGCUUUUUCCAGGU
siRNA 486	486	ACCUGGAAAAAGCAGUUCA	1626	UGAACUGCUUUUUCCAGGU
siRNA 487	487	CCUGGAAAAAGCAGUUCAG	1627	CUGAACUGCUUUUUCCAGG
siRNA 488	488	CUGGAAAAAGCAGUUCAGU	1628	ACUGAACUGCUUUUUCCAG

siRNA 489	489	UGGAAAAAGCAGUUCAGUC	1629	GACUGAACUGCUUUUCCA
siRNA 490	490	GGAAAAAGCAGUUCAGUCU	1630	AGACUGAACUGCUUUUCC
siRNA 491	491	GAAAAAGCAGUUCAGUCUU	1631	AAGACUGAACUGCUUUUC
siRNA 492	492	AAAAAGCAGUUCAGUCUUU	1632	AAAGACUGAACUGCUUUU
siRNA 493	493	AAAAAGCAGUUCAGUCUUU	1633	AAAAAGACUGAACUGCUUU
siRNA 494	494	AAAGCAGUUCAGUCUUUUC	1634	GAAAAAGACUGAACUGCUU
siRNA 495	495	AAGCAGUUCAGUCUUUUCG	1635	CGAAAAAGACUGAACUGCU
siRNA 496	496	AGCAGUUCAGUCUUUUCGG	1636	CCGAAAAAGACUGAACUGCU
siRNA 497	497	GCAGUUCAGUCUUUUCGGU	1637	ACCGAAAAAGACUGAACUGC
siRNA 498	498	CAGUUCAGUCUUUUCGGUA	1638	UACCGAAAAAGACUGAACUG
siRNA 499	499	AGUUCAGUCUUUUCGGUAU	1639	AUACCGAAAAAGACUGAACU
siRNA 500	500	GUUCAGUCUUUUCGGUAUG	1640	CAUACCGAAAAAGACUGAAC
siRNA 501	501	UUCAGUCUUUUCGGUAUGA	1641	UCAUACCGAAAAAGACUGAA
siRNA 502	502	UCAGUCUUUUCGGUAUGAU	1642	AUCAUACCGAAAAAGACUGA
siRNA 503	503	CAGUCUUUUCGGUAUGAUG	1643	CAUCAUACCGAAAAAGACUG
siRNA 504	504	AGUCUUUUCGGUAUGAUGU	1644	ACAUCAUACCGAAAAAGACU
siRNA 505	505	GUCUUUUCGGUAUGAUGUU	1645	AACAUCAUACCGAAAAAGAC
siRNA 506	506	UCUUUUCGGUAUGAUGUUG	1646	CAACAUCAUACCGAAAAAGA
siRNA 507	507	CUUUUUCGGUAUGAUGUGU	1647	ACAACAUCAUACCGAAAAAG
siRNA 508	508	UUUUUCGGUAUGAUGUUGUC	1648	GACAACAUCAUACCGAAAA
siRNA 509	509	UUUCGGUAUGAUGUUGUCC	1649	GGACAACAUCAUACCGAAA
siRNA 510	510	UUCGGUAUGAUGUUGUCCU	1650	AGGACAACAUCAUACCGAA
siRNA 511	511	UCGGUAUGAUGUUGUCCUG	1651	CAGGACAACAUCAUACCGA
siRNA 512	512	CGGUAUGAUGUUGUCCUGA	1652	UCAGGACAACAUCAUACCG
siRNA 513	513	GGUAUGAUGUUGUCCUGAA	1653	UUCAGGACAACAUCAUACC
siRNA 514	514	GUAUGAUGUUGUCCUGAAG	1654	CUUCAGGACAACAUCAUAC
siRNA 515	515	UAUGAUGUUGUCCUGAAGA	1655	UCUUACGGACAACAUCAUA
siRNA 516	516	AUGAUGUUGUCCUGAAGAC	1656	GUUCUACGGACAACAUCAU
siRNA 517	517	UGAUGUUGUCCUGAAGACG	1657	CGUCUUACGGACAACAUCA
siRNA 518	518	GAUGUUGUCCUGAAGACGG	1658	CCGUCUACGGACAACAUUC
siRNA 519	519	AUGUUGUCCUGAAGACGGG	1659	CCCGUCUUACGGACAACAU
siRNA 520	520	UGUUGUCCUGAAGACGGGG	1660	CCCCGUCUACGGACAACA
siRNA 521	521	GUUGUCCUGAAGACGGGGC	1661	GCCCCGUCUUACGGACAAC
siRNA 522	522	UUGUCCUGAAGACGGGGCU	1662	AGCCCCGUCUACGGACAA
siRNA 523	523	UGUCCUGAAGACGGGGCUA	1663	UAGCCCCGUCUUACGGACA
siRNA 524	524	GUCCUGAAGACGGGGCUAG	1664	CUAGCCCCGUCUACGGAC
siRNA 525	525	UCCUGAAGACGGGGCUAGA	1665	UCUAGCCCCGUCUUACGGA
siRNA 526	526	CCUGAAGACGGGGCUAGAU	1666	AUCUAGCCCCGUCUACGG
siRNA 527	527	CUGAAGACGGGGCUAGAU	1667	UAUCUAGCCCCGUCUUCAG
siRNA 528	528	UGAAGACGGGGCUAGAUU	1668	AUAUCUAGCCCCGUCUUA
siRNA 529	529	GAAGACGGGGCUAGAUUU	1669	AAUAUCUAGCCCCGUCUUC
siRNA 530	530	AAGACGGGGCUAGAUUUG	1670	CAUAUCUAGCCCCGUCUU
siRNA 531	531	AGACGGGGCUAGAUUUGG	1671	CCAAUAUCUAGCCCCGUCU
siRNA 532	532	GACGGGGCUAGAUUUGGG	1672	CCCAAUAUCUAGCCCCGUC
siRNA 533	533	ACGGGGCUAGAUUUGGGA	1673	UCCCAAUAUCUAGCCCCGU
siRNA 534	534	CGGGGCUAGAUUUGGGAG	1674	CUCCCAAUAUCUAGCCCCG
siRNA 535	535	GGGGCUAGAUUUGGGAGA	1675	UCUCCCAAUAUCUAGCCCC
siRNA 536	536	GGGCUAGAUUUGGGAGAA	1676	UUCUCCCAAUAUCUAGCCC
siRNA 537	537	GGCUAGAUUUGGGAGAAA	1677	UUUCUCCCAAUAUCUAGCC
siRNA 538	538	GCUAGAUUUGGGAGAAAC	1678	GUUUCUCCCAAUAUCUAGC
siRNA 539	539	CUAGAUUUGGGAGAAACA	1679	UGUUCUCCCAAUAUCUAG
siRNA 540	540	UAGAUUUGGGAGAAACAA	1680	UUGUUUCUCCCAAUAUCUA

siRNA 541	541	AGAUUUGGGAGAAACAAA	1681	UUUGUUUCUCCCAAUAUCU
siRNA 542	542	GAUUAUUGGGAGAAACAAAG	1682	CUUUUUUUUCUCCCAAUAUC
siRNA 543	543	AUAUUGGGAGAAACAAAGU	1683	ACUUUGUUUCUCCCAAUAU
siRNA 544	544	UAUUGGGAGAAACAAAGUG	1684	CACUUUGUUUCUCCCAAUA
siRNA 545	545	AUUGGGAGAAACAAAGUGG	1685	CCACUUUGUUUCUCCCAAU
siRNA 546	546	UUGGGAGAAACAAAGUGGA	1686	UCCACUUUGUUUCUCCCAA
siRNA 547	547	UGGGAGAAACAAAGUGGAA	1687	UUCCACUUUGUUUCUCCCA
siRNA 548	548	GGGAGAAACAAAGUGGAAG	1688	CUUCCACUUUGUUUCUCCC
siRNA 549	549	GGAGAAACAAAGUGGAAGA	1689	UCUCCACUUUGUUUCUCC
siRNA 550	550	GAGAAACAAAGUGGAAGAU	1690	AUCUCCACUUUGUUUCUC
siRNA 551	551	AGAAACAAAGUGGAAGAUG	1691	CAUCUUCCACUUUGUUUCU
siRNA 552	552	GAAACAAAGUGGAAGAUGC	1692	GCAUCUCCACUUUGUUUC
siRNA 553	553	AAACAAAGUGGAAGAUGCU	1693	AGCAUCUCCACUUUGUUU
siRNA 554	554	AACAAAGUGGAAGAUGCUU	1694	AAGCAUCUCCACUUUGUU
siRNA 555	555	ACAAAGUGGAAGAUGCUUU	1695	AAAGCAUCUCCACUUUGU
siRNA 556	556	CAAAGUGGAAGAUGCUUUC	1696	GAAAGCAUCUCCACUUUG
siRNA 557	557	AAAGUGGAAGAUGCUUUCU	1697	AGAAAGCAUCUCCACUUU
siRNA 558	558	AAGUGGAAGAUGCUUUCUA	1698	UAGAAAGCAUCUCCACUU
siRNA 559	559	AGUGGAAGAUGCUUUCUAC	1699	GUAGAAAGCAUCUCCACU
siRNA 560	560	GUGGAAGAUGCUUUCUACA	1700	UGUAGAAAGCAUCUCCAC
siRNA 561	561	UGGAAGAUGCUUUCUACAA	1701	UUGUAGAAAGCAUCUCCA
siRNA 562	562	GGAAGAUGCUUUCUACAAA	1702	UUUGUAGAAAGCAUCUCC
siRNA 563	563	GAAGAUGCUUUCUACAAAG	1703	CUUUGUAGAAAGCAUCUUC
siRNA 564	564	AAGAUGCUUUCUACAAAGG	1704	CCUUUGUAGAAAGCAUCUU
siRNA 565	565	AGAUGCUUUCUACAAAGGU	1705	ACCUUUGUAGAAAGCAUCU
siRNA 566	566	GAUGCUUUCUACAAAGGUG	1706	CACCUUUGUAGAAAGCAUC
siRNA 567	567	AUGCUUUCUACAAAGGUGA	1707	UCACCUUUGUAGAAAGCAU
siRNA 568	568	UGC UUUCUACAAAGGUGAA	1708	UUCACCUUUGUAGAAAGCA
siRNA 569	569	GCUUUCUACAAAGGUGAAC	1709	GUUCACCUUUGUAGAAAGC
siRNA 570	570	CUUUCUACAAAGGUGAACU	1710	AGUUCACCUUUGUAGAAAG
siRNA 571	571	UUUCUACAAAGGUGAACUC	1711	GAGUUCACCUUUGUAGAAA
siRNA 572	572	UUCUACAAAGGUGAACUCA	1712	UGAGUUCACCUUUGUAGAA
siRNA 573	573	UCUACAAAGGUGAACUCAG	1713	CUGAGUUCACCUUUGUAGA
siRNA 574	574	CUACAAAGGUGAACUCAGG	1714	CCUGAGUUCACCUUUGUAG
siRNA 575	575	UACAAAGGUGAACUCAGGC	1715	GCCUGAGUUCACCUUUGUA
siRNA 576	576	ACAAAGGUGAACUCAGGCU	1716	AGCCUGAGUUCACCUUUGU
siRNA 577	577	CAAAGGUGAACUCAGGCUG	1717	CAGCCUGAGUUCACCUUUG
siRNA 578	578	AAAGGUGAACUCAGGCUGA	1718	UCAGCCUGAGUUCACCUUU
siRNA 579	579	AAGGUGAACUCAGGCUGAA	1719	UUCAGCCUGAGUUCACCUU
siRNA 580	580	AGGUGAACUCAGGCUGAAU	1720	AUUCAGCCUGAGUUCACCU
siRNA 581	581	GGUGAACUCAGGCUGAAUG	1721	CAUUCAGCCUGAGUUCACC
siRNA 582	582	GUGAACUCAGGCUGAAUGA	1722	UCAUUCAGCCUGAGUUCAC
siRNA 583	583	UGAACUCAGGCUGAAUGAG	1723	CUCAUUCAGCCUGAGUUCA
siRNA 584	584	GAACUCAGGCUGAAUGAGG	1724	CCUCAUUCAGCCUGAGUUC
siRNA 585	585	AACUCAGGCUGAAUGAGGA	1725	UCCUCAUUCAGCCUGAGUU
siRNA 586	586	ACUCAGGCUGAAUGAGGAA	1726	UUCUCAUUCAGCCUGAGU
siRNA 587	587	CUCAGGCUGAAUGAGGAAA	1727	UUUCUCAUUCAGCCUGAG
siRNA 588	588	UCAGGCUGAAUGAGGAAAA	1728	UUUUUCAUUCAGCCUGA
siRNA 589	589	CAGGCUGAAUGAGGAAAAA	1729	UUUUUCUCAUUCAGCCUG
siRNA 590	590	AGGCUGAAUGAGGAAAAAU	1730	AUUUUUCAUUCAGCCCU
siRNA 591	591	GGCUGAAUGAGGAAAAAUU	1731	AAUUUUUCAUUCAGCC
siRNA 592	592	GCUGAAUGAGGAAAAAUUA	1732	UAAUUUUUCAUUCAGC

siRNA 593	593	CUGAAUGAGGAAAAAUUAU	1733	AUAAUUUUUCCUCAUUCAG
siRNA 594	594	UGAAUGAGGAAAAAUUAUG	1734	CAUAAUUUUUCCUCAUUCA
siRNA 595	595	GAAUGAGGAAAAAUUAUGG	1735	CCAUAAUUUUUCCUCAUUC
siRNA 596	596	AAUGAGGAAAAAUUAUGGA	1736	UCCAUAUUUUUCCUCAUU
siRNA 597	597	AUGAGGAAAAAUUAUGGAA	1737	UUCCAUAUUUUUCCUCAU
siRNA 598	598	UGAGGAAAAAUUAUGGAAG	1738	CUUCCAUAUUUUUCCUCA
siRNA 599	599	GAGGAAAAAUUAUGGAAGA	1739	UCUCCAUAUUUUUCCUC
siRNA 600	600	AGGAAAAAUUAUGGAAGAA	1740	UUCUCCAUAUUUUUCCU
siRNA 601	601	GGAAAAAUUAUGGAAGAAA	1741	UUUCUCCAUAUUUUUCC
siRNA 602	602	GAAAAAUUAUGGAAGAAAA	1742	UUUUUCCAUAUUUUUCC
siRNA 603	603	AAAAAUUAUGGAAGAAAAAG	1743	CUUUUCUCCAUAUUUUUU
siRNA 604	604	AAAAUUAUGGAAGAAAAGC	1744	GCUUUUUCCAUAUUUUUU
siRNA 605	605	AAAUUAUGGAAGAAAAGCA	1745	UGCUUUUCUCCAUAUUUU
siRNA 606	606	AAUUAUGGAAGAAAAGCAG	1746	CUGC UU UU CUCCAUAUUU
siRNA 607	607	AUUAUGGAAGAAAAGCAGA	1747	UCUGCUUUUCUCCAUAUU
siRNA 608	608	UUAUGGAAGAAAAGCAGAA	1748	UUCUGCUUUUUUCCAUAUA
siRNA 609	609	UAUGGAAGAAAAGCAGAAC	1749	GUUCUGCUUUUCUCCAUA
siRNA 610	610	AUGGAAGAAAAGCAGAACG	1750	CGUUCUGCUUUUUUCCAUA
siRNA 611	611	UGGAAGAAAAGCAGAACGG	1751	CCGUUCUGCUUUUCUCCA
siRNA 612	612	GGAAGAAAAGCAGAACGGU	1752	ACCGUUCUGCUUUUCUCC
siRNA 613	613	GAAGAAAAGCAGAACGGUG	1753	CACCGUUCUGCUUUUCUCC
siRNA 614	614	AAGAAAAGCAGAACGGUGA	1754	UCACCGUUCUGCUUUUCU
siRNA 615	615	AGAAAAGCAGAACGGUGAA	1755	UUCACCGUUCUGCUUUUCU
siRNA 616	616	GAAAAGCAGAACGGUGAAA	1756	UUUCACCGUUCUGCUUUUC
siRNA 617	617	AAAAGCAGAACGGUGAAAG	1757	CUUUCACCGUUCUGCUUUU
siRNA 618	618	AAAGCAGAACGGUGAAAGU	1758	ACUUUCACCGUUCUGCUUU
siRNA 619	619	AAGCAGAACGGUGAAAGUG	1759	CACUUUCACCGUUCUGCUU
siRNA 620	620	AGCAGAACGGUGAAAGUGG	1760	CCACUUUCACCGUUCUGCU
siRNA 621	621	GCAGAACGGUGAAAGUGGG	1761	CCCACUUUCACCGUUCUGC
siRNA 622	622	CAGAACGGUGAAAGUGGGA	1762	UCCCACUUUCACCGUUCUG
siRNA 623	623	AGAACGGUGAAAGUGGGAG	1763	CUCCCACUUUCACCGUUCU
siRNA 624	624	GAACGGUGAAAGUGGGAGA	1764	UCUCCCACUUUCACCGUUC
siRNA 625	625	AACGGUGAAAGUGGGAGAU	1765	AUCUCCCACUUUCACCGUU
siRNA 626	626	ACGGUGAAAGUGGGAGAU	1766	UAUCUCCCACUUUCACCGU
siRNA 627	627	CGGUGAAAGUGGGAGAUAC	1767	GUUUCUCCCACUUUCACCG
siRNA 628	628	GGUGAAAGUGGGAGAUACA	1768	UGUAUCUCCCACUUUCACC
siRNA 629	629	GUGAAAGUGGGAGAUACAU	1769	AUGUAUCUCCCACUUUCAC
siRNA 630	630	UGAAAGUGGGAGAUACAUU	1770	AAUGUAUCUCCCACUUUCA
siRNA 631	631	GAAAGUGGGAGAUACAUUG	1771	CAAUGUAUCUCCCACUUUC
siRNA 632	632	AAAGUGGGAGAUACAUUGG	1772	CCAAUGUAUCUCCCACUUU
siRNA 633	633	AAGUGGGAGAUACAUUGGA	1773	UCCAAUGUAUCUCCCACUU
siRNA 634	634	AGUGGGAGAUACAUUGGAU	1774	AUCCAAUGUAUCUCCCACU
siRNA 635	635	GUGGGAGAUACAUUGGAUC	1775	GAUCCAAUGUAUCUCCCAC
siRNA 636	636	UGGGAGAUACAUUGGAUCU	1776	AGAUCCAAUGUAUCUCCCA
siRNA 637	637	GGGAGAUACAUUGGAUCUU	1777	AAGAUCCAAUGUAUCUCCC
siRNA 638	638	GGAGAUACAUUGGAUCUUC	1778	GAAGAUCCAAUGUAUCUCC
siRNA 639	639	GAGAUACAUUGGAUCUUCU	1779	AGAAGAUCCAAUGUAUCUC
siRNA 640	640	AGAUACAUUGGAUCUUCUC	1780	GAGAAGAUCCAAUGUAUCU
siRNA 641	641	GAUACAUUGGAUCUUCUCA	1781	UGAGAAGAUCCAAUGUAUC
siRNA 642	642	AUACAUUGGAUCUUCUCAU	1782	AUGAGAAGAUCCAAUGUAU
siRNA 643	643	UACAUUGGAUCUUCUCAU	1783	AAUGAGAAGAUCCAAUGUA
siRNA 644	644	ACAUUGGAUCUUCUCAUUG	1784	CAAUGAGAAGAUCCAAUGU

siRNA 645	645	CAUUGGAUCUUCUCAUUGG	1785	CCAAUGAGAAGAUCCAAUG
siRNA 646	646	AUUGGAUCUUCUCAUUGGA	1786	UCCAAUGAGAAGAUCCAAU
siRNA 647	647	UUGGAUCUUCUCAUUGGAG	1787	CUCCAAUGAGAAGAUCCAA
siRNA 648	648	UGGAUCUUCUCAUUGGAGA	1788	UCUCCAAUGAGAAGAUCCA
siRNA 649	649	GGAUCUUCUCAUUGGAGAG	1789	CUCUCCAAUGAGAAGAUC
siRNA 650	650	GAUCUUCUCAUUGGAGAGG	1790	CCUCUCCAAUGAGAAGAUC
siRNA 651	651	AUCUUCUCAUUGGAGAGGA	1791	UCCUCUCCAAUGAGAAGAU
siRNA 652	652	UCUUCUCAUUGGAGAGGAU	1792	AUCCUCUCCAAUGAGAAGA
siRNA 653	653	CUUCUCAUUGGAGAGGAUA	1793	UAUCCUCUCCAAUGAGAAG
siRNA 654	654	UUCUCAUUGGAGAGGAUAA	1794	UUAUCCUCUCCAAUGAGAA
siRNA 655	655	UCUCAUUGGAGAGGAUAAA	1795	UUUAUCCUCUCCAAUGAGA
siRNA 656	656	CUCAUUGGAGAGGAUAAAG	1796	CUUUAUCCUCUCCAAUGAG
siRNA 657	657	UCAUUGGAGAGGAUAAAGA	1797	UCUUUAUCCUCUCCAAUGA
siRNA 658	658	CAUUGGAGAGGAUAAAGAA	1798	UUCUUUAUCCUCUCCAAUG
siRNA 659	659	AUUGGAGAGGAUAAAGAAAG	1799	CUUCUUUAUCCUCUCCAAU
siRNA 660	660	UUGGAGAGGAUAAAGAAAGC	1800	GCUUCUUUAUCCUCUCCAA
siRNA 661	661	UGGAGAGGAUAAAGAAAGCA	1801	UGCUUCUUUAUCCUCUCCA
siRNA 662	662	GGAGAGGAUAAAGAAAGCAG	1802	CUGCUUCUUUAUCCUCUCC
siRNA 663	663	GAGAGGAUAAAGAAAGCAGG	1803	CCUGCUUCUUUAUCCUCUC
siRNA 664	664	AGAGGAUAAAGAAAGCAGGA	1804	UCCUGCUUCUUUAUCCUCU
siRNA 665	665	GAGGAUAAAGAAAGCAGGAA	1805	UUCUGCUUCUUUAUCCUC
siRNA 666	666	AGGAUAAAGAAAGCAGGAAC	1806	GUUCUGCUUCUUUAUCCU
siRNA 667	667	GGAUAAAGAAAGCAGGAACA	1807	UGUUCUGCUUCUUUAUCC
siRNA 668	668	GAUAAAGAAAGCAGGAACAG	1808	CUGUUCUGCUUCUUUAUCC
siRNA 669	669	AUAAAGAAAGCAGGAACAGA	1809	UCUGUUCUGCUUCUUUAU
siRNA 670	670	UAAAGAAAGCAGGAACAGAG	1810	CUCUGUUCUGCUUCUUUA
siRNA 671	671	AAAGAAAGCAGGAACAGAGA	1811	UCUCUGUUCUGCUUCUUU
siRNA 672	672	AAGAAAGCAGGAACAGAGAC	1812	GUUCUGUUCUGCUUCUU
siRNA 673	673	AGAAGCAGGAACAGAGACA	1813	UGUCUGUUCUGCUUCU
siRNA 674	674	GAAGCAGGAACAGAGACAG	1814	CUGUCUGUUCUGCUUC
siRNA 675	675	AAGCAGGAACAGAGACAGU	1815	ACUGUCUGUUCUGCUU
siRNA 676	676	AGCAGGAACAGAGACAGUU	1816	AACUGUCUGUUCUGCU
siRNA 677	677	GCAGGAACAGAGACAGUUA	1817	UAACUGUCUGUUCUGC
siRNA 678	678	CAGGAACAGAGACAGUUAU	1818	AUAACUGUCUGUUCUG
siRNA 679	679	AGGAACAGAGACAGUUAUG	1819	CAUAACUGUCUGUUCU
siRNA 680	680	GGAACAGAGACAGUUAUGC	1820	GCAUAACUGUCUGUUC
siRNA 681	681	GAACAGAGACAGUUAUGCG	1821	CGCAUAACUGUCUGUUC
siRNA 682	682	AACAGAGACAGUUAUGCGG	1822	CCGCAUAACUGUCUGU
siRNA 683	683	ACAGAGACAGUUAUGCGGA	1823	UCCGCAUAACUGUCUGU
siRNA 684	684	CAGAGACAGUUAUGCGGAU	1824	AUCCGCAUAACUGUCUG
siRNA 685	685	AGAGACAGUUAUGCGGAUU	1825	AAUCCGCAUAACUGUCU
siRNA 686	686	GAGACAGUUAUGCGGAUUC	1826	GAAUCCGCAUAACUGUC
siRNA 687	687	AGACAGUUAUGCGGAUUCU	1827	AGAAUCCGCAUAACUGUC
siRNA 688	688	GACAGUUAUGCGGAUUCUC	1828	GAGAAUCCGCAUAACUG
siRNA 689	689	ACAGUUAUGCGGAUUCUCU	1829	AGAGAAUCCGCAUAACUG
siRNA 690	690	CAGUUAUGCGGAUUCUCUU	1830	AAGAGAAUCCGCAUAAC
siRNA 691	691	AGUUAUGCGGAUUCUCUUG	1831	CAAGAGAAUCCGCAUAAC
siRNA 692	692	GUUAUGCGGAUUCUCUGA	1832	UCAAGAGAAUCCGCAUA
siRNA 693	693	UUAUGCGGAUUCUCUGAA	1833	UUCAAGAGAAUCCGCAUA
siRNA 694	694	UAUGCGGAUUCUCUGAAA	1834	UUUCAAGAGAAUCCGCAU
siRNA 695	695	AUGCGGAUUCUCUGAAAA	1835	UUUUCAAGAGAAUCCGCA
siRNA 696	696	UGCGGAUUCUCUGAAAAA	1836	UUUUUCAAGAGAAUCCGCA

siRNA 697	697	GCGGAUUCUCUUGAAAAAA	1837	UUUUUUCAAGAGAAUCCGC
siRNA 698	698	CGGAUUCUCUUGAAAAAAG	1838	CUUUUUUCAAGAGAAUCCG
siRNA 699	699	GGAUUCUCUUGAAAAAAGU	1839	ACUUUUUUCAAGAGAAUCC
siRNA 700	700	GAUUCUCUUGAAAAAAGUG	1840	CACUUUUUUCAAGAGAAUC
siRNA 701	701	AUUCUCUUGAAAAAAGUGU	1841	ACACUUUUUUCAAGAGAAU
siRNA 702	702	UUCUCUUGAAAAAAGUGUU	1842	AACACUUUUUUCAAGAGAA
siRNA 703	703	UCUCUUGAAAAAAGUGUUU	1843	AAACACUUUUUUCAAGAGA
siRNA 704	704	CUCUUGAAAAAAGUGUUUG	1844	CAAAACACUUUUUCAAGAG
siRNA 705	705	UCUUGAAAAAAGUGUUUGA	1845	UCAAACACUUUUUCAAGA
siRNA 706	706	CUUGAAAAAAGUGUUUGAA	1846	UUCAAACACUUUUUCAAG
siRNA 707	707	UUGAAAAAAGUGUUUGAAG	1847	CUUCAAAACACUUUUUCA
siRNA 708	708	UGAAAAAAGUGUUUGAAGA	1848	UCUUCAAACACUUUUUCA
siRNA 709	709	GAAAAAAGUGUUUGAAGAG	1849	CUCUUCAAACACUUUUUC
siRNA 710	710	AAAAAAGUGUUUGAAGAGA	1850	UCUCUUCAAACACUUUUU
siRNA 711	711	AAAAAGUGUUUGAAGAGAA	1851	UUCUCUUCAAACACUUUU
siRNA 712	712	AAAAGUGUUUGAAGAGAAG	1852	CUUCUCUUCAAACACUUUU
siRNA 713	713	AAAGUGUUUGAAGAGAAGA	1853	UCUUCUCUUCAAACACUUU
siRNA 714	714	AAGUGUUUGAAGAGAAGAC	1854	GUCUUCUCUUCAAACACUU
siRNA 715	715	AGUGUUUGAAGAGAAGACU	1855	AGUCUUCUCUUCAAACACU
siRNA 716	716	GUGUUUGAAGAGAAGACUG	1856	CAGUCUUCUCUUCAAACAC
siRNA 717	717	UGUUUGAAGAGAAGACUGA	1857	UCAGUCUUCUCUUCAAACA
siRNA 718	718	GUUUGAAGAGAAAGACUGAA	1858	UUCAGUCUUCUCUUCAAAC
siRNA 719	719	UUUGAAGAGAAGACUGAAA	1859	UUUCAGUCUUCUCUUCAAA
siRNA 720	720	UUGAAGAGAAGACUGAAAG	1860	CUUUCAGUCUUCUCUUCAA
siRNA 721	721	UGAAGAGAAGACUGAAAGU	1861	ACUUCAGUCUUCUCUUCA
siRNA 722	722	GAAGAGAAGACUGAAAGUG	1862	CACUUUCAGUCUUCUCUUC
siRNA 723	723	AAGAGAAGACUGAAAGUGA	1863	UCACUUUCAGUCUUCUCUU
siRNA 724	724	AGAGAAGACUGAAAAGUGAA	1864	UUCACUUUCAGUCUUCUCU
siRNA 725	725	GAGAAGACUGAAAGUGAAA	1865	UUUCACUUUCAGUCUUCUC
siRNA 726	726	AGAAGACUGAAAAGUGAAAA	1866	UUUUCACUUUCAGUCUUCU
siRNA 727	727	GAAGACUGAAAAGUGAAAAA	1867	UUUUUCACUUUCAGUCUUC
siRNA 728	728	AAGACUGAAAAGUGAAAAAU	1868	AUUUUUCACUUUCAGUCUU
siRNA 729	729	AGACUGAAAAGUGAAAAUA	1869	UAUUUUUCACUUUCAGUCU
siRNA 730	730	GACUGAAAAGUGAAAAAUAC	1870	GUUUUUUCACUUUCAGUC
siRNA 731	731	ACUGAAAAGUGAAAAAUACA	1871	UGUAAUUUUUCACUUUCAGU
siRNA 732	732	CUGAAAAGUGAAAAAUACAG	1872	CUGUAAUUUUUCACUUUCAG
siRNA 733	733	UGAAAAGUGAAAAAUACAGA	1873	UCUGUAAUUUUUCACUUUCA
siRNA 734	734	GAAAGUGAAAAAUACAGAG	1874	CUCUGUAAUUUUUCACUUUC
siRNA 735	735	AAAGUGAAAAAUACAGAGU	1875	ACUCUGUAAUUUUUCACUUU
siRNA 736	736	AAGUGAAAAAUACAGAGUG	1876	CACUCUGUAAUUUUUCACUU
siRNA 737	737	AGUGAAAAAUACAGAGUGG	1877	CCACUCUGUAAUUUUUCACU
siRNA 738	738	GUGAAAAAUACAGAGUGGU	1878	ACCACUCUGUAAUUUUUCAC
siRNA 739	739	UGAAAAAUACAGAGUGGUG	1879	CACCACUCUGUAAUUUUUCA
siRNA 740	740	GAAAAAUACAGAGUGGUGU	1880	ACACCACUCUGUAAUUUUUC
siRNA 741	741	AAAAAUACAGAGUGGUGUU	1881	AACACCACUCUGUAAUUUU
siRNA 742	742	AAAAUACAGAGUGGUGUUA	1882	UAACACCACUCUGUAAUUUU
siRNA 743	743	AAAUACAGAGUGGUGUUAC	1883	GUAAACCACUCUGUAAUUUU
siRNA 744	744	AAUACAGAGUGGUGUUACG	1884	CGUAAACCACUCUGUAAUU
siRNA 745	745	AUACAGAGUGGUGUUACGG	1885	CCGUAAACCACUCUGUAAU
siRNA 746	746	UACAGAGUGGUGUUACGGC	1886	GCCGUAAACCACUCUGUA
siRNA 747	747	ACAGAGUGGUGUUACGGCG	1887	CGCCGUAAACCACUCUGU
siRNA 748	748	CAGAGUGGUGUUACGGCGG	1888	CCGCCGUAAACCACUCUG

siRNA 749	749	AGAGUGGUGUACGGCGGU	1889	ACCGCCGUAACACCACUCU
siRNA 750	750	GAGUGGUGUACGGCGGUG	1890	CACCGCCGUAACACCACUC
siRNA 751	751	AGUGGUGUACGGCGGUGG	1891	CCACCGCCGUAACACCACU
siRNA 752	752	GUGGUGUACGGCGGUGGA	1892	UCCACCGCCGUAACACCAC
siRNA 753	753	UGGUGUACGGCGGUGGAA	1893	UUCACCGCCGUAACACCA
siRNA 754	754	GGUGUACGGCGGUGGAAA	1894	UUUCCACCGCCGUAACACC
siRNA 755	755	GUGUACGGCGGUGGAAAA	1895	UUUUCCACCGCCGUAACAC
siRNA 756	756	UGUACGGCGGUGGAAAAAG	1896	CUUUUCCACCGCCGUAACA
siRNA 757	757	GUUACGGCGGUGGAAAAAGU	1897	ACUUUUCCACCGCCGUAAC
siRNA 758	758	UUACGGCGGUGGAAAAAGUU	1898	AACUUUUCACCGCCGUA
siRNA 759	759	UACGGCGGUGGAAAAAGUUU	1899	AAACUUUUCCACCGCCGUA
siRNA 760	760	ACGGCGGUGGAAAAAGUUUA	1900	UAAACUUUCCACCGCCGU
siRNA 761	761	CGGCGGUGGAAAAAGUUUAA	1901	UUAAACUUUCCACCGCCG
siRNA 762	762	GGCGGUGGAAAAAGUUUAAA	1902	UUUAAACUUUCCACCGCC
siRNA 763	763	GCGGUGGAAAAAGUUUAAAG	1903	CUUUAAACUUUCCACCGC
siRNA 764	764	CGGUGGAAAAAGUUUAAAGU	1904	ACUUUAAACUUUCCACCG
siRNA 765	765	GGUGGAAAAAGUUUAAAGUU	1905	AACUUUAAACUUUCCACC
siRNA 766	766	GUGGAAAAAGUUUAAAGUUG	1906	CAACUUUAAACUUUCCAC
siRNA 767	767	UGGAAAAAGUUUAAAGUUGC	1907	GCAACUUUAAACUUUCCA
siRNA 768	768	GGAAAAAGUUUAAAGUUGCC	1908	GGCAACUUUAAACUUUCC
siRNA 769	769	GAAAAAGUUUAAAGUUGCCU	1909	AGGCAACUUUAAACUUUC
siRNA 770	770	AAAAGUUUAAAGUUGCCUA	1910	UAGGCAACUUUAAACUUUU
siRNA 771	771	AAAGUUUAAAGUUGCCUAA	1911	UUAGGCAACUUUAAACUUU
siRNA 772	772	AAGUUUAAAGUUGCCUAAG	1912	CUUAGGCAACUUUAAACUU
siRNA 773	773	AGUUUAAAGUUGCCUAAGA	1913	UCUUAGGCAACUUUAAACU
siRNA 774	774	GUUUAAAGUUGCCUAAGAA	1914	UUCUUAGGCAACUUUAAAC
siRNA 775	775	UUUAAAGUUGCCUAAGAAG	1915	CUUCUUAGGCAACUUUAAA
siRNA 776	776	UUAAGUUGCCUAAGAAGA	1916	UCUUUUAGGCAACUUUAA
siRNA 777	777	UAAAGUUGCCUAAGAAGAG	1917	CUCUUCUUAGGCAACUUUA
siRNA 778	778	AAAGUUGCCUAAGAAGAGA	1918	UCUCUUUUAGGCAACUUU
siRNA 779	779	AAGUUGCCUAAGAAGAGAA	1919	UUCUCUUCUUAGGCAACUU
siRNA 780	780	AGUUGCCUAAGAAGAGAAU	1920	AUUCUCUUUUAGGCAACU
siRNA 781	781	GUUGCCUAAGAAGAGAAUG	1921	CAUUCUCUUCUUAGGCAAC
siRNA 782	782	UUGCCUAAGAAGAGAAUGU	1922	ACAUUCUCUUUUAGGCAA
siRNA 783	783	UGCCUAAGAAGAGAAUGUC	1923	GACAUUCUUCUUAGGCA
siRNA 784	784	GCCUAAGAAGAGAAUGUCU	1924	AGACAUUCUCUUUUAGGC
siRNA 785	785	CCUAAGAAGAGAAUGUCUA	1925	UAGACAUUCUUCUUUAGG
siRNA 786	786	CUAAGAAGAGAAUGUCUAA	1926	UUAGACAUUCUCUUUUAG
siRNA 787	787	UAAGAAGAGAAUGUCUAAA	1927	UUUAGACAUUCUUCUUUA
siRNA 788	788	AAGAAGAGAAUGUCUAAAU	1928	AUUUAGACAUUCUCUUCU
siRNA 789	789	AGAAGAGAAUGUCUAAUA	1929	UAUUUAGACAUUCUUCU
siRNA 790	790	GAAGAGAAUGUCUAAAUAA	1930	UUUUUAGACAUUCUCUUC
siRNA 791	791	AAGAGAAUGUCUAAAUAAA	1931	UUUUAUUUAGACAUUCUU
siRNA 792	792	AGAGAAUGUCUAAAUAAAU	1932	AUUUAUUUAGACAUUCUCU
siRNA 793	793	GAGAAUGUCUAAAUAAAUUG	1933	CAUUUAUUUAGACAUUCUC
siRNA 794	794	AGAAUGUCUAAAUAAAUUGG	1934	CCAUUUUUUAGACAUUCU
siRNA 795	795	GAAUGUCUAAAUAAAUUGGA	1935	UCCAUUUUUAGACAUUC
siRNA 796	796	AAUGUCUAAAUAAAUUGGAU	1936	AUCCAUUUUUUAGACAUU
siRNA 797	797	AUGUCUAAAUAAAUUGGAUU	1937	AAUCCAUUUUUUAGACAU
siRNA 798	798	UGUCUAAAUAAAUUGGAUUG	1938	CAAUCCAUUUUUUAGACA
siRNA 799	799	GUCUAAAUAAAUUGGAUUGC	1939	GCAAUCCAUUUUUUAGAC
siRNA 800	800	UCUAAAUAAAUUGGAUUGC	1940	AGCAAUCCAUUUUUUUAGA

siRNA 801	801	CUAAAUAAAUGGAUUGCUU	1941	AAGCAAUCCAUUUAUUUAG
siRNA 802	802	UAAAUAAAUGGAUUGCUUU	1942	AAAGCAAUCCAUUUAUUUA
siRNA 803	803	AAAUAAAUGGAUUGCUUUU	1943	AAAAGCAAUCCAUUUAUUU
siRNA 804	804	AAUAAAUGGAUUGCUUUUU	1944	AAAAAGCAAUCCAUUUAUU
siRNA 805	805	AUAAAUGGAUUGCUUUUUA	1945	UAAAAAGCAAUCCAUUUAU
siRNA 806	806	UAAAUGGAUUGCUUUUUAG	1946	CUAAAAAGCAAUCCAUUUA
siRNA 807	807	AAAUGGAUUGCUUUUUAGC	1947	GCUAAAAAGCAAUCCAUUU
siRNA 808	808	AAUGGAUUGCUUUUUAGCA	1948	UGC UAAAAAGCAAUCCAUU
siRNA 809	809	AUGGAUUGCUUUUUAGCAA	1949	UUGCUAAAAAGCAAUCCA
siRNA 810	810	UGGAUUGCUUUUUAGCAAU	1950	AUUGCUAAAAAGCAAUCCA
siRNA 811	811	GGAUUGCUUUUUAGCAAUA	1951	UAUUGCUAAAAAGCAAUCC
siRNA 812	812	GAUUGCUUUUUAGCAAUAG	1952	CUAUUGCUAAAAAGCAAUC
siRNA 813	813	AUUGCUUUUUAGCAAUAGA	1953	UCUAUUGCUAAAAAGCAAU
siRNA 814	814	UUGCUUUUUAGCAAUAGAG	1954	CUCUAUUGCUAAAAAGCAA
siRNA 815	815	UGCUUUUUAGCAAUAGAGC	1955	GCUCUAUUGCUAAAAAGCAA
siRNA 816	816	GCUUUUUAGCAAUAGAGCU	1956	AGCUCUAUUGCUAAAAAGC
siRNA 817	817	CUUUUUAGCAAUAGAGCUG	1957	CAGCUCUAUUGCUAAAAAG
siRNA 818	818	UUUUUAGCAAUAGAGCUGC	1958	GCAGCUCUAUUGCUAAAAA
siRNA 819	819	UUUUAGCAAUAGAGCUGCU	1959	AGCAGCUCUAUUGCUAAAA
siRNA 820	820	UUUAGCAAUAGAGCUGCUU	1960	AAGCAGCUCUAUUGCUAAA
siRNA 821	821	UUAGCAAUAGAGCUGCUUU	1961	AAAGCAGCUCUAUUGCUAA
siRNA 822	822	UAGCAAUAGAGCUGCUUUC	1962	GAAAGCAGCUCUAUUGCUA
siRNA 823	823	AGCAAUAGAGCUGCUUUCU	1963	AGAAAGCAGCUCUAUUGCU
siRNA 824	824	GCAAUAGAGCUGCUUUCUA	1964	UAGAAAGCAGCUCUAUUGC
siRNA 825	825	CAAUAGAGCUGCUUUCUAG	1965	CUAGAAAGCAGCUCUAUUG
siRNA 826	826	AAUAGAGCUGCUUUCUAGU	1966	ACUAGAAAGCAGCUCUAUU
siRNA 827	827	AUAGAGCUGCUUUCUAGUG	1967	CACUAGAAAGCAGCUCUAU
siRNA 828	828	UAGAGCUGCUUUCUAGUGG	1968	CCACUAGAAAGCAGCUCUA
siRNA 829	829	AGAGCUGCUUUCUAGUGGU	1969	ACCACUAGAAAGCAGCUCU
siRNA 830	830	GAGCUGCUUUCUAGUGGUA	1970	UACCACUAGAAAGCAGCUC
siRNA 831	831	AGCUGCUUUCUAGUGGUAA	1971	UUACCACUAGAAAGCAGCU
siRNA 832	832	GCUGCUUUCUAGUGGUAAA	1972	UUUACCACUAGAAAGCAGC
siRNA 833	833	CUGCUUUCUAGUGGUAAAG	1973	CUUUACCACUAGAAAGCAG
siRNA 834	834	UGC UUCUAGUGGUAAAGG	1974	CCUUUACCACUAGAAAGCAA
siRNA 835	835	GCUUUCUAGUGGUAAAGGA	1975	UCCUUUACCACUAGAAAGC
siRNA 836	836	CUUUCUAGUGGUAAAGGAA	1976	UUCUUUACCACUAGAAAG
siRNA 837	837	UUUCUAGUGGUAAAGGAAG	1977	CUUCUUUACCACUAGAAA
siRNA 838	838	UUCUAGUGGUAAAGGAAGG	1978	CCUUCUUUACCACUAGAA
siRNA 839	839	UCUAGUGGUAAAGGAAGGG	1979	CCCUUCUUUACCACUAGA
siRNA 840	840	CUAGUGGUAAAGGAAGGGG	1980	CCCCUUCUUUACCACUAG
siRNA 841	841	UAGUGGUAAAGGAAGGGGU	1981	ACCCCUUCUUUACCACUA
siRNA 842	842	AGUGGUAAAGGAAGGGGUC	1982	GACCCCUUCUUUACCACU
siRNA 843	843	GUGGUAAAGGAAGGGGUCA	1983	UGACCCCUUCUUUACCAC
siRNA 844	844	UGGUAAAGGAAGGGGUCAC	1984	GUGACCCCUUCUUUACCA
siRNA 845	845	GGUAAAGGAAGGGGUCACC	1985	GGUGACCCCUUCUUUACC
siRNA 846	846	GUAAAGGAAGGGGUCACCU	1986	AGGUGACCCCUUCUUUAC
siRNA 847	847	UAAAGGAAGGGGUCACCU	1987	CAGGUGACCCCUUCUUUA
siRNA 848	848	AAAGGAAGGGGUCACCUA	1988	UCAGGUGACCCCUUCUUU
siRNA 849	849	AAGGAAGGGGUCACCUGAA	1989	UUCAGGUGACCCCUUCUU
siRNA 850	850	AGGAAGGGGUCACCUGAAA	1990	UUUCAGGUGACCCCUUCCU
siRNA 851	851	GGAAGGGGUCACCUGAAAA	1991	UUUUAGGUGACCCCUUCC
siRNA 852	852	GAAGGGGUCACCUGAAAAA	1992	UUUUUAGGUGACCCCUUCC

siRNA 853	853	AAGGGGUCACCUGAAAAAU	1993	AUUUUUCAGGUGACCCCUU
siRNA 854	854	AGGGGUCACCUGAAAAUA	1994	UAUUUUUCAGGUGACCCCU
siRNA 855	855	GGGGUCACCUGAAAAUAG	1995	CUAUUUUCAGGUGACCCC
siRNA 856	856	GGGUCACCUGAAAAUAGG	1996	CCUAUUUUUCAGGUGACCC
siRNA 857	857	GGUCACCUGAAAAUAGGA	1997	UCCUAUUUUUCAGGUGACC
siRNA 858	858	GUCACCUGAAAAUAGGAC	1998	GUCCUAUUUUUCAGGUGAC
siRNA 859	859	UCACCUGAAAAUAGGACA	1999	UGUCCUAUUUUUCAGGUGA
siRNA 860	860	CACCUGAAAAUAGGACAU	2000	AUGUCCUAUUUUUCAGGUG
siRNA 861	861	ACCUGAAAAUAGGACAUU	2001	AAUGUCCUAUUUUUCAGGU
siRNA 862	862	CCUGAAAAUAGGACAUUU	2002	AAAUGUCCUAUUUUUCAGG
siRNA 863	863	CUGAAAAUAGGACAUUUU	2003	AAAAUGUCUAUUUUUCAG
siRNA 864	864	UGAAAAUAGGACAUUUUU	2004	AAAAAUGUCCUAUUUUUCA
siRNA 865	865	GAAAAUAGGACAUUUUUA	2005	UAAAAUGUCCUAUUUUUC
siRNA 866	866	AAAAUAGGACAUUUUUUAU	2006	AUAAAAUGUCCUAUUUUU
siRNA 867	867	AAAAUAGGACAUUUUUUAU	2007	AAUAAAAUGUCCUAUUUU
siRNA 868	868	AAAUAGGACAUUUUUUAUA	2008	UAUAAAAUGUCCUAUUUU
siRNA 869	869	AAUAGGACAUUUUUUAUA	2009	UUAUAAAAUGUCCUAUU
siRNA 870	870	AUAGGACAUUUUUUAUAAA	2010	UUUAAUAAAAUGUCCUAU
siRNA 871	871	UAGGACAUUUUUUAUAAA	2011	UUUUAAUAAAAUGUCCUA
siRNA 872	872	AGGACAUUUUUUAUAAAAU	2012	AUUUUAAUAAAAUGUCCU
siRNA 873	873	GGACAUUUUUUAUAAAAUA	2013	UAUUUUAAUAAAAUGUCC
siRNA 874	874	GACAUUUUUUAUAAAAUAA	2014	UUAUUUUAAUAAAAUGUC
siRNA 875	875	ACAUUUUUUAUAAAAUAAA	2015	UUUAUUUUAAUAAAAUGU
siRNA 876	876	CAUUUUUAUAAAAUAAAG	2016	CUUUUAUUUAUAAAAUG
siRNA 877	877	AUUUUUAUAAAAUAAAGU	2017	ACUUUAUUUUAAUAAAAU
siRNA 878	878	UUUUUAUAAAAUAAAGUU	2018	AACUUUAUUUAUAAAAA
siRNA 879	879	UUUUUAUAAAAUAAAGUUC	2019	GAACUUUAUUUUAAUAAA
siRNA 880	880	UUUAUUAAAAUAAAGUUCU	2020	AGAACUUUAUUUAAUAAA
siRNA 881	881	UUAUUAAAAUAAAGUUCUC	2021	GAGAACUUUAUUUUAAUA
siRNA 882	882	UAUUAAAAUAAAGUUCUCU	2022	AGAGAACUUUAUUUUAAUA
siRNA 883	883	AUUAAAAUAAAGUUCUCU	2023	AAGAGAACUUUAUUUUAAU
siRNA 884	884	UUAAAAUAAAGUUCUCUA	2024	UAAGAGAACUUUAUUUUAA
siRNA 885	885	UAAAAUAAAGUUCUCUAG	2025	CUAAGAGAACUUUAUUUU
siRNA 886	886	AAAAUAAAGUUCUCUAGC	2026	GCUAAGAGAACUUUAUUUU
siRNA 887	887	AAAUAAAGUUCUCUAGCG	2027	CGCUAAGAGAACUUUAUUU
siRNA 888	888	AAUAAAGUUCUCUAGCGU	2028	ACGCUAAGAGAACUUUAUU
siRNA 889	889	AUAAGUUCUCUAGCGUU	2029	AACGCUAAGAGAACUUUAU
siRNA 890	890	UAAAGUUCUCUAGCGUUU	2030	AAACGCUAAGAGAACUUUA
siRNA 891	891	AAAGUUCUCUAGCGUUUG	2031	CAAACGCUAAGAGAACUUU
siRNA 892	892	AAGUUCUCUAGCGUUUGU	2032	ACAAACGCUAAGAGAACUU
siRNA 893	893	AGUUCUCUAGCGUUUGUG	2033	CACAAACGCUAAGAGAACU
siRNA 894	894	GUUCUCUAGCGUUUGUGG	2034	CCACAAACGCUAAGAGAAC
siRNA 895	895	UUCUCUAGCGUUUGUGGA	2035	UCCACAAACGCUAAGAGAA
siRNA 896	896	UCUCUAGCGUUUGUGGAA	2036	UUCACAAACGCUAAGAGAA
siRNA 897	897	CUCUAGCGUUUGUGGAAU	2037	AUUCACAAACGCUAAGAG
siRNA 898	898	UCUAGCGUUUGUGGAAUC	2038	GAUUCACAAACGCUAAGA
siRNA 899	899	CUUAGCGUUUGUGGAAUCU	2039	AGAUUCACAAACGCUAAG
siRNA 900	900	UUAGCGUUUGUGGAAUCUG	2040	CAGAUUCACAAACGCUAA
siRNA 901	901	UAGCGUUUGUGGAAUCUGC	2041	GCAGAUUCACAAACGCUA
siRNA 902	902	AGCGUUUGUGGAAUCUGCC	2042	GGCAGAUUCACAAACGCU
siRNA 903	903	GCGUUUGUGGAAUCUGCCG	2043	CGGCAGAUUCACAAACGCG
siRNA 904	904	CGUUUGUGGAAUCUGCCGA	2044	UCGGCAGAUUCACAAACG

siRNA 905	905	GUUUGUGGAAUCUGCCGAG	2045	CUCGGCAGAUUCCACAAAC
siRNA 906	906	UUUGUGGAAUCUGCCGAGC	2046	GCUCGGCAGAUUCCACAAA
siRNA 907	907	UUGUGGAAUCUGCCGAGCC	2047	GGCUCGGCAGAUUCCACAA
siRNA 908	908	UGUGGAAUCUGCCGAGCCA	2048	UGGCUCGGCAGAUUCCACA
siRNA 909	909	GUGGAAUCUGCCGAGCCAU	2049	AUGGCUCGGCAGAUUCCAC
siRNA 910	910	UGGAAUCUGCCGAGCCAUU	2050	AAUGGCUCGGCAGAUUCCA
siRNA 911	911	GGAAUCUGCCGAGCCAUUU	2051	AAAUGGCUCGGCAGAUUCC
siRNA 912	912	GAAUCUGCCGAGCCAUUUU	2052	AAAAUGGCUCGGCAGAUUC
siRNA 913	913	AAUCUGCCGAGCCAUUUUG	2053	CAAAAUGGCUCGGCAGAUU
siRNA 914	914	AUCUGCCGAGCCAUUUUGU	2054	ACAAAUGGCUCGGCAGAU
siRNA 915	915	UCUGCCGAGCCAUUUUGUG	2055	CACAAAUGGCUCGGCAGAU
siRNA 916	916	CUGCCGAGCCAUUUUGUGG	2056	CCACAAAUGGCUCGGCAG
siRNA 917	917	UGCCGAGCCAUUUUGUGGA	2057	UCCACAAAUGGCUCGGCA
siRNA 918	918	GCCGAGCCAUUUUGUGGAA	2058	UUCACAAAUGGCUCGGC
siRNA 919	919	CCGAGCCAUUUUGUGGAAA	2059	UUUCACAAAUGGCUCGG
siRNA 920	920	CGAGCCAUUUUGUGGAAAU	2060	AUUUCCACAAAUGGCUCG
siRNA 921	921	GAGCCAUUUUGUGGAAAUU	2061	AAUUUCCACAAAUGGCUC
siRNA 922	922	AGCCAUUUUGUGGAAAUUG	2062	CAUUUCCACAAAUGGCU
siRNA 923	923	GCCAUUUUGUGGAAAUUGG	2063	CCAAUUUCCACAAAUGGC
siRNA 924	924	CCAUUUUGUGGAAAUUGGG	2064	CCCAUUUCCACAAAUGG
siRNA 925	925	CAUUUUGUGGAAAUUGGGA	2065	UCCCAUUUCCACAAAUG
siRNA 926	926	AUUUUGUGGAAAUUGGGAU	2066	AUCCCAUUUCCACAAAU
siRNA 927	927	UUUUGUGGAAAUUGGGAUC	2067	GAUCCCAUUUCCACAAA
siRNA 928	928	UUUGUGGAAAUUGGGAUCC	2068	GGAUCCCAUUUCCACAAA
siRNA 929	929	UUGUGGAAAUUGGGAUCCA	2069	UGGAUCCCAUUUCCACAA
siRNA 930	930	UGUGGAAAUUGGGAUCCAU	2070	AUGGAUCCCAUUUCCACA
siRNA 931	931	GUGGAAAUUGGGAUCCAUA	2071	UAUGGAUCCCAUUUCCAC
siRNA 932	932	UGGAAAUUGGGAUCCAUAU	2072	AUAUGGAUCCCAUUUCCA
siRNA 933	933	GGAAAUUGGGAUCCAUAUC	2073	GAUAUGGAUCCCAUUUCC
siRNA 934	934	GAAAUUGGGAUCCAUAUCU	2074	AGAUUAUGGAUCCCAUUUC
siRNA 935	935	AAAUUGGGAUCCAUAUCUG	2075	CAGAUUAUGGAUCCCAUUU
siRNA 936	936	AAUUGGGAUCCAUAUCUGG	2076	CCAGAUUAUGGAUCCCAUU
siRNA 937	937	AUUGGGAUCCAUAUCUGGA	2077	UCCAGAUUAUGGAUCCCAU
siRNA 938	938	UUGGGAUCCAUAUCUGGAG	2078	CUCCAGAUUAUGGAUCCCAA
siRNA 939	939	UGGGAUCCAUAUCUGGAGA	2079	UCUCAGAUUAUGGAUCCCA
siRNA 940	940	GGAUCCAUAUCUGGAGAC	2080	GUCUCCAGAUUAUGGAUCCC
siRNA 941	941	GGAUCCAUAUCUGGAGACA	2081	UGUCUCCAGAUUAUGGAUCC
siRNA 942	942	GAUCCAUAUCUGGAGACAC	2082	GUGUCUCCAGAUUAUGGAUC
siRNA 943	943	AUCCAUAUCUGGAGACACU	2083	AGUGUCUCCAGAUUAUGGAU
siRNA 944	944	UCCAUAUCUGGAGACACUU	2084	AAGUGUCUCCAGAUUAUGGA
siRNA 945	945	CCAUAUCUGGAGACACUUC	2085	GAAGUGUCUCCAGAUUAUGG
siRNA 946	946	CAUAUCUGGAGACACUUCC	2086	GGAAGUGUCUCCAGAUUAUG
siRNA 947	947	AUAUCUGGAGACACUUCCC	2087	GGGAAGUGUCUCCAGAUUAU
siRNA 948	948	UAUCUGGAGACACUUCCCA	2088	UGGGAAGUGUCUCCAGAUUA
siRNA 949	949	AUCUGGAGACACUUCCCAA	2089	UUGGGAAGUGUCUCCAGAU
siRNA 950	950	UCUGGAGACACUUCCCAAG	2090	CUUGGGAAGUGUCUCCAGA
siRNA 951	951	CUGGAGACACUUCCCAAGG	2091	CCUUGGGAAGUGUCUCCAG
siRNA 952	952	UGGAGACACUUCCCAAGGC	2092	GCCUUGGGAAGUGUCUCCA
siRNA 953	953	GGAGACACUUCCCAAGGCC	2093	GGCCUUGGGAAGUGUCUCC
siRNA 954	954	GAGACACUUCCCAAGGCCU	2094	AGGCCUUGGGAAGUGUCUC
siRNA 955	955	AGACACUUCCCAAGGCCUG	2095	CAGGCCUUGGGAAGUGUCU
siRNA 956	956	GACACUUCCCAAGGCCUGC	2096	GCAGGCCUUGGGAAGUGUC

siRNA 957	957	ACACUCCCAAGGCCUGCC	2097	GGCAGGCCUUGGGAAGUGU
siRNA 958	958	CACUCCCAAGGCCUGCCU	2098	AGGCAGGCCUUGGGAAGUG
siRNA 959	959	ACUCCCAAGGCCUGCCUC	2099	GAGGCAGGCCUUGGGAAGU
siRNA 960	960	CUUCCCAAGGCCUGCCUCA	2100	UGAGGCAGGCCUUGGGAAG
siRNA 961	961	UUCCCAAGGCCUGCCUCAC	2101	GUGAGGCAGGCCUUGGGA
siRNA 962	962	UCCCAAGGCCUGCCUCACC	2102	GGUGAGGCAGGCCUUGGGA
siRNA 963	963	CCCAAGGCCUGCCUCACCU	2103	AGGUAGGCAGGCCUUGGG
siRNA 964	964	CCAAGGCCUGCCUCACCUC	2104	GAGGUGAGGCAGGCCUUGG
siRNA 965	965	CAAGGCCUGCCUCACCUC	2105	GGAGGUAGGCAGGCCUUG
siRNA 966	966	AAGGCCUGCCUCACCUC	2106	UGGAGGUAGGCAGGCCU
siRNA 967	967	AGGCCUGCCUCACCUC	2107	GUGGAGGUAGGCAGGCCU
siRNA 968	968	GGCCUGCCUCACCUC	2108	GGUGAGGUAGGCAGGCC
siRNA 969	969	GCCUGCCUCACCUC	2109	GGGUGGAGGUAGGCAGGC
siRNA 970	970	CCUGCCUCACCUC	2110	GGGUGGAGGUAGGCAGG
siRNA 971	971	CUGCCUCACCUC	2111	GGGGUGGAGGUAGGCAG
siRNA 972	972	UGCCUCACCUC	2112	AGGGGUGGAGGUAGGCAG
siRNA 973	973	GCCUCACCUC	2113	CAGGGGUGGAGGUAGGC
siRNA 974	974	CCUCACCUC	2114	GCAGGGGUGGAGGUAGG
siRNA 975	975	CUCACCUC	2115	GGCAGGGGUGGAGGUGAG
siRNA 976	976	UCACCUC	2116	GGGCAGGGGUGGAGGUGA
siRNA 977	977	CACCUC	2117	UGGGCAGGGGUGGAGGUG
siRNA 978	978	ACCUC	2118	GUGGCAGGGGUGGAGGU
siRNA 979	979	CCUC	2119	GGUGGCAGGGGUGGAGG
siRNA 980	980	CUCC	2120	AGGUGGCAGGGGUGGAG
siRNA 981	981	UCC	2121	AAGGUGGCAGGGGUGGA
siRNA 982	982	CC	2122	CAAGGUGGCAGGGGUGG
siRNA 983	983	C	2123	UCAAGGUGGCAGGGGUG
siRNA 984	984	A	2124	AUCAAGGUGGCAGGGGUG
siRNA 985	985	C	2125	GAUCAAGGUGGCAGGGG
siRNA 986	986	C	2126	GGAUCAAGGUGGCAGGG
siRNA 987	987	C	2127	UGGAUCAAGGUGGCAGG
siRNA 988	988	C	2128	AUGGAUCAAGGUGGCAGG
siRNA 989	989	C	2129	CAUGGAUCAAGGUGGCAG
siRNA 990	990	U	2130	GCAUGGAUCAAGGUGGCAG
siRNA 991	991	G	2131	AGCAUGGAUCAAGGUGGC
siRNA 992	992	C	2132	GAGCAUGGAUCAAGGUGG
siRNA 993	993	C	2133	GGAGCAUGGAUCAAGGUGG
siRNA 994	994	C	2134	AGGAGCAUGGAUCAAGGUG
siRNA 995	995	A	2135	AAGGAGCAUGGAUCAAGGU
siRNA 996	996	C	2136	AAAGGAGCAUGGAUCAAGG
siRNA 997	997	C	2137	CAAAGGAGCAUGGAUCAAG
siRNA 998	998	U	2138	UCAAGGAGCAUGGAUCAAG
siRNA 999	999	U	2139	GUCAAAGGAGCAUGGAUCA
siRNA 1000	1000	G	2140	GGUCAAGGAGCAUGGAUC
siRNA 1001	1001	A	2141	AGGUCAAAGGAGCAUGGAU
siRNA 1002	1002	U	2142	GAGGUCAAAGGAGCAUGGA
siRNA 1003	1003	C	2143	GGAGGUCAAAGGAGCAUGG
siRNA 1004	1004	C	2144	AGGAGGUCAAAGGAGCAUG
siRNA 1005	1005	A	2145	GAGGAGGUCAAAGGAGCAU
siRNA 1006	1006	U	2146	CGAGGAGGUCAAAGGAGCA
siRNA 1007	1007	G	2147	ACGAGGAGGUCAAAGGAGC
siRNA 1008	1008	C	2148	CACGAGGAGGUCAAAGGAG

siRNA 1009	1009	UCCUUUGACCUCUCGUGU	2149	ACACGAGGAGGUCAAAGGA
siRNA 1010	1010	CCUUUGACCUCUCGUGUG	2150	CACACGAGGAGGUCAAAGG
siRNA 1011	1011	CUUUGACCUCUCGUGUGA	2151	UCACACGAGGAGGUCAAAG
siRNA 1012	1012	UUUGACCUCUCGUGUGAG	2152	CUCACACGAGGAGGUCAAA
siRNA 1013	1013	UUGACCUCUCGUGUGAGA	2153	UCUCACACGAGGAGGUCAA
siRNA 1014	1014	UGACCUCUCGUGUGAGAA	2154	UUCUCACACGAGGAGGUCA
siRNA 1015	1015	GACCUCUCGUGUGAGAAC	2155	GUUCUCACACGAGGAGGUC
siRNA 1016	1016	ACCUCCUCGUGUGAGAACC	2156	GGUUCUCACACGAGGAGGU
siRNA 1017	1017	CCUCCUCGUGUGAGAACCC	2157	GGGUUCUCACACGAGGAGG
siRNA 1018	1018	CUCCUCGUGUGAGAACCCC	2158	GGGGUUCUCACACGAGGAG
siRNA 1019	1019	UCCUCGUGUGAGAACCCCU	2159	AGGGGUUCUCACACGAGGA
siRNA 1020	1020	CCUCGUGUGAGAACCCCUU	2160	AAGGGGUUCUCACACGAGG
siRNA 1021	1021	CUCGUGUGAGAACCCCUUU	2161	AAAGGGGUUCUCACACGAG
siRNA 1022	1022	UCGUGUGAGAACCCCUUUG	2162	CAAAGGGGUUCUCACACGA
siRNA 1023	1023	CGUGUGAGAACCCCUUUGC	2163	GCAAAGGGGUUCUCACACG
siRNA 1024	1024	GUGUGAGAACCCCUUUGCC	2164	GGCAAAGGGGUUCUCACAC
siRNA 1025	1025	UGUGAGAACCCCUUUGCCA	2165	UGGCAAAGGGGUUCUCACA
siRNA 1026	1026	GUGAGAACCCCUUUGCCAG	2166	CUGGCAAAGGGGUUCUCAC
siRNA 1027	1027	UGAGAACCCCUUUGCCAGA	2167	UCUGGCAAAGGGGUUCUCA
siRNA 1028	1028	GAGAACCCCUUUGCCAGAG	2168	CUCUGGCAAAGGGGUUCUC
siRNA 1029	1029	AGAACCCCUUUGCCAGAGU	2169	ACUCUGGCAAAGGGGUUCU
siRNA 1030	1030	GAACCCCUUUGCCAGAGUG	2170	CACUCUGGCAAAGGGGUUC
siRNA 1031	1031	AACCCCUUUGCCAGAGUGA	2171	UCACUCUGGCAAAGGGGUU
siRNA 1032	1032	ACCCCUUUGCCAGAGUGAG	2172	CUCACUCUGGCAAAGGGGU
siRNA 1033	1033	CCCCUUGCCAGAGUGAGA	2173	UCUCACUCUGGCAAAGGGG
siRNA 1034	1034	CCCUUUGCCAGAGUGAGAC	2174	GUUCACUCUGGCAAAGGG
siRNA 1035	1035	CCUUGCCAGAGUGAGACG	2175	CGUCACUCUGGCAAAGG
siRNA 1036	1036	CUUUGCCAGAGUGAGACGU	2176	ACGUCACUCUGGCAAAG
siRNA 1037	1037	UUUGCCAGAGUGAGACGUG	2177	CACGUCACUCUGGCAAAA
siRNA 1038	1038	UUGCCAGAGUGAGACGUGU	2178	ACACGUCACUCUGGCAA
siRNA 1039	1039	UGCCAGAGUGAGACGUGUG	2179	CACACGUCACUCUGGCA
siRNA 1040	1040	GCCAGAGUGAGACGUGUGC	2180	GCACAGUCACUCUGGC
siRNA 1041	1041	CCAGAGUGAGACGUGUGCA	2181	UGCACACGUCACUCUGG
siRNA 1042	1042	CAGAGUGAGACGUGUGCAG	2182	CUGCACACGUCACUCUG
siRNA 1043	1043	AGAGUGAGACGUGUGCAGA	2183	UCUGCACACGUCACUCU
siRNA 1044	1044	GAGUGAGACGUGUGCAGAA	2184	UUCUGCACACGUCACUC
siRNA 1045	1045	AGUGAGACGUGUGCAGAAU	2185	AUUCGCACACGUCUCACU
siRNA 1046	1046	GUGAGACGUGUGCAGAAUG	2186	CAUUCGCACACGUCUCAC
siRNA 1047	1047	UGAGACGUGUGCAGAAUGA	2187	UCAUUCGCACACGUCUCA
siRNA 1048	1048	GAGACGUGUGCAGAAUGAA	2188	UUCAUUCGCACACGUCUC
siRNA 1049	1049	AGACGUGUGCAGAAUGAAC	2189	GUUCAUUCGCACACGUCU
siRNA 1050	1050	GACGUGUGCAGAAUGAACU	2190	AGUUCAUUCGCACACGUC
siRNA 1051	1051	ACGUGUGCAGAAUGAACUA	2191	UAGUUCAUUCGCACACGU
siRNA 1052	1052	CGUGUGCAGAAUGAACUAA	2192	UUAGUUCAUUCGCACACG
siRNA 1053	1053	GUGUGCAGAAUGAACUAAG	2193	CUUAGUUCAUUCGCACAC
siRNA 1054	1054	UGUGCAGAAUGAACUAAGC	2194	GCUUAGUUCAUUCGCACA
siRNA 1055	1055	GUGCAGAAUGAACUAAGCC	2195	GGCUUAGUUCAUUCGCAC
siRNA 1056	1056	UGCAGAAUGAACUAAGCCC	2196	GGGCUUAGUUCAUUCGCA
siRNA 1057	1057	GCAGAAUGAACUAAGCCCC	2197	GGGGCUUAGUUCAUUCGUC
siRNA 1058	1058	CAGAAUGAACUAAGCCCCA	2198	UGGGGCUUAGUUCAUUCUG
siRNA 1059	1059	AGAAUGAACUAAGCCCCAG	2199	CUGGGGCUUAGUUCAUUCU
siRNA 1060	1060	GAAUGAACUAAGCCCCAGA	2200	UCUGGGGCUUAGUUCAUUC

siRNA 1061	1061	AAUGAACUAAGCCCCAGAG	2201	CUCUGGGGCUUAGUUCAU
siRNA 1062	1062	AUGAACUAAGCCCCAGAGG	2202	CCUCUGGGGCUUAGUUCAU
siRNA 1063	1063	UGAACUAAGCCCCAGAGGG	2203	CCCUUGGGGCUUAGUUCA
siRNA 1064	1064	GAACUAAGCCCCAGAGGGU	2204	ACCCUCUGGGGCUUAGUUC
siRNA 1065	1065	AACUAAGCCCCAGAGGGUU	2205	AACCCUCUGGGGCUUAGUU
siRNA 1066	1066	ACUAAGCCCCAGAGGGUUU	2206	AAACCCUCUGGGGCUUAGU
siRNA 1067	1067	CUAAGCCCCAGAGGGUUUU	2207	AAAACCUCUGGGGCUUAG
siRNA 1068	1068	UAAGCCCCAGAGGGUUUUA	2208	UAAAACCUCUGGGGCUUA
siRNA 1069	1069	AAGCCCCAGAGGGUUUUA	2209	UUAAAACCUCUGGGGCUU
siRNA 1070	1070	AGCCCCAGAGGGUUUUAAU	2210	AUUAAAACCUCUGGGGCU
siRNA 1071	1071	GCCCCAGAGGGUUUUAAUG	2211	CAUUAAAACCUCUGGGGC
siRNA 1072	1072	CCCCAGAGGGUUUUAAUGG	2212	CCAUUAAAACCUCUGGGG
siRNA 1073	1073	CCCAGAGGGUUUUAAUGGC	2213	GCCAUUAAAACCUCUGGG
siRNA 1074	1074	CCAGAGGGUUUUAAUGGCU	2214	AGCCAUUAAAACCUCUGG
siRNA 1075	1075	CAGAGGGUUUUAAUGGCUU	2215	AAGCAUUAAAACCUCUG
siRNA 1076	1076	AGAGGGUUUUAAUGGCUUG	2216	CAAGCAUUAAAACCUCUC
siRNA 1077	1077	GAGGGUUUUAAUGGCUUGC	2217	GCAAGCAUUAAAACCUC
siRNA 1078	1078	AGGGUUUUAAUGGCUUGCC	2218	GGCAAGCAUUAAAACCCU
siRNA 1079	1079	GGGUUUUAAUGGCUUGCCU	2219	AGGCAAGCAUUAAAACCC
siRNA 1080	1080	GGUUUUAAUGGCUUGCCUG	2220	CAGGCAAGCAUUAAAAACC
siRNA 1081	1081	GUUUUAAUGGCUUGCCUGC	2221	GCAGGCAAGCAUUAAAAAC
siRNA 1082	1082	UUUUAAUGGCUUGCCUGCU	2222	AGCAGGCAAGCAUUAAAA
siRNA 1083	1083	UUUAAUGGCUUGCCUGCUG	2223	CAGCAGGCAAGCAUUAAA
siRNA 1084	1084	UUAAUGGCUUGCCUGCUGU	2224	ACAGCAGGCAAGCAUUAA
siRNA 1085	1085	UAAUGGCUUGCCUGCUGUU	2225	AACAGCAGGCAAGCAUUA
siRNA 1086	1086	AAUGGCUUGCCUGCUGUUU	2226	AAACAGCAGGCAAGCAUU
siRNA 1087	1087	AUGGCUUGCCUGCUGUUUC	2227	GAAAACAGCAGGCAAGCAU
siRNA 1088	1088	UGGCUUGCCUGCUGUUUCC	2228	GGAAACAGCAGGCAAGCCA
siRNA 1089	1089	GGCUUGCCUGCUGUUUCCC	2229	GGGAAACAGCAGGCAAGCC
siRNA 1090	1090	GCUUGCCUGCUGUUUCCCA	2230	UGGGAAACAGCAGGCAAGC
siRNA 1091	1091	CUUGCCUGCUGUUUCCCAC	2231	GUGGGAAACAGCAGGCAAG
siRNA 1092	1092	UUGCCUGCUGUUUCCACAA	2232	UGUGGGAAACAGCAGGCAA
siRNA 1093	1093	UGCCUGCUGUUUCCACAUA	2233	AUGUGGGAAACAGCAGGCA
siRNA 1094	1094	GCCUGCUGUUUCCACAUA	2234	UAUGUGGGAAACAGCAGGC
siRNA 1095	1095	CCUGCUGUUUCCACAUAUA	2235	UUUUGUGGGAAACAGCAGG
siRNA 1096	1096	CUGCUGUUUCCACAUAUA	2236	UUUUGUGGGAAACAGCAG
siRNA 1097	1097	UGCUGUUUCCACAUAUAAC	2237	GUUUUUGUGGGAAACAGCA
siRNA 1098	1098	GCUGUUUCCACAUAUAACU	2238	AGUUUUGUGGGAAACAGC
siRNA 1099	1099	CUGUUUCCACAUAUAACUA	2239	UAGUUUUGUGGGAAACAG
siRNA 1100	1100	UGUUUCCACAUAUAACUAC	2240	GUAGUUUUGUGGGAAACA
siRNA 1101	1101	GUUUUCCACAUAUAACUACC	2241	GGUAGUUUUGUGGGAAAC
siRNA 1102	1102	UUUUUCCACAUAUAACUACCU	2242	AGGUAGUUUUGUGGGAAA
siRNA 1103	1103	UUUUUCCACAUAUAACUACCUC	2243	GAGGUAGUUUUGUGGGAA
siRNA 1104	1104	UCCUCCACAUAUAACUACCUCA	2244	UGAGGUAGUUUUGUGGGGA
siRNA 1105	1105	CCCACAUAUAACUACCUCAAG	2245	CUGAGGUAGUUUUGUGGGG
siRNA 1106	1106	CCACAUAUAACUACCUCAAGG	2246	CCUGAGGUAGUUUUGUGGG
siRNA 1107	1107	CACAUAUAACUACCUCAAGGA	2247	UCCUGAGGUAGUUUUGUGG
siRNA 1108	1108	ACAUAUAACUACCUCAAGGAG	2248	CUCCUGAGGUAGUUUUGUG
siRNA 1109	1109	CAUAUAACUACCUCAAGGAGU	2249	ACUCCUGAGGUAGUUUUG
siRNA 1110	1110	AUAUAACUACCUCAAGGAGUC	2250	GACUCCUGAGGUAGUUUAU
siRNA 1111	1111	UAAUAACUACCUCAAGGAGUCA	2251	UGACUCCUGAGGUAGUUUA
siRNA 1112	1112	AAUAUAACUACCUCAAGGAGUCAC	2252	GUGACUCCUGAGGUAGUUU

siRNA 1113	1113	AACUACCUCAGGAGUCACU	2253	AGUGACUCCUGAGGUAGUU
siRNA 1114	1114	ACUACCUCAGGAGUCACUG	2254	CAGUGACUCCUGAGGUAGU
siRNA 1115	1115	CUACCUCAGGAGUCACUGU	2255	ACAGUGACUCCUGAGGUAG
siRNA 1116	1116	UACCUCAGGAGUCACUGUA	2256	UACAGUGACUCCUGAGGUA
siRNA 1117	1117	ACCUCAGGAGUCACUGUAA	2257	UUACAGUGACUCCUGAGGU
siRNA 1118	1118	CCUCAGGAGUCACUGUAAA	2258	UUUACAGUGACUCCUGAGG
siRNA 1119	1119	CUCAGGAGUCACUGUAAAA	2259	UUUUACAGUGACUCCUGAG
siRNA 1120	1120	UCAGGAGUCACUGUAAAAU	2260	AUUUUAACAGUGACUCCUGA
siRNA 1121	1121	CAGGAGUCACUGUAAAAUA	2261	UAUUUUACAGUGACUCCUG
siRNA 1122	1122	AGGAGUCACUGUAAAAUAA	2262	UUUUUUUAACAGUGACUCCU
siRNA 1123	1123	GGAGUCACUGUAAAAUAAA	2263	UUUUUUUUACAGUGACUCC
siRNA 1124	1124	GAGUCACUGUAAAAUAAAC	2264	GUUUUUUUUAACAGUGACUC
siRNA 1125	1125	AGUCACUGUAAAAUAAACU	2265	AGUUUUUUUUACAGUGACU
siRNA 1126	1126	GUCACUGUAAAAUAAACUG	2266	CAGUUUUUUUUUAACAGUGAC
siRNA 1127	1127	UCACUGUAAAAUAAACUGG	2267	CCAGUUUUUUUUUAACAGUGA
siRNA 1128	1128	CACUGUAAAAUAAACUGGC	2268	GCCAGUUUUUUUUUAACAGUG
siRNA 1129	1129	ACUGUAAAAUAAACUGGCC	2269	GGCCAGUUUUUUUUUAACAGU
siRNA 1130	1130	CUGUAAAAUAAACUGGCCU	2270	AGGCCAGUUUUUUUUUAACAG
siRNA 1131	1131	UGUAAAAUAAACUGGCCUU	2271	AAGGCCAGUUUUUUUUUAACA
siRNA 1132	1132	GUAAAAUAAACUGGCCUUG	2272	CAAGGCCAGUUUUUUUUUAC
siRNA 1133	1133	UAAAAUAAACUGGCCUUGU	2273	ACAAGGCCAGUUUUUUUUUA
siRNA 1134	1134	AAAAUAAACUGGCCUUGUU	2274	AACAAGGCCAGUUUUUUUUU
siRNA 1135	1135	AAAUAAACUGGCCUUGUUG	2275	CAACAAGGCCAGUUUUUUUU
siRNA 1136	1136	AAUAAACUGGCCUUGUUGU	2276	ACAACAAGGCCAGUUUUUUU
siRNA 1137	1137	AUAAACUGGCCUUGUUGUC	2277	GACAACAAGGCCAGUUUUUAU
siRNA 1138	1138	UAAACUGGCCUUGUUGUCU	2278	AGACAACAAGGCCAGUUUUA
siRNA 1139	1139	AAACUGGCCUUGUUGUCUU	2279	AAGACAACAAGGCCAGUUUU
siRNA 1140	1140	AACUGGCCUUGUUGUCUUA	2280	UAAGACAACAAGGCCAGUUU

Table 21. Additional Sequences

SEQ ID NO:	5' to 3' Sequence
2443	GGGGTGGGGAGGGAGCGAGAGGAATCCGACCCTGTCTCAGCCACAGCCTCCGAGGTCTCCAAGTAAAGGGAAGGA TCTTTAGCTGCATTAGACTTCAAAGCGTTTAGACAGTTTCTCCATCTTACGGAGCGGTGAACGGGCTCAGGAATGTG GAGCGTTTCTGGCGTCAAGCAGGTCAAAGTCAGCGCTGCTTTTTTACAGACACTGCTTTTCTTACAGTCTTCGACTA TAAACTCTACAAGAATAGGAATCTTCGTATTTTTTCTCTGCTGAATTCCTAGTGCCAGATTAGTGCTTGGCACATG ATTATAAGCGCCATGGCTATGGCTAGTGTTAAATTGCTTGCCGGTGTTTAAAGAAAGCCAGATGCCTGGATTGGACTC TGGGGTGTTCCTCGAGGGACACCTTCATCATACAACTCTGTACTTCTGGAATCGATCTTGATTTTCTAGTACCA AGTTACGTGCACCAAATTATAAAACACTTTTTTATAATATTTTCTCACTGAGACTCCAGGGCTTTTACTATCTCCAGA ATGTATTTTCTTTTCCGTAAGACTCAAAAGTAATATAAGGTCTACAAAATCTACTAAAAGTCTCTGCAAAAAGT AGATGAAGAGGACTCTGATGAAGAAAGCCATCATGATGAGATGAGTGAGCAGGAAGAAGGAGCTTGAGGATGATCCT ACTGTAGTCAAAAACATAAAGACCTGGAAAAAGCAGTTCAGTCTTTTTCGGTATGATGTTGTCCTGAAGACGGGGCT AGATATTGGGAGAAACAAAGTGGAAAGATGCTTTCTACAAAGGTGAACCTCAGGCTGAATGAGGAAAAATTATGGAAG AAAAGCAGAACGGTGAAAGTGGGAGATACATTGGATCTTCTCATTGGAGAGGATAAAGAAGCAGGAACAGAGACAG TTATGCGGATTCTCTTGAAAAAAGTGTGTTGAAGAGAAGACTGAAAAGTGAAATAACAGAGTGGTGTACGGCGGTGG AAAAGTGTAAAGTTGCCTAAGAAGAGAATGTCTAAATAAATGATTGCTTTTGTAGCAATAGAGCTGCTTTCTAGTGGT AAAGGAAGGGGTACCTGAAAAATAGGACATTTTATTAATAAAGTCTCTTAGCGTT
2462	GGGGTGGGGAGGGAGCGAGAGGAATCCGACCCTGTCTCAGCCACAGCCTCCGAGGTCTCCAAGTAAAGGGAAGGA TCTTTAGCTGCATTAGACTTCAAAGCGTTTAGACAGTTTCTCCATCTTACGGAGCGGTGAACGGGCTCAGGAATGTG GAGCGTTTCTGGCGTCAAGCAGGTCAAAGTCAGCGCTGCTTTTTTACAGACACTGCTTTTCTTACAGTCTTCGACTA TAAACTCTACAAGAATAGGAATCTTCGTATTTTTTCTCTGCTGAATTCCTAGTGCCAGATTAGTGCTTGGCACATG ATTATAAGCGCCATGGCTATGGCTAGTGTTAAATTGCTTGCCGGTGTTTAAAGAAAGCCAGATGCCTGGATTGGACTC TGGGGTGTTCCTCGAGGGACACCTTCATCATACAACTCTGTACTTCTGGAATCGATCTTGATTTTCTAGTACCA AGTTACGTGCACCAAATTATAAAACACTTTTTTATAATATTTTCTCACTGAGACTCCAGGGCTTTTACTATCTCCAGA ATGTATTTTCTTTTCCGTAAGACTCAAAAGTAATATAAGGTCTACAAAATCTACTAAAAGTCTCTGCAAAAAGT AGATGAAGAGGACTCTGATGAAGAAAGCCATCATGATGAGATGAGTGAGCAGGAAGAAGGAGCTTGAGGATGATCCT ACTGTAGTCAAAAACATAAAGACCTGGAAAAAGCAGTTCAGTCTTTTTCGGTATGATGTTGTCCTGAAGACGGGGCT AGATTTTGGGAGAAACAAAGTGGGAGATACATTGGATCTTCTCATTGGAGAGGATAAAGAAGCAGGAACAGAGACAG TTATGCGGATTCTCTTGAAAAAAGTGTGTTGAAGAGAAGACTGAAAAGTGAAATAACAGAGTGGTGTACGGCGGTGG

SEQ ID NO:	5' to 3' Sequence
	AAAAGTTTAAAGTTGCCTAAGAAGAGAAATGTCTAAATAAATGGATTGCTTTTAGCAATAGAGCTGCTTTC TAGTGGT AAAGGAAGGGGTCACCTGAAAAATAGGACATTTTATTTAAATAAAGTTCCTTAGCGTT

CLAIMS

What is claimed is:

1. A composition comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases central nervous system (CNS) MTRES1.
2. The composition of claim 1, wherein the CNS MTRES1 decreased by about 10% or more, as compared to prior to administration.
3. A composition comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount increases cognitive function or slows cognitive decline.
4. The composition of claim 3, wherein the cognitive function is increased by about 10% or more, as compared to prior to administration.
5. The composition of claim 3, wherein the cognitive decline is slowed by about 10% or more, as compared to prior to administration.
6. A composition comprising an oligonucleotide that targets MTRES1 and when administered to a subject in an effective amount decreases a marker of neurodegeneration.
7. The composition of claim 6, wherein the marker of neurodegeneration comprises a central nervous system (CNS) or cerebrospinal fluid (CSF) marker of neurodegeneration.
8. The composition of claim 6, wherein the marker of neurodegeneration comprises a measurement of central nervous system (CNS) amyloid plaques, CNS tau accumulation, cerebrospinal fluid (CSF) beta-amyloid 42, CSF tau, CSF phospho-tau, CSF or plasma neurofilament light chain (NfL), Lewy bodies, or CSF alpha-synuclein.
9. The composition of any one of claims 6-8, wherein the marker of neurodegeneration is decreased by about 10% or more, as compared to prior to administration.
10. The composition of any one of claims 1, 3, or 6, wherein the oligonucleotide comprises a modified internucleoside linkage.
11. The composition of claim 10, wherein the modified internucleoside linkage comprises alkylphosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester, or a combination thereof.
12. The composition of claim 10, wherein the modified internucleoside linkage comprises one or more phosphorothioate linkages.
13. The composition of any one of claims 1, 3, or 6, wherein the oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 modified internucleoside linkages.
14. The composition of any one of claims 1, 3, or 6, wherein the oligonucleotide comprises a modified nucleoside.
15. The composition of claim 14, wherein the modified nucleoside comprises a locked nucleic acid (LNA), hexitol nucleic acid (HLA), cyclohexene nucleic acid (CeNA), 2'-methoxyethyl, 2'-O-alkyl, 2'-O-allyl, 2'-O-allyl, 2'-fluoro, or 2'-deoxy, or a combination thereof.
16. The composition of claim 14, wherein the modified nucleoside comprises a LNA.

17. The composition of claim 14, wherein the modified nucleoside comprises a 2',4' constrained ethyl nucleic acid.

18. The composition of claim 14, wherein the modified nucleoside comprises a 2'-O-methyl nucleoside, 2'-deoxyfluoro nucleoside, 2'-O-N-methylacetamido (2'-O-NMA) nucleoside, a 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE) nucleoside, 2'-O-aminopropyl (2'-O-AP) nucleoside, or 2'-ara-F, or a combination thereof.

19. The composition of claim 14, wherein the modified nucleoside comprises one or more 2' fluoro modified nucleosides.

20. The composition of claim 14, wherein the modified nucleoside comprises a 2' O-alkyl modified nucleoside.

21. The composition of any one of claims 1, 3, or 6, wherein the oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 modified nucleosides.

22. The composition of claim any one of claims 1, 3, or 6, wherein the oligonucleotide comprises a lipophilic moiety attached at a 3' or 5' terminus of the oligonucleotide.

23. The composition of claim 22, wherein the lipophilic moiety comprises cholesterol, retinoic acid, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, ibuprofen, naproxen, dimethoxytrityl, or phenoxazine.

24. The composition of claim 22, wherein the lipophilic moiety comprises a C4-C30 hydrocarbon chain.

25. The composition of claim 22, wherein the lipophilic moiety comprises a lipid.

26. The composition of claim 25, wherein the lipid comprises myristoyl, palmitoyl, stearoyl, lithocholoyl, docosanoyl, docosahexaenoyl, myristyl, palmityl stearyl, or α -tocopherol, or a combination thereof.

27. The composition of claim any one of claims 1, 3, or 6, wherein the oligonucleotide comprises a small interfering RNA (siRNA) comprising a sense strand and an antisense strand.

28. The composition of claim 27, wherein the sense strand is 12-30 nucleosides in length.

29. The composition of claim 27, wherein the antisense strand is 12-30 nucleosides in length.

30. A composition comprising an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an siRNA comprising a sense strand and an antisense strand, each strand is independently about 12-30 nucleosides in length, and at least one of the sense strand and the antisense strand comprises a nucleoside sequence comprising about 12-30 contiguous nucleosides of SEQ ID NO: 2443.

31. The composition of claim 27, wherein any one of the following is true with regard to the sense strand:

all purines comprise 2' fluoro modified purines, and all pyrimidines comprise a mixture of 2' fluoro and 2' methyl modified pyrimidines;

all purines comprise 2' methyl modified purines, and all pyrimidines comprise a mixture of 2' fluoro and 2' methyl modified pyrimidines;

all purines comprise 2' fluoro modified purines, and all pyrimidines comprise 2' methyl modified pyrimidines;

all pyrimidines comprise 2' fluoro modified pyrimidines, and all purines comprise a mixture of 2' fluoro and 2' methyl modified purines;

all pyrimidines comprise 2' methyl modified pyrimidines, and all purines comprise a mixture of 2' fluoro and 2' methyl modified purines; or

all pyrimidines comprise 2' fluoro modified pyrimidines, and all purines comprise 2' methyl modified purines.

32. The composition of claim 27, wherein any one of the following is true with regard to the antisense strand:

all purines comprise 2' fluoro modified purines, and all pyrimidines comprise a mixture of 2' fluoro and 2' methyl modified pyrimidines;

all purines comprise 2' methyl modified purines, and all pyrimidines comprise a mixture of 2' fluoro and 2' methyl modified pyrimidines;

all purines comprise 2' methyl modified purines, and all pyrimidines comprise 2' fluoro modified pyrimidines;

all pyrimidines comprise 2' fluoro modified pyrimidines, and all purines comprise a mixture of 2' fluoro and 2' methyl modified purines;

all pyrimidines comprise 2' methyl modified pyrimidines, and all purines comprise a mixture of 2' fluoro and 2' methyl modified purines; or

all pyrimidines comprise 2' methyl modified pyrimidines, and all purines comprise 2' fluoro modified purines.

33. The composition of claim 27, wherein the oligonucleotide comprises a phosphate at the 5' end of the antisense strand.

34. The composition of claim 27, wherein the oligonucleotide comprises a phosphate mimic at the 5' end of the antisense strand.

35. The composition of claim 34, wherein the phosphate mimic comprises a 5'-vinyl phosphonate (VP).

36. The composition of any one of claims 1, 3, or 6, wherein the oligonucleotide comprises an antisense oligonucleotide (ASO).

37. The composition of claim 36, wherein the ASO is 12-30 nucleosides in length.

38. A composition comprising an oligonucleotide that inhibits the expression of MTRES1, wherein the oligonucleotide comprises an ASO about 12-30 nucleosides in length and a nucleoside sequence complementary to about 12-30 contiguous nucleosides of SEQ ID NO: 2443.

39. The composition of any one of claims 1, 3, 6, or 38, further comprising a pharmaceutically acceptable carrier.

40. A method of treating a subject having a neurological disorder, comprising administering an effective amount of the composition of claim 39 to the subject.

41. The method of claim 40, wherein the neurological disorder comprises dementia, Alzheimer's disease, delirium, cognitive decline, vascular dementia, or Parkinson's disease.